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The venom of the puff adder, Bitis arietans, is known to contain numerous bioactive 
components, including disintegrins and C-type lectins that modulate platelet function. 
We have isolated two novel C-type lectins, which we called Ba100 and Ba25, using 
fibrinogen and platelet receptor affinity chromatography respectively, from the venom 
of the puff adder, Bitis arietans found in the Western Cape region of South Africa. 
Functional studies have demonstrated the ability of these two proteins to modulate 
platelet function either through their fibrinogenase activity (Ba100) or through their 
ability to target the platelet receptors GPIb  and 2 1 (Ba25) (Jennings et al 1999, 2005 
and unpublished data). As platelets are known to modulate intercellular interactions, 
cellular adhesion, transendothelial migration and share common receptors with 
lymphocytes, including the collagen receptor 2 1, which is involved in T lymphocyte 
adhesion and signaling, we postulated that Ba100 and Ba25 might be able to modulate 
lymphocyte function.  
The studies in this thesis investigated the effect of Ba100 and Ba25 on the proliferation 
of T lymphocytes in response to the mitogenic lectin Phytohaemagglutinin (PHA), 
several recall antigens and alloantigens participating in a mixed lymphocyte reaction. 
The results indicated quite clearly that both Ba100 and Ba25 could inhibit in a dose-
dependent manner, calcium-dependent T lymphocyte proliferation mediated by these 
stimuli. Neither Ba100 nor Ba25 were able to inhibit calcium-independent T 
lymphocyte proliferation pathways such as proliferation in response to anti-CD28 
antibody and a phorbol ester, phorbol 12-myristrate 13-acetate (PMA). 
Proliferation in the presence of Ba100 at a concentration of 200 nM resulted in 
inhibition of the generation of lymphocytes expressing the activation markers HLA-DR 
and CD25 and downregulated the expression of adhesion/co-stimulatory molecules 
(CD11a, CD49d and CD29) and the costimulatory molecule CD28 on lymphocytes. 
Ba100 also inhibited the generation of T cell subsets that play a critical role in the 
alloimmune response: CTLs, NK cells and memory cells as well as increasing the 
CD4:CD8 ratio possibly reflecting the inability of CD8 lymphocytes to proliferate due 
to inhibition of the IL-2/IL-2 receptor pathway as Ba100 downregulated CD25 (IL-2 











Lymphocyte intracellular production of Th1 cytokines (IL-2, IFN- , TNF- ) and the 
Th2 cytokine IL-4 in response PMA and ionomycin stimulation in the presence of 
Ba100 (200nM) was inhibited. Investigation of lymphocyte progression through the cell 
cycle in response to PHA stimulation indicated that when Ba100 was included in the 
reaction, inhibition of cell cycle progression from the G0 – G1 phase into the S phase 
occurred. This was associated with downregulation of proliferating cell nuclear antigen 
(PCNA) expression. 
Although the inclusion of Ba25 (200 nM) in PBMC proliferation reactions resulted in 
inhibition of proliferation, a minimal change in the expression of T cell activation 
markers was observed. An immunosuppressive cytokine profile characterized by 
increased IL-4 and IL-10 production and decreased IFN-  production was detected 
during a mixed lymphocyte reaction in the presence of Ba25(200nM). Ba25 did not 
affect cell cycle progression nor proliferating cell nuclear antigen expression. The 
proliferation inhibitory properties of Ba25 appeared to be related rather to its ability to 
induce the generation of immunosuppressive prostaglandins. Indomethacin, a non-
selective cyclooxygenase inhibitor added to PHA-induced PBMC proliferation reactions 
in the presence of Ba25 was able to reverse the Ba25-dependent inhibition of 
lymphocyte proliferation. We have not investigated the molecular mechanisms by 
which the C-type lectins Ba100 and Ba25 inhibit T lymphocyte proliferative responses. 
Possible mechanisms could include: i) acting as competitive ligands with lymphocyte 
integrin receptors, thereby preventing inside-out and outside-in lymphocyte signaling. 
This could be mediated through binding to the Lewis x trisaccharide which is known to 
bind other C-type lectins including the selectins, scavenger receptor C-type lectin and 
the dendritic cell receptor DC-SIGN; ii) interfering with optimal antigen-presenting cell 
function through competitive binding with their lectin receptors. 
Thus, the ability of Ba100 and Ba25 to modulate platelet function and inhibit calcium-
dependent T lymphocyte proliferation suggests a potential role for these two proteins in 
modulating the alloimmune response as both platelets and T lymphocytes are critical 
components of the inflammatory response. They may well prove after indepth analysis 
of their structure-function relationships to be capable of being developed as therapeutic 
agents that can prevent allograft rejection. Proof of concept rodent models of 
transplantation demonstrated that both Ba100 and Ba25 could prolong allograft survival 
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1.  Introduction 














1.  INTRODUCTION 
The venoms of Viperidae and Crotalidae snakes are a rich source of proteins with 
biological activity against various factors involved in coagulation and fibrinolysis. They 
may act as procoagulants, anticoagulants or haemorrhagins (Ouyang et al 1992; Hutton 
& Warrel 1993; Marsh 1994; Markland 1998a; Lu et al 2005a). These properties have 
been utilized to analyse pathways of coagulation, to develop diagnostic assays assessing 
platelet function and coagulation as well as therapeutically in the development of anti-
thrombotic agents (Marsh 2001; Morita 2004b; Marsh & Williams 2005; Schöni 2005; 
Wijeyewickrema et al 2005; Koh et al 2006). The bioactive components of snake venom 
proteins have been classified into various families including serine proteases, 
metalloproteinases, C-type lectins, disintegrins and phospholipases A(2) (Kamiguti et al 
1998; Markland 1998; Morita 2004a). These bioactive components have been shown to 
target platelets, erythrocytes and leukocytes and C-type lectins are potent modulators of 
platelet function (Lu et al 2005b; Morita et al 2005; Ogawa et al 2005). 
We have isolated two novel C-type lectins, Ba100 and Ba25, from the venom of the 
Western Cape, South African puff adder, Bitis arietans, using fibrinogen and platelet 
receptor affinity chromatography respectively and have demonstrated their ability to 
modulate platelet function (Jennings et al 1999; 2005). The venom of Bitis arietans is 
known to contain a disintegrin, Bitistatin (Shebuski et al 1989) and another C-type 
lectin, Bitiscetin (Hamako et al 1996), and both have platelet function modulating 
activity different from that of Ba100 and Ba25. Ba100 inhibited platelet aggregation in 
platelet-rich plasma and clot formation in whole blood. This was due to fibrinogenase 
activity of Ba100 that cleaves the fibrinogen A  and B  chain preventing fibrinogen 
crosslinking and fibrin clot formation (Jennings et al 1999). Ba25 stimulated platelet 
agglutination in platelet-rich plasma and inhibited clot formation in whole blood. Ba25 
interacts with the GPIb  receptor of the platelet von Willebrand receptor complex 
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receptor 2 1 leading to activation of the platelet fibrinogen receptor GPIIaIIIb and 
increased fibrinogen binding. Ba25 also inhibited collagen-induced platelet P-selectin 
expression (Jennings et al 2005, Jennings unpublished data). Thus, these two novel C-
type lectins modulate platelet function and prevent clot formation. 
The C-type lectin protein family acting as recognition molecules also play a critical role 
in the immune system being involved in direct defense, cell recognition and trafficking 
within the immune system and in immune regulation. The C-type lectin-like domain 
(CTLD) family was originally classified into seven groups based on their overall 
domain structure (Weiss et al 1998; Drickamer 1999), but now consists of seventeen 
groups. The members of this CTLD superfamily and their diverse functions have been 
reviewed (Zelensky & Gready 2005). Very briefly, the C-type lectins playing an 
important role in the immune system are the: 
i) Collectins including the serum mannose binding proteins and pulmonary 
surfactant proteins that are the first line of host defense recognizing 
pathogen-associated molecular patterns and initiating direct opsonisation, 
agglutination, complement activation and phagocytosis of pathogens (Van 
De Wetering et al 2004; Degn et al 2007; Gupta & Surolia 2007). 
ii) Selectins (L-, E- and P-selectins) that direct adhesive interactions between 
leukocytes, platelets and the endothelium (Lasky 1992, 1995; Barthel et al 
2007; Wang et al 2007). They play a critical role in the rolling of leukocytes 
along the endothelium and are involved in the initial recruitment of 
leukocytes into sites of inflammation or secondary lymphoid tissue (Kelly et 
al 2007). All 3 selectins recognize sulphated and sialylated derivatives of the 
Lewis x and Lewis a trisaccharide of the endothelium (Sanders et al 1996). 
Lymphocyte homing and recruitment is mediated by specific interaction 
between L-selectin and the carbohydrate ligand 6-sulpho sialyl Lewis x on 
high endothelial venules (Mitoma et al 2007). 
iii) Dendritic cell receptors that are involved in antigen presentation and 
interactions with T lymphocytes: the dendritic cell inhibitory 
immunoreceptor, DCIR (Bates et al 1999), the dendritic cell lectin-DLEC 
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cells (Engering et al 2002) and the dendritic cell associated lectins, Dectin 1 
and 2 (Ariizumi et al 2000a,b; Yokota et al 2001; Kanazawa et al 2004). DC-
SIGN, dectin-1 and dectin-2 act as pattern recognition receptors for 
pathogens (van Kooyk & Geijtenbeek 2002). Dectin-1 has been shown to 
promote T cell proliferation (Ariizumi 2000a). 
iv) Scavenger receptor C-type lectin (SRCL), an endocytic endothelial receptor 
that binds to the leukocyte cell surface Lewis x trisaccharide (Nakamura et al 
2001; Coombs et al 2005; Feinberg et al 2007). 
v) The macrophage mannose receptor involved in direct defense, binding to and 
phagocytosing pathogens (East & Isacke 2002). 
vi) The immunomodulatory natural killer lectin-like receptors: NKR-P1, Ly-49 
and CD94/NKG2 that transduce both inhibitory and activating signals to the 
NK cell (Ryan et al 2001). 
The ability of snake C-type lectins to modulate platelet function and haemostasis has 
been extensively investigated (Lu et al 2005b; Morita et al 2005; Ogawa et al 2005) and 
more recently, snake C-type lectin-like proteins have been shown to modulate integrin-
mediated functions such as adhesion, migration and invasion of tumour cells (Sarray et 
al 2001, 2004, 2007). Although studies have shown that snake phospholipase A2 and 
disintegrins are able to modulate neutrophil function affecting neutrophil migration, 
chemotaxis, apoptosis and superoxide production (Sundell et al 2003; Coelho et al 
2004; Tseng et al 2004a,b; Gambero et al 2004), no research has been directed at 
investigating the ability of snake C-type lectin-like proteins to modulate T lymphocyte 
proliferative responses. 
It is known that platelets play a major role in inflammation by releasing pro-
inflammatory factors and expressing cell surface receptors that bind to other blood cells, 
the extracellular matrix and the endothelium (Kasirer-Friede et al 2007). Thus, platelets 
are able to modulate intercellular interactions, adhesion and transendothelial migration 
(Weyrich et al 2003). Studies have shown that platelets enhance CD4 lymphocyte 
adhesion to extracellular matrix under flow conditions by the formation of heterotypic 
platelet-lymphocyte co-aggregates involving the platelet receptor IIb 3, 1 integrins as 
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2006). Activated platelets promote activated T cell adhesion to fibronectin under flow 
via integrin ( 5 1 and L 2), CD40-CD40L and P-selectin-PSGL-1 mediated 
interactions (Shenkman et al 2006). Activated platelets have been shown to play a role 
in the alloimmune response and promote rejection by releasing the soluble form of 
CD154 which interacts with CD40 on the surface of antigen-presenting cells and 
dendritic cells leading to their activation (Xu et al 2006). 
It has been shown that platelets in peripheral blood are significantly more activated in 
renal transplant recipients with acute rejection compared to patients with normal graft 
function (Zhang et al 2003). A clinical study in renal transplant patients with acute 
rejection demonstrated that Lipo-PGE1, a platelet activation inhibitor, shortened the 
graft function recovery time and improved both patient and graft 1 year survival times 
(Zhang et al 2005). Thus, platelet activation is an important component of the allograft 
rejection process. 
Platelets have receptors that are common to lymphocytes ( 2 1, 5 1, v 3 and 6 1) 
and the endothelium ( 2 1, v 3 and 5 1) (Pribilia et al 2004, Kasirer-Friede et al 
2007) and thus these 2 novel C-type lectins that have been shown to modulate platelet 
function, may modulate platelet-leukocyte, platelet-endothelial and leukocyte-leukocyte 
interactions by targeting common receptors. 
Allograft rejection is a complex process involving receptors on host leukocytes, host 
platelets and the microvascular endothelial cells of the transplanted organ that promote 
cellular interactions resulting in localization, adhesion and concentration of leukocyte 
effector cells within the graft. Vascular endothelial cells provide a contiguous barrier 
separating tissue cells of vascularized organs from the molecular components of plasma 
and circulating blood cells (Gimbrone 1987). When vascularized organs are 
transplanted into an allogeneic host, endothelial cells of donor origin prevent host 
leukocytes from immediately attacking the allograft. With endothelial injury, the 
platelets adhere to the exposed extracellular matrix, the clotting cascade is activated, 
resulting in fibrin deposition which further promotes platelet aggregation and platelet-
endothelial and platelet-leukocyte adhesive interactions. The endothelium, 
inflammatory leukocytes and platelets release pro-inflammatory factors including 
thromboxanes, leukotrienes, platelet activating factors and platelet-derived growth 
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2003). Graft rejection is typically accompanied by evidence of localised intravascular 
coagulation with thrombus formation which is characterised by fibrin deposition in the 
rejected organ and infiltration of activated leukocytes (Orosz 1994). 
Adhesion processes are a basic component underlying the immune response associated 
with graft rejection and thrombus formation. The specific adhesion of cells to other cells 
is mediated by selectins, integrin receptors and surface proteins of the immunoglobulin 
(Ig) superfamily (Smith 2008). Cell interactions with the extracellular matrix, 
comprising laminin, fibronectin, von Willebrand factor and thrombospondin occur via 
integrin receptor binding to the amino acid sequences Lys-Gly-Asp (KGD) (Kloczewiak 
et al 1984; Gresham et al 1992), Arg-Gly-Asp (RGD) (Ruoslahti & Pierschbacher 1987) 





 T lymphocytes interacting with microvascular endothelial cells of 
the transplanted organ play a pivotal role in initiating the process of graft rejection. The 
recruitment of lymphocytes to sites of immune response or inflammation involves direct 
cell-cell adhesive interactions between lymphocytes and antigen-presenting vascular 
endothelial cells (Choi et al 2004; Kelly et al 2007; Rao et al 2007). This is mediated by 
various adhesion receptors including T lymphocyte receptors of the selectin (Lawrence 
& Springer 1991; Lasky 1992; McEver et al 1995) and Ig superfamily such as L-
selectin and CD2 which bind endothelial cell carbohydrate moieties and LFA-3 of the Ig 
superfamily respectively. Adhesion is also mediated by lymphocyte VLA-4 ( 4 1) of 
the 1 integrin family, and CD11a/CD18 of the 2 integrin family which bind to 
extracellular matrix protein ligands and/or counter-receptors of the Ig superfamily, 
VCAM-1, ICAM-1 and ICAM-2 expressed on the surfaces of endothelial cells 
(Bevilacqua et al 1993; Pribilia et al 2004; Rao et al 2007; Smith 2008). ICAM-1 and 
ICAM-2, the endothelial ligands for LFA-1 (CD11a/CD18), are constitutively 
expressed, but VCAM-1, the ligand for VLA-4 is not expressed on unstimulated 
endothelium (Springer 1990a,b; Bevilacqua 1993; Kelly et al 2007). The expression and 
upregulation of the adhesive activity of these molecules is mediated by IL-1, IL-2, IL-4 
and tumour necrosis factor (TNF ) and the initial interaction of lymphocyte CD2 
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Exposure of the endothelium to TNF  and IL-1, besides upregulating endothelial 
receptors such as ICAM-1, ICAM-2, VCAM-I and E-selectin (Pober et al 1986a,b; 
Nawroth & Stern 1986a, 1987a; Collins et al 1995a), also alters the surface of the 
endothelium from an anticoagulant state to a procoagulant state (Nawroth et al 1985; 
Nawroth & Stern 1986b, 1987b; Rao et al 2007). This is associated with changes in the 
synthesis and surface expression of endothelial proteins such as tissue factor (Nawroth 
et al 1985; Collins et al 1995b). Tissue factor plays a major role in promoting 
coagulation by activating factor XIa, followed by activation of factors IX, VIII, X and 
prothrombin and subsequently the assembly of the prothrombinase complex and 
thrombin generation (Nawroth et al 1985; Stern et al 1985). Thrombin, as a key enzyme 
in the hemostatic process, upregulates the expression of P-selectin on endothelial cells 
and platelets, initiates fibrin formation and activates the platelet IIb 3 receptor which 
then binds dimeric fibrinogen molecules (Nawroth & Stern 1986b). Thrombus 
formation occurs as a result of platelets binding via 3 integrin receptors and 
carbohydrate moieties to the fibrin meshwork and to endothelial cells expressing P-
selectin and integrins of the Ig superfamily. 
Thus, platelets and lymphocytes both play critical roles in allograft injury. Agents 
which are able to modulate the function of both platelets and lymphocytes inhibiting 
cell-cell and cell-extracellular matrix interactions as well as inhibiting the deposition of 
fibrin and subsequent thrombus formation could have the potential for inhibiting the 
thrombotic/vascular/immune responses associated with solid organ allograft rejection. 
 
 
Hypothesis: The novel C-type lectins, Ba100 and Ba25, isolated from the venom of 
Bitis arietans, that have been shown to modulate platelet function could have the 
potential to modulate lymphocyte activation and the generation of effector mechanisms 
that are involved in the alloimmune response leading to allograft injury and thus could 
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2.  AIM OF THE STUDY 
The aim of the study was to assess the ability of the novel C-type lectins, Ba100 and 
Ba25, to inhibit T lymphocyte proliferative responses. 
We investigated the ability of Ba100 and Ba25 to modulate: 
1. Calcium-dependent T lymphocyte proliferation pathways: 
a. Peripheral blood mononuclear cell (PBMC) proliferation in response to the 
mitogenic lectin phytohaemagglutinin (PHA), recall antigens and allo-
antigens. 
b. Isolated CD4 lymphocyte proliferation in response to OKT3 (a 
muromonoclonal anti-CD3 antibody) and fibronectin. 
2. Calcium-independent T lymphocyte proliferation pathways:  
a. PBMC proliferation in response to anti-CD28 antibody and a phorbol ester, 
phorbol 12-myristate 13-acetate (PMA). 
3. Lymphocyte populations and the phenotype of lymphocytes after PBMC 
proliferation in response to PHA or in a primary mixed lymphocyte reaction 
(MLR). 
4. Suppressor cell activity and cytotoxic activity of MLR generated effectors. 
5. Cytokine production. 
6. Cell cycle progression and proliferating cell nuclear antigen expression. 
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8. Rodent models of transplantation. 
a. Assessing the effect on rat survival following heterotopic heart 
transplantation. 
b. Histological assessment following rat orthotopic renal transplantation 
- severity of rejection 
- histological evidence of toxicity  
 
The data obtained from these studies indicating that Ba100 and Ba25 inhibited T 
lymphocyte proliferation processes has been compared with the known 
immunosuppressive agents Cyclosporin, FK506 (Tacrolimus) and Rapamycin that are 
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CHAPTER TWO: 
LITERATURE REVIEW : SNAKE VENOM  BIOACTIVE 
COMPONENTS, DIAGNOSTIC AND THERAPEUTIC 
USES 
 
1.  INTRODUCTION 
Snake venom is a complex mixture of biologically active proteins and peptides that 
exert their toxicological effects by targeting their substrates or receptors following 
envenomation. The major toxicological effects include: 
i) local tissue dying at the site of the snake bite 
ii) flaccid paralysis 
iii) myolysis 
iv) haemorrhage and coagulopathy 
v) renal failure 
vi) cardiotoxicity 
 
There are 5 major families of venomous snakes (Clemetson et al 2005; Du et al 2006) 
i) Hydrophiladae family (mainly myotoxic) 
ii) Viperidae and Crotalidae family (haemorrhagic) 
iii) Elapidae family (neurotoxic and haemorrhagic) 
iv) Colubridae family (toxic effects not characterized) 
 
This review will concentrate on the toxic components of the Viperidae and Crotalidae 
family. 
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Snake toxins may have multiple targets and toxins from different snake venom protein 
families are able to bind to a common target (Clemetson et al 2001; Du et al 2006). The 
venom composition within snake species can show considerable geographic variation 
(Chippaux et al 1991). The underlying causes for this variation is not fully understood, 
but dietary variation in addition to genetics may be partly responsible for the variation 
in venom composition (Daltry et al 1996; Sasa et al 1999). 
The venoms of the Viperidae, Crotalidae and Elapidae families affect haemostasis 
through their toxic effects on blood cells, plasma proteins and the blood vessel wall. 
These snake venom toxins include phospholipase A2, serine proteases, 
metalloproteinases, disintegrins and C-type lectins (Ouyang et al 1992; Hutton & 
Warrel 1993; Marsh 1994; Markland 1998a; Clemetson et al 2005; Du et al 2006; 
Clemetson et al 2007). 
Snake toxins such as metalloproteinases, serine proteases and C-type lectins are able to 
inhibit or activate a number of coagulation factors including fibrinogen, thrombin, 
prothrombin, factor V, factor IX and factor X. C-type lectins, disintegrins and 
disintegrin-like proteins are able to modulate platelet activity either directly or by using 
co-factors such as IgM (Navdaev et al 2001; Navdaev & Clemetson 2001) and von 
Willebrand factor (Brinkhous et al 1983; Hamako et al 1996). 
Snake phospholipase A2 causes haemolysis and the haemolytic activity is dependent on 
the charge of the phospholipase A2 and its phospholipid substrate (Wang et al 1996; 
Zhao et al 1998; Doley et al 2004). Basic phospholipases are more haemolytic.  
Galactose-specific C-type lectins, existing mainly as homodimers can agglutinate 
erythrocytes (Hirabayashi et al 1991; Ozeki et al 1994; Nikai et al 1995; Wang & Xu 
2000).  
Snake venom metalloproteinases, disintegrins and phospholipase A2 can modulate 
leukocyte function (Du et al 2006). Metalloproteinases such as mocarhagin (Naja 
mocambique) cleave platelet GPIb, but is also able to cleave a 10-amino acid peptide 
from the N-terminus of P-selectin glycoprotein ligand Ι (PSGL-I), preventing P-selectin 
binding and is able to disrupt platelet-neutrophil interactions (De Luca et al 1995a; 
Ward et al 1996; Du et al 2006). 
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Triflamp, a metalloproteinase (Trimeresurus flavoviridis) reduces platelet-neutrophil 
adhesion through proteolysis of PSGL-1 (Tseng et al 2004a). 
Disintegrins, by binding to integrins, are able to modulate leukocyte activation and their 
interactions with other cells. Jarastatin (Bothrops jaracara), a RGD-containing 
disintegrin is able to induce integrin-coupled signaling, resulting in focal adhesion 
kinase and phosphoinositide-3-kinase activation in human neutrophils. Jarastatin 
induces Erk-2 translocation to the nucleus and delays spontaneous apoptosis of 
neutrophils (Coelho et al 2004). The disintegrin, Rhodostomin has been shown to block 
Mac-1 dependent adhesion of neutrophils to immobilized fibrinogen with a resultant 
decrease in superoxide production (Tseng et al 2004b). 
Snake phospholipase A2 (from the venom of Naja mocambique) causes neutrophil 
migration as a result of activation of endogenous phospholipase A2, following activation 
of GTP-binding protein and protein kinase C (Gambero et al 2004; Du et al 2006). 
Thus, snake venom components are able to target platelets, erythrocytes and leukocytes. 
This chapter will concentrate on snake phospholipase A2, metalloproteinases, 
disintegrins, snake C-type lectins and their bioactivity; the bioactivity of venom from 
Bitis arietans and briefly discuss the use of snake venom components in medicine. 
 
2.  SNAKE PHOSPHOLIPASE A2 
Snake phospholiase A2 belongs to the enzyme superfamily that hydrolyses the sn-2 acyl 
groups of membrane phospholipids releasing arachidonic acid and lysophospholipids. 
Snake phospholipases may exist as monomers, homodimers and heterodimers and have 
variable enzyme activity. They may exert toxic effects on nerves and muscle, but are 
also toxic to platelets, leukocytes and erythrocytes. 
Snake phospholipase A2 can both induce or inhibit platelet activation, but the 
mechanisms are not yet defined and are not dependent on its pI value. 
An acidic phospholipase A2 from the venom of Agkistrodon halys pallas (Chen et al 
1987), and praelongin 2bIII (Acanthopsis praelongus) (Sim 1998) inhibit platelet 
aggregation. An acidic PLA2 (Agkistrodon acutus) inhibits ADP-induced platelet 
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aggregation in platelet-rich plasma and induces aggregation of washed platelets (Chen 
& Chen 1989). The platelet aggregation effect could be inhibited by asprin suggesting 
that the generation of arachidonic acid from phospholipids in the platelet membrane and 
the formation of thromboxane may play a role in the induction of platelet aggregation 
(Chen & Chen 1989). 
 
3.  SNAKE VENOM METALLOPROTEINASES (SVMPs) 
The SVMPs are a subgroup of the reprolysins. SVMPs are synthesized as latent 
precursor pro-proteinases which may undergo processing to produce the active 
proteinases and are classified according to structure into 4 main groups: i) MP-I has a 
single zinc-metalloproteinase, ii) MP-II contains MP-I and a disintegrin domain in the 
C-terminus, iii) MP-III contains MP-II and an additional cysteine-rich domain, iv) MP-
IV has the MP-III domain structure with additional lectin-linked domains connected by 
disulphide bonds (Bjarnason & Fox 1995; Fox & Serrano 2005). 
SVMPs affect haemostasis in various ways. They may be haemorrhagic, fibrinolytic, 
fibrinogenolytic and can inhibit platelet aggregation. 
 
3.1.  Fibrin(ogen)olytic activity of SVMPs 
Several SVMPs as well as serine proteases with fibrinogenolytic and/or fibrinolytic 
activity have been identified (Mebs & Panholzer 1982; Takeya et al 1993; Marsh 1994; 
Omori-Satoh et al 1995; Yamakawa et al 1995; Jia et al 1996; Swenson & Markland 
2005). 
These fibrin(ogen)ases cleave either selectively or in combination the  and  chains of 
fibrin(ogen) and occasionally cleave the  chain (Hung et al 1994; Hung & Chiou 1994; 
Assakura et al 1994). 
These fibrin(ogen)olytic enzymes are direct acting and do not require other factors for 
their activity. The activity of these enzymes leads to either non-clottable fibrin(ogen) 
products or hypercoagulability if the protease has thrombin-like activity. The interaction 
of fibrinogen with its receptor, the integrin IIb3 (GPIIbIIIa) on the platelet is 
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essential for haemostasis (Ruoslahti 1991) and is critical for mediating interactions 
between platelets in the early stages of thrombus formation. The enzymatic cleavage of 
soluble fibrinogen resulting in the formation of fibrinogen molecules that are unable to 
bind to IIb3, interferes with platelet-platelet interactions that are important for 
aggregation. 
Most SVMPs are both fibrinogenolytic and fibrinolytic and preferentially cleave the 
A-chain. The serine proteases preferentially cleave the B-chain (Swenson & 
Markland 2005). Examples of SVMPs with both fibrinogenolytic and fibrinolytic 
activity include neuwiedase, an -chain fibrinogenase from Bothrops neuwiedii 
(Rodrigues et al 2000, 2001; Izidoro et al 2003), fibrolase, an -chain fibrinogenase 
from Agkistrodon contortrix contortrix (Ahmed et al 1990a, b) and brevelysin L6, an -
fibrinogenase from Agkistrodon halys brevicaudus (Terrada et al 1999). 
Brevinase (Agkistrodon blomhoffi brevicaudus) is a serine proteinase with -
fibrinogenase and fibrinolytic activity (Lee et al 1999; Lee & Park 2000). 
 
3.2.  SVMPs targeting the platelet receptor 
Some SVMPs have been found to target platelet receptors including GPIb of the von 
Willebrand receptor GPIb-IX-V and the platelet collagen receptors, integrin 21 and 
GPVI, thereby affecting platelet aggregation (Jia et al 1996). 
Mocarhagin (N. mocambique) inhibits platelet aggregation by removing the fragment 
His-1-Glu-282 from GPIb (Ward et al 1996). Crotalin (Crotalus atrox), a MP-I 
SVMP, inhibits platelet aggregation by the proteolysis of GPIb (Wu et al 2001a). The 
MP-III SVMPs atrolysin A (Crotalus atrox) (Jia et al 1997) and jararhagin (Bothrops 
jararaca) (Paine et al 1992; De Luca et al 1995b) inhibit platelet adhesion to collagen 
through the collagen receptor 21 and thereby prevent platelet activation. This is 
thought to be mediated through the cysteine-rich domain of the MP-III SVMPs. 
Alborhagin (T. albolabris) is able to activate platelets through the collagen receptor 
GPVI leading to GPIIbIIIa-dependent platelet aggregation (Andrews et al 2001). 
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4.  DISINTEGRINS 
Disintegrins are a family of cysteine-rich low molecular weight peptides (40-100 amino 
acids) that usually contain the RGD (Arg-Gly-Asp) sequence within an amino acid loop 
maintained by disulphide bridges and are able to bind to integrins. Disintegrins have 
been isolated from the venom of various Viperidae and Crotalidae snakes (Gould et al 
1990; McLane et al 1998; Calvete et al 2005; Barja-Fidalgo et al 2005) and are formed 
either by the proteolytic processing of multidomain metalloproteinases (Kini & Evans 
1992; Takeya et al 1993; Calvete et al 2005) or synthesized from short-coding mRNAs 
(Okuda et al 2002; Sanz et al 2006). 
Disintegrins can be divided into 5 different groups depending on the length and the 
number of disulphide bonds of the polypeptides (Gould et al 1990; Calvete et al 2000a, 
2003, 2005). 
i) Short disintegrins containing 41-51 amino acids and four disulphide bonds 
(echistatin, eristostatin, obtustatin). 
ii) Medium sized disintegrins containing 70-73 amino acids and 6 disulphide 
bonds (barbourin, flavoridin, atrolysin E, trigramin, albolabrin, elegantin, 
agkistrostatin, applagin, batroxostatin). 
iii) Long disintegrins containing a 84 amino acid polypeptide cross-linked by 7 
disulphide bonds (bitistatin, bilitoxin-1). 
iv) PIII disintegrins are derived from PIII SVMPs (snake venom haemorrhagic 
metalloproteinases). They are modular proteins containing an N-terminal 
disintegrin-like domain of approximately 100 amino acids including 16 
cysteine residues involved in the formation of eight disulphide bonds and a 
C-terminal 110-120 residue cysteine-rich domain cross-linked by six 
disulphide bonds (jararhagin, ecarin, trimerelysin, mocarhagin, 
graminelysin). 
v) Dimeric disintegrins that include homo- and heterodimers. They contain 
subunits of about 67 amino acids with 10 cysteines involved in the formation 
of four intra-chain disulphide bonds and two interchain cysteine linkages 
(Calvete et al 2000b; Bilgrami et al 2004) (acostatin, piscivostatin, 
contortostatin, EMF-10, schistatin). 
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More than one disintegrin may be found in the venom of the same viper, e.g. 
agkistrostatin and applagin are both found in the venom of Agkistrodon piscivorus 
(Chao et al 1989). In addition, more than one variant of a disintegrin may exist, such as 
the three variants of trigramin from the venom of T. gramineus (Dennis et al 1990). The 
venom of Bitis arietans, the sub-Saharan puff adder, contains five variants including 
bitistatin 1,2,3 & 4 (Shebuski et al 1989) and bitan  (Dennis et al 1990). It is not 
known whether these variants are as a result of multiple genes or as a result of 
population variation.  
Some disintegrins have been shown to have homology with extracellular matrix 
proteins. A region of homology, containing the tetrapeptide sequence PRNP found in 
the  chain of fibrinogen in position 267-270 (Doolittle et al 1979) is found at the C 
terminus of trigramin, albolabrin and echistatin (Gould et al 1990). Homology has been 
shown between trigramin and the human von Willebrand factor precursor, collagen 1 
(I) and laminin B1 (Huang et al 1989). 
A number of high molecular weight protein ligands such as fibronectin, vitronectin, 
collagen, thrombospandin, laminin, fibrinogen, von Willebrand factor and complement 
C3bi contain RGD which acts as a common integrin recognition site (Ruoslahti & 
Pierschbacher 1987; Ruoslahti 1996).  
Disintegrins bind with high affinity to the 1 and 3 families of integrins with a potency 
that is 500-2000 times greater than that of short RGDX peptides (Gould et al 1990; 
McLane et al 1998, 2004). The RGD sequence is the cell recognition site that enables 
the selective binding to integrins, thereby inhibiting integrin-related functions such as 
cellular adhesion and signal transduction (McLane et al 1998, 2004; Barja-Fidalgo et al 
2005). Each disintegrin has a unique RGD containing integrin binding loop. The spatial 
configuration conferred by the disulphide bridges and the RGD integrin binding loop 
contribute to the higher binding affinity compared to linear RGD peptides (Gould et al 
1990; Ruoslahti 1996; McLane et al 1998). The amino acid sequences adjacent to the 
RGD loop play a role in determining the biological activities and ligand-binding 
selectivity of disintegrins (Gould et al 1990; Ruoslahti 1996; Lu et al 1996; McLane et 
al 1998). Besides the RGD tripeptide, other tripeptide sequences such as KGD, MVD, 
MLD, VGD, ECD and MDG have also been identified as integrin-binding motifs in 
snake venom disintegrins (McLane et al 1998). 
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Disintegrins not only inhibit integrin-related functions, but are also able to interact with 
and activate integrin-signaling pathways depending on the cell type and associated 
environment (McLane et al 2004; Barja-Fidalgo et al 2005). Disintegrins inhibit binding 
of RGD-containing ligands to the platelet receptor IIb3 integrin, thereby impairing 
platelet aggregation responses dependent on this receptor (McLane et al 1994; Perutelli 
1995). This binding of disintegrins to the IIb3 integrin can occur without prior 
activation of this receptor. Interaction with the RGD-containing loop allows expression 
of the ligand-induced binding site (LIBS) on the 3 subunit (Juliano et al 1996; 
Kamiguti et al 1998). Disintegrins are potent inhibitors of fibrinogen binding to the 
glycoprotein GPIIbIIIa receptor of platelets (Huang et al 1987a, 1989; Gan et al 1988, 
Shebuski et al 1989, Chao et al 1989, Dennis et al 1990). 
Jarastatin (JT) isolated from Bothrops jararaca venom has been shown to activate 
integrin-coupled signaling in neutrophils (Barja-Fidalgo et al 2005). JT activates MAPK 
pathway by inducing IL-8 synthesis, a potent inducer of migration, exocytosis and 
neutrophil respiratory burst (Baggiolini & Clark-Lewis 1992) and delays neutrophil 
apoptosis (Coelho et al 2004). 
The monomeric disintegrins echistatin, kistrin and flavoridin are able to activate NF-kB 
via the PI3-K pathway, thereby interfering with CD25 expression and T lymphocyte 
proliferation (Barja-Fidalgo et al 2005). 
Disintegrins have also been shown to interfere with other integrin-mediated cell 
functions (Kamiguti et al 1998) such as inhibition of tumour cell-extracellular matrix 
adhesion (Knudsen et al 1988; Sheu et al 1994; Beviglia et al 1995) and metastasis 
(Trikha et al 1994; Morris et al 1995). 
The use of venom disintegrins has enabled the elucidation of cellular signaling events 
such as cellular activation and proliferation, cell adhesion and migration and 
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5.  SNAKE C-TYPE LECTINS 
Snake C-type lectins are important haemorrhagic components of snake venom. They are 
named because of the resemblance of their prototypical foldings to those found in 
classic C-type lectins such as the selectins and the mannose binding protein (Chou et al 
1996). The classic C-type lectins are calcium-dependent and carbohydrate binding. 
Most snake venom C-type lectin-like proteins do not bind carbohydrates and the 
calcium-binding loop is deleted. 
The snake venom C-type lectins can be divided into the i) true C-type lectins with one 
canonical C-type lectin carbohydrate recognition domain (CRD) that binds sugars and 
agglutinates erythrocytes (Drickamer & Taylor 1993) and ii) the C-type lectin-like 
proteins with CRD-related non-carbohydrate binding C-type lectin-like domains 
(CTLDs) that do not bind sugars (Drickamer 1999; Clemetson et al 2005). The CRD-
containing snake venom C-type lectins are disulphide-bond-linked homodimers and can 
form large multimers. The CTLD-containing snake venom C-type lectins are 
disulphide-bonded heterodimers composed of  and  subunits. These two subunits 
associate tightly and domain swopping between the subunits results in a conformational 
change in the central loop and formation of a concave surface (Lu et al 2005b; Ogawa et 
al 2005). The concave surface between the two subunits is thought to be the main 
binding site for the ligands, but has no carbohydrate binding ability. Both shape-fitting 
and electrostatic interactions play a role in binding (Lu et al 2005b). The snake C-type 
lectin-like proteins are divided into: i) coagulation-factor binding proteins binding to 
factors IX, X, thrombin and prothrombin or ii) platelet receptor binding proteins binding 
to the platelet receptors GPIb, GPVI, GPIaIIa (α2β1) and CLEC-2 (Ogawa et al 2005; 
Morita et al 2005; Lu et al 2005b). 
These platelet receptor binding C-type lectin-like proteins may act as both platelet 
aggregation agonists and antagonists (Ogawa 2005). Only the interaction with platelet 
receptors and integrins will be discussed. See Table 1 for list of snake venom C-type 
lectins affecting haemostasis (Adapted from the list in the review paper by Lu et al 
2005b). 
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Table 1. Snake C-type lectins affecting haemostasis 
               (see the review paper by Q. Lu et al. Toxicon 2005b; 45: 1089-1098). 
Protein name Species Target Sequence 
Mucetin Trimeresurus mucrosquamatus GPIb + 
Murocetin Trimeresurus mucrosquamatus GPIb + 
Flavocetin-A Trimeresurus flavoviridis GPIb + 
Mamushigin Agkistrodon halys blomhoffii GPIb + 
Alboaggregin-B Trimeresurus albolabris GPIb - 
Alboaggregin-C Trimeresurus albolabris GPIb - 
Agglucetin Agkistrodon acutus GPIb + 
GPIB-BP Bothrops jararaca GPIb + 
Agkicetin C Agkistrodon acutus GPIb + 
CHH-A and B Crotalus horridus horridus GPIb + 
Echicetin Echis carinatus GPIb, IgM + 
Lebecetin Macrovipera lebetina GPIb - 
TSV-GPIB-BP Trimeresurus stejnegeri GPIb + 
Tokaracetin Trimeresurus tokarensis GPIb - 
Purpureotin Trimeresurus purpureomaculatus GPIb + 
Convulxin Crotalus durissus terrificus GPVI, GPIb + 
Alboaggregin-A Trimeresurus albolabris GPIb, GPVI + 
Stejnulxin Trimeresurus stejnegeri GPVI + 
Ophioluxin Ophiophagus Hannah GPVI - 
Alboluxin Trimeresurus albolabris GPIb, GPVI - 
Botrocetin Bothrops jararaca VWF/GPIb + 
Bitiscetin Bitis arietans VWF/GPIb + 
EMS16 Echis multisquamatus GPIa/IIa + 
Aggretin Calloselasma rhodostoma GPIb, GPIa/IIa + 
Rhodocetin Calloselasma rhodostoma GPIa/IIa + 
Bilinexin Agkistrodon bilineatus GPIb, GPIa/IIa  
Agkisacutacin Agkistrodon acutus Unknown + 
Agkaggregin Agkistrodon acutus Unknown - 
Rhodoaggretin Calloselasma rhodostoma Unknown - 
Jararaca IX/X-bp Bothrops jararaca IX/X + 
Habu IX/X bp Trimeresurus flavoviridis IX/X + 
TSV-FIX-BP Trimeresurus stejnegeri IX + 
AHP IX-bp Agkistrodon halys pallas IX + 
Halyxin Agkistrodon halys brevicaudus IX/X + 
ACF Agkistrodon acutus X + 
ECLV Echis carinatus leucogaster IX/X + 
Bothrojaracin Bothrops jararaca Thrombin - 
TSL Trimeresurus stejnegeri Galactose + 
LSL Lachesis stenophrys Galactose + 
RSL Crotalus atrox Galactose + 
BAL Bitis arietans Galactose + 
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5.1.  C-type lectin-like proteins that bind to platelet receptors 
Platelets are critical in maintaining haemostasis both in an uninjured blood vessel and in 
limiting blood loss from an injured vessel. Important receptors involved in platelet 
aggregation include amongst others, the von Willebrand receptor complex GPIb-IX-V, 
the collagen receptors GPVI and the integrin 21 as well as the platelet fibrinogen 
receptor, the integrin IIb3 which also binds von Willebrand factor (vWF) (Ruggeri & 
Mendolicchio 2007; Kasirer-Friede et al 2007). The N-terminal 45 kDa domain of the 
GPIb receptor contains the binding sites for vWF and -thrombin (Du et al 2006). 
Following injury to the blood vessel wall and exposure of vWF, platelets adhere to the 
site of injury and initiate formation of platelet plugs. Platelets adhere via GPIb to the 
exposed A1 domain of vWF initiating platelet aggregation and thrombus formation (Du 
et al 2006). The platelet collagen receptor GPVI, an immunoglobulin family protein 
which is constitutively expressed, also plays a role in platelet aggregation by adhering 
to the exposed collagen (Kuijpers et al 2003; Lecut et al 2004).  
Binding of vWF to GPIb in the GPIb-IX-V receptor complex directly activates the 
collagen integrin receptor 21 increasing its affinity for collagen with subsequent 
activation of the IIb3 receptor leading to platelet agglutination or aggregation 
depending on the level of signaling (Ozaki et al 2005; Du et al 2006). Direct collagen 
interaction with the platelet collagen receptors GPVI and 21 also activates IIb3 
(Lecut at al 2004). GPVI is associated with vWF receptor complex GPIb-IX-V on the 
membrane of resting and activated platelets. GPIb-IX-V and 21 play synergistic roles 
in platelet adhesion. Once adherent, the activated platelets release secondary agonists 
such as ADP, thromboxane A2 and serotonin and express adhesive protein ligands (Jin 
et al 1998; Turner et al 2001; Weyrich et al 2003; Kasirer-Friede et al 2007). The 
activated IIb3 binds to fibrinogen which crosslinks the IIb3 of platelets as well as 
binding to vWF leading to platelet aggregation. With the initiation of platelet 
aggregation, the coagulation cascade is also initiated leading prothrombin activation and 
thrombin formation. Thrombin further activates platelets by cleaving protease activated 
receptors expressed on the surface of platelets and propagates thrombus formation 
(Ruggeri & Mendolicchio 2007). 
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These platelet adhesion receptors are targeted by several C-type lectin-like proteins and 
these proteins have played important roles in elucidating the structure/binding sites of 
platelet receptors as well as pathways of platelet activation (Wijeyewickrema et al 
2005). 
 
5.1.1.  GP1b-binding C-type lectin-like proteins 
The snake C-type lectin-like proteins which act via GP1b of the vWF binding complex 
either: 
i) inhibit platelet activation by blocking binding of von Willebrand factor (vWF) 
and/or thrombin and these are usually simple heterodimers, examples of which 
are echicetin (Echis carinatus) (Peng et al 1993, 1994, 1995; Polgar et al 1997a), 
agkicetin (Agkistrodon acutus) (Chen & Tsai 1995) and lebecetin (Macrovipera 
lebetina) (Sarray et al 2003). 
ii) agglutinate or activate and aggregate platelets and these are usually multimeric 
and include the alboaggregins (Trimeresurus albolabris) (Andrews et al 1996; 
Kowalska et al 1998; Dormann et al 2001), agglucetin (Agkistrodon acutus) 
(Wang et al 2001), mucrocetin (Trimeresurus mucrosquamatus) (Huang et al 
2004) and mucetin (Trimeresurus mucrosquamatus) (Lu et al 2004). 
Agglucetin (Wang et al 2001) and alboaggregin B (Peng et al 1991) agglutinates 
platelets via GP1b without activating platelets. Alboaggregin A activates platelets via 
both GP1b and the collagen receptor GPV1 (Dormann et al 2001). Mucetin and 
mucrocetin both activate platelets via GP1b, but to different degrees. Mucetin binds to 
the platelet GP1b, leading to IIb3 activation and full platelet aggregation (Lu et al 
2004) and mucrocetin only induces platelet agglutination (Huang et al 2004).  
Agkicetin-C (Deinagkistrodon acutus) is a potent GPIb-IX-V antagonist and inhibits 
both vWF and thrombin interaction through binding to the AA201-282 region of GPIb 
(Xu et al 2005). 
The GP1b-binding proteins act differently in vitro and in vivo due to additional 
interactions with plasma and the endothelium. 
Formatted: Font color: Black
Formatted: Font color: Black
Formatted: Font color: Black
Formatted: Font: Italic, Font color: Black
Formatted: Font color: Black
Formatted: Font: Italic, Font color: Black










Chapter 2 25 
 
5.1.2.  von Willebrand factor (vWF)-binding C-type lectin-like proteins 
Botrocetin and Bitiscetin are C-type lectin-like proteins that induce interactive vWF-
GP1b binding on platelets leading to agglutination and aggregation. The bitiscetin and 
botrocetin-induced binding depends on the optimization of interactions between the A1 
domain of vWF and the 45-kDa domain of GP1b with the C-type lectin-like proteins 
enhancing and stabilizing these interactions (Fukuda et al 2002; Maita et al 2003). 
 
5.1.3.  GPV1-binding C-type lectin-like proteins 
GPV1 is the major signaling receptor for collagen on platelets and is a member of the Ig 
superfamily closely related to FcR and NK receptors (Clemetson et al 1999). 
Crosslinking of GPV1 results in tyrosine phosphorylation of the ITAM 
(immunoreceptor tyrosine-based activation motif) of the Fc chain by the Src kinases 
Fyn and Lyn. This leads to binding and activation of the tandem SH2 domain-
containing tyrosine kinase, Syk, initiating a downstream signaling cascade that activates 
several effector enzymes, including PLC2, small G-proteins and phosphoinositide-3 
kinase. Clustering of GPV1 induces strong platelet activation. Convulxin (Crotalus 
durissus terrificus) (Polgar et al 1997b), alboaggregin A (Trimeresurus albolabris) 
(Asazuma et al 2001; Dormann et al 2001), stejnulxin (Trimeresurus stejnegeri) (Lee et 
al 2003) and ophioluxin (Ophiophagus hannah) (Du et al 2002a) are multimeric C-type 
lectins that induce platelet activation by clustering the receptor, GPV1. Ophioloxin and 
Stejnulxin are more GPVI specific than convulxin and alboaggrenin A which bind to 
other platelet receptors as well. 
 
5.1.4.  21-binding C-type lectin-like proteins 
The 21 integrin (GP1aIIa) is an important collagen receptor on platelets. 21 
mediates adhesion and plays a role in generating intracellular signals needed to stabilize 
thrombus. Aggretin (Calloselasma rhodostoma) (Navdaev et al 2001b), rhodocetin 
(Calloselasma rhodostoma) (Eble & Tuckwell 2003), bilinexin (Agkistrodon bilineatus) 
(Du et al 2001) and EMS16 (E. multisquamatus) (Marcinkiewicz et al 2000) all interact 
with 21. EMS16 and Rhodocetin are potent and selective inhibitors of 21 
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preventing platelet aggregation (Marcinkiewicz et al 2000; Eble & Tuckwell 2003). The 
action of Bilinexin and aggretin depends on their interaction with other platelet 
receptors in addition to 21. 
 
5.1.5.  CLEC-2 (C-type lectin receptor) binding C-type lectin-like proteins 
Aggretin (rhodocytin) from the venom of Calloselasma rhodostoma has been shown to 
induce platelet activation through binding to GPIb-IX-V and the collagen receptor 21 
and consequent tyrosine phosphorylation of Syk, p125 (FAK) and phospolipase C2 
without involvement of the PI3-kinase pathway (Navdaev et al 2001b; Chung et al 
2001; Suzuki-Inoue et al 2001). Recent studies have shown that aggretin (rhodocytin) 
can induce platelet activation independent of these two receptors and GPVI, by binding 
of a novel C-type lectin receptor (CLEC-2) leading to tyrosine phosphorylation of its 
cytosolic tail, binding of Syk and initiation of downstream tyrosine phosphorylation 
events and activation of phospholipase C2 (Bergmeier et al 2001; Suzuki-Inoue 2006). 
 
5.1.6.  GPIb, GPVI and GPIaIIa-binding C-type lectin-like proteins 
Some snake C-type lectins may bind to more than one platelet receptor. Convulxin 
(Crotalus durissus terrificus) (Polgar et al 1997b; Kanaji et al 2003), Alboaggregin A 
(Trimeresurus albolabris) (Dormann et al 2001) and alboluxin (Trimeresurus 
albolabris) (Du et al 2002b) bind to both GPIb and GPVI platelet receptors inducing 
platelet activation and aggregation. Aggretin (Calloselasma rhodostoma) (Navdaev et al 
2001b) and bilinexin (Agkistrodon bilineautus) (Du et al 2001) bind to GPIb and the 
21 (GPIaIIa) platelet receptors. Bilinexin agglutinates platelets and Aggretin strongly 
activates and aggregates platelets. 
To date no snake C-type lectins binding to the platelet receptor IIb3 have been 
identified. 
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6.  BITIS ARIETANS 
Using a combination of reversed phase HPLC and proteonomic analysis, the protein 
composition of the venom of puff adder, Bitis arietans has been found to consist of: 
Zn
2+
 -metalloproteinases (38.5%), serine proteases (19.5%), disintegrins (17.8%), C-
type lectin-like proteins (13.2%), phospholipases A2 (4.3%), Kunitz-type inhibitors 
(4.1%), cystatins (1.7%) and unknown (0.9%) (Juárez et al 2006). Investigations into 
the potential diagnostic and therapeutic uses of the venom of Bitis arietans have focused 
on the disintegrin, Bitistatin and the C-type lectin, Bitiscetin. 
 
6.1.  Ba100 
We have isolated a novel protease, Ba100, which has similarity to C-type lectins, from 
the venom of the Western Cape, South African puff adder, Bitis arietans, using 
fibrinogen affinity chromatography (Jennings et al 1999). Ba100 has an apparent 
molecular mass of 100 kDa under non-reducing conditions and a pI of 5.4. Under 
reducing conditions, the protease dissociates into subunits of 21 kDa and 16 kDa. N-
terminal amino acid sequencing has shown these two chains to have 66.7% homology 
as well as homology to the N-termini of other C-type lectins present in the venom from 
Crotalids and Vipers that are able to modulate platelet aggregation (Hamako et al 1996; 
Jennings et al 1999; Dormann et al 2001; Navdaev et al 2001b) (see Figure 1). The N-
terminal sequence of the 16kDa subunit is PFCCPFGWSGYDQYCYKPFDEP and of 
the 21kDa subunit is DFECPTEW(C+S) (A+P)YDQHCYRAFDEP. However, the 
ability of Ba100 to bind to fibrinogen is thought to be independent of the carbohydrate 
binding domain present in C-type lectins as binding occurs in the absence of calcium or 
magnesium. The fibrinogenase activity of Ba100 initially cleaves the A and then the 
B chain, but not the  chain of fibrinogen, rendering the molecule unable to polymerise 
into fibrin clots. Reduced Ba100 is unable to degrade fibrinogen, suggesting that a 
disulphide-bonded structure may be required for enzyme function. Ba100 is distinct 
from previously characterised puff adder venom phospholipases, C-type lectin-like 
proteins, haemorrhaggins and another fibrinogenase with the ability to cleave the fibrin-
specific  chain crosslink site (Purves & Purves 1989; Júarez et al 2006). Both serine 
and metalloprotease inhibitors were able to partially inhibit the fibrinogenolytic activity 
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of Ba100 suggesting that Ba100 probably has both serine protease and 
metalloproteinase activity. 
Functional studies demonstrated the ability of Ba100 (25 nM - 1000 nM) to inhibit 
platelet aggregation in platelet-rich plasma, inhibit clot formation and reduce clot 
strength in whole blood in a concentration-dependent manner (Jennings et al 1999). The 
inhibition of the aggregation of platelets in platelet rich plasma appeared to be 
predominantly as a result of its proteolytic action on fibrinogen which prevents 
fibrinogen from crosslinking rather than through the binding of Ba100 to the platelet 
fibrinogen receptor GPIIbIIIa as no binding of Ba100 to purified GPIIbIIIa using 
affinity chromatography could be detected. The thromboelastogram findings that Ba100 
prolonged the initiation of clot formation and reduced clot strength are in accordance 
with the fibrinogenolytic activity of Ba100 which interferes with the formation of a 
completely cross-linked fibrin matrix (Jennings et al 1999). 
 
6.2.  Ba25 
Ba25, is another novel C-type lectin that we isolated from the venom of the Western 
Cape, South African puff adder, Bitis arietans, using a platelet receptor GPIIbIIIa 
affinity column. It was found to have an apparent molecular mass of 25 kDa under non-
reducing conditions and a pI of 7.4. Ba25 is a heterodimer composed of disulphide-
linked subunits of 18 kDa and 14 kDa and on amino-acid analysis was shown to be 
cysteine rich (Jennings et al 2005). N-terminal sequence analysis of the two subunits 
confirms that Ba25 is a novel protein and shows homology to another C-type lectin 
from Bitis arietans, Bitiscetin (Hamako et al 1996; Matsui et al 2002) and the 
fibrinogenase Ba100 (Jennings et al 1999). Ba25 also shows a high degree of homology 
to other C-type lectins in the venom from Vipers and Crotalids that modulate platelet 
aggregation (Peng et al 1994; Andrews et al 1996; Hamako et al 1996; Kawasaki et al 
1996; Yamada et al 1996; Polgár et al 1997a; Kowalska et al 1998; Sakurai et al 1998; 
Sarray et al 2003). The N-terminal sequence of the 18kDa subunit is 
DQDCLSDWSSHEGHCYKVFDK and of the 14kDa subunit is 
ANCASGWAYGQHCYC (Jennings et al 2005) (see Figure 2). 
Ba25 binds to the platelet fibrinogen receptor GPIIbIIIa isolated from intact platelets 
after immobilization on sepharose, thereby allowing large quantities of this protein to be 
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isolated devoid of other venom proteins (Jennings et al 2005). Our studies with intact 
platelets indicated that there may be little direct interaction of Ba25 with this receptor 
on intact live platelets in line with other studies with snake C-type lectins that have 
shown their lack of binding to GPIIbIIIa. FITC-labelled Ba25 did bind to intact resting 
platelets with increased binding when the platelets were stimulated with ADP. As ADP 
stimulation of platelets activates the platelet fibrinogen receptor GPIIbIIIa as well as the 
collagen receptor 21 (Kamae et al 2006; Schoenwaelder et al 2007), this suggested 
that Ba25 may associate with GPIIbIIIa on intact platelets, but may also interact with 
the collagen receptor 21. Flow cytometry analysis of the binding of specific 
antibodies anti-CD42b (clone SZ2) and anti-CD49b (clone Gi9) to platelet receptors 
GPIb and the 2 subunit of the collagen receptor 21 in the presence of Ba25 was 
used to elucidate potential platelet receptors to which Ba25 binds. These studies 
strongly suggested that Ba25 interacts with the GPIb receptor of the GPIb-IX-V 
complex possibly close to the binding site of vWF, as well as interacting with the 
collagen receptor 21 (Jennings et al 2005 and Jennings unpublished data). Utilization 
of antibodies to fibrinogen binding sites on GPIIbIIIa allowed for the conclusion that 
the interaction of Ba25 with the GPIb receptor induces activation of the platelet 
fibrinogen receptor GPIIbIIIa leading to increased fibrinogen binding and subsequently 
the observed platelet agglutination (Jennings et al 2005). Such interactions of Ba25 with 
GPIb could be similar to that of the binding of vWF to GPIb in the GPIb-IX-V 
complex which directly activates 21 to increase its affinity for collagen with 
subsequent activation of GPIIbIIIa and platelet agglutination or aggregation (Ozaki et al 
2005; Du et al 2006 ). The ability of Ba25 to bind to multiple platelet receptors is a 
typical feature of C-type lectins (see section 5.1.6). 
As aspirin did not inhibit the platelet aggregation capacity of Ba25, the metabolites of 
arachidonic acid are not involved in the aggregation process. Ba25 binding in the 
presence or absence of fibrinogen did not induce protein phosphorylation or the 
expression of procoagulant proteins on the platelet membrane (Jennings et al 2005 and 
Jennings unpublished data). Platelet aggregation by Ba25 in the presence of fibrinogen 
was not associated with -granule release (no CD62P expression) or dense granule 
release, as measured by the release of radioactive serotonin (Jennings et al 2005). Ba25 
binding to the GPIb receptor and 21 probably induces a conformational change in 
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the GPIIbIIIa receptor such that fibrinogen can bind in an activation independent 
manner with promotion of platelet agglutination. In addition, collagen-induced 
expression of P-selectin, the receptor involved in platelet binding to leukocytes, was 
prevented by Ba25 (Jennings et al 2005).  
Bioactivity studies have shown that Ba25 stimulates platelet agglutination in platelet-
rich plasma and promotes agglutination of washed platelets suspended in fibrinogen 
without the addition of other agglutinating stimuli. The thromboelastogram (TEG) 
demonstrated that Ba25 inhibited clot formation in whole blood by affecting all 
parameters of the TEG. In particular, the reduction in the reaction time suggested that 
Ba25 is an inhibitor of early stage blood clotting events such as cell-cell and cell-surface 
interactions. Ba25 had no inhibitory effect on aggregation of washed platelets in 
response to thrombin and no effect on clotting factors other than a possible involvement 
of the intrinsic pathway and von Willebrand factor.  
 
6.3.  Bitistatin 
Bitistatin, a disintegrin with platelet aggregation inhibitory properties has been isolated 
from the venom of the sub-Saharan puff adder, Bitis arietans (Shebuski et al 1989). 
Bitistatin is a single-chain peptide containing 83 amino acids, 14 cysteine residues and 
is internally cross-linked with 7 disulphide bonds with a molecular mass of 9 kDa 
(Shebuski et al 1989; Gould et al 1990; Calvete et al 1997). Bitistatin contains the 
tripeptide sequence, RGD which is found in position 64-66 and binds with high affinity 
to the IIb3 integrin (Knight & Romano 2005). The amino acid sequence of bitistatin 
shows considerable homology to oth r snake venom derived disintegrins: trigramin 
(68% homology) and echistatin (49% homology) (Shebuski et al 1989). Bitistatin was 
shown to inhibit ADP-induced human platelet aggregation in a dose dependent manner 
with the IC50 of 237 nM. The inhibitory effects of bitistatin on platelet aggregation are 
reversible. The bioactivity of bitistatin depends on its disulphide bonds as reduction and 
carboxyamidomethylation of the cysteine residues resulted in a 60-fold decrease in its 
inhibitory potency (Shebuski et al 1989). 
As Bitistatin binds to the platelet receptor GPIIbIIIa, a number of studies have 
investigated whether radiolabelled bitistatin could be used to diagnose acute peripheral 
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thrombi and pulmonary emboli. In animal models, the use of radiolabelled-Bitistatin has 
been able to diagnose deep vein thromboses and pulmonary embolism in a single test 
(Knight et al 1996; 2000). Short-chain Bitistatin analogues (Baidoo et al 2004) and a 
recombinant Bitistatin (Knight & Romano 2005) have also been developed for use in 
radiological imaging of thromboembolic disease. 
In Phase I clinical studies, [99
m
Tc]-r Bitistatin administered at low doses for imaging, 
binds to circulating platelets, but has no adverse effects on platelets and thus could 
potentially be used clinically to diagnose acute thrombo-embolic disease in humans 
(Knight et al 2007a). 
Bitistatin has been successful in in vivo animal models in maintaining reperfusion and 
preventing reocclusion following experimental coronary artery thrombosis (Shebuski et 
al 1989; 1990) and in preventing platelet loss during extracorporeal circulation (Shigeta 
et al 1992). 
The vitronectin receptor (v3) is expressed on the surface of certain tumour cells, e.g. 
melanoma, breast cancer, glioblastoma and osteosarcoma. v3 binds to ligands with 
the RGD sequence, modulating cell adhesion and migration and thereby influencing 
tumour angiogenesis and metastasis (Felding-Habermann & heresh 1993). v3 is 
highly expressed on the endothelium of new vessels (Brooks et al 1994; Shattil et al 
1995). Studies have investigated using radiolabelled Bitistatin as a diagnostic tool in 





in microPET imaging confirmed tumour uptake and this was mediated by both v3 
and IIb3 integrin binding (McQuade et al 2004). In vitro studies have shown that 
[99
m
Tc]-bitistatin is internalized by tumour cells expressing v3, but not by 
endothelial cells expressing v3 (Knight et al 2007b). These properties of 
radiolabelled Bitistatin can potentially be used for the diagnosis and treatment of 
malignancy. 
 
Formatted: Font color: Black
Formatted: Font color: Black










Chapter 2 32 
6.4.  Bitiscetin 
Bitiscetin is a C-type lectin protein isolated from venom of Bitis arietans. Bitiscetin is a 
25 kDa heterodimer composed of disulphide linked alpha (16kDa) and beta (13kDa) 
subunits with a pI of 9.1 (Hamako et al 1996).  
Bitiscetin is a potent inducer of von Willebrand factor-dependent platelet agglutination. 
Bitiscetin activates the binding of the von Willebrand factor A1 domain to the platelet 
membrane glycoprotein Ib (GPIb). This activation is dependent on the formation of a 
bitiscetin-vWF A1 complex (Hirotsu et al 2001; Matsui et al 2002; Maita et al 2003; 
Matsui & Hamako 2005). The bitiscetin N-terminal sequence shows 71% homology 
with the 18kDa subunit of B25 and 52.6% homology with the 16 kDa subunit of Ba100 
(see Figures 1 and 2). 
The action of Bitiscetin is similar to that of Botrocetin (B. jararaca), a C-type lectin 
which also forms a stable complex with the A1 domain of vWF (Matsui et al 2002). 
Both botrocetin and bitiscetin activate vWF by binding close to the GPIb-binding 
surface, thereby inducing vWF-A1 binding to GPIb without conformational changes in 
the vWF A1 domain (Hirotsu et al 2001; Sen et al 2001; Fukuda et al 2002; Maita et al 
2003). 
A distinct second form of Bitiscetin, Bitiscetin-2 has been isolated from the venom of 
Bitis arietans (Obert et al 1999, 2006). The 29 kDa Bitiscetin-2 is composed of 2 chains 
of similar molecular mass ( 15 kDa) and binds to the vWF A3 domain, inhibiting the 
binding of vWF to collagen (Obert et al 1999, 2006). 
 
7.  DIAGNOSTIC USES OF SNAKE VENOM 
Snake venom toxins have been extensively utilized in the study of haemostasis and in 
assays for coagulation factors. 
Snake venoms have varying effects on haemostasis (Marsh 1994; Markland 1997, 
1998a; Pirkle 1998; Braud et al 2000; Matsui et al 2000; Lu et al 2005a). They may be 
coagulants (thrombin-like and prothrombin-activating toxins), anticoagulants (protein C 
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activators), inhibitors/activators of platelet function, haemorrhagins and activators of 
fibrin(ogen)olysis. 
 
7.1.  Snake venom thrombin-like enzymes (SVTLEs) 
SVTLEs include batroxobin and reptilase (Bothrops atrox), ancrod (Callosellasma 
rhodostoma) and ACTE (Agkistrodon c. contortrix). They are not inhibited by heparin 
and can be used to test plasma samples containing heparin or to remove fibrinogen from 
samples containing heparin (Marsh & Williams 2005). 
The reptilase time can be used in place of the thrombin time as a rapid fibrinogen assay 
in samples containing heparin (Funk et al 1971). It can also be used to assay 
antithrombin III in plasma prepared free of fibrinogen (Howie et al 1973). 
The reptilase time is prolonged in the presence of fibrin degradation products, 
hypofibrinogenaemia and in defects of fibrin polymerization (Latallo & Teisseyre 1971; 
Matsuda et al 1985; Cunningham et al 2002a). Very high fibrinogen titres may be 
associated with a prolonged reptilase time, but a normal thrombin time (van Cott et al 
2002). Batroxobin (Bothrops atrox) can be used as a fibrin stimulant in a functional 
assay of tissue plasminogen activator (Ranby et al 1982). 
 
7.2.  Prothrombin activators 
Commercially available prothrombin activators include ecarin (Echis carinatus), 
textarin (Pseudonaja textilis), Noscarin (Notechis scutatus) and an enzyme from the 
venom of Taipan (Oxyuranus s. scutellatus) (Rosing & Tans 1992). Snake venom 
prothrombin activators are of limited value in patients on warfarin as they cleave both 
normal prothrombin and functionally abnormal forms of prothrombin (Kornalik et al 
1969). These prothrombin activators have been used to prepare non-enzymatic forms of 
meizothrombin and thrombin (Rosing & Tans 1992), to study prothrombin activation 
(Yamada et al 1996) and in the diagnosis of disseminated intravascular coagulation 
(Sakuragawa et al 1975) and dysprothrombinaemias (Weinger et al 1980; Collados et al 
1997). 
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The Pefakit APC-R factor V Leiden diagnostic kit includes the prothrombin activator 
noscarin and RVV-V, a factor V activator and is a sensitive screening test for factor V 
Leiden mutations (Wilmer et al 2004). 
The Pefakit PICT (Prothrombinase induced clotting time) diagnostic assay which 
includes RVV-V was designed as a universal test to monitor the efficacy of 
anticoagulants such as low molecular heparin, unfractionated heparin, direct thrombin 
inhibitors and direct/indirect factor Xa inhibitors (Schöni 2005). 
7.3.  Factor V activators 
A serine protease from the venom of Russell’s viper is a selective activator of factor V 
(RVV-V) and has been used to assay factor V and its activation (Marsh & Williams 
2005). It has also been used to define the cleavage sites in wild type and recombinant 
factor V (Keller et al 1995). 
 
7.4.  Factor X activators 
Russell’s viper venom also contains an activator of factor X (RVV-X) and has been 
used to assay factor X (Bachmann et al 1958), as a lupus anticoagulant assay 
(Thiagarajan et al 1986) and to distinguish between factor VII and factor X deficiency 
(Quick 1971). The Stypven time
TM
 is the plasma clotting time using RVV-X (Denson 
1961). A prolonged Stypven time suggests Factor X deficiency (Quick 1971). A normal 
Stypven time together with a prolonged prothrombin time suggests factor VII 
deficiency. RVV-X has also been used to identify Factor X recognition sites 
(Chattopadhyay & Fair 1989) and as an assay for platelet factor 3 (Jy et al 1995). 
 
7.5.  Assays for lupus anticoagulants 
Lupus anticoagulants interfere with phospholipid-dependent clotting assays, i.e. 
activated partial thromboplastin time (APTT), prothrombin time (PT) and kaolin 
clotting time (KCT). 
A number of snake venom activators have been used to assay lupus anticoagulant and 
include: 
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i) RVV-X (Thiagarajan et al 1986). 
ii) Prothrombin activators from the venom of the taipan (Oxyuranus 
scutellatus), Australian brown snake (Pseudonaja textilis) and saw-scaled 
viper (Echis carinatus). 
The dilute Russel’s viper venom time (d RVVT) is a quick assay and variations of  
d RVVT has increased its sensitivity to assay lupus anticoagulant (Moore et al 2000). 
A sensitive and relatively specific confirmatory test for lupus anticoagulant has been 
developed using Textarin
TM
 from the Australian brown snake and Ecarin
TM
 from the 
saw-scaled viper (Triplett et al 1993; Forastiero et al 1994). A Textarin/Ecarin ratio time 
of >1.3 is abnormal. A combination of the Taipan snake venom time and the Ecarin 
time was able to detect the presence of lupus anticoagulants in patients on Warfarin 
(Moore et al 2003). 
 
7.6.  Protein C activators 
The active form of protein C (APC) plays an important role in haemostasis. It is a 
vitamin K-dependent anticoagulant proteinase that inactivates Factor Va and VIIIa. 
Protac, a protein C activator from the venom of the Southern copperhead snake (A. 
contortrix contortrix) (Stocker et al 1987) is used to measure activated protein C 
(Nathan et al 1987; Stocker et al 1988) and in functional clotting assays (Martinoli & 
Stocker 1986). A global clotting assay called ProC Global has been designed to assess 
the functionality of the protein C anticoagulant pathway. It is based on the ability of 
endogenous activated protein C generated by the activation of protein C by Protac to 
prolong the activated partial thromboplastin time. The ProcC global assay identifies 
carriers of Factor V Leiden, individuals with activated protein C resistance and protein 
C deficiency (Toulon et al 2000).  
The ACV (A. contortrix venom) test based on the ratio of APTT in the absence or 
presence of Protac can be used to identify defects in the protein C anticoagulant 
pathway (Robert et al 1996). 
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7.7.  von Willebrand factor studies 
Botrocetin (Bothrops jararaca) depends on von Willebrand factor to induce platelet 
aggregation and has been used to detect vWF activity (Read et al 1983; Brinkhous et al 
1988). Botrocetin
TM
 together with the antibiotic ristocetin have been used to detect 
molecular variants of vWF. Botrocetin partially aggregates platelets in patients with 
Bernard-Soulier disease where the glycoprotein Ib (GP1b) is absent, whereas ristocetin 
is unable to do this as it is dependent on GP1b. 
The botrocetin/ristocetin combination has been used to characterize the human platelet 
vWF (Williams et al 1994). Alboaggregin B (Trimesurus albolabris), a vWF-dependent 
platelet aggregant has been used to quantitate vWF receptors on the GP1b molecule. 
 
8.  THERAPEUTIC USES OF SNAKE VENOMS 
The bioactivity of various snake venom components has been used therapeutically in a 
wide variety of clinical conditions. 
8.1.  Neurotoxin 
Cobrotoxin, a short-chain post-synaptic -neurotoxin and -cobrotoxin, a long chain -
neurotoxin, isolated from Naja atra have been shown to have analgesic activity in a 
rodent pain model. Cobrotoxin, a specific ligand for muscle-based 1 nAChR (nicotinic 
acetylcholine receptors) results in a centrally mediated analgesia via an opiate-
independent mechanism. -cobrotoxin has high affinity for the neuronal 7nAChR 
resulting in an opiate-independent, anti-nociceptive analgesic effect (Chen et al 2006; 
Zhang et al 2006).  
8.2.  Toxins affecting the cardiovascular system 
Captopril, the first oral ACE inhibitor was developed following the observation that 
venom from Bothrops jaracusa caused severe hypotension and was found to contain an 
ACE inhibitor (Patlak 2003). Cardiotoxin from the Indian cobra has been used 
successfully in combination with crotoxin in the treatment of metastatic cancer (Costa et 
al 1998). 
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8.3.  Phospholipase A2 (PLA2) 
A PLA2 isolated from Naja Naja venom is cytotoxic to Ehrlich ascites tumour cells and 
is a potential chemotherapeutic agent (Basavarajappa & Gowda 1992). 
Crotoxin (Crotalus durissus terrificus), a cytotoxic PLA2, is a pre-synaptic neurotoxin 
with cytotoxic activity and has shown promising results in a phase I clinical trial in 
patients with advanced cancer. There was documented reduction in primary tumour size 
and metastases (Cura et al 2002). 
 
8.4.  Toxins affecting haemostasis 
These toxins are either activators or inhibitors of haemostasis and belong to the group of 
serine proteases, metalloproteinases, C-type lectins, disintegrins and phospholipases. 
These venom components have been used to develop inhibitors of platelet aggregation 
and blood clotting. 
8.4.1.  Thrombin-like enzymes 
Thrombin cleaves both fibrinopeptide A and B from fibrinogen and activates Factor 
XIII. Snake venom thrombin-like enzymes can usually only cleave fibrinopeptide A, are 
unable to activate factor XIII and thus clots cannot be crosslinked and are easily broken 
down. 
Thrombin-like enzymes which have clinically been used include Reptilase (Bothrops 
atrax) and Ancrod (Callosellasma rhodostoma). The STAT study (Stroke treatment 
with Ancrod Trial) showed that the administration of intravenous Ancrod compared to 
placebo was asscociated with a favourable 3 month functional status in patients with 
ischaemic strokes (Sherman et al 2000). Ancrod was less beneficial than the 
recombinant tissue type plasminogen activator or pro-urokinase (Fisher & Schaebitz 
2000; Madhavan et al 2002). Ancrod has been used recently in the treatment of acute 
ischaemic stroke to limit infarct size (Samsa et al 2002). Ancrod has been used 
therapeutically in patients with heparin-associated thrombocytopaenia and thrombosis 
(HATT) syndrome (Illig & Ouriel 1996) and as an alternative to heparin in 
cardiopulmonary bypass (von Segesser et al 2001). Reptilase (Batroxobin) has been 
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shown to reduce the risk of stroke/transient ischaemic attacks in patients with 
concomitant hyperfibrinogenaemia (Xu et al 2007). 
 
8.4.2.  Prothrombin inhibitors 
Defibrase (Bothrops moojeni) is a prothrombin/thrombin inhibitor and has been used in 
the treatment of angina pectoris and acute ischaemic strokes (Stocker & Barlow 1976). 
8.4.3.  Fibrin(ogen)olytic enzymes 
The fibin(ogen)olytic enzymes are usually metalloproteinases or serine proteases. These 
enzymes break down fibrin-rich clots and prevent progression of clot formation. These 
properties have been used clinically to dissolve thrombus in intravascular catheters or 
for treatment of vascular thromboses. A number of fibrin(ogen)olytic enzymes have 
been tested in vitro and in vivo and include a fibrinogenase from Vipera lebetina 
(Gasmi et al 1997); afaacytin (Cerastes cerastes) (Laraba-Djebari et al 1995); fibrolase 
(A. contortrix) (Markland 1998b) and atroxase (Western diamond-back rattlesnake) 
(Baker & Tu 1996). 
Alfimeprase, a truncated recombinant form of fibrolase has been used in phase II 
clinical trials for treatment of peripheral arterial occlusions and for management of 
occluded vascular access catheters (Toombs 2001; Swenson et al 2004). 
8.4.4.  Disintegrins 
These integrin inhibitors have been used to design drugs to target and inhibit integrins, 
especially RGD-dependent integrins involved in disease processes, including 
thromboembolic disease, angiogenesis and malignancy. In thromboembolic disease, the 
aim is to target the platelet fibrinogen receptor II3. Drugs developed have included 
Eptifibatide (integrelin), a KGD-containing protein that was modeled on the active site 
of the disintegrin barbourin (Sistrurus m. barbouri) and Tirofiban (Aggrastat) that is 
modeled on the disintegrin echistatin (Scarborough et al 1991; Marwick 1998; Hantgan 
et al 2004). Eptifibatide and Tirofiban are both approved for the management of acute 
coronary ischaemic syndrome and prevention of thrombotic complications following 
coronary balloon angioplasty and coronary stenting (Pang et al 2002; Gilchrist 2003; 
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van Werkum et al 2007; Zeymer & Wienbergen 2007; Casterella et al 2008; Marmur et 
al 2008). 
Platelets are known to contribute to tumour growth, angiogenesis and metastasis (Trikha 
& Nakada 2002). Inhibitors of platelet integrins have been investigated as potential 
chemotherapeutic agents. The platelet receptor GPIIbIIIa complex interacts with 
vitronectin, fibrinogen, fibronectin and von Willebrand factor. The RGD-containing 
snake venom disintegrins interfere with platelet aggregation by reversibly blocking the 
GPIIbIIIa receptor. These disintegrins include trigramin (Trimeresurus gramineus), 
rhodostomin (A. rhodostoma) and triflavin (T. flavoviridis) (Huang et al 1987a, 1987b, 
1991). The monomeric RGD disintegrins accutin (Yeh et al 1998), triflavin (Sheu et al 
1997), rhodostomin (Yeh et al 2001; Huang et al 2001), salmosin (Kim et al 2004) and 
the homodimeric RGD-disintegrin contortrostatin (Zhou et al 2000) have been shown to 
inhibit angiogenesis by binding via V3 to endothelial cells. 
By blocking V3 integrin in tumours, salmosin, triflavin and contortrostatin are able 
to inhibit the adhesion of tumour cells to ECM, reducing motility and inhibiting 
metastasis.  
The fibronectin receptor, 51 integrin is a RGD-dependent integrin that plays a role in 
the pathology of vascular diseases (Hein et al 2001) and cancer (Adachi et al 2000) and 
is thus a potential therapeutic target using disintegrins. 
MLD- and KTS-disintegrins are specific for leukocyte integrins and collagen receptors 
and are being investigated as potential therapeutic agents (Marcinkiewicz 2005). 
8.4.5.  C-type lectin-like proteins 
Snake C-type lectin-like proteins have anti-coagulant, procoagulant and platelet-
modulating activity. These properties can be used both therapeutically and 
diagnostically to elucidate pathways involved in haemostasis including platelet 
activation and clotting mechanisms as well as elucidating the structural-functional 
relationships of platelet glycoproteins and clotting factors (Morita 2004a,b, 2005; 
Clemetson et al 2007).  
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Labectin and Labecetin, C-type lectins from venom of Macrovipera lebetina have been 
shown to bind to 51 and V-containing integrins (Sarray et al 2004, 2007). Labectin 
has been shown both in vitro and in vivo to inhibit angiogenesis by blocking the 
adhesive properties of the fibronectin receptors, the 51 and V integrins. This 
property could potentially be used to target and inhibit pathogenic angiogenesis 
(Pilorget et al 2007). Both Labectin and Labecetin have been shown in vitro to inhibit 
tumour cell adhesion, migration, invasion and proliferation by inhibiting 51 and V-
containing integrins (Sarray et al 2004, 2007) and this has potential therapeutic benefit 
in the management of malignancy. 
Both convulxin (Crotalus durissus terrificus) and Crotacetin (Crotalus durissus 
cascavella) exhibit antimicrobial activity against Gram-positive and –negative bacteria 
(Rádis-Baptista et al 2006). The antimicrobial activity in convulxin is most likely also 
due to other contaminating proteins. 
The diagnostic and therapeutic use of the bioactive components of snake venom has 
mainly focused on their ability to modulate haemostasis and very little research has 
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Figure 1.  Comparison of the Amino-terminal sequences of the 16kDa and the 21kDa  subunits of 







p16 P F C C P F G W S G Y D Q Y C Y K P F D E P 100 
p21 D F E C P T E W S P Y D Q H C Y R A F D E P 66.7 
                        
1 D F D C P S G W S A Y D W Y C Y K P F N E P 76.2 
2 G F C C P L G W S S Y D E H C Y Q V F P P K 66.7 
3 G F C C P L G W S S Y D E H C Y Q V F Q Q K 60.0 
4 G A D C P S G W S S Y E G H C Y K P F N E P 68.4 
5 D F N C P P G W S A Y D Q Y C Y Q V I K E P 66.7 
6   D C P S G W S S F K Q Y C Y K P F K Q L 66.7 
7 D F H C L P G W S A Y D Q Y C Y R V F N E P 66.7 
8 DP G C L P - G W S S Y K G H C Y K V F K   52.6 
 
Fig. 1. The 16 kDa and 21 kDa subunits of Ba100 show amino-terminal sequence homology with other C-type 
lectins from snake venom. Amino acids that are identical to those in the 16 kDa subunit of Ba100 are in blue. 
Sequence homology is shown as a percentage on the right. (1) Stejnaggregin-A from Trimeresurus stejnegeri 
(Chinese green tree viper); (2) Flavocetin-A from Trimeresurus flavoviridis (Habu); (3) Mucrocetin from 
Trimeresurus mucrosquamatus (Taiwan Habu); (4) Aggretin from Agkistrodon rhodostoma (Malayan pit viper); (5) 
Agglucetin-alpha from Agkistrodon acutus (Hundred pace snake); (6) Tokaracetin from Protobothrops tokarensis 
(Tokara habu); (7) Alboaggregin-A from Trimeresurus albolabris (White lipped pit viper), (8) Bitiscetin from Bitis 
arietans. Sequence data was obtained from http://www.ebi.ac.uk/fasta33/. 
 









p18 D Q D C L S D W S S H E G H C Y K V F D K 100 
1 D Q D C L P G W S S H E G H C Y K V F N L 85 
2   D C L P G W S S H E G H C Y K V F N Q 79 
3 A A D C P S D W S S H E G H C Y K F F Q Q 79 
4 G A D C P S D W S S Y E G H C Y R V F Q K 79 
5 G A D C L S G W S S Y E G H C Y K A F E K 79 
6 D P G C L P D W S S Y K G H C Y K V F K K 71 
7   D C P S D W S S Y E G H C Y R V F N E 74 
8 D Q D C L S G W S F Y E G H C Y Q L F R L 74 
9   D C P P D W S S Y E G H C Y R F F K E 70.6 
10 G A D C P S G W S S Y E G H C Y K P F N E 68 
11  A N C A S G W  A Y G Q H C Y C     40 
12 P F C C P F G W S G Y D Q Y C Y K P F D E 38 
 
Fig. 2. Ba25 shows amino-terminal sequence homology with other C-type lectins from snake venom. Amino acids 
that are identical to those in the 18 kDa subunit of Ba25 are in blue. Sequence homology is shown as a percentage on 
the right. (1) Lebecetin from Vipera lebetina; (2) Carinactivase from Echis carinatus; (3) Bothrojaracin from 
Bothrops jararaca; (4) Mamushigin from Agkistrodon halys blomhoffi; (5) Factor IX/X binding protein from 
Trimeresurus flavoviridis; (6) Bitiscetin from Bitis arietans; (7) Alboaggregin from Trimeresurus albolabris; (8) 
Echicetin from Echis carinatus; (9) Botrocetin from B. jararaca (10) Aggretin from Agkistrodon rhodostoma; (11) 
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CHAPTER THREE: 
LITERATURE REVIEW :  MECHANISMS OF 
TRANSPLANT REJECTION 
 
1.  INTRODUCTION 
Allorejection is the ability of the T cells to recognise and respond to foreign 
histocompatibility antigens of other members of the same species. T cell recognition of 
the allo-antigen is the central event initiating cellular rejection of allografts. 
The immune response to the transplanted organ can be divided into three phases: the 
afferent, efferent (effector) and regulatory phases. The afferent phase of the process 
involves activation of the recipient’s immune system following recognition of foreign 
histocompatibility antigens (allo-antigens) of the organ donor by recipient lymphocytes. 
The initiation of this afferent phase occurs either in the lymphoid tissue of the recipient 
as a result of release of donor cells or allo-antigens from the graft or in the graft itself 
following infiltration by recipient lymphocytes into the transplanted organ.  
The efferent phase occurs later as a result of triggering of both humoral and cellular 
effector mechanisms of the immune system by activated lymphocytes stimulated in the 
afferent phase of the response. The three main effector mechanisms include CD4 T cell 
responses especially the delayed-type hypersensitivity reaction; cytotoxic T cell 
responses and allo-antibody/complement responses (Rocha et al 2003). These combined 
cellular and humoral mechanisms lead to injury and the destruction of the transplanted 
organ. Thus, T lymphocytes and the major histocompatibility complexes are critical 
elements in the initiation of the rejection process.  
Feedback regulatory mechanisms which downregulate activated T lymphocytes are 
essential for keeping immune responses in check and may contribute to allograft 
tolerance. 
Cytokines and chemokines exert their actions in an autocrine or paracrine manner in 
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2.  CHARACTERISTICS OF THE ALLOIMMUNE RESPONSE 
The principal histocompatibility antigens involved in the initiation of an allogeneic 
reaction are expressed on the plasma membranes of cells and are encoded by the major 
histocompatibility complex on chromosome 6 of humans (Krensky et al 1990, Krensky 
1997). MHC class 1 molecules (HLA A, B, C) are expressed on all nucleated cells. 
MHC class II molecules (HLA DR, DQ, DP) are expressed on dendritic cells, 
macrophages, Kupffer cells and activated T and B cells (Unanue 1992). 
Crystallographic analysis of both HLA class I and II molecules showed a peptide 
antigen binding groove with an antiparallel beta-sheet floor and two sides composed of 
alpha helices (Brown et al 1993; Germain 1994; Jardetzky et al 1996). HLA 
polymorphisms allow binding of virtually infinite numbers of peptides determined by 
the interaction of specific antigen peptide motifs with anchoring residues in the antigen 
binding groove (Rudensky et al 1991; Hunt et al 1992a, 1992b). MHC class I molecules 
bind peptides from the cytoplasmic environment, which contain endogenous self 
peptides and viral peptides generated during viral infections, and present these peptides 
exclusively to CD8 T cells. MHC class II molecules bind exogenous peptides that have 
been endocytosed and processed within lysosomes and present exclusively to CD4 T 
cells. MHC also encodes other genes with immune function including transporters 
associated with antigen processing (TAP), large multifunctional proteosome 
components, tumour necrosis factors, complement proteins and heat shock protein 70. 
Recognition of foreign antigenic peptides in the context of MHC molecules by the T 
cell receptor, initiates T cell mediated immune responses (Krensky et al 1990; Krensky 
1997). 
 
2.1.  Antigen processing, presentation and T cell receptor recognition:  
       direct, indirect and semi-direct pathways 
There are two distinct pathways of T cell allorecognition: the direct and indirect 
pathways. Transplanted organs express MHC molecules of the donor resulting in either 
direct or indirect antigen recognition (Sayegh et al 1994; Jiang et al 2004; Hornick 
2006; Caballero et al 2006). The recipient T cell receptor (TCR) recognition of donor 
allogeneic-MHC is a principal event in the afferent phase of allograft rejection (Krensky 
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allo-recognition involves interaction of the TCR/CD3 complex, the allo-MHC and the 
peptide antigen bound within the antigen-binding site of the MHC molecules. Thymic 
selection of T cells is based on the T cell recognition of peptide antigens expressed by 
self-MHC molecules (Suzuki et al 1995; Alam et al 1996; Marrack & Kappler 1997). 
Only TCRs with an intermediate affinity for self-MHC-antigen complexes which do not 
react strongly with self-antigens are positively selected.  TCRs which do not react with 
self-MHC-antigen complexes, do not provide activation signals for survival and die. 
Those that react too strongly to self-MHC-antigen complexes are deleted. However, 
alloreactivity is the result of self-MHC-restricted TCR recognition of cross-reactive 
components of allogeneic MHC (Auchincloss & Sultan 1996; Magee & Sayegh 1997). 
i) The direct pathway is characterised by the recognition of allo-MHC-peptide 
complexes on donor antigen presenting cells (APC) by recipient T cells (CD4 cells 
recognising allo-MHC class II and CD8 cells recognising allo-MHC class I). Dendritic 
cells are the alloantigen-presenting cells that mediate the priming of naïve T cells 
(Lechler & Batchelor 1982) and these dendritic cells are able to migrate to the 
recipient’s lymphoid tissue (Larsen et al 1990). This pathway is responsible for the 
vigorous in vitro response seen in the primary allogeneic mixed lymphocyte reaction 
(MLR). In vivo, the direct pathway is the principal route of T cell sensitization leading 
to acute allograft rejection (Braun et al 1993). TCR stimulation in the direct pathway 
occurs because of molecular mimicry between the three-dimensional allogeneic MHC-
peptide complexes and self-MHC-peptide complexes (Lechler et al 1990; Auchincloss 
& Sultan 1996; Magee & Sayegh 1997; Smith & Lutz 1997). Thus, even though the 
allo-MHC molecules are foreign proteins, they do not require processing and 
presentation as peptide antigens in order to stimulate the T cell response. This is 
confirmed in studies of reactions against allo-MHC molecules that do not contain 
endogenous peptide antigens in the antigen-binding sites and by the inhibition of 
alloreactivity with synthetic peptides mimicking the -helices of the allo-MHC (Lechler 
& Lombardi 1991; Wecker & Auchincloss 1992). However, endogenous peptides, 
including processed MHC peptides, normally bound within the antigen-binding sites of 
the allo-MHC molecules, may also be involved in TCR stimulation via the direct 
pathway (Lombardi et al 1989; Mattson et al 1989; Lechler & Lombardi 1991). Thus, 
specific donor peptide antigens may also stimulate the alloreactive recipient’s TCR. The 










Chapter 3 48 
frequency of T cells that directly recognise allo-MHC is high, 100 – 1000x greater than 
the response to nominal antigens (Lindahl & Wilson 1977; Sherman & Chattopadhyay 
1993). Also, unlike the response to nominal antigens, the direct response to allo-MHC 
requires no previous exposure or priming and can be initiated by naïve T cells. 
ii) The indirect pathway is characterised by recipient TCR stimulation by donor allo-
antigens (allo-MHC or tissue-specific antigens) which have been processed and 
presented as peptides by recipient antigen-presenting cells. This pathway, thus reflects 
the normal physiological pathway of T cell recognition of foreign antigens or auto-
antigens in the context of self MHC molecules as seen in infections and autoimmune 
diseases. The direct pathway is thought to be responsible for the initial vigorous 
immune response involved in acute rejection (Lechler & Batchelor 1982) with the 
indirect pathway playing a critical role in the development of chronic rejection (Vella et 
al 1997; Ciubotariu et al 1998a). The indirect pathway requires previous priming to 
antigen. The precursor frequency of T cells that recognise a specific antigen through the 
indirect pathway is relatively low, approximately 100 – 1000x lower than that for 
directly alloreactive T cells. The indirect pathway of allorecognition is able to induce 
the full range of alloresponses including proliferation and cytokine production by CD4 
T cells (Benichou et al 1992); delayed type hypersensitivity responses (Waaga et al 
1998); cytotoxic T lymphocyte generation (Lee et al 1994) and anti-donor IgG 
formation by B cells (Steele et al 1996). 
There are two distinct features of the indirect pathway: immunodominance and epitope 
or antigen spreading. 
Immunodominance: In mouse and human models of transplantation, recipient MHC-
restricted T cell responses were found to be limited to a single or a few dominant 
epitopes on the donor MHC antigen (Liu et al 1993; Benichou et al 1994). These 
immunodominant epitopes represent allogeneic determinants that are efficiently 
processed and presented by host APCs to activate T cells. Immunodominance reflects a 
hierarchy of allogeneic determinants that are recognised by T cells via the indirect 
pathway. During graft rejection, the recipient T cells are sensitised to a limited number 
of allogeneic determinants, despite the presence of numerous other foreign determinants 
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Epitope or antigen spreading: The hierarchy of allogeneic determinants of donor MHC 
peptides that are recognised by the indirect pathway can change during the course of 
rejection. Early in the course of rejection, T cell responses are limited to a single or a 
few immunodominant determinants. With time, the alloresponse can shift to another 
allodeterminant on the same (intramolecular) or different MHC molecule 
(intermolecular spreading) (Benichou et al 1992, 1994). This spreading of antigenic 
determinants may reflect differences in antigen processing from various anatomic sites 
or differences in T cell trafficking during the rejection process. Epitope spreading may 
be important in the amplification and progression of allograft rejection as the emergence 
of different allogeneic determinants leads to the recruitment of different T cell clones 
over time. The occurrence of epitope spreading was shown to correlate with the 
frequency of chronic rejection in heart transplant patients (Ciubotariu et al 1998a). 
T cells that are primed to intact allo-MHC through the direct pathway are present in 
high frequency and induce CTL formation, delayed hypersensitivity reactions and allo-
antibody formation leading to acute cellular rejection. The importance of the direct 
pathway decreases over time with the depletion of donor passenger leukocytes and the 
importance of the indirect pathway increases as T cells begin to recognise new epitopes 
via epitope spreading. The indirectly primed T cells produce cytokines, chemokines, 
allo-antibodies, growth factors (PDGF, FGF, TGF- ), activate macrophages and 
provide help for B cells and precursor CTLs. The walls of intraparenchymal graft 
vessels are targeted and transplant vasculopathy, the hallmark of chronic rejection, 
results. 
iii) The semi-direct pathway of allorecognition has recently been proposed linking the 
direct and indirect pathways (Caballero et al 2006). Intact donor MHC molecules are 
transferred from donor to recipient antigen-presenting cells and then presented to 
recipient T cells. Recipient DCs acquire and present donor MHC class I molecules to 
direct pathway CD8 T cells and internalized and processed donor MHC class II 
molecules are presented as peptides to CD4 T cells with indirect allospecificity 
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2.2.  T cell activation in the alloimmune response 
As described above, the alloimmune response involves the interaction of both naïve and 
memory alloreactive T cells with antigen-presenting cells (dendritic cells) of both donor 
and recipient origin (Lombardi et al 1990). Donor and recipient dendritic cells are 
activated in the graft and surrounding tissues and then migrate to secondary lymphoid 
organs. Dendritic cells interact with alloreactive naïve T cells and central memory T 
cells that recirculate within secondary lymphoid tissue and this circulation is controlled 
by chemokines and sphingosine-1-phosphate receptors (Mandala et al 2002). Naïve T 
cells are predominantly triggered by dendritic cells in the secondary lymphoid tissue 
(Lakkis et al 2000; Zhou et al 2003), but memory T cells can be activated by graft 
endothelium (Biederman & Pober 1998). 
Full T lymphocyte activation requires 3 signals. The first signal is antigen-specific, 
MHC-restricted and involves triggering of the TCR by the MHC-peptide antigen 
complex on the antigen-presenting cell (Krensky et al 1990; Bromley et al 2001a,b), 
leading to clustering of the TCR/CD3 complex to CD4 or CD8 molecules and formation 
of the immunological synapse (Bromley et al 2001a,b). This leads to the initiation of 
transcription and expression of IL-2 and the IL-2 receptor. 
The process of antigen recognition also results in secretion of IL-1 and IL-6 by antigen-
presenting cells. The second co timulatory signal is not antigen-specific and involves 
both positive and negative costimulatory pathways (Janeway & Bottomly 1994; Sayegh 
& Turka 1998; Alegre et al 2001; Frauwirth & Thompson 2002; Greenwald et al 2002, 
2005; Watts 2005). The second costimulatory signal mediates reorganization of the 
immunological synapse and sustains lymphocyte proliferation and differentiation into 
effector cells and memory cells. In the absence of the second costimulatory signal, 
activated T cells are unable to produce any significant amounts of cytokines (Schwartz 
et al 1989; Applebaum & Boussiotis 2003; Schwartz 2003), do not proliferate and 
become unable to respond to appropriate stimulation, i.e. anergic (Gimmi et al 1993), or 
undergo apoptosis (Noel et al 1996). The initial costimulatory signal involves the 
CD28/B7 pathway with interaction of B7-1/CD80 and B7-2/CD86 on the dendritic cells 
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The combination of first and second signal leads to activation of three signal 
transduction pathways (Nel 2002): i) the calcium-calcineurin pathway, ii) Ras-MAP-
kinase pathway and iii) the protein-kinase C-nuclear factor- B (NF- B) pathway. These 
three pathways respectively lead to activation of the transcription factors NFAT 
(nuclear factor of activated T cells), activating protein 1 (AP-1) and NF- B. This leads 
to expression of IL-2, IL-2 receptor, CD40 ligand and other cytokines including IL-15.  
IL-2 and IL-15 provide signal 3 activating mTOR (mammalian target of rapamycin) 
through the phosphoinositide-3-kinase pathway and initiating cell cycle progression. 
The cytokine  chain which binds to Janus kinase 3 (JAK 3) initiating signal 3 is shared 
by a number of cytokines (IL-2, IL-4, IL-7, IL-15, IL-21) (Alves et al 2007). 
Lymphocyte replication and proliferation also requires purine and pyrimidine synthesis. 
These three signals lead to generation and proliferation of effector T cells.  
The CD40/CD40 ligand pathway is another important early costimulatory pathway 
involved in T cell activation (Hancock et al 1996; Peng et al 1996; Van Gool et al 1996; 
Grewal & Flavell 1996). CD40, a member of the TNFR family, is expressed on antigen-
presenting cells (Foy et al 1996; Grewal & Flavell 1998) and endothelial cells 
(Hollenbaugh et al 1995; Karmann et al 1995; Yellin et al 1995; Larsen & Pearson 
1997; Reul et al 1997) and is stimulated by CD40 ligand (CD154) expressed on T cells 
including activated CD4 T cells and a subset of CD8 T cells and NK cells (Noelle et al 
1992; Roy et al 1993, 1995; Larsen et al 1996; Larsen & Pearson 1997; Niimi et al 
1998). 
Signal 1 rapidly induces CD40 ligand expression by CD4 T cells and to lesser extent on 
CD8 T cells (Larsen & Pearson 1997). CD40/CD40 ligand pathway augments the 
CD28/B7 costimulatory pathway by upregulating B7-1/B7-2 expression on antigen-
presenting cells, but is also able to independently stimulate T cells (Roy et al 1995; Van 
Essen et al 1995; Blotta et al 1996; Larsen & Pearson 1997). CD40 ligand signaling in 
the presence of IL-12 increases IFN-  production by activated T cells (Konieczny et al 
1998; McDyer et al 1998; Peng et al 1998). CD28 and CD40 ligand costimulation 
enhance IL-4 production (Blotta et al 1996). CD40 ligand stimulation of CD40 triggers 
signals for B cell antibody production and upregulates MHC and B7-1/B7-2 expression 
on antigen-presenting cells (Ranheim & Kipps 1993; Hancock et al 1996; Van Kooten 
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molecules, cytokines, chemokines and growth factors (Hollenbaugh et al 1995; 
Karmann et al 1995; Henn et al 1998; Slupsky et al 1998). 
T cells also express the inhibitory CTLA-4 which like CD28 binds to B7-1 and B7-2, 
but with a higher affinity (Peach et al 1994; Greene et al 1996; van der Merwe et al 
1997; McAdam et al 1998; Stamper et al 2001; Collins et al 2002). CD28 is 
constitutively expressed, but CTLA-4 expression is upregulated and is maximal 48-72 
hours after TCR stimulation and inhibits TCR and CD28-mediated signal transduction 
(Lee et al 1998). CTLA-4/B7 pathway may also play a regulatory role involving 
dendritic cells (Grohman et al 2002; Finger & Bluestone 2002; Munn et al 2004). CTLA 
on Tregs binds to B7 molecules on dendritic cells stimulating production of IFN- , 
which acts in an autocrine and paracrine manner to stimulate indole amine 2,3-
dioxygenase (IDO). IDO degrades tryptophan and this depletion together with the 
tryptophan degradation products inhibits T cell proliferation and promotes apoptosis 
(King & Thomas 2007). 
CD40/CD40 ligand binding also plays in important role in dendritic cell function and 
macrophage activation. CD40 ligation induces antigen-presenting cells to release pro-
inflammatory cytokines – IL-1 , IL-6, IL-8 and TNF-  (Kiener et al 1995), nitric oxide 
(Tian et al 1995) and matrix metalloproteinases (Malik et al 1998) that break down the 
extracellular matrix and facilitate infiltration by inflammatory cells. CD40 ligation 
increases antigen-presenting cell expression of ICAM-1 and CD44H and IL-12 
production (Cella et al 1996; Guo et al 1996; Kato et al 1996; Koch et al 1996). CD40 
ligation inhibits both spontaneous and Fas-mediated apoptosis of antigen-presenting 
cells (Larsen & Pearson et al 1997). 
In addition to the classical positive costimulatory pathways of CD28/B7 and 
CD40/CD40 ligand and the negative CTLA-4 pathway (Alegre et al 2001; Saloman & 
Bluestone 2001), other novel costimulatory molecules playing a role include other 
members of the CD28/CTLA/B7 and TNFR/TNF family (Coyle & Gutiemez-Ramos 
2001; Locksley et al 2001; Sharpe & Freeman 2002; Yamada et al 2002; Carreno & 
Collins 2003; Croft 2003; Salama & Sayegh 2003; Watts 2005). These novel 
costimulatory molecules differ in their timing and distribution of their expression and in 
the delivery of positive or negative signals. The outcome of the T cell response depends 
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not limited to T cell-antigen-presenting cell interactions, but also include T cell – T cell 
and T cell – B cell interactions as well as T cell signaling with non-lymphoid cells such 
as parenchymal cells and the endothelium (Kroczek et al 2004). 
These costimulatory pathways have been targeted as potential therapeutic strategies to 
induce long-term allograft acceptance (Wekerle et al 2002; Snanoudj et al 2006; Weaver 
& Charafeddine 2008). 
 
3.  ROLE OF T CELL SUBSETS IN ALLOGRAFT REJECTION 
3.1.  CD4 T cell subsets 
CD4 T cells are thought to be critical in the initiation of graft rejection (Krieger et al 
1996). Activated CD4 T cells in both the direct and indirect pathways proliferate and 
secrete a variety of cytokines that are necessary to initiate the immune response 
(Krensky et al 1990; Lakkis et al 1998; Keane-Myers et al 1998; O’Garra 1998). The 
cytokines act in an autocrine manner on CD4 T cells themselves or in a paracrine 
manner as growth and activation factors for CD8 cytotoxic T cells, B cells and 
macrophages resulting in destruction of the transplanted organ by direct lysis of target 
cells, antibody production and delayed-type hypersensitivity mechanisms respectively 
(Sayegh & Turka 1998; Rocha et al 2003). 
 
3.1.1.  CD4 Th0, Th1 and Th2 cells 
CD4 Th cells secrete cytokines which provide help for activation, proliferation and 
differentiation of other lymphocytes (Strom et al 1996; Lakkis 1998; Keane-Myers et al 
1998; O’Garra 1998). At the time of activation, CD4 Th0 cells secrete IL-2, IFN-  and 
IL-4. Activation results in development of two major phenotypes, Th1 and Th2 CD4 
cells, which differ phenotypically by the secretion of distinct cytokine profiles. CD4 
Th1 cells are induced by IL-12 and IFN-  to secrete IL-2, IL-3, IFN-  and TNF- / . 
CD4 Th1 cytokines promote immunopathologic functions by mediating delayed-type 
hypersensitivity (DTH), promoting generation of the cytotoxic T cells (CTLs), 
activating natural killer cells, activating macrophages with consequent production of 
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TNF-  upregulate the expression of B7 costimulatory molecules, thereby, enhancing T 
cell activation (Pechhold et al 1997). Th1 cells have a restricted effect on B cells, but 
the induction of IgG 2a antibodies with complement-fixing and opsonizing activities 
may contribute to rejection (Demetris et al 1992). CD4 Th1 cells also express 
fucosyltransferases necessary for the synthesis of glycosylated ligands for endothelial E-
selectin and P-selectin that are involved in lymphocyte migration into sites of 
inflammation (van Wely et al 1998). CD4 Th2 cells are induced by IL-4 to secrete IL-4, 
IL-5, IL-6, IL-10 and IL-13. CD4 Th2 cytokines provide B cell help by stimulating 
secretion of IgG1 and IgE antibodies. IL-10 downregulates the expression of B7 
costimulatory molecules diminishing activation of T cells (Li et al 1996). Th2 cytokines 
(IL-5) are also able to activate and recruit eosinophils and mast cells into sites of 
inflammation. In the presence of IL-4 and inhibition of CD4 Th1 cell proliferation, CD4 
Th2 cells can mediate IL-5 dependent eosinophilic rejection (Surquin et al 2005; Wu et 
al 2006). 
CD4 Th1 IFN-  inhibits Th2 cell proliferation and cytokine secretion. CD4 Th2 IL-10 
inhibits Th1 proliferation and cytokine expression. There is, thus, a reciprocal regulation 
resulting in a dynamic balance between Th1 and Th2 profiles within sites of 
inflammation (Romagnani 1991; Mosmann & Sad 1996). Many factors affect the 
differentiation and progression of CD4 Th0 cells to either a Th1 or Th2 phenotype 
(Abbas et al 1996; Murphy & Reiner 2002). These factors include pro- and anti-
inflammatory cytokines produced by cells of innate and adaptive immunity at the site of 
tissue injury, antigen concentration and binding affinities, costimulatory molecules, 
routes of antigen introduction and adhesion molecule upregulation. The balance 
between the transcription factors T-bet (IL-12) and GATA3 (IL-4) is the crucial 
determinant between Th1 and Th2 development respectively. 
Thus, CD4 Th1 cells contribute to rejection by: 
i) the provision of signals that promote the generation of CD8 CTL activity either 
directly by secreting IL-2 or indirectly by activating dendritic cells to promote CTL 
differentiation; 
ii) providing help signals that promote differentiation and activation of allo-antibody 
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iii) activating antigen-independent effector leukocytes which damage engrafted tissue 
(delayed-type hypersensitivity, DTH). Activated Th1 cells are critical for DTH. 
Through their secretion of IFN-  and TNF- , Th1 cells recruit and trigger macrophages 
to produce toxic molecules such as nitric oxide (NO), reactive oxygen intermediates, 
degradative enzymes and TNF- . NO is cytotoxic at high concentrations and also 
causes vasodilatation, increased vascular permeability, extravasation and tissue oedema 
that is seen in DTH. TNF-  binds to TNFR and can induce T cell apoptosis or necrosis 
through caspase activation. Activated neutrophils release myeloperoxidase which in turn 
generates toxic metabolites such as reactive oxygen species and H2O2. This leads to 
tissue swelling and induration and the presence of an inflammatory infiltrate rich in T 
cells, macrophages and neutrophils characteristic of the DTH reaction. This reaction 
requires primed antigen-specific memory Th1 cells and alone is capable of mediating 
allograft rejection (Dalloul et al 1996; Valujskikh et al 1998). The immunoregulatory 
cytokines,TGF-  and IL-10 downregulate the DTH response and have been shown to be 
associated with allograft acceptance (VanBuskirk et al 2000). 
Th1 cells are thought to be more responsible for allograft rejection via DTH and CTL 
responses. CD4 Th2 cytokines may be able to counteract acute rejection by suppressing 
DTH, inhibiting IFN- - mediated activation of macrophages and stimulating the 
production of non-complement fixing and non-opsonizing antibodies. 
However, studies have confirmed that Th2 cytokines are not essential for prolonged 
graft survival and an immune response driven by both Th1 or Th2 cells is damaging to 
the graft, but a Th2 response may be less damaging (Strom et al 1996; Saleem et al 
1996; Wasowska et al 1996; Nickerson et al 1994; 1997; Lakkis et al 1997; Rocha et al 
2003; Alegre et al 2007). The difference in expression of most chemokines and 
costimulatory receptors between Th1 and Th2 cells is quantitative. 
 
3.1.2.  CD4 Th17 cells  
CD4 Th0 cells under the influence of TGF , IL-6 and IL-23 develop into IL-17-
secreting CD4 Th17 cells (Bettelli et al 2007; Goriely & Goldman 2007) and induce 
neutrophil inflammation (Weaver et al 2007). IL-27 inhibits the activity of Th17 cells 
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(Lohr et al 2006; Korn et al 2007; Wahl 2007). Neutrophils play an important role in 
acute allograft rejection especially in the setting of costimulatory blockade and in the 
absence of IFN-  and IL-4 (Miura et al 2003; El-Sawy et al 2005; Surquin et al 2005).  
 
3.1.3.  Regulatory CD4 cells 





Tregs, IL-10-producing type I regulatory cells and murine TGF-producing Th3 cells 
(Groux et al 1996; Letterio & Roberts 1997; Seder et al 1998; Jiang et al 2006a; Yong et 
al 2007). Regulatory T cells are predominantly CD4
+
, but other T cell subsets such as 
CD8
+
 T reg (Zhou et al 2001; Gilliet & Liu 2002), veto CD8
+



















 T cells have also been 
shown to have regulatory capacity (Ciubotariu et al 1998b; Zhang et al 2000, Seino et al 
2001; Karim et al 2002; Mills 2004; Yi et al 2006). 
CD4
+
 T reg cells can be divided into two groups, the natural and the adaptive Tregs, 










 thymocytes and 10% of peripheral CD4
+
 T cells (Itoh et al 1999; Jordan et 
al 2001) and are predominantly found in lymphoid organs (Cottrez & Groux 2004). 
There is no definitive cell surface marker as CD45 RB, CTLA-4, glucocorticoid-
induced TNF-receptor family related receptor (GITR), CD122, CD103, CD134 and 
CD62L are all expressed on other CD4 T cell subsets especially activated T cells (Wood 
& Sakaguchi 2003; Yi et al 2006). FOXP3 (forkhead/winged helix transcription factor) 





 TCR  cells (Fontenot et al 2003; Hori et al 2003).  




 Tregs suppress effector T cell 
proliferation through a cell contact dependent and largely cytokine independent 
mechanism (Takahashi et al 1998; Suri-Payer & Cantor 2001; Piccirillo & Shevach 
2001). CTLA-4 and GITR expressed on the surface of Tregs play a role in mediating 
suppression of T effector function (Takahashi et al 2000; Shimizu et al 2002). However, 
IL-10 and TGF-  play an important role in natural Treg mediated unresponsiveness to 
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important in maintaining overall immune homeostasis and preventing autoreactivity 





 regulatory cells are responsive to chemokines that engage with CCR4 and 
CCR8 receptors, thereby enabling regulatory cells to localize at sites of inflammation 




 regulatory cells do not proliferate in response to 




 regulatory cells 
regulate the proliferation of both CD4
+
 (Levings et al 2001; Sanchez-Fueyo et al 2002) 
and CD8
+
 cells (Piccirillo & Shevach 2001; Yamagiwa et al 2001; Sanchez-Fueyo et al 
2002). The suppressive effect is dependent on TCR stimulation of the regulatory cells 
and direct cell contact with the target cells and is not antigen-specific (Thornton & 




 regulatory cells are able to suppress 
polyclonally- and alloantigen-stimulated T cell proliferation (Levings et al 2001; 










 regulatory cells constitutively express CTLA4 in both mice (Takahashi et 
al 2000; Read et al 2000; Salomon et al 2000) and humans (Jonuleit et al 2001; 
Dieckmann et al 2001; Stephens et al 2001; Levings et al 2001). 
There are two populations of adaptive Tregs that are important in the development of 
transplantation tolerance (Walsh et al 2004; Kang et al 2007): the Th3 cells (mice) that 
secrete TGF  in response to ingestion of antigen in the development of oral tolerance 
(Chen et al 1994) and Tr1 cells (human) that secrete large amounts of IL-10 (Groux et al 
1997). 
Adaptive Tregs depend on peripheral factors for their development such as the 
availability of TGF  and the maturity and type of stimulating antigen-presenting cell 
(Steinman et al 2003). Adaptive Tregs do not depend on cell-contact, but suppress 
immune responses through immunosuppressive cytokines such as IL-10 and TGF-  
(Stassen et al 2004). Tr1 cells migrate to sites of inflammation (Cottrez & Groux 2004). 
Adaptive Tregs are identified according to secretion of cytokines. Dendritic cells are 
able to induce a Th3 or Tr1 Treg phenotype irrespective of their maturation state 
(Wakkach et al 2003; Lavelle et al 2003). In addition, Tregs have been shown to 
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molecules and IL-12 (Kang et al 2007). Tregs prevent interactions between dendritic 
cells and T effector cells that are essential for effective priming of T effector cells 





 Tregs play an important role in inducing effector T cells to adopt a Tr1 







 effector cells through stimulation via TCR in the presence of IL-10 and TGF  






 Tregs (Fu et al 2004; Bushell et al 2005). 
Adaptive Tregs are thought to develop and act directly within the graft (Josien et al 
1998). The predominant mode of allorecognition by Tregs is via the indirect pathway 
(Caballero et al 2006). Both natural Tregs and adaptive Tregs are probably necessary for 
the induction of transplantation tolerance (Cottrez & Groux 2004; Waldmann et al 2004; 
Walsh et al 2004). Clinical transplantation tolerance procedures need to delete 
alloreactive T cells and spare/amplify Tregs (Lechler et al 2003). 
 
3.2.  Cytotoxic T lymphocytes 
CTLs are primarily derived from CD8 T cells, but CD4 T cells may also be cytotoxic 
after they are activated by the indirect allorecognition pathway (Shresta et al 1998). 
CD8 CTLs are primed and activated by direct presentation of donor MHC class I 
antigens by donor APCs (Arakelov & Lakkis 2000; Barry & Bleackley 2002; Russel & 
Ley 2002) or by activated donor vascular endothelial cells (Kreisel et al 2002). The 
requirement for costimulatory molecules is controversial as different studies using 
CD40-CD40 ligand blockade have shown conflicting results for CD8 CTL activation 
(Jones et al 2000; Zhai et al 2003). Activated CD8 T cells primarily damage grafts by 
direct cytolysis of graft parenchymal or vascular cells bearing antigens which the CTL’s 
TCR recognizes. CD8 T cell cytolysis is initiated by direct presentation of foreign 
MHC-I molecules. The mature cytoxic CD8 T cells secrete IFN-  and TNF- . Two 
cytolytic mechanisms for CTLs have been identified. These include secretory (granule 
exocytosis) and non-secretory (Fas/Fas-ligand) pathways which are calcium-dependent 
and calcium-independent, respectively (Liu et al 1996; Kagi et al 1996; Russel & Ley 
2002; Barry & Bleackley 2002). In the secretory mechanism, antigen-specific CTLs 
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calreticulin and Fas ligand within 24 – 48 hours following activation. Antigen-specific 
CTLs tightly engage their target cells and release the cytolytic granules that flow 
vectorially to the site of contact and fuse with the target cell membranes (Yannelli et al 
1986). In the presence of calcium, perforin polymerises and forms pores within the 
target cell membrane, facilitating access of cytolytic proteins to the cytoplasm and 
promoting osmotic lysis. Granzymes trigger apoptosis of the target cell by activating a 
series of cysteine-containing aspartate-specific proteases (caspases) either by direct 
cleavage of procaspase-3 or by indirect activation of procaspase-9 and subsequent 
cleavage of procaspase-3 (Chinnaiyan et al 1996a; Sutton et al 2000; Wang et al 2001). 
Granulysin induces target cell lysis by the generation of intracellular ceramide from 
sphingomylein or as a result of activation of caspases (Pena & Krensky 1997). In the 
non-secretory, calcium-independent mechanism, Fas ligand (FasL) is upregulated on the 
cell surface membrane of CTLs within several hours of antigen-specific activation. The 
FasL-bearing CTL is able to engage Fas (CD95) expressed constitutively or induced by 
cytokines on the cell surface of target cells. The binding of FasL to the Fas receptor 
leads to the aggregation of intracellular death domains and the recruitment of Fas-
associated death domains and pro-caspase-8 to form a death-inducing signaling complex 
that results in apoptosis (Boldin et al 1995; Chinnaiyan et al 1995, 1996b; Kischkel et al 
1995). CD8 CTLs use both the perforin/granzyme and FasL pathways of cytotoxicity, 
but CD4 CTLs preferentially use the FasL pathway (Shresta et al 1998). CD8 T cells 
may produce signals that have cytotoxic action or mediate DTH through the secretion of 
IFN-  in the vicinity of target cells. Effective stimulation of CD8 cytotoxicity is thought 
to require costimulation by CD40:CD40L in a CD4 dependent fashion, but there have 
been conflicting studies (Jones et al 2000; Zhai et al 2003). Other alternative 
costimulatory molecules, such as LFA-1, LIGHT and membrane lymphotoxin may 
influence CTL activation (Guo et al 2001; Scheu et al 2002; Corbascio et al 2002). 
CD8 T cells express chemokine receptors including CXCR3 and CX3CR1 and secrete a 
large number of chemokines such as CXCL8 (IL-8), CXCL10 (IP-10), CCL3 (MIP-1 ), 
CCL3, CCL4 (MIP-1 ) and CCL5 (RANTES), thereby establishing a chemokine 
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3.3.  NK cells 
NK cells are large granular leukocytes which are able to kill virus-infected or tumour 
cells without prior antigen-specific activation (See et al 1997; Lanier 1998a; Biron et al 
1999; Cerwenka & Lanier 2001). NK cells have a unique mechanism of lysis as they do 
not express TCRs or any molecules that are able to recognise antigen. They do not 
require prior sensitization and are not antigen-specific. 
NK cells express both inhibitory self MHC-I specific killer Ig-like receptors (KIRs) and 
triggering natural cytotoxicity receptors (Timonen 1997; Lanier 1998a,b,c; Ryan et al 
2001; Middleton et al 2002; McQueen & Parham 2002; Moretta et al 2002). NK cell 
activation is controlled by the balance of signals received from the engagement of these 
2 receptors. 
NK cells kill those target cells that lack or express insufficient self MHC class I 
molecules by cell-to-cell cytotoxicity (Liu et al 1996; Kagi et al 1996; Russel & Ley 
2002; Barry & Bleackley 2002). NK cells lyse target cells via the granzyme exocytosis 
pathway (Shresta et al 1995). NK cells also express a low affinity receptor for the Fc 
portion of IgG (CD16) and bind to and kill antibody-coated target cells (antibody-
dependent cell cytotoxicity) as well as secreting TNF-  which may induce apoptosis of 
TNFR-expressing graft cells. Activated NK cells express chemokine receptors CXCR1 
and CXCR3 and release numerous cytokines and chemokines leading to mononuclear 
cell recruitment and activation. 
NK cells are important effector cells mediating rejection of allogeneic haemopoietic 
cells (Murphy et al 1987; Manilay & Sykes 1998), and their role in mediating both solid 
organ graft rejection and tolerance as well as their role in xenograft rejection is now 
recognized (Kitchens et al 2006). 
NK cells appear to play a significant role in allograft rejection in the setting of co-
stimulatory blockade (Maier et al 2001). NK cells may facilitate acute rejection via a 
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i) NK cells are able to promote a CD4 Th1 phenotype directly, enhancing 
antigen-specific T cell proliferation (McNerney et al 2006) and IFN-  
production or indirectly via enhancement of dendritic cell maturation 
(Gerosa et al 2005; Moretta et al 2006). 
ii) Activated NK cells secreting IFN-  can upregulate MHC molecule 
expression on endothelial cells, thereby enhancing endothelial cell 
recognition by alloreactive T cells (Gerosa et al 2005; Moretta et al 2006). 
iii) NK cells infiltrating allografts secrete the early chemokines (MIP-1 , MIP-
1 , CXC1, CCL3, CXCL10 and CX3CL1) that attract the alloreactive T 
cells (Kondo et al 2000; Obara et al 2005). 
NK cells lacking the inhibitory Ly49 receptors for donor MHC class I molecules 
promote rejection, whereas Ly49G2+ NK cells suppress alloimmune responses 
(McNerney et al 2006). 
NK cells have been shown to be clinically relevant in acute rejection in renal 
transplantation (Fuggle 1991; Blancho et al 1992; Kummer et al 1995) and liver 
transplantation (Bishara et al 2001). NK cells play an important role in xenograft 
rejection (Seebach & Waneck 1997; Rieben & Seebach 2005). Failure of NK inhibitory 
receptors to recognize xenogeneic MHC class I molecules leads to NK cell activation 
with either direct perforin mediated damage or cytokine-induced xenoreactive T cell 
activation (Schneider et al 2001; Xu et al 2002). NK cells promote a pro-inflammatory 
endothelium, thereby recruiting inflammatory cells (Goodman et al 1996; Dawson et al 
2000). ADCC also occurs in response to xenoreactive antibodies binding to galactose-  
(1,3)- galactose on the xenograft (Sandrin et al 1993). 
NK cells may also be able to promote induction of allograft tolerance in the setting of 
costimulatory blockade. This may involve perforin dependent downregulation of CD4 
and CD8 cells in the alloimmune response (Beilke et al 2005) or the destruction of 
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3.4.  Memory T cells 
Alloreactive memory T cells differ from naïve T cells in gene expression profile, 
costimulatory requirements for activation, homeostasis and homing properties, and are 
more resistant to tolerance induction (Chalasani et al 2002; Sprent & Surh 2002). 
Effector memory T cells require minimal costimulation signaling from B7 and CD40 on 
APCs (London et al 2000). Targetting of alternative co-stimulatory receptors such as the 
CD27/CD70 pathway has resulted in longterm cardiac allograft survival in CD28-
deficient mice (Yamada et al 2005). Memory T cells have been shown to be a major 
barrier to the successful induction of tolerance (Brook et al 2006; Valujskikh 2006). 
This is irrespective of the mechanism of generation of memory cells including: i) 
heterologous immunity where memory cells are generated following prior exposure to 
allo-antigens or to micro-organisms that induce cross-reactive memory T cells (Adams 
et al 2003), ii) homeostatic proliferation of memory T cells following partial T cell 
depletion (Wu et al 2004). Thus, present immunosuppressive protocols that result in 
partial T cell depletion may promote memory T cell generation and prevent tolerance 
induction. Experimentally this has been overcome by the transfer of unprimed 
regulatory cells following T cell depletion therapy or by the addition of non-depleting 
anti-CD4 and anti-CD8 antibodies that reduce memory cell homeostatic proliferation 
(Neujahr et al 2006). Outbred large animals living in non-pathogen-free environments 
and humans have a large number of memory type alloreactive T cells that are cross-
reactive to previously sensitised environmental antigens. Thus, treatment protocols 
capable of inducing longterm tolerance in rodents, e.g. combination of anti-CD154 and 
donor-specific transfusion may fail in large animal models or primed recipients (Zhai et 
al 2002). Depletion of memory CD8 T cells in combination with anti-CD154 antibody 
and global immunosuppression has been shown to induce mixed chimerism and 
tolerance in a non-human primate model of donor bone marrow/kidney transplantation 
(Koyama et al 2007). The precursor frequency of CD8 T cells determines their 
requirement for CD28/CD154 costimulation. High antigen-specific precursor frequency 
CD8 T cells are less dependent on the CD28/CD154 costimulation pathways for full 
activation (Ford et al 2007). Thus, clinical transplant tolerance may need therapeutic 
regimens that tolerise distinct memory CD4 and CD8 T cell subsets (Kaech & Ahmed 
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4.  ALLOANTIBODY RESPONSES 
B cells bind soluble antigens via surface immunoglobulins, indirectly process them into 
peptides and transport them into the groove of surface MHC II molecules. These 
CXCR5-expressing antigen-primed B cells along with a subset of activated CD4 Th 
cells migrate to B cell follicles in response to the B cell ligand CXCL13 expressed on 
follicular stromal cells (Mackay 2001; Moser & Loetscher 2001). During T cell – B cell 
interaction, the indirectly primed CD4 Th cells recognize MHC II-peptide complexes 
expressed on B cells and provide costimulatory signals through CD40L which binds to 
CD40 on the B cell. These Th cell costimulatory signals play a central role in B cell 
activation, proliferation and differentiation into terminally differentiated antibody-
producing plasma cells and memory B cells, allo-antibody production and isotype and 
subclass switching (Foy et al 1996; Lederman et al 1996; Lipsky et al 1997; Fink & 
McMahan 2000; Calame et al 2003). Allo-antibodies circulate and reach the allograft 
through the endothelial pores. Graft cells coated with antibodies can be killed by 
activation of the complement cascade or by perforin/granzyme-mediated NK 
cytotoxicity (i.e. antibody-determined cell mediated cytotoxicity (ADCC)) (Baldwin et 
al 1995, 2001). The severity of tissue injury caused by these antibodies depends on the 
isotype, affinity and antibody titre as well as the expression of target antigen. It has been 
shown that IgG1 allo-monoclonal antibodies to MHC class I antigens can augment graft 
injury by stimulating endothelial cells to produce MCP-1 and by activating 
mononuclear cells through their Fc receptors (Lee et al 2007). Graft-infiltrating cells 
such as macrophages, neutrophils and eosinophils are also activated by the crosslinking 
of their FcRs by allo-antibodies and complement. 
Anti-donor antibodies present at the time of transplant are able to trigger hyperacute 
rejection. Preformed antibodies directed against ABO-blood group carbohydrate 
antigens, donor MHC class I and to a lesser degree MHC class II, as a result of previous 
blood transfusions, pregnancy or previous transplantation, immediately bind to the 
vascular endothelium of the graft after revascularization. These preformed antibodies 
rapidly activate the complement system and the coagulation cascades leading to 
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Graft infiltrating B cells are also able to present graft-derived peptides, thereby locally 
activating alloreactive T cells via the indirect pathway of allorecognition (Alegre et al 
2007). 
 
5.  BLOCKADE OF CO-STIMULATING PATHWAYS AND  
     TOLERANCE INDUCTION 
T cell costimulation is mediated by a network of signaling pathways. The various co-
stimulatory pathways play different roles: some provide the classical costimulatory 
signals required to initiate priming of naïve T cells, others are necessary to sustain T cell 
activation and others provide signals to downregulate T cell responses. Blockade of 
these various pathways can result in many different tolerance mechanisms including 
immune regulation, anergy and deletion (Wekerle et al 2002; Snanoudj et al 2006; 
Weaver et al 2008). However, immune tolerance, a state of unresponsiveness to the 
donor graft (Sykes et al 2007) is difficult to achieve (Salama et al 2007). Disruption of a 
single pathway is usually not sufficient to promote tolerance or long-term allograft 
survival. Clinical success is more likely to be obtained by the blockade of a number of 
co-stimulatory pathways. 
 
5.1.  Blockade of CD28/CTLA-4 : B7 pathway 
Most experimental models have looked at the role of CTLA4-Ig or monoclonal 
antibodies blocking CD28 interaction with its ligands B7-1 (CD80) and B7-2 (CD86), 
as well as anti-CD154 mAbs to block CD40:CD40L (CD154) interactions. These 
models rely on the eventual deletion of alloreactive T cells, as in the absence of 
costimulation which induces cell survival genes, T cells become susceptible to the 
induction of apoptosis (Dai et al 1998; Wells et al 1999). CD4 cells are more susceptible 
to costimulatory blockade than CD8 cells, and in some models, costimulatory blockade 
induces tolerance only in conjunction with CD8 depleting agents (Trambley et al 1999; 
Jones et al 2000). 
CTLA4 (CD152) plays a role in inducing clonal anergy, reducing the number and 
activity of CD4 Th1, Th2 and CD8 T cells responding to an allogeneic challenge 
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2005). CTLA4 is needed for the induction of a division-arrest form of anergy (Wells et 
al 2001), but is not required for anergy through CD28-blockade (Frauwith et al 2000; 
Wells et al 2001) and is not essential for anergising CD8 cells (Frauwith et al 2001). 
CTLA plays an important role in tolerising CD4 cells in vivo (Greenwald et al 2001). 
A recombinant fusion protein, CTLA4-Ig, which consists of the extracellular binding 
domain of CTLA4 linked to a modified Fc domain of human IgG1, binds with a higher 
affinity than CD28 to B7 molecules and thereby acts as a potent competitive antagonist 
of the CD28:B7-mediated T cell costimulation (Linsley et al 1991). The administration 
of CTLA4-Ig resulted in longterm survival of xenogeneic human-to-mice pancreatic 
islet grafts (Lenschow et al 1992) as well as prolonged survival of rat cardiac allografts 
(Turka et al 1992). However, a true state of tolerance was not obtained, as all the grafts 
were ultimately rejected. Subsequent studies in MHC mismatched cardiac allografts 
showed that the administration of donor specific transfusion (donor splenocytes) on the 
day of transplantation, followed by a single injection of CTLA4-Ig on day 2 post 
transplantation, was effective in achieving tolerance (Lin et al 1993). It has 
subsequently been confirmed that donor antigen in conjunction with CTLA4-Ig or 
prolonged blockade is required in cardiac allograft models for the induction of tolerance 
and prevention of chronic allograft vasculopathy (Pearson et al 1996; Sayegh et al 
1997). The role of donor cells in the promotion of tolerance induction in these animal 
models is not known.  
However, the timing of the administration of CTLA4-Ig is important and has been 
shown to be most effective, if CTLA4-Ig is administered after transplantation (Lin et al 
1993; Sayegh et al 1995). It is thought that this may be due to the fact that cycling T 
cells are more susceptible to the absence of co-stimulatory signals than resting T cells 
(Sayegh & Turka 1998). In addition, T cells express CTLA4 on their surface after 
activation and this transduces a negative regulatory signal to the cell (Walunas et al 
1996). Thus, delaying the administration of CTLA4-Ig would enable B7 molecules to 
bind to CTLA4, which may be required for the induction of tolerance (Perez et al 1997). 
Several studies of transplantation in rats, mice and non-human primates including 
studies of cardiac, renal, liver, intestine and islet allografts, have confirmed that 
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instances donor-specific tolerance (Lenschow et al 1992; Turka et al 1992; Lin et al 
1993; Sayegh et al 1995; Levisetti et al 1997; Schaub et al 1998; Newell et al 1999). 
Both CTLA4-Ig and anti-CD154 are most effective when used together with donor-
specific transfusion (Lin et al 1993; Markees et al 1997). Donor-specific transfusion and 
anti-CD154 results in substantial prolongation of MHC-mismatched skin grafts, but 
permanent graft survival is only achieved in a small percentage of euthymic recipients 
(Markees et al 1997). However, with the same treatment, permanent graft survival can 
be achieved in most thymectomised mice (Markees et al 1998). In this model, tolerance 
induction is dependent on the continuous presence of CD4 cells and could be blocked 
by anti-CD152 and anti-IFN  mAbs administered at the time of tolerance induction 
(Markees et al 1998). Clonal deletion of alloreactive T cells plays a prominent role in 
this regimen and CD8 depletion can substitute for donor-specific transfusion in this 
model (Iwakoshi et al 2000). 
Recently, the use of a monoclonal antibody that modulates CD28 prevented acute and 
chronic renal allograft rejection in a murine model. This was associated with the 
generation of TCR class II B7 regulatory cells (Haspot et al 2005). 
i)  The role of B7-1 and B7-2 in allograft rejection 
Blockade of B7-1 (CD80) or B7-2 (CD86) in acute rejection models has varying 
outcomes (Lenschow et al 1995; Hancock et al 1996; Zheng et al 1997). Anti-B7-2 
mAb prolongs allograft survival in mice, especially when administered at time of 
transplantation, but a ti-B7-1 has little effect (Lenschow et al 1995; Judge et al 1999). 





by blocking CTLA4 interaction (Yamada et al 2001). In contrast, anti-B7-2 mAb, in the 
absence of CD28, prolongs engraftment (Yamada et al 2001). 
The B7/CTLA-4 interaction is necessary for the CD4+ CD25+ Treg function (von 
Boehmer 2005) and in a skin transplant model, CTLA-4 pathway blockade prevented 
the regulatory activity of CD4+ CD25+ T cells (Kingsley et al 2002). 
In non-human primate studies, targeting B7-1 and B7-2 either with blocking mAbs or 
with CTLA4-Ig prolongs both renal and islet cell allograft survival. However, the 
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signaling or the concomitant administration of rapamycin (Kirk et al 1997, 2001b; 
Adams et al 2002; Birsan et al 2003). LEA29Y (Belatacept), a high affinity variant of 
CTLA4-Ig has shown promise as an immunosuppressive agent in non-human primate 
studies (Adams et al 2005). It acts synergistically with anti-CD40 to prolong islet 
allograft survival (Adams et al 2005). A Phase II multicentre clinical trial has 
demonstrated efficacy in preventing acute rejection and chronic allograft nephropathy in 
renal transplant patients (Vincenti et al 2005) and Phase III clinical trials have begun. 
In non-human primates, costimulatory blockade with anti-CD154 mAb is more effective 
than CTLA4-Ig. Anti-CD154 is able to induce T cell IL-10 production and apoptosis 
(Blair et al 2000). Dendritic cells, macrophages and endothelial cells express CD40 and 
blockade of the CD40:CD154 pathway inhibits activation of these cells, blocks the 
expression of adhesion molecules and suppresses the secretion of inflammatory 
cytokines (Kirk et al 2001a; Adler & Turka 2002). 
 
5.2.  Blockade of the CD40:CD40L pathway 
CD40 blockade using anti-CD154 promotes longterm allograft survival in a number of 
murine cardiac and pancreatic islet transplant models (Parker et al 1995; Larsen et al 
1996a) and synergises with CD28 blockade (Larsen et al 1996b; Hancock et al 1996; 
Elwood et al 1998). Effective CD40 blockade requires prolonged administration to 
enable permanent engraftment of islet cell and cardiac allografts (Parker et al 1995; 
Hancock et al 1996). The addition of donor antigen at the time of transplantation 
increases the number of recipients achieving longterm engraftment, promotes donor-
specific tolerance and can prevent chronic arteriopathy in cardiac transplant models 
(Parker et al 1995; Hancock et al 1996; Markees et al 1997). Donor specific tolerance 
with CD40 blockade depends on the presence of CD4 cells, IFN-  and CTLA-signaling 
(Markees et al 1998). 
The combination of CTLA4-Ig with anti-CD40 has been successful in promoting 
longterm acceptance of rat skin and cardiac allografts (Larsen et al 1996b) and 
prolonged renal allograft survival in a non-human primate model (Kirk et al 1997; 
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Promising results have been obtained using anti-CD154 monotherapy in non-human 
primate studies. Prolonged anti-CD154 therapy can result in prolonged renal and 
pancreatic islet allograft survival (Kirk et al 1997, 1999; Kenyon et al 1999a, 1999b). 
This regimen induces prolonged immunosuppression rather than true tolerance as 
withdrawal of therapy has eventually led to allograft rejection. In non-human primates 
with cardiac transplants, blockade of CD40 ligand with a humanised monoclonal 
antibody was effective in delaying acute rejection (Chang et al 1997). 
AB1793, a novel human anti-human CD154 mAb prevented rejection of renal allografts 
in cynomologous monkeys (Schuler et al 2004). 
Recently it has been shown that the combination of anti-CD154/anti-CD28 
costimulation blockade together with rapamycin resulted in prolonged induction of 
chimerism following stem cell transplantation (Kean et al 2007). 
Anti-CD154 mAb therapy has been complicated by the development of thrombo-
embolic events in both non-human primate studies and phase I human clinical trials 
(Kawai et al 2000; Schuler et al 2004). In an attempt to avoid the thrombo-embolic 
complications associated with CD154 blockade, a combination of antagonistic 
antibodies against CD40 and CD86 were evaluated and found to prevent renal allograft 
rejection in non-human primates (Haanstra et al 2003; 2005). Recently a chimeric-anti-
CD40 mAb that synergises with Belatacept (a high affinity variant of CTLA4-Ig) has 
been shown to prolong islet cell allograft survival in non-human primates (Adams et al 
2005).  
 
5.3.  Blockade of B7-H1(PD-L1)/B7-DC(PD-L2):PD-1 pathway 
B7-H1/B7-DC: PD-1 pathway plays an important role in terminating the alloimmune 
response either through negative signaling leading to anergy or apoptosis (Clarkson & 






 Tregs (Krupnick et al 
2005). 
Stimulating PD-1 negative signals using a dimeric PD-L1 Ig fusion protein together 
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In a murine cardiac allograft model, PD-1, PD-L1 and PD-L2 are all upregulated during 
rejection despite the administration of cyclosporin or rapamycin. PD-L1 Ig or PD-L2 Ig 
alone had no effect on allograft rejection in wild-type recipients. However, the 




 recipients or in combination with subtherapeutic 
cyclosporin significantly enhanced cardiac allograft survival. The combination of PD-
L2 Ig and cyclosporin had no effect (Ozkaynak et al 2002).  
 
5.4.  Blockade of ICOS:ICOS-L pathway 
ICOS signaling is required for the activation and function of T effector cells (Coyle et al 
2000). In the transplant setting, studies have shown that the functional consequences of 
ICOS signaling or inhibition are influenced by both the nature of the immune response 
and the timing of the therapeutic intervention with ICOS blockade. 
In a murine cardiac allograft model, ICOS expression is upregulated on graft-infiltrating 
cells during rejection. Administration of blocking ICOS mAb or ICOS-Ig fusion protein 
prolonged cardiac allograft survival (Ozkaynak et al 2001; Kosuge et al 2003). Anti-
ICOS antibody therapy decreased CD4 and CD8 T cell graft infiltration and prevented 
upregulation of ICOS mRNA (Tafuri et al 2001). Combination therapy of low dose 
cyclosporin and anti-ICOS antibody led to long-term murine cardiac allograft survival 
(> 100 days) (Ozkaynak et al 2001). 
Combination therapy with ICOS Ig and CTLA4 Ig resulted in long-term acceptance of 
murine cardiac allografts and also donor-specific tolerance shown by acceptance of 
donor, but not third party skin grafts. ICOS Ig or anti-ICOS antibody alone prolonged 
survival time, but all cardiac allografts were eventually rejected (Kosuge et al 2003). 
Combination therapy of anti-ICOS antibody and subtherapeutic FK506 in a murine 
model of intrahepatic islet allografts prevented islet allograft rejection (Nakamura et al 
2003). In a rat liver transplant model, anti-ICOS antibody prolonged graft survival and 
reduced ICOS expression on graft infiltrating T cells (Guo et al 2002). 
Therapeutic ICOS blockade during the effector phase is more effective in promoting 
longterm cardiac allograft survival than early blockade at the time of transplantation in 
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effect was independent of CD28 costimulation, but not of CTLA4 signaling (Harada et 
al 2003). 
Anti-ICOS mAb synergises with rapamycin to prolong murine islet cell allograft 
survival (Nanji et al 2004). ICOS-B7h blockade synergises with donor specific 
transfusion to promote longterm survival of MHC class II mismatched skin grafts 
(Sandner et al 2005). This synergism is associated with a reduction in alloreactive clone 
size due to apoptosis of host allo-antigen specific CD4 T cells (Sandner et al 2005). 
Combined blockade of CD154 and ICOS prevented chronic arterial vasculopathy and 
led to longterm murine cardiac allograft survival (Guillonneau et al 2005) and tolerance 
in a murine islet allograft model (Nanji et al 2006). 
 
5.5.  Blockade of OX-40:OX-40L (CD134:CD134L) pathway 
In alloimmune responses, blockade of the OX40:OX40 ligand pathway synergises with 
CD28 blockade to promote longterm survival of rodent skin and cardiac allografts 
(Yuan et al 2003). OX40:OX40L pathway appears to play a role in mediating 
memory/effector responses as a combination of OX40:OX40L and CD28 blockade is 
able to prevent rejection in a presensitised model using adoptive transfer of primed 
lymphocytes into athymic heart transplant recipients (Yuan et al 2003). OX40:OX40L 
pathway plays an important role in CD28/CD154-independent rejection (Demirci et al 
2004; Vu et al 2004). 
Blockade of OX40:OX40L interaction ameliorates GVHD in a murine model of 
allogeneic bone marrow transplantation (Tsukada 2000). 
 
5.6.  Blockade of LIGHT:HVEM pathway 
LIGHT costimulates T cell proliferation and is required for dendritic cell-mediated 
allogeneic T cell responses (Tamada et al 2000). In a murine cardiac allograft rejection 
model, combination therapy with HVEM-Ig and Cyclosporin enhanced mean allograft 
survival (21 days) compared to HVEM-Ig (mean 7 days) or Cyclosporin alone (10 days) 
(Ye et al 2002). HVEM-Ig decreased graft arterial disease in a murine cardiac allograft 
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5.7.  Blockade of membrane lymphotoxin (mLT) 
Membrane lymphotoxin is an important regulatory molecule for CD8 T cells mediating 
rejection. Blockade of this regulatory molecule can be used to inhibit costimulation 
blockade-resistant CD8 T cell mediated allograft rejection (Guo et al 2001). 
Blockade of mLT by a fusion protein LT R-Ig or anti-mLT mAb inhibited CD8 T cell 
mediated rejection of murine intestinal allografts. This was associated with decreased 
MIG (monokine-induced by IFN- ) and secondary lymphoid chemokine gene 
expression within the allografts and spleen respectively. Blocking mLT did not inhibit 
CD4 T cell mediated rejection (Guo et al 2001). Combination of CTLA4-Ig and LT R-
Ig inhibited CD4 and CD8 T cell mediated rejection in a murine intestinal allograft 
model (Guo et al 2001). 
 
5.8.  Blockade of CD27:CD70 pathway 
Anti-CD70 mAb alone or in combination with anti-OX40L mAb had no effect on 
murine islet allograft survival (Wu et al 2001b). Anti-CD70 mAb did prolong cardiac 





 mice (Yamada et al 2005). Blockade of CD27:CD70 signaling 
synergises with interruption of CD28 signaling and mediates its effects via modulation 
of effector/memory alloreactive CD8 T cell activation (Clarkson & Sayegh 2005; 
Yamada et al 2005). 
 
5.9.  Blockade of CD137 (4-1BB):CD137L (4-1BBL) pathway 
The CD137:CD137L pathway is important for CD8 effector cell proliferation and 
survival (Shuford et al 1997; Pulle et al 2006). CD137 blockade inhibited CD8
+
 but not 
CD4
+
-mediated rejection of murine intestinal allografts (Wang et al 2003). CD137 
blockade could possibly be used as adjunctive therapy for blocking CD8 T cell driven 
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6.  ROLE OF ADHESION MOLECULES, CYTOKINES,  
     CHEMOKINES AND THE ENDOTHELIUM IN ALLOGRAFT  
     REJECTION 
6.1.  Lymphocyte-endothelium interactions 
Adhesion molecules act as receptors and counter-receptors (ligands) in the interactions 
between effector cells and target cells, the migration of leukocytes and adhesion of 
leukocytes to endothelial cells and the extracellular matrix (Adams et al 1989, 1996; 
Springer 1990a,b, 1994; Butcher 1991; Albelda et al 1994; Wardlaw et al 1996; 
Lautenschlager et al 1996, 1997; Cavenagh et al 1998; Fuggle & Koo 1998; Choi et al 
2004; Kelly et al 2007; Rao et al 2007). Adhesion molecules play a critical role in the 
lymphocyte/endothelial cell interactions involved in solid organ rejection (Lawrence & 
Springer 1991; Springer 1994; Briscoe et al 1998). With the release of inflammatory 
mediators such as cytokines from activated endothelium, the endothelium changes from 
an anti-adhesive to a pro-adhesive state (Bevilacqua 1993). The interaction between 
leukocytes and activated endothelial cells results in low affinity binding and rolling of 
leukocytes along the endothelium, with the circulating lymphocyte being tethered to 
activated endothelium predominantly by means of selectin-mediated interactions 
(Lawrence & Springer 1991; Lasky 1992). 4 integrins ( 4 7 and 4 1/VLA-4) also 
play a role in the initial capture of lymphocytes (Steeber & Tedder 2000; Steeber et al 
2005). Tethering enables th  beta-chemokines such as RANTES, MCP-1 and MIP-1  
and  to bind to G-protein coupled lymphocyte receptors, thereby triggering expression 
of activated integrins such as LFA-1, VLA-1 and VLA-4, which results in strong 
adhesion of the lymphocytes to the endothelial wall (Schall 1991; Tanaka et al 1993; 
Taub et al 1993a,b; Adams et al 1994). VLA-4 must form a bimolecular complex with 
CD44 in order to mediate firm adhesion of activated T cells (Nandi et al 2004). 
Important adhesion molecules on the endothelial cells belong to the Immunoglobulin 
supergene family and include ICAM-1, 2 and 3, platelet-endothelial cell adhesion 
molecule (PECAM-1) and VCAM-1. Transendothelial migration occurs under the 
influence of pro-migratory factors such as MIP-1  and involves interactions between 
lymphocyte integrins VLA-4 and LFA-1 with the basal membrane and ICAM-1 
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Once lymphocytes have migrated into the interstitium, the lymphocyte is able to interact 
with the antigenic peptide. T lymphocyte activation follows engagement of antigen by 
the TCR, followed by the second important costimulatory signal. This adhesion cascade 
is involved in the recruitment of alloreactive T cells into allografts (Briscoe et al 1998; 
Fujisaki et al 1998). Studies have shown that activated endothelial cells participate in 
allograft rejection as a result of: i) selective recruitment of CD4 T cell subsets, ii) 
costimulation of T cells and resulting production of cytokines, iii) involvement in the 
signaling pathways of CD40:CD40 ligand, Fas:FasL and the TNF/TNFR family 
(Briscoe et al 1998). Antigen activation of T cells leads to differentiation into effector T 
cells or memory T cells. The recruitment of differentiated T cells to peripheral sites of 
inflammation is mediated by the interaction of adhesion molecules on activated 
endothelial cells of the microvasculature with ligands expressed by activated, but not 
naïve T cells. Memory T cells exclusively express ligands for endothelial E-selectin and 
P-selectin (Lichtman et al 1997). Episodes of rejection have been shown to be preceded 
by endothelial cell expression of E-selectin, but vascular cell adhesion molecule 1 
(VCAM-1) is only expressed on endothelial cells at the time of T cell infiltration into 
tissues (Briscoe et al 1995). It has been shown that CD4 Th1 cells express functional 
selectin ligands, but CD4 Th2 cells do not, thereby explaining the selective recruitment 
of CD4 Th1 cells into sites of DTH reactions (Lichtman & Abbas 1997; Borges et al 
1997; Tietz et al 1998; Austrup et al 1997). Chemokine expression by endothelial cells 
stimulated by ischaemia-reperfusion injury and cytokines also plays a role in the 
selective recruitment of T cell subsets in allograft rejection (Kondo et al 1996, 1997; 
Fairchild et al 1997; Nadeau et al 1995; Nagano et al 1997). CD4 Th1 and Th2 subsets 
express different types of chemokine receptors and thus endothelial expression of 
chemokines also contributes to selective diapedesis of T cell subsets.  
Activated endothelial cells are able to costimulate the enhanced IL-2 secretory response 
of CD4 T cells required for proliferation and differentiation (Sperling & Bluestone 
1996; Briscoe et al 1998) predominantly via endothelial LFA-3 (CD58) interacting with 
the T cell receptor CD2 (Hughes et al 1990; Savage et al 1991). Endothelial cell 
expression of B7 is able to costimulate through the CD28/CTLA4 pathways (Sperling & 
Bluestone 1996; Strom et al 1996; Hancock et al 1996). Endothelial cells also 
costimulate effector cytokine (IL-2, IL-4 and IFN- ) production (Briscoe et al 1997; Ma 
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1995; Yellin et al 1995), as well as low levels of CD40 ligands (Reul et al 1997; Mach 
et al 1997). Endothelial cells are able to induce CD40 ligand expression by CD4 T cells 
either through TCR recognition of MHC-class II-alloantigen complexes or T cell 
(CD2)–endothelial (CD58, LFA-3) interactions (Karmann et al 1996). CD40 ligands 
expressed by T cells are able to activate endothelial cell expression of adhesion 
molecules and cytokines (Noelle et al 1992; Hollenbaugh et al 1995). Thus, 
bidirectional CD40:CD40 ligand costimulation of endothelial cells and T cells may be a 
critical factor in allograft rejection (Vierling 1999). This is supported by studies which 
show that i) CD40 is primarily expressed by endothelial cells during allograft rejection 
(Reul et al 1997); ii) inflammatory cytokines stimulate endothelial expression of CD40 
(Noelle et al 1992); iii) recipient endothelial CD40 is crucial for acute allograft rejection 
(Foy et al 1996); iv) interference with CD40:CD40 ligand interactions inhibits 
alloreactivity and prolongs allograft survival (Durie et al 1994a; Larsen et al 1996a; 
Blazar et al 1997; Kirk et al 1997, 2001a; Niimi et al 1998). CD40 ligand stimulation of 
endothelial CD40 by infiltrating lymphocytes or activated platelets induces expression 
of adhesion molecules (E-selectin, ICAM-1 and VCAM-1), cytokines/chemokines (IL-
6, IL-8, leukaemia inhibitory factor) and growth factors (granulocyte-macrophage 
colony-stimulating factor) involved in the recruitment of leukocytes, especially CD4 
Th1 cells into sites of inflammation (Karmann et al 1995; Hollenbaugh et al 1995; Reul 
et al 1997; Henn et al 1998). 
Cytokine-induced expression of adhesion molecules on endothelial cells leads to the 
development of endotheliitis, a histological hallmark of rejection, which is characterised 
by lymphocytic adhesion on the luminal surface, transendothelial migration and 
ultimately peri-endothelial accumulations of lymphocytes. 
 
6.2.  The role of chemokines and chemokine receptors in allograft  
         rejection 
Chemokines are chemoattractant proteins which are classified into four subtypes 
depending on the spacing of cysteine residues within the amino terminal region: C, CC, 
CXC and CX3C. Chemokines have a role to play in leukocyte activation, 
selectin/integrin upregulation, haematopoiesis, angiogenesis and adaptive immunity 
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Functionally, chemokines may be divided into those expressed constitutively in 
secondary lymphoid organs and those induced at sites of tissue inflammation. The first 
group of chemokines, the lymphoid chemokines, are critical for attracting naïve 
lymphocytes into secondary lymphoid organs, where they are activated by antigenic 
peptides presented by dendritic cells (Cyster 1999). The lymphoid chemokines are 
important for immune surveillance (Sallusto et al 2000). The inflammatory chemokines 
function to recruit neutrophils, monocytes, immature dendritic cells and lymphocytes 
during tissue inflammation. The inflammatory chemokines are regulated by pro-
inflammatory stimuli, e.g. IL-1, TNF- , LPS and regulate innate and adaptive immune 
responses. Chemokines mediate their activities through seven transmembrane spanning, 
G-protein-coupled receptors differentially expressed on leukocyte populations and 
somatic tissues (Murphy et al 2000; El-Sawy et al 2002). Chemokine receptors not only 
bind to specific chemokines, but their expression is also regulated according to cell 
subsets (e.g. Th1 cells express CCR5 and CXCR3 and Th2 cells express CCR3 and 
CCR4) and the state of cell activation (e.g. immature DCs express CCR1-6, but mature 
DCs downregulate these six receptors and upregulate CCR7 expression (Sallusto 
1999a,b; Sozzani et al 2000; Colvin & Thomson 2002). The CC and CXC chemokines 
bind to 2 or more receptors, but the C and CX3C chemokines bind to only one receptor. 
The chemokine receptors can bind to more than one chemokine (Murphy et al 2000; 
Nelson & Krensky 2001). Chemokines bind to heparin sulphate proteoglycans and 
glycosaminoglycans on endothelial cells and tissue matrix and are thus able to induce 
directional transendothelial migration of leukocytes.  
In organ transplantation, ischaemia-reperfusion plays an important role in chemokine-
mediated recruitment and activation of non-specific and specific effector leukocytes 
leading to innate immune activation and further propagation of allospecific responses. 
In transplanted organs, chemokine receptors are expressed on a variety of infiltrating 
leukocytes that follow the expression and secretion of corresponding chemokines by 
endothelial, epithelial and stromal cells. Chemokines play a role in antigen-nonspecific 
graft injury (Nelson & Krensky 2001; El-Sawy et al 2002). 
CD4 Th1 and Th2 subsets express different types of chemokine receptors and the 
endothelial expression of chemokines contributes to the selective migration of T cell 
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injury and cytokines also plays a role in selective recruitment of T cell subsets in 
allograft rejection (Nadeau et al 1995; Kondo et al 1996, 1997; Fairchild et al 1997; 
Nagano et al 1997). Chemokines within the micro-environment are also able to promote 
T cell-endothelial cell interaction. Binding of the chemokine stromal cell-derived factor 
1 to endothelial cells enhances leukocyte adhesion to ICAM-1 expressed on 
endothelium (Campbell et al 1998). Following cytokine activation, endothelial cells also 
express chemokine receptors, especially CXCR4 that are able to bind with stromal cell-
derived factor 1 and may promote angiogenesis (Gupta et al 1998). 
Chemokines play a critical role in the recruitment of leukocytes into transplanted organs 
(Melter et al 1999; Nelson & Krensky 2001; El-Sawy et al 2002; Colvin & Thomson 
2002). Two general cascades of chemokine production occur during acute rejection 
(Morita et al 2001). Chemokines are expressed very early following transplantation 
(within 3 – 72 hours) and are part of the innate immune response to tissue injury 
occurring during surgery that is directed at the recruitment of neutrophils, macrophages 
and NK cells. Within minutes following organ reperfusion, pro-inflammatory cytokines 
including TNF-  and IL-1 are produced by graft endothelial and parenchymal cells. 
These cytokines stimulate the vascular endothelium and graft parenchymal cells to 
produce neutrophil- and macrophage-attractant chemokines including IL-8/CXCL8, 
Gro- , MIP-2 and MCP-1/CCL2 at early times post transplant. TNF-  and IL-1 also 
induce upregulated adhesion molecule and MHC molecule expression on vascular 
endothelium (Bergese et al 1995; Dragun et al 2001). The neutrophil chemoattractants 
Gro-  and MIP-2 are produced at high levels within 3 hours of reperfusion resulting in 
rapid neutrophil infiltration (Laskowski et al 2000; Miura et al 2001a). This is followed 
by the production of chemokines directing the recruitment of macrophages, NK cells 
and T cells, i.e. MCP-1/CCL2 and macrophage inflammatory proteins (MIP-1 /CCL3 
and MIP-1 /CCL4), but at lower levels (El-Sawy et al 2002).  
IP-10 (IFN-  inducible protein), a potent attractant of antigen-activated T cells is 
induced by IFN-  and TNF-  (Narumi et al 2000) and may be an important factor 
mediating transition from early non-specific infiltration to allo-antigen-specific graft 
infiltration. MIP-1  preferentially recruits CD8 T cells, whereas MIP-1  preferentially 
recruits CD4 T cells (Krakauer et al 1999). As the initial inflammatory response 
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chemokines (48-72 hours+) include MIG (monokine induced by IFN /CXCL9), IP-
10/CXCL10, I-TAC and RANTES (regulated upon activation normal T cell expressed 
and secreted) (Fairchild 1998). The expression of these late chemokines is dependent on 
the presence of T cells within the allograft and is part of the adaptive immune response. 
The production of the chemokines, except for IP-10, is dependent on locally produced 
IFN- . IP-10 attracts resting and activated T cells, NK cells and monocytes (Krakauer et 
al 1999). MIG attracts resting and activated T cells, whilst RANTES primarily recruits 
memory CD4 T cells, monocytes and eosinophils into the allograft (Krakauer et al 
1999). 
Studies suggest that circulating memory-phenotype CD8 T cells that are not previously 
primed to graft alloantigen are directed to sites of neutrophil-mediated inflammatory 
foci in the vascular endothelium of allografts and T cells with reactivity to allogeneic 
class I are stimulated to produce IFN- . IFN-  binding to IFN-  receptors on the 
endothelial cells stimulates production of MIG by the endothelium. IFN- , IL-8 and 
other chemokines bind to proteoglycans on the endothelial cell surface. As neutrophils 
and macrophages arrest on the endothelial surface, their IFN-  receptors bind the 
immobilised IFN-  and this stimulates the leukocyte to produce MIG and IP-10 as they 
infiltrate the allograft parenchyma (Miura et al 2001b; Kapoor et al 2000; El-Sawy et al 
2002). 
Dendritic cell/chemokine interactions play an important role in allograft rejection. 
Immature dendritic cells migrate to sites of inflammation in response to the inducible 
chemokines (CCL-2-5) released by activated endothelial cells (Sozzoni et al 2000; Caux 
et al 2000) and mature dendritic cells are recruited to secondary lymphoid tissues by 
constitutively expressed chemokines, CCL19 and CCL21 (Colvin & Thomson 2002). 
Chemokines secreted by dendritic cells are involved in T cell recruitment (Colvin & 
Thomson 2002). 
Chemokines may also play a role in chronic allograft rejection. RANTES (CCL5) 
production has been found to correlate with leukocyte infiltration as well as preceding 
intimal thickening of arterial vessels in cardiac allograft vasculopathy (Yun et al 2001). 
Different chemokines may vary in their importance in determining allograft survival 
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gene expression during allograft rejection has shown that CXCL5 and CCL2 expression 
was independent of T cell infiltration, whilst intragraft expression of CCL3, CCL4, 
CCL5, CXCL9, CXCL10, XCL1 and CCL1 was T cell dependent and increased with 
time after transplantation (Carvalho-Gaspar et al 2005). Studies have shown that 
combination therapies blocking chemokine/chemokine receptor expression together 
with administration of immunosuppressive agents (e.g. Cyclosporin A in CCR1 and 
CXCR3 KO models) can result in indefinite graft survival (Gao et al 2000; Hancock et 
al 2000; Colvin & Thomson 2002). Combined CXCR3 and CCR5 blockade has been 
shown to prolong cardiac allograft survival in a fully MHC mismatched murine model 
(Schnickel et al 2006). Combined blockade of CCR1 and CCR5 attenuated the 
development of cardiac allograft vasculopathy (Yun et al 2004). 
 
6.3.  The role of cytokines in acute allograft rejection 
Cytokines are produced by a variety of cells (including lymphocytes, monocytes, 
dendritic cells and stromal cells) involved in the immune response (Abbas et al 1997). 
Cytokines are involved not only in the process of acute rejection of transplanted organs, 
but also in the induction of immunological tolerance. Professional antigen-presenting 
cells, mainly dendritic cells, are essential for initiating the alloimmune response. These 
cells allow for specific activation of T lymphocytes by engagement of the T cell 
receptor and provide co-stimulatory signals. Once activated, alloreactive T lymphocytes 
proliferate and differentiate into effector and helper cells. The majority of helper T cells 
are of the CD4 phenotype, whilst effector T lymphocytes such as cytotoxic T 
lymphocytes (CTL) are mainly CD8
+





cells is influenced by cytokines produced by dendritic cells. Interleukin 12 which is 
secreted by activated dendritic cells facilitates differentiation of CD8
+
 T cells into CTL 
and the differentiation of CD4
+
 T cells into the pro-inflammatory Th1 phenotype (Lane 
& Brocker 1999). The Th1-derived cytokines include IL-2, IL-3, IFN-  and TNF  and 
promote the immunopathological reactions leading to allograft injury. 
Cytokine pathways, however, are highly redundant, as has been shown in acute allograft 
rejection experiments performed in cytokine gene-knockout mice. Despite the essential 
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numbers of allospecific CTLs (Steiger et al 1995; Dai et al 1998). Double gene-
knockout mice deficient in both IL-2 and IL-4 reject fully allogeneic pancreatic islet 
cells as vigorously as wild-type recipients, suggesting that other T cell mitogens whose 
receptors share the common cytokine receptor gamma chain ( c), such as IL-7, IL-9 and 
IL-15 (Alves et al 2007), mediate T cell proliferation in the absence of IL-2 or IL-4 (Li 
et al 1998). Antibodies which target c significantly prolong pancreatic islet allograft 
survival in mice (Chang et al 2000). Interferon-  has been shown in vitro to be a potent 
monocyte and T cell activator, yet the absence of interferon-  or its receptor in recipient 
mice does not delay the acute rejection of fully allogeneic cardiac or pancreatic islet 





 double-knockout mice (Saleem et al 1996). Antagonising IL-12, 
despite inducing Th2 cytokine expression within the allograft, accelerated cardiac 
allograft rejection and this was associated with allograft IFN-  gene expression (Picotti 
et al 1996). Thus, although each cytokine may contribute to the rejection process, no 
single cytokine is necessary for rejection to occur. An exception to cytokine redundancy 
is the finding that IFN-  is essential for acute rejection of MHC class II incompatible 
allografts. It is thought that IFN-  is essential for the initiation of alloimmune responses 
to MHC class II antigens by upregulating MHC class II expression on antigen-
presenting cells and endothelial cells (Goes et al 1995, 1996; Ring et al 1999). 
 
7.  REGULATION OF THE ALLOIMMUNE RESPONSE 
Feedback immune regulatory mechanisms which downregulate activated T 
lymphocytes, are essential for keeping immune responses in check and for maintaining 
tolerance to self-antigens (van Parijs & Abbas 1998). The regulation of an activated T 
cell population leads to a decrease in effector function and eventual disappearance of 
activated T lymphocytes, leaving long-lived functionally quiescent memory 
lymphocytes as the only surviving indicators of previous antigen exposure. 
Intrinsic mechanisms that terminate adaptive immune responses and restore the 
quiescent state of activated alloreactive T cells include deletion (van Parijs & Abbas 
1998; Wells et al 1999), anergy (Schwartz 2003), clonal exhaustion (Bishop et al 1997) 
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alloreactive T cells also receive suppressive signals from regulatory T cells (Wood & 
Sakaguchi 2003; Boschiero et al 2007). 
Activated T cells are shortlived as peripheral deletion mechanisms operate to delete 
specificities from the proliferating lymphocyte repertoires. As the antigenic stimuli and 
the innate immune reaction subsides, lymphocytes fail to acquire signals from survival 
factors and passive cell death (PCD) is triggered as a result of reduced expression of 
members of the anti-apoptotic Bcl family (van Parijs & Abbas 1998; Li et al 2001a). IL-
2 via IL-2R  and gamma chain signaling induces not only T cell proliferation and 
survival, but also sensitizes cells to apoptosis (activation-induced cell death, AICD) via 
the Fas/Fas ligand pathway, a feature that is essential for tolerance induction and is not 
shared by other T cell growth factors (Marrack et al 2000; Li et al 2001a; Khaled & 
Durum 2002; Alves et al 2007). AICD as a result of continued antigenic stimulation 
also leads to death of neighbouring T cells. Interventions that promote PCD via the IL-
15Fc or AICD via the IL-2 Fc induce indefinite allograft survival in mice (Li et al 
2001b). At the costimulatory level, CTLA-4 and a number of other novel negative 
costimulatory molecules exert a negative feedback loop, thereby inhibiting IL-2 
synthesis and progression through the cell cycle (Alegre et al 2001; Sharpe & Freeman 
2002; Greenwald et al 2002, 2005). 
In clinical transplantation, longterm regulation of the allo-immune response and 
tolerance induction is difficult as the transplanted organ is not only highly antigenic, but 
a persistent source of alloantigens and there is marked redundancy of activation 
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LITERATURE REVIEW :  IMMUNOSUPPRESSIVE 
AGENTS 
 
1.  INTRODUCTION 
T cells play a central role in the specific immune response of an acute allograft 
rejection. The generation of the immune response to most antigens is critically 
dependent on the initial phase of T cell activation and proliferation. Immunosuppressive 
regimens have looked at preventing T cell activation or effector function. Prior to 
interaction with the antigen-presenting cell and recognition of the alloantigen, the 
mature resting T cell is in the G0 phase of the cell cycle. Following contact with the 
antigen-presenting cell and binding of the alloantigen presented in the context of the 
MHC molecule to the T cell receptor (TCR) on the T lymphocyte surface through either 
direct or indirect pathways, T cell activation is initiated, resulting in generation of 
signals required for cell cycle entry (G0 – G1 phase transition) (Colvin 1990; Sayegh et 
al 1994) and the expression of high affinity receptors for T-cell growth factors including 
IL-2 and IL-4. 
Following engagement of the TCR with the alloantigens, a series of tyrosine kinases 
including Lck, Fyn and ZAP-70 are recruited and activated, resulting in phosphorylation 
and activation of phospholipase C and a rise in intracellular calcium (Colvin 1990). The 
rise in intracellular calcium leads to activation of calcineurin, a serine-threonine 
phosphatase that transduces signals to the nucleus to transcribe genes encoding 
cytokines that are required for the transition of the T cell from the resting to the 
activated state. In order to sustain full T cell activation, additional co-stimulatory 
signals need to be provided by the antigen-presenting cells (Steinman & Young 1991). 
The co-stimulatory signals driven by CD28, synergise with TCR stimulation, allowing 
transcription of genes for cytokines that induce T cells to move from the resting G0 
phase to the activated G1 state (Schwartz et al 1989; Schwartz 2003; Appleman & 
Boussiotis 2003). The progression from G1 to the S phase is regulated through the 












and all acting on common intracellular elements in a pathway that controls enzymes 
such as the cyclin/cyclin-dependent kinases that are important in the induction of cell 
division. De novo purine and pyrimidine synthesis is required in order for lymphocytes 
to complete cell division. Immunosuppressive agents interacting at different steps in 
these pathways help prevent T-cell activation and proliferation and control graft 
rejection. 
At present, the standard immunosuppressant regimens include 5 drug classes: 
1. Calcineurin inhibitors – Cyclosporin, FK506 (Tacrolimus). 
2. Antimetabolites – azathioprine, mycophenolate mofetil 
3. Corticosteroids 
4. mTOR inhibitors – Rapamycin (Sirolimus) 
5. Anti-T cell antibodies – ATG (antithymocyte globulin), anti-CD3 antibody 
(OKT3), IL-2 receptor antibody 
 
At present, costimulatory blockade, as discussed in Chapter 5, is not in routine practice. 
Immunosuppressive agents act as pharmacological probes of lymphocyte signal 
transduction as characterisation of the biochemical processes altered by 
immunosuppressives, yields important information regarding signal transduction 
pathways involved in T-cell activation. They also provide insight into the potential 
development of novel immunosuppressants. 
The calcineurin inhibitors (Cyclosporin and FK506/Tacrolimus) and the mMTOR 












2.  CALCINEURIN INHIBITORS 
2.1.  Cyclosporin and FK506 (Tacrolimus) 
Cyclosporin and FK506 are both microbial products with potent immunosuppressant 
properties resulting in a selective inhibition of T cell activation. Cyclosporin was 
isolated from cultures of the fungus Tolypocladium inflatum gams from a soil sample 
collected in Southern Norway (Petcher et al 1976), whilst FK506 (Tacrolimus) (Kino et 
al 1987a) was isolated in the fermentation broth of Streptomyces tsukubaensis, a soil 
micro-organism found in soil samples collected in the Tsukuba area of Northern Japan. 
Cyclosporin is a cyclic undecapeptide with hydrophobic characteristics due to N-
methylation of 7 of the 11 peptide nitrogens and shielding of the hydrophilic side chains 
at positions 11, 1 and 2 in the internal side of the molecule (Mason 1992). FK506 is a 
macrolide lactone with a hemiketal-masked ,  - diketoamide incorporated into a 23 
member ring (Tanaka et al 1987a,b). Although chemically unrelated, Cyclosporin and 
FK506 both inhibit similar subsets of calcium-dependent activation pathways (Lin et al 
1991) involved in the regulation of lymphokine gene expression, activation-driven T 
cell death and exocytosis. Cyclosporin and FK506 both exert their inhibitory effect 
during the G0 to G1 phase of T cell activation and block the expression of the same set 
of early lymphokine genes (Tocci et al 1989; Metcalfe & Richards 1990).  
 
2.1.1.  Biochemical targets and mechanisms of action of calcineurin inhibitors 
Cyclosporin and FK506 only become biologically active, when complexed with distinct 
endogenous intracellular receptors (cytosolic binding proteins) known as 
immunophilins. These intracellular receptors are abundant, ubiquitous and 
phylogenetically well conserved (Koletsky et al 1986; Siekierka et al 1990). The major 
cytosolic receptor for Cyclosporin is cyclophilin A, a 18 kDa protein (Harding et al 
1986), whilst the major FK506 binding protein (FKBP) is a 12 kDa cytosolic protein 
named FKBP12 (Siekierka et al 1989; Harding et al 1989).  Cycophilin A (Takahashi et 
al 1989; Fischer et al 1989) and FKBP12 (Siekierka et al 1989; Harding et al 1989) are 
peptidyl-prolyl isomerases (PPIases), which catalyse the cis-trans isomerisation of 
peptidyl-prolyl bonds in peptides and proteins. FKPB12 prefers substrates with 












which is a more promiscuous enzyme (Harrison & Stein 1990). Although, Cyclosporin 
(Takahashi 1989; Fischer et al 1989) and FK506 (Siekierka et al 1989; Harding et al 
1989) both act as inhibitors of the PPIase activity of their respective cytosolic binding 
proteins, the inhibition of the PPIase activity is unrelated to their immunusuppressive 
properties (Bierer et al 1990b; Sigal et al 1991; Dumont et al 1994). The formation of 
the immunophilin-drug complexes is essential for the biological activity of Cyclosporin 
and FK506, in a gain-of-function model. These active complexes interfere with 
intracellular calcium-dependent signal transduction pathways, processes that are central 
to T cell activation (Bierer et al 1990a, 1990b; De Franco 1991; Schreiber 1991; 
Schreiber & Crabtree 1992). The common biological target for these drug-
immunophilin complexes is the calcium- and calmodulin-dependent serine-threonine 
phosphatase, calcineurin (Liu et al 1991; Fruman et al 1992; Schreiber & Crabtree 
1992), a critical, rate-limiting component of the TCR-linked signal transduction 
pathway leading to cytokine gene transcription (O'Keefe et al 1992; Clipstone & 
Crabtree 1992; Shibasaki et al 2002).  
The signal transduction cascade begins with antigen presentation to the T cell receptor 
which leads to an increase in intracellular calcium (Liu 1993) and a subsequent 
activation of the calmodulin-calcineurin complex. The nuclear factor of activated T cell 
(NF-AT) plays an essential role in conveying the signal from the cytoplasm to the 
nucleus in order to activate transcription of the IL-2 genes (Shaw et al 1988; Sigal & 
Dumont 1992; McCaffrey et al 1993). This T-cell specific transcription factor has two 
subunits, one of which is phosphorylated and thereby confined to the cytoplasm, while 
the other is predominantly nuclear (Flanagan et al 1991). IL-2 gene transcription can 
only take place once the nuclear and cytoplasmic NF-AT subunits are combined. An 
increase in intracellular calcium activates calcineurin phosphatase, which then 
dephosphorylates the cytoplasmic NF-AT. The dephosphorylated cytoplasmic NF-AT 
subunit is then free to translocate to the nucleus and associate with the nuclear subunit, 
thus forming a fully active NF-AT complex, an essential component of the 
transcriptional apparatus required for the expression of IL-2 and other pro-inflammatory 
cytokine genes such as IL-3, IL-4, IFN-  and TNF (Flanagan et al 1991). The 
immunophilin-drug complexes of Cyclosporin and FK506 inhibit the transcriptional 
activity of NF-AT by preventing the assembly of a functional transcription factor 












of a drug-immunophilin complex interfere with the TCR-mediated activation of 
calcineurin, thereby blocking transcription of the IL-2 gene in T lymphocytes (O’Keefe 
et al 1992; Sigal & Dumont 1992; Fruman et al 1992; Siekierka 1994; Crabtree & 
Clipstone 1994).  
In addition, both Cyclosporin and FK506 block the activation of JNK and p38 
pathways, but not the ERK pathway during T cell activation. This inhibition occurs at a 
level upstream of mitogen-activated protein kinase (MAPK) kinase kinase (MAPKK-K) 
and is independent of calcineurin inhibition (Matsuda et al 2000). The inhibition of both 
the calcineurin-dependent NF-AT pathway and the calcineurin –independent JNK and 
p38 activation pathways leads to impaired IL-2 gene transcription (Matsuda at al 1998, 
2000). Since IL-2 plays a critical role as a growth and regulatory factor for T cells, 
inhibition of IL-2 production is one of the principal mechanisms of immunosuppression 
by FK506 and Cyclosporin.  
Cyclosporin has been shown to affect the lymphocyte plasma membrane causing early 
depolarisation (Damjanovich et al 1987) and transient rigidification (Niebylski et al 
1991). Cyclosporin has also been shown to increase the production of lysophospholipid 




-ATPase which is upregulated during T 
cell activation (Anderson et al 1993). 
 
2.1.2.  Effect on T lymphocyte proliferation 
FK506 and Cyclosporin inhibit calcium-dependent T cell activation pathways triggered 
by the T cell receptor/CD3 complex (Kay et al 1989a,b; Johansson & Möller 1990; Lin 
et al 1991; Bierer et al 1991a; Jiang et al 1991), the cell surface CD2 receptor (Kay & 
Benzie 1989; Bierer et al 1991b) and the combination of protein kinase C activation and 
calcium influx (Kay et al 1989b; Dumont et al 1990a, 1990b). 
This has been demonstrated using in vitro models of murine and human T cell 
proliferation in response to a variety of the stimuli. Both Cyclosporin and FK506 have 
been shown to inhibit T cell proliferation in response to mitogenic lectins such as 
Concanavalin A (Con A) and phytohaemagglutinin A (PHA); monoclonal antibodies 
against the T cell receptor/CD3 complex and other cell surface receptors and the 












1989a,b, 1990; Bloemena et al 1989; Dumont et al 1990b; Johansson and Möller 1990; 
Bierer et al 1991a)).  Cyclosporin and FK506 also suppress proliferation of alloreactive 
cells in mixed lymphocyte reactions (MLR) (Hess & Tutschka 1980; Kino et al 1987b; 
Yoshimura et al 1989a; Thomas et al 1990), as well as inhibit antigen-specific 
proliferation of cloned helper and cytotoxic T-cells (Herold et al 1986; Sawada et al 
1987; Havele & Paetkau 1988). FK506 is approximately 30-100 times more potent than 
Cyclosporin in vitro in inhibiting T cell proliferative responses including mixed 
lymphocyte reactions and cytotoxic T-cell generation (Kino et al 1987b; Sawada et al 
1987), exhibiting an IC50 of approximately 0.2 nM – 0.5 nM  as compared to the IC50 
of 10 to 100 nM seen with Cyclosporin (Sigal & Dumont 1992). In addition, in the 
concentration range similar to that which inhibits cell division, FK506 has also been 
shown to inhibit the generation of cytotoxic T cells specific for allogeneic targets. In 
vitro cellular cytotoxicity mediated by NK cells and killer cells and antibody-dependent 
cell-mediated cytotoxicity is unaffected by FK506 (Beck & Akiyama 1989; Markus et 
al 1991; Wasik et al 1991; Alamartine et al 1994). Cyclosporin also fails to inhibit 
alloreactive NK cell proliferation and cytotoxicity (Lefkowitz et al 1988; Kosugi & 
Shearer 1991; Petersson et al 1997). 
In a human MLR model, Cyclosporin and FK506 inhibited induced FOXP3 gene 





following alloantigen stimulation (Lim et al 2007) as well as inhibiting de novo FOXP3 




 T cells in vitro (Gao et al 2007). 













 Tregs in renal transplant recipients (Korczak-Kowalska et al 2007). 
Cyclosporin inhibits the differentiation of both FOXP3
+
 Tregs and CD4 Th17 cells 





 regulatory T cells following alloantigen stimulation (Uss et al 2007). 
However, even at M concentrations, Cyclosporin and FK506 have been shown to have 
little effect on the proliferative responses induced by growth-promoting cytokines such 
as IL-2 or IL-4 (Hess et al 1982; Kino et al 1987b, Yoshimura 1989b; Kay et al 1989b; 
Dumont et al 1990a,b). Cyclosporin and FK506 have no effect on calcium-independent 
T cell activation such as that triggered by the CD28 surface molecule or protein kinase 












al 1991a; Chang et al 1991; Lin et al 1991). The calcium-independent CD28 pathway is 
an alternative pathway of the T cell activation, which is triggered by the interaction of 
the CD28 molecule on T cells with its specific ligands B7-1 and B7-2 expressed on 
monocytes/macrophages and activated B cells and serves as a co-stimulatory signal for 
the TCR/CD3 pathway resulting in markedly enhanced IL-2 production (Fraser et al 
1991).  
Both Cyclosporin and FK506 act early in T cell signal transduction, blocking calcium-
dependent T-cell division between the resting phase G0 and activation phase G1 of the 
cell cycle and suppressing the transcription of early phase cytokine genes (Tocci et al 
1989; Metcalfe & Richards 1990; Chang et al 1991; Morris et al 1991). As a result, the 
anti-proliferative effect is only observed, when both drugs are added within the first few 
hours of T cell stimulation (Hess & Tutschka 1980; Kay & Benzie 1984; Tocci et al 
1989; Kay et al 1989b, 1990; Dumont et al 1990b; Metcalfe & Richards 1990; 
Henderson et al 1991). The inhibitory activity of FK506 and Cyclosporin on T-cell 
proliferation is only partially reversed by exogenously added IL-2 (Hess 1985; Gelfand 
et al 1987; Dumont et al 1990b; Lin et al 1991), suggesting that both agents are 
effective only when endogenous IL-2 is involved in T lymphocyte growth and that other 
gene products and pathways critical for cell cycle progression remain intact. 
 
2.1.3.  Effect on cytokine gene expression and production 
T cell activation is initiated by the recognition of foreign antigen via the TCR/CD3 
complex. The TCR/CD3 mediated signaling pathway simultaneously requires the help 
of cytokines such as IL-1 and IL-6 that are produced by antigen-presenting cells 
(Weaver & Unanue 1990). These signals produced at the cell membrane are transferred 
into the nucleus of T lymphocyte through a complex series of biochemical reactions 
(Nel 2002). FK506 (Kay et al 1989a,b) and Cyclosporin (Bijsterbosch & Klaus 1985) 
do not affect the early events in these processes such as the generation of the 
intracellular second messengers, inositol triphosphate (IP3) and diacylglycerol (DAG), 
which result in the increase in intracellular concentration of calcium and activation of 
protein kinase C (PKC) respectively and the subsequent phosphorylation of some 
cytoplasmic proteins (Fidelus & Laughter 1986; Fujii et al 1989; Bierer et al 1990b; 












crucial for T cell activation and proliferation is eventually induced. Both FK506 and 
Cyclosporin inhibit these more distal components of the T cell activation pathway. 
Cyclosporin has been shown to inhibit the expression of IL-2 gene in heterogenous T 
cell populations (Kronke et al 1984; Granelli-Piperno 1988a, 1990) as well as in cloned 
T-cell lines (Herold et al 1986). FK506 has been shown to inhibit the transcription of 
mRNA for several cytokines including IL-2, IL-3, IL-4, GM-CSF, TNF- , and 
interferon  (Tocci et al 1989) at an in vitro concentration 10 to 100 times less than that 
for Cyclosporin. Both FK506 and Cyclosporin have been shown in vitro to inhibit TNF-
 and IL-Iβ production by PBMCs stimulated with immobilised anti-CD3/CD28 
monoclonal antibody, but FK506 was a more potent inhibitor (Sakuma et al 2000). 
FK506 is similarly more potent than Cyclosporin in inhibiting transcription of proto-
oncogenes such as ras, myc and rel as well as suppressing the IL-2 and IL-7 receptor 
expression (Peters et al 1993; Morris 1993, 1996; Manez et al 1995; Thomson et al 
1995; De Mattos et al 1996). FK506 and Cyclosporin both preferentially suppress 
cytokine production stimulated by Th1 cells (such as IL-2, TNF-  and interferon-  
which are important in cell-mediated immunity) over cytokines produced by Th2 cells 
such as IL-4, IL-5 and IL-10 which are more involved in B cell stimulation and 
antibody production (Thomson et al 1995).  
FK506 (Bierer et al 1991a) and Cyclosporin (Thompson et al 1989) do not inhibit IL-2 
production in the calcium-independent CD28 pathway, an alternative pathway for T cell 
activation. FK506 and Cyclosporin only inhibit activation events which result in a 
notable rise in intracellular calcium concentration.  
FK506 and Cyclosporin directly interfere with the transcription of the IL-2 gene 
(Bunjes et al 1981; Dos Reis & Shevach 1982; Kronke et al 1984; Granelli-Piperno et al 
1984; Tocci et al 1989). The IL-2 gene is silent in resting T cells, but is activated after 
antigen recognition by the specific TCR/CDR complex and subsequent signal 
transduction into the nucleus. As discussed above, the expression of the IL-2 gene is 
controlled by the interaction of specific nuclear transcription factors with their 
corresponding DNA sites on the IL-2 gene enhancer/promoter (Fujita et al 1986; 
Durand et al 1988; Crabtree 1989). Several transcription factors including NF-AT, NF-
B, AP-1 and Oct-1 are involved in regulation of IL-2 gene expression. NF-AT (nuclear 












cells (Shaw et al 1988), whilst the others are commonly found in almost all cells and 
tissues and are responsible for regulation of the transcription of various genes. 
Cyclosporin and FK506 specifically inhibit the binding of NF-AT to its binding site on 
the IL-2 enhancer, have no effect on AP-1 binding activity and the binding of NF- B 
and Oct-1 is only marginally affected (Emmel et al 1989; Granelli-Piperno et al 1990; 
Mattila et al 1990). The highly restricted distribution of the cytoplasmic NF-AT may 
account for the selective action of FK506 and Cyclosporin on T cells. Both Cyclosporin 
and FK506 inhibit calcium-dependent activation of NF- B multimers which requires 
new protein synthesis, but protein synthesis-independent induction of NF- B by PMA 
is not suppressed (Mattila et al 1990). 
Cyclosporin does not inhibit the transcriptional initiation of the IL-2 receptor (IL-2R) 
gene (Reed et al 1986; Tocci et al 1989), but in vitro studies have shown that IL-2R 
expression is variably inhibited by Cyclosporin and Tacrolimus depending on the 
stimulus and duration of culture (Lillehoj et al 1984; Ryffel et al 1995; Dumont et al 
1990b; Foxwell et al 1990; Woo et al 1990c) and can be reversed by the addition of 
exogenous IL-2. 
Activation of T-cells with ionomycin plus PMA results in the rapid disappearance of 
ets-1 mRNA which is normally expressed constitutively by mature T cells (Bhat et al 
1990). FK506 has been shown to block this downregulation, thereby restoring ets-1 
mRNA expression to a resting level (Dumont et al 1991). 
 
2.1.4.  Other immunosuppressive effects 
FK506 and Cyclosporin do not inhibit T cell adhesion (Eiras et al 1991), but FK506 
inhibits migration of CD4 and CD8 T cells in response to various chemotactic factors 
(Adams & Liu 1996). FK506 and Cyclosporin have been shown to inhibit various types 
of exocytosis-related events in both lymphocytes and non-lymphocytes including TCR-
mediated degranulation of cytotoxic T cells (Dutz et al 1993), calcium ionophore-
induced degranulation of neutrophils and basophils (Forrest et al 1991; De Paulis et al 
1992) and IgE receptor mediated histamine and serotonin release from mast cells and 












Cyclosporin and FK506 have been shown to inhibit the release of granule-associated 
serine esterase from murine cytotoxic lymphocytes triggered with anti-CD3 or by the 
combination of calcium ionophore and PMA (Lancki et al 1989; Trenn et al 1989; Dutz 
et al 1993). Thus, both Cyclosporin and FK506 interfere with calcium-dependent 
cytoplasmic events that control the vectorial translocation of secretory granules across 
the plasma membrane.  
Cyclosporin blocks activation induced cell death (AICD) of peripheral T cells (Wells et 
al 1999; Li et al 1999; Strauss et al 2002; Takahashi et al 2004). FK506 has been shown 
to inhibit activation induced cell death (Strauss et al 2002; Takahashi et al 2004) as well 
as augment activation induced cell death of peripheral T cells (Migita et al 1995). 
Activation induced cell death is required for the generation and maintenance of self-
tolerance and therefore calcineurin inhibitors  may interfere with the potential to 
develop allograft tolerance. 
Cyclosporin has been shown to induce increased PGE production by human monocytes. 
This increased PGE production was sensitive to indomethacin, a non-selective 
cyclooxygenase inhibitor, but Cyclosporin also increased the availability of free 
arachidonic acid (Whisler et al 1984). 
 
2.1.5.  Effect on B lymphocytes 
Cyclosporin and FK506 inhibit the proliferative response of purified murine and human 
B cells induced by stimuli which result in the rapid increase in intracellular calcium 
levels including anti-IgM antibodies, Staphylococcus aureas Cowan strain 1 (SAC) or 
phorbol ester plus calcium ionophore at concentrations that inhibit T-cell responses 
(Klaus 1988; Walliser et al 1989; Wicker et al 1990; Morikawa et al 1992), whereas 
calcium-independent lipopolysaccharide-induced B cell proliferation is not affected by 
FK506 (Walliser et al 1989). In vitro, FK506 inhibits IgM and IgG production by 
mitogen-stimulated human B lymphocytes, but does not inhibit IL-6 production 
(Yoshimura et al 1989b) or IL-6-induced IgM and IgG production (Yoshimura et al 
1989b; Stevens et al 1991). In vivo, FK506 suppresses T-cell dependent IgM production 
by murine and rat splenic plasma cells (Kino et al 1987a,b; Woo et al 1988, 1990b; 
Tsuji et al 1990; Lagodzinski et al 1991). These effects may be attributed in part to 












1990), but FK506 also has a direct inhibitory effect on calcium-dependent B cell 
activation. FK506 and Cyclosporin block induction of the TNF-  gene transcription by 
anti-Ig antibody in human B cells (Goldfeld et al 1992). FK506 also appears to inhibit 
human B cell proliferation responses to certain calcium-independent stimuli including 
the protein kinase C activator PMA and IL-2 (Morikawa et al 1992). FK506 and 
Cyclosporin block B cell division in the late activation G1 phase of the cell cycle and as 
a result, inhibition of B cell proliferation is evident, even when the drug is added as late 
as 24 hours following the stimulation with anti-IgG (Muraguchi et al 1983; Wicker et al 
1990). FK506 causes cell death upon activation of murine B cells (Wicker et al 1990).  
 
2.1.6.  Effect on non-lymphoid cellular activation 
Cyclosporin and FK506 do not affect IL-1 mRNA expression or production by 
macrophages (Granelli-Piperno 1988b; Tocci et al 1989). Low doses of Cyclosporin 
have been reported to inhibit LPS-induced TNF-  bio-activity in the supernatant of 
macrophage cultures, but do not block expression of TNF-  mRNA, thus suggesting 
that Cyclosporin may affect a post-transcriptional step of TNA-  biosynthesis in 
macrophages (Nguyen et al 1990). FK506 does not interfere with antigen presentation 
nor modify mononuclear phagocyte function (Peters et al 1993; Manez et al 1995; 
Thomson et al 1995; Morris 1996). Cyclosporin has been shown to inhibit alloantigen 
presentation by murine macrophages without affecting the expression of MHC class II 
molecules (Little et al 1990). The doses of Cyclosporin required to suppress antigen 
presentation are much higher than those required to suppress cytokine production. The 
concentration of FK506 which results in significant inhibition of soluble antigen-
induced human T-cell proliferation does not significantly impair the accessory function 
of mononuclear phagocytes (Woo et al 1990a) and thus direct inhibition of antigen 
processing does not appear to be an important factor in the in vivo mechanism of action 












3.  mTOR INHIBITORS 
3.1.  Rapamycin 
Rapamycin is a lipophilic macrolide, produced by a strain of Streptomyces 
hygroscopicus, isolated from a soil sample on Easter Island, with both 
immunosuppressive and anti-proliferative properties (Sehgal et al 1975; Vezina 1975). 
Unlike Cyclosporin and Tacrolimus, it does not inhibit early phase lymphocyte 
activation genes, but is a potent inhibitor of cytokine and growth-factor mediated 
cellular proliferation, thereby preventing cell cycle progression from the G1 to the S 
phase in the T cells (Terada et al 1993; Sehgal et al 1995; Sehgal 1995, 1998).  
 
3.1.1.  Biochemical targets and mechanisms of action of Rapamycin 
Rapamycin binds to the immunophilin, FKBP12, but the mechanism of action of 
rapamycin is distinct from that of Cyclosporin or FK506. The immunosuppressive 
effects of rapamycin relate to the formation of the rapamycin-FKBP12 complex (Wood 
& Bierer 1994; Wiederrecht & Etzkorn 1994; Galat & Metcalfe 1995). Although the 
formation of the rapamycin-FKBP12 complex is essential for rapamycin’s biological 
activity, the inhibition of the immunophilin’s PPIase activity is not associated with the 
drug’s immunosuppressive properties (Sehgal et al 1994; Wood & Bierer 1994; 
Wiederrecht & Etzkorn 1994; Galat & Metcalfe 1995). The formation of the drug-
immunophilin complex results in “gain of function” with the complex modulating the 
activity of other specific intracellular targets. 
The rapamycin-FKBP complex binds to a specific cell-cycle regulatory protein called 
the mammalian target of rapamycin (mTOR) and inhibits its activation. Despite their 
structural similarity and shared immunophilins, the mechanism of rapamycin is distinct 
from FK506. FK506, like Cyclosporin, inhibits T cell proliferation in the G0-G1 phase 
of the cell cycle and rapamycin prevents cell cycle progression from G1-S phase in 
various cell types (Terada et al 1993; Albers et al 1993; Jayaraman & Marks 1993; 
Marx et al 1995). 
Unlike Tacrolimus and Cyclosporin, the rapamycin-FKBP12 complex does not inhibit 












rapamycin-FKBP12 complex to mTOR (Abraham & Wiederrecht 1996; Abraham 
1998). 
Like FK506, rapamycin has 2 domains – an effector domain forming a composite 
surface with FKBP which interacts with mTOR and a binding domain which mediates 
the interaction with FKBP. The FK-binding domain is conserved in FK506 and 
rapamycin and both drugs compete for this domain resulting in mutual antagonism 
(Dumont et al 1990a; Bierer et al 1990a). In mTOR, the binding domain is a 133 
hydrophobic amino acid region just upstream of the lipid kinase domain, and contains a 
critical serine residue (Ser
2035
) (Chiu et al 1994; Chen et al 1995). The FKBP12-
rapamycin complex binds to and inhibits the function of the target protein, mTOR, a 
serine-threonine kinase with homology to phosphotidyl-inositol 3-kinase (PI-3-kinase). 
mTOR autophosphorylates its serine residues (Zheng et al 1995).  
mTOR plays a critical role in the signal 3 pathway of T cell activation leading to 2 
pathways of translational control by mitogenic stimuli – the activation of p70
S6
 kinase 
pathway and the eIF-4E/PHAS-I pathway (Abraham & Wiederrecht 1996; Abraham 
1998; Rowinsky 2004; Jastrzebski et al 2007). mTOR is a downstream mediator of the 
PI-3-kinase/AKT signaling pathway and plays a central role controlling cellular growth 
and division (Schmelzle & Hall 2000; Gingas et al 2001; Huang et al 2003; Fingar & 
Blenis 2004). mTOR, once activated, transduces signals that initiate synthesis of 
ribosomal proteins, translation of a specific subset of messenger RNA transcripts and 
generation of cyclin-dependent kinases, promoting the progression of the cell cycle, 
leading to activation, growth and proliferation of T and B cells and antibody production 
(Brown & Schreiber 1996; Abraham & Wiederrecht 1996; Abraham 1998; Gummert et 
al 1999; Rovira et al 2000; Lee & Hung 2007). 
Following the calcium-dependent signal 1 pathway and in the presence of the calcium-
independent signal 2 pathway, the nuclear factor of activated T-cells (NF-AT) is 
dephosphorylated after activation of calcineurin. Following transition to the nucleus, 
NF-AT promotes cytokine and growth factor transcription. These growth factors, 
including IL-2, IL-4, IL-7, IL-12, IL-15, IFN- , platelet-derived growth factor, basic 
fibroblastic growth factor, transforming growth factor-  and insulin bind in an autocrine 
or paracrine manner to their specific receptors on the cell surface thereby delivering 












autophosphorylation. T-cell activation via CD28 is also sensitive to rapamycin, 
suggesting that mTOR activation is also possible through signal 2. 
As a result of the binding of the FKBP12-rapamycin complex to its effector protein 
mTOR, a number of biochemical events essential for cell cycle progression are 
inhibited, resulting in cell arrest in the late G1 phase just prior to entry into the S phase 
(Bierer et al 1990a; Morice et al 1993; Terada et al 1993; Sehgal 1995, 1998). The 
Rapamycin-FKBP12 complex inhibits mTOR and the signal 3 pathway, i.e. G1-S 
transition, translation and cytokine-driven T-cell proliferation. 
Rapamycin inhibits activation of p70
S6
 kinase which is critical for phosphorylation of 
the ribosomal S6 protein, a protein involved in the efficient translation of critical cell-
cycle regulatory proteins (Sehgal et al 1994; Wood & Bierer 1994). Rapamycin-
FKBP12 complex does not inhibit p70
S6
 kinase activation in a cell-free system, 
suggesting that rapamycin may mediate its inhibition by direct or indirect inhibition of 
other phosphatases (Wood & Bierer 1994). Rapamycin disrupts a Ras-dependent signal 
transduction pathway required for the activation of the p70
S6
 kinase. 
The initial activation step of peripheral T lymphocytes results in expression of all three 
G1 cyclins (D2, E and A) together with their appropriate cdk partners (cdk4, cdk6 and 
cdk2 respectively) (Firpo et al 1994). The activity of the cyclin-cdk complexes depends 
on a signal provided by IL-2 and other growth promoting cytokines. Rapamycin 
significantly decreases the kinase activity of the cyclin-dependent kinase 4-cyclin D and 
cyclin-dependent kinase 2-cyclin E complexes (Firpo et al 1994; Sehgal et al 1994; 
Wood & Bierer 1994) which normally reach their peak in the mid to late G1 phase 
(Sherr 1994). The activation of the cyclin-dependent kinases during cell cycle 
progression involves a change in their stoichiometry with the cyclin-dependent kinase 
inhibitors p21 and p27
kip1
. Rapamycin blocks removal of the kinase inhibitor p27 from 
the cdk/cyclin complexes, thus preventing the activation of the cyclin-dependent kinase-
cyclin complexes (Nourse et al 1994). Thus, the block in the cell cycle progression into 
the G1 phase is partly due to the persistance of high levels of p27
kip1 
in activated T cells. 
IL-2 stimulation overcomes the p27
kip1 
induced block by inducing both a progressive 
decrease in p27
kip1
 protein levels and the assembly of additional G1 cyclin-cdk 
complexes (Firpo et al 1994; Nourse et al 1994). The degradation of p27
kip1 
occurs via 












downregulation of the Kip1 protein which is normally induced by IL-2 and as a result 
the G1 cyclin-cdk complexes remain saturated with p27
kip1 
and are unable to execute 
critical regulating functions such as hyperphosphorylation of the retinoblastoma protein 
(Terada et al 1993) as well as preventing disassociation of the retinoblastoma-E2F 
complex which occurs following activation of cdk4/cyclin D and cdk2/cyclin E 
complexes. As a result, there is a decreased synthesis of cell cycle proteins, cdc2, cyclin 
A (Flanagan & Crabtree 1993) and TTK, a serine threonine tyrosine kinase (Schmandt 
et al 1994), events that are important in enabling progression through the G1 phase of 
the cell cycle. mTOR, the target of the FKBP12-Rapamycin complex is a critical 
component of the signaling pathway marking the Kip1 protein for ubiquitin-dependent 
proteolysis (Abraham & Wiederrecht 1996). 
Rapamycin has been shown to inhibit p70
56 
kinase mediated activation of CREM τ, a 
member of the cAMP-responsive element binding factor (CREB/ATF) family, thereby 
blocking cAMP-induced late gene transcription (de Groot et al 1994). Rapamycin has 
also been shown to selectively block IL-2 –induced transcription of proliferating cell 
nuclear antigen (PCNA), an obligate cofactor of DNA polymerase- , an important 
component for DNA replication (Feuerstein et al 1995). Rapamycin inhibited the 
binding of CREB/ATF transcription fact rs to CRE elements in the murine proximal 
PCNA promotor, suggesting that rapamycin may inhibit PCNA gene expression by 
preventing the interaction of CREB/ATF transcription factors with CRE elements in the 
proximal PCNA promotor (Feuerstein et al 1995). 
Rapamycin inhibits CD28 mediated down-regulation of I B  resulting in the inhibition 
of nuclear translocation of c-Rel, a CD28 response element-binding factor that causes 
sustained upregulation of IL-2 gene expression (Lai & Tan 1994). 
3.1.2.  Effect on lymphocyte proliferation 
Rapamycin inhibits both calcium-dependent and -independent T cell activation 
pathways (Sehgal et al 1994; Wood & Bierer 1994).  
In vitro studies have shown that rapamycin inhibits murine, porcine and human T 
lymphocyte proliferation in response to the following stimuli: mitogenic lectins, 
antigen, cross-linking of receptors with monoclonal antibodies (anti-CD3 and anti-












IL-4 and IL-6). The IC50 values range from 0.1 – 300 nM depending on the stimulator 
(Sehgal & Bansbach 1993; Sehgal et al 1994; Wood & Bierer 1994; Sehgal 1995, 
1998). Rapamycin inhibits proliferation of activated T cells when the drug is added up 
to 12 hours after stimulation, whereas Cyclosporin and FK506 are ineffective when 
added 2 hours after activation (Dumont et al 1990b; Sigal & Dumont 1992; Sehgal & 
Bansbach 1993). IL-12, IL-7 and IL-15 dependent T cell proliferation is inhibited by 
rapamycin (Bertagnolli et al 1994; Sehgal et al 1994). Thus, unlike Cyclosporin and 
FK506 which block calcium-dependent cytokine transcription early in the G1 phase, 
rapamycin inhibits cytokine mediated signal transduction pathways later in the G1 
phase. (Feuerstein et al 1995). 
Rapamycin is able to induce T cell clonal anergy even in the presence of full T cell 
activation (Signal 1 and 2) by interrupting the biochemical events which would occur 
during the progression through the cell cycle from G1 into the S phase (Powell et al 
1999). 











 T effector cells (Battaglia et al 2005, 





 T cells (Gao et al 2007). Rapamycin, but not Cyclosporin, 







Tregs (Coenen et al 2007a). Rapamycin has also been shown to simultaneously promote 
TGF- -mediated generation of murine FOXP3
+
 Tregs and inhibit TGF- /IL-6 mediated 
differentiation of CD4 Th17 cells (Kopf et al 2007).  In a human MLR model, 
Rapamycin does not inhibit the induction of FOXP3 gene transcription (Baan et al 
2005), but has been shown to inhibit the expansion of naturally occurring Tregs (Lim et 







 Tregs (Korczak-Kowalska et al 2007). In a MLR model, Rapamycin 




 T regulatory cells 
(Uss et al 2007). 
Rapamycin also suppresses natural killer, lymphokine-activated killer and antibody-
dependent cell cytotoxicity functions of human lymphocytes, but at concentrations that 












Rapamycin is able to preserve or promote activation induced cell death of peripheral T 
cells (Wells et al 1999; Li et al 1999; Takahashi et al 2004; Gao et al 2007). 
Rapamycin inhibits IL-2 dependent as well as independent proliferation of purified 
normal human B cells in response to Staphylococcus aureus and soluble CD40L in the 
mid-G1 phase of the cell cycle (Aagaard-Tillery & Jelinek 1994). It prevents 
Staphylococcus aureus-induced and IL-2 or IL-6 dependent B cell differentiation into 
antibody-producing cells, thereby resulting in a decrease in production of 
immunoglobulins M, G and A (Kim et al 1994). 
 
3.1.3.  Effect on cytokine production and response 
Unlike Cyclosporin and Tacrolimus, rapamycin has limited effects on cytokine 
production. It does not inhibit the transcription of IL-2, IL-3 and IL-4, granulocyte-
macrophage colony stimulating factor, TNF-  or interferon-  in mitogen-activated T 
cells.  
Rapamycin has no effect on the expression of early response genes such as c-fos, c-jun 
or c-myc, but inhibits transcription of bcl-2, a proto-oncogene which is induced by IL-2 
and which may be critical for cell-cycle progression (Miyazaki et al 1995). 
In contrast to its limited effects on cytokine production, rapamycin blocks proliferative 
responses to IL-1, IL-2, IL-3, IL-4, IL-6, basic fibroblast growth factor, stem cell factor, 
platelet-derived growth factor, insulin growth factor-1, colony-stimulating factors and 
IL-12 (Sehgal et al 1994; Wood & Bierer 1994; Bertagnolli et al 1994). 
 
3.1.4.  Effect on protein synthesis 
Progression of mitogen-stimulated cells through the G1 phase is dependent on regulated 
alterations in both transcription of specific genes and the translation of certain mRNA 
transcripts. The initiation of translation is frequently the rate limiting step in protein 
synthesis (Hershey 1991; Sonenberg 1993). Eukaryotic mRNA’s have a 7-
methylguanylate cap at the 5 -terminus and this cap region acts as the recognition site 
for the eukaryotic initiation factor (eIF)-4F complex. The cap-binding protein, eIF-4E, 












The binding activity of eIF-4E is regulated by its interaction with PHAS-I, a heat stable 
inhibitor of eIF-4E function (Pause et al 1994; Lin et al 1994). Stimulation of cells with 
growth factors such as IL-2 results in hyperphosphorylation of PHAS-I and its release 
of the associated eIF-4E. Mitogenic stimuli enhance the initiation of translation by 
activating protein kinases which phosphorylate PHAS-1. Rapamycin blocks the increase 
in phosphorylation in PHAS-I and the release of active eIF-4E, induced by IL-2 or 
insulin (Lin et al 1995), thereby blocking eIF-4E dependent initiation of translation. 
Rapamycin has been shown to have a selective suppressive action on mitogen-induced 
protein synthesis, with rapamycin specifically interfering with the synthesis of proteins 
from a class of mRNAs bearing the polypyrimidine tracts at the 5  termini (Jefferies et 
al 1994; Terada et al 1994). These polypyrimidine-containing mRNAs are transcripts 
that encode ribosomal proteins and elongation factors suggesting that rapamycin has a 
suppressive effect on the components of the protein synthetic machinery itself 
(Abraham & Wiederrecht 1996). 
 
3.1.5.  Effect on non-immune cell proliferation 
Rapamycin also inhibits growth factor-mediated proliferation of non-immune cells. It 
blocks basic fibroblast growth factor-induced proliferation of bovine aortic and human 
umbilical vein endothelial cells and 3T3 fibroblasts (Akselband et al 1991). It also 
inhibits basic fibroblast growth factor and platelet-derived growth factor stimulated 
proliferation of smooth muscle cells (Gregory et al 1993; Marx et al 1995). 
Rapamycin has been shown to inhibit tumour growth as a result of cell cycle arrest and 
the induction of apoptosis (Luan et al 2002). Rapamycin is able to downregulate 
anchorage-independent growth through inhibition of the eIF4E growth factor (Bjornsti 
et al 2004). 
Rapamycin has been shown in murine models to inhibit primary and metastatic growth 
by antiangiogenesis. The antiangiogenic activities are linked to a decrease in production 
of vascular endothelial growth factor and to a markedly inhibited response of vascular 
endothelial cells to stimulation by VEGF (Guba et al 2002). 
In a mouse model, rapamycin conditioning of renal cancer cells upregulated E-cadherin 












invasive cuboidal cells that formed cell-cell adhesions, preventing metastatic spread. 
Rapamycin increased p27
kip1
, reduced cyclin 1, and arrested growth in the G1/S phase in 
this model (Luan et al 2002). 
 
4.  INTERACTIONS BETWEEN CYCLOSPORIN, FK506 AND 
     RAPAMYCIN 
In vitro combination studies have shown that Cyclosporin and rapamycin act 
synergistically in the inhibition of T cell and B cell proliferation (Kahan et al 1991). 
Equimolar concentrations of FK506 and Rapamycin inhibit Concanavalin A induced T 
cell proliferation in an additive manner. Rapamycin has been shown at a 50-100 M 
excess to block the immunosuppressive effects of FK506 on T and B cell proliferation 
assays (Bierer et al 1990a; Wicker et al 1990) on T cell IL-2 production, IL-2R  
expression, exocytosis, NF-AT-dependent transcription and apoptosis (Bierer et al 
1990a, Staruch et al 1991) and exocytosis of human neutrophils and basophils (DePaulis 
et al 1991; Forrest et al 1991). FK506 at a 100-fold M excess is able to block the 
immunosuppressive effects of rapamycin (Dumont et al 1990a). The 
immunosuppressive effects of Cyclosporin on T cell responses are always enhanced by 
the addition of FK506 or rapamycin independent of the drug concentration (Metcalfe & 
Richards 1990). The reciprocal antagonism of rapamycin and FK506 reflects the 
competition between the two macrolides for a common intracellular binding site (Bierer 
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CHAPTER FIVE: 
EXPERIMENTAL SECTION:  MODULATION OF 
LYMPHOCYTE PROLIFERATION BY Ba100 
 
1. Introduction 
1.1. Experimental approach 
2. Results 
2.1. PBMC proliferation assays in response to the mitogen, PHA 
(i) Effect of Ba100 on PHA-induced proliferation 
(ii) Effect of pre-incubation with Ba100 on PHA-induced PBMC proliferation 
(iii) Effect of Ba100 on PHA-induced PBMC proliferation when added 2 h after 
PHA 
(iv) Effect of washing away Ba100 on PHA-induced PBMC proliferation 
      2.1.1.  Lymphocyte populations and phenotype of the lymphocytes after PBMC  
                 proliferation in response to PHA in the absence or presence of Ba100 
2.2. PBMC proliferation assays in response to various antigens 
2.3. PBMC proliferation to alloantigens in a primary mixed lymphocyte reaction (MLR) 
      2.3.1. Primary mixed lymphocyte reaction (MLR) 
      2.3.2 Lymphocyte populations and phenotype of the lymphocytes generated in a  
               primary MLR in the absence or presence of Ba100 
2.4. Functional analysis of lymphocytes in the primary MLR 
      2.4.1. Suppressor cell activity of the primary MLR generated effectors on a fresh 
                 MLR 
      2.4.2. Cell mediated lympholytic (cytotoxic) activity of the MLR generated effectors 
                in a 
51
Cr release assay 
2.5. CD4 lymphocyte proliferation assays 
      2.5.1. Effect of Ba100 on isolated CD4 and CD8 lymphocyte proliferation in  
                response to PHA 
      2.5.2. Effect of Ba100 on OKT3 and fibronectin-induced proliferation of CD4  
                lymphocytes 
2.6. Effect of Ba100 on PBMC proliferation in response to anti-CD28 antibody and a  
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2.7. Effect of Ba100 on processes involved in T lymphocyte proliferation 
      2.7.1. Effect of Ba100 on cytokine production 
            i) Kinetics of lymphocyte intracellular cytokine production in response to PMA  
               and ionomycin stimulation 
2.7.2. Effect of Ba100 on intracellular IL-2 production by lymphocytes in response  
          to PMA and ionomycin (4h stimulation) 
2.7.3. Effect of Ba100 on intracellular IFN- , TNF-α and IL-4 production by   
          lymphocytes in response to PMA and ionomycin (4h stimulation)   
     2.7.4. Effect of addition of exogeneous IL-2 on PHA-induced PBMC proliferation in  
               the presence of Ba100 
     2.7.5. Effect of Ba100 on the distribution of PHA-stimulated PBMCs in the various 
                phases of the cell cycle 
                i) The distribution of PHA-stimulated PBMCs in the various phases of the cell  
                    cycle 
               ii) The effect of Ba100 on the distribution of PHA-stimulated lymphocytes in 
                    various phases of the cell cycle after 24, 40 and 48 h stimulation 
      2.7.6. Effect of Ba100 on proliferating cell nuclear antigen (PCNA) expression by  
                PHA-stimulated PBMCs 
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1.  INTRODUCTION 
Our initial studies investigating the bioactivity of the novel C-type lectin, Ba100, that 
we isolated from the Western Cape, South African puff adder, Bitis Arietans, looked at 
interactions with platelets (Jennings et al 1999). Although Ba100 did not aggregate 
washed platelets, it inhibited dose-dependently (10 - 1000 nM) aggregation of platelets 
in platelet-rich plasma using ADP as a stimulant. 50% inhibition was achieved at a 
concentration of 150 nM. Ba100 also reduced the rate of clot formation in a dose-
dependent manner as assessed by measuring the α angle of the thromboelastogram 
(Jennings et al 1999). This inhibition of platelet aggregation and effect on clot 
formation was found to be due to its fibrinogenase activity that cleaves the A  and B  
chains of fibrinogen preventing fibrinogen crosslinking and fibrin clot formation.  
As discussed in Chapter 1, C-type lectins play an important role in the immune system 
(Zelensky & Gready 2005) and plant lectins such as Concanavalin A (Con A) and 
Phytohaemagglutinin (PHA) are known stimulators of T lymphocyte proliferation. T 
cell activation leading to the generation and proliferation of effector T lymphocytes 
involves a number of inter-related steps, including: i) early signal transduction events ii) 
transcriptional activation of various genes iii) expression of new cell surface 
adhesive/costimulatory molecules iv) secretion of effector cytokines/chemokines and/or 
performance of cytolytic functions and v) induction of mitotic activity. Antigen-specific 
interactions between antigen-presenting cells (APCs) and T lymphocytes leading to full 
activation and consequent T lymphocyte proliferation is dependent on antigen 
recognition involving the TCR/CD3 complex, cellular adhesion and costimulation. 
CD25 (  chain of the interleukin-2 receptor) is expressed in the early phase of T cell 
proliferation and the clonal proliferation of activated T cells depends on the expression 
of this receptor (Taniguchi & Minami 1993). In addition to the early expression of 
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of bidirectional cell surface adhesive/costimulatory molecules such as LFA-1 
(CD11a/CD18) interacting with CD54 (ICAM-1) (Mackay & Imhof 1993). Besides 
stabilizing APC-T cell interactions, these adhesive/costimulatory molecules provide 
important costimulatory signals for TCR-mediated activation of resting T cells (van 
Seventer et al 1990). TCR stimulation is insufficient to sustain full activation of T cell 
and additional signals are required (Steinman & Young 1991). Antigen-presenting cells 
are important as they deliver co-stimulatory signals to T cells which, via independent 
intracellular pathways, synergise with TCR stimulation leading to cytokine production 
and T cell activation and proliferation (Schwartz et al 1989).  
Engagement of the T cell receptor and activation of co-stimulatory signals such as the 
CD28 co-stimulatory pathway (Ledbetter et al 1990; June et al 1994; Solomon & 
Bluestone 2001; Sharpe & Freeman 2002) allows gene transcription and the production 
of cytokines that enable T cells to move from a resting G0 to the activated G1 phase. 
The progression from G1 through to the S phase is regulated through a variety of 
receptors on the T cell surface including the IL-2 receptor. The binding of T cell growth 
factors such as IL-2 to the high affinity receptors, initiates signaling events required for 
the progression of the T cell in the G1 phase into the S phase and ultimately into 
mitosis. The enzymes critical for the induction of cell division include the cyclin/cyclin-
dependent kinases and de novo purine and pyrimidine synthesis is essential before 
lymphocytes can complete cell division. 
The mitogenic lectins, Concanavalin A (Con A) and Phytohaemagglutinin (PHA) 
induce signals through the TCR leading to increased intracellular calcium and 
consequent IL-2 production and IL-2 receptor expression (Vermot Desroches et al 1991; 
Komada et al 1996). The expression of CD25, HLA-DR, LFA-1 and ICAM-1 is 
upregulated on T lymphocytes proliferating in response to PHA or Con A (Vermot 
Desroches et al 1991; Barten et al 2001). Con A is also able to bind to the CD2 receptor 
and activate protein kinase C (Imboden & Stobo 1985). PHA induces signals through 
the crosslinking of LFA-1, which acts synergistically with the TCR/CD3 complex to 
induce tyrosine phosphorylation and activation of the focal adhesion kinase pathway 
(Tabassam et al 1999 a, b) 
In view of its C-type lectin structure and its protease/fibrinogenase activity on 
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that Ba100 might also have immunomodulatory potential. The aim of this chapter was 
to investigate whether Ba100 was able to inhibit T lymphocyte proliferation as well as 
the consequences of T cell activation such as the induction of T cell activation markers 
and adhesive/costimulatory molecules, cytokine production and cell cycle progression. 
Standard T lymphocyte proliferation assays assessing both calcium-dependent and -
independent T lymphocyte proliferation pathways were used to investigate the effect of 
Ba100 on T lymphocyte proliferation. 
1.1.  Experimental approach 
The initial studies investigated the effect of Ba100 on T lymphocyte proliferation in 
response to the mitogen, PHA. As significant inhibition of proliferation was observed, 
further studies focused on establishing the best inhibitory concentration of Ba100 and 
whether this protein modulated responses early or late in T lymphocyte proliferation. 
Ba100 modulation of proliferation in response to recall antigens, allo-antigens in a 
mixed lymphocyte reaction (MLR) as well as proliferation occurring as a result of 
calcium-independent T cell activation pathways (T lymphocyte proliferation in response 
to anti-CD28 antibody and a phorbol ester, phorbol 12-myristate 13-acetate (PMA)) was 
then investigated.  
The effect of Ba100 on lymphocyte populations following stimulation with PHA or in a 
MLR as well as the expression of various receptors on responding lymphocytes was 
investigated using flow cytometry. Particular emphasis was placed on: 
i) Cell surface activation markers 
- CD25 (Interleukin-2 receptor  chain) which is expressed in the early phase 
after T cell activation. The clonal proliferation of activated T cells depends on 
the expression of this receptor (Taniguchi & Minami 1993). 
- HLA-DR which is expressed on activated T lymphocytes and is involved in co-











Chapter 5 106 
ii) Adhesion/stimulatory molecules 
- CD2 which binds to LFA-3 (CD53) and augments lymphocyte proliferation 
probably via a direct effect on the TCR (Davis & van der Merwe 1996; Yashiro 
et al 1998). 
- CD11a, a component of CD11a/CD18 (LFA-1), the counter receptor for CD54 
(ICAM-1). Both are bidirectionially expressed on the surface of APCs and T 
lymphocytes (Mackay & Imhof 1993). LFA-1–ICAM-1 binding provides a 
costimulatory signal for TCR-mediated activation of resting T lymphocytes (van 
Seventer et al 1990). CD11a also interacts with ICAM-2 and ICAM-3 
augmenting adhesion and TCR activation (Zuckerman et al 1998). 
- CD49d/CD29 (VLA-4) which interacts with VCAM-1 on endothelium and 
fibronectin promoting lymphocyte adhesion and transendothelial migration. This 
receptor is upregulated during lymphocyte proliferation (Wayner et al 1989; 
Elices et al 1990). 
iii) Costimulatory molecule CD28:  
- The CD28/B7 pathway is the key positive costimulatory pathway (Salomon & 
Bluestone 2001; Sharpe & Freeman 2002). 
The functional capacity of lymphocyte subpopulations activated in primary and 
secondary MLR cultures (induction of cytolytic lymphocytes and alloantigen-induced 
suppressor cells) in the presence of Ba100 was assessed. 
Having demonstrated the ability of Ba100 to inhibit calcium-dependent T lymphocyte 
proliferation pathways, inhibit the generation of lymphocytes expressing activation 
markers and downregulate the expression of adhesive/costimulatory molecules, we then 
investigated the effects of Ba100 on: 
i) Intracellular cytokine production during lymphocyte proliferation. 
ii) Cell cycle progression 
Our observation that Ba100 did cause cell cycle arrest, resulted in an investigation of 
the effect of Ba100 on proliferating cell nuclear antigen (PCNA) expression (an 
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2.  RESULTS 
2.1.  PBMC proliferation assays in response to the mitogen, PHA 
i)  Effect of Ba100 on PHA-induced PBMC proliferation 
The effect of various concentrations of Ba100 on proliferation of PBMC in response to 
PHA was investigated and the data from a representative experiment is shown in  
Figure 1. 
























































PBMC (1x105 cells/well) were incubated with PHA (0.00575 mitogenic units) or PHA + Ba100 (200, 100 and 50nM 
concentrations) at 37° C. 
Ba100 was preincubated with PBMC for 30 minutes at 37 C prior to the addition of PHA. 
At 72h, [3H] thymidine was added, incorporation measured 18h later and results are expressed as mean DPM of 6 
replicates  SD. 
Background [3H] thymidine incorporation into PBMC in absence of PHA or presence of Ba100 were 210   10 DPM 
and 280  35 DPM respectively. [3H] thymidine incorporation into PHA-stimulated PBMC was 169 660  2840 
DPM. 
Results of a representative dose response to Ba100 are shown and are expressed as % suppression of PBMC 
proliferation to PHA  SD based on the PHA-stimulated control.  * p < 0.0001, comparing % suppression at each 
successive concentration. 
 
In the absence of PHA, Ba100 did not alter background [
3
H] thymidine incorporation. 
When Ba100 was preincubated with PBMC for 30 min prior to the addition of PHA, a 
dose dependent inhibition of the proliferation of the PBMC was observed (Figure 1). 2 
further dose response experiments confirmed a simple linear relationship between the 
concentration of Ba100 and % suppression of PBMC proliferation in response to PHA 
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confirm the effect of a 30 min preincubation period of Ba100 (200nM) on PHA-induced 
PBMC proliferation. For each experiment, inhibition of proliferation was observed and 
the range of suppression of proliferation for these 10 experiments was 45 – 67% (mean 
56.6%, median 58% suppression). Exclusion of trypan blue by cells harvested at 72 h 
indicated that the cells were not being killed by Ba100 and thus the inhibition of 
proliferation was not due to cytotoxicity. 
 
ii)  Effect of pre-incubation with Ba100 on PHA-induced PBMC proliferation 
We investigated whether pre-incubation with Ba100 was required for the inhibitory 
effect on PHA-induced PBMC proliferation. 




















PHA PHA + Ba100 (200nM)
 
 
PBMC (1x105 cells/well) were incubated with PHA (0.00575 mitogenic units) or PHA + Ba100 (200nM) at 37 C. 
Ba100 was either pre-incubated for 30 min or 60 min with PBMC at 37 C prior to the addition of PHA or added to 
the PBMC when the PHA was added. 
At 72 h, [3H] thymidine was added and incorporation measured 18h later. 
Background [3H] thymidine incorporation for cells only or cells + Ba100 (200 nM) never averaged above 334 DPM. 
Results of a representative experiment are shown and are expressed as mean DPM of 6 replicates ± SD. 
 
 
We found that pre-incubation of PBMC with Ba100 was not required for its anti-
proliferative effect (Figure 2). The percentage suppression of PHA-induced PBMC 
proliferation with a 30 min and 60 min preincubation period (49.8%  1.3 (SD) and 
52.3%  1.12 (SD) suppression respectively) was the same as that when Ba100 was 
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confirmed in 2 further experiments (regression coefficient 0.005, SE 0.016). For 
standardization purposes, a 30 minute pre-incubation period was used in all the 
experiments, unless otherwise stated.  
 
iii)  Effect of Ba100 on PHA-induced PBMC proliferation when added 2h after 
      PHA 
The ability of Ba100 to modulate PHA-induced PBMC proliferation after the stimulus 
for proliferation had been added, was investigated. To assess whether Ba100 acted early 
or late in T cell signal transduction, Ba100 was added 2 hours after the addition of the 
mitogenic stimulus, PHA. 






Suppression of PBMC 
proliferation to PHA 
Mitogen Ba100 (200 nM) 
PHA - 354 418 ± 16317 - 
PHA 30 min pre-incubation 184 297 ± 2493 48% ± 0.71 
PHA Added 2h after PHA 349 534 ± 3660 0% 
 
PBMC (1x105 cells/well) were incubated with PHA (0.00575 mitogenic units) or PHA + Ba100 (200 nM) at 37 C. 
Ba100 was preincubated with PBMC for 30 min at 37 C prior to the addition of PHA or Ba100 was added 2 h after 
PHA. 
At 72 h, [3H] thymidine was added and incorporation measured 18h later. 
Background [3H] thymidine incorporation into PBMC in the absence of PHA or presence of Ba100 were 274  20 
DPM and 344  55 DPM respectively. 
Results of a representative experiment are shown and are expressed as mean DPM of 6 replicates ± SD or % 
suppression of PBMC proliferation to PHA ± SD. 
 
Ba100 was unable to inhibit PHA-induced PBMC proliferation if added 2h after PHA 
(Table 1), suggesting that Ba100 exerted its inhibitory effect early on in T cell 
activation. This was reproducible in two further experiments. 
iv)  Effect of washing away Ba100 on PHA-induced PBMC proliferation 
The effect of preincubating Ba100 with PBMC, then washing it away before the 
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Suppression of PBMC 
proliferation to PHA 
Mitogen Ba100 (200 nM) 
PHA - 142 096  7754 - 
PHA 30 min pre-incubation 70 988  1473 50% 1.41 
PHA 30 min pre-incubation,  
then wash 
153 309   8420 0% 
 
PBMC (1x105 cells/well) were incubated with PHA (0.00575 mitogenic units) or PHA + Ba100 (200 nM) at 37 C. 
Ba100 was pre-incubated with PBMC for 30 min at 37 C prior to the addition of PHA. For one reaction Ba100 was 
washed away after the 30 min pre-incubation period. 
At 72 h, [3H] thymidine was added and incorporation measured 18h later. 
Background [3H] thymidine incorporation into PBMC in the absence of PHA or presence of Ba100 were 377  30 
DPM and 385  55 DPM respectively. 
Results of a representative experiment are shown and are expressed as mean DPM of 6 replicates  SD or % 
suppression of PBMC proliferation to PHA  SD. 
 
Removing Ba100 from the reaction prior to the addition of PHA resulted in a complete 
loss of the inhibitory effect of Ba100 on PHA-induced PBMC proliferation (Table 2). 
Ba100 needs to be present during the proliferation period for its inhibitory effect to be 
observed. This was reproducible in two further experiments. 
 
2.1.1.  Lymphocyte populations and phenotype of the lymphocytes after PBMC  
           proliferation in response to PHA in the absence or presence of Ba100 
Flow cytometry was used to analyse the phenotype of the lymphocyte population after 
proliferation of PBMC in response to PHA in the absence or presence of Ba100 (200 
nM). Both the % of cells in the lymphocyte gate (set on lymphocyte forward and side 
scatter properties) expressing a particular receptor and the MFI (mean fluorescent 
intensity) of the antibody binding was determined. Lymphocytes in the lymphocyte gate 
were analysed for expression of activation markers HLA-DR and the interleukin 2 
receptor (CD25); adhesion receptors CD2, CD11a, CD49d and CD29; co-stimulatory 
molecules CD28; CTL markers in the form of S6F1 and NK cell markers in the form of 
CD56. Anti-CD19 was used to detect B cells and anti-CD3 to detect T cells. Anti-CD4 
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Table 3. Lymphocyte populations and phenotype after proliferation of PBMC in 
response to PHA in the absence or presence of Ba100 (200 nM). 
Receptors PHA-stimulated cells PHA-stimulated cells % Change 
 -Ba100 + Ba100 (200 nM) + Ba100 (200 nM) 
 % Positive 
cells 
MFI % Positive 
cells 
MFI % Positive 
cells 
MFI 
CD3 78.5 8.3 74.9 7.9 No change No change 
CD4 47.1 18.3 49.8 19.2 No change No change 
CD8 33.4 17.7 28.1 14.1 15.9%  20.3%  
CD56 8.8 4.6 8.3 4.5 No change No change 
S6F1 17.8 30.1 9.9 11.6 44.4%  61.5%  
CD19 15.2 4.1 14.3 3.6 No change No change 
HLA-DR 58.4 22.5 19.5 13.5 66.6%  40.0%  
CD25 87.2 21.5 62.5 6.2 28.3%  71.2%  
CD2 87.2 13.1 86.2 12.1 No change No change 
CD11a 52.8 11.8 31.5 7.4 40.3%  37.3%  
CD49d 38.5 4.4 18.3 2.9 52.5%  34.1%  
CD29 56.6 6.3 22.4 4.3 60.4%  31.7%  
CD28 29.5 7.0 3.0 4.4 89.8%  37.1%  
CD4 : CD8 1.4  1.8  28.6%   
 
PBMC (1x105 cells/well) were incubated with PHA (0.00575 mitogenic units) or PHA + Ba100 (200 nM) at 37 C.  
Ba100 was pre-incubated for 30 min with PBMC at 37 C prior to the addition of PHA. 
At 72 h, the cells were harvested, then labeled with antibodies directed to the indicated lymphocyte receptors and 
single colour analysis of antibody binding was done by flow cytometry on gated lymphocytes. 
Results of a representative experiment are shown and are expressed as % of cells in the lymphocyte gate expressing 
the receptor and the MFI (mean fluorescent intensity or number of receptors per cell) of the antibody binding. The 
change in these parameters in the presence of Ba100 is expressed as a % of that in the absence of Ba100.  indicates 
a decrease from that in the absence of Ba100 and  indicates an increase from that in the absence of Ba100. 
A change in the % of cells expressing a specific receptor and a change in MFI in the presence of Ba100 was 
considered a real change if this was more than a 10% and 20% change respectively. Only real changes decided by 
these two criteria are shown in the last 2 columns. 
 
From the results of a representative experiment given in Table 3, it appears that PBMC 
proliferation in response to PHA in the presence of Ba100 resulted in impaired 
generation of lymphocytes that expressed: 
i) activation markers HLA-DR and CD25. 
ii) adhesion molecules CD11a, CD49d and CD29. 
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iv) the CTL marker S6F1. 
 
In the presence of Ba100, for those lymphocytes that did express these receptors, the 
number of receptors expressed per cell was reduced. There was no change in the 
percentage of B cells in the lymphocyte population. An increase in the CD4:CD8 ratio 
was seen. 
This impaired generation of lymphocytes that expressed these receptors was confirmed 
in a further 5 experiments after proliferation of PBMC in response to PHA in the 
presence of Ba100 (200 nM). The range of suppression and median suppression for both 
percentage of cells expressing a receptor and the number of receptors expressed per cell 
are tabulated in Table 4. From the data, it is clear that these results are consistent with 
those shown in Table 3, except that in this set of experiments, no change in the 
CD4:CD8 ratio was detected. 
 
Table 4.  Change in lymphocyte populations and phenotype after proliferation of 
PBMC in response to PHA in the presence of Ba100 (200 nM). 
Receptors PHA-stimulated PBMC + Ba100 (200 nM) 
 % Positive cells MFI 
 Range of 
suppression 
Median  Range of 
suppression 
Median  
HLA-DR 51.2 – 73.3% 64.6% 38.0 – 41.0% 38.0% 
CD25 31.0 – 44.0% 32.5% 65.2 – 80.6% 65.2% 
CD2 No change  No change  
CD11a 32.0 – 56.7% 42.6% 41.2 – 45.3% 41.7% 
CD49d 32.7 – 50.5% 46.4% 36.5 – 42.8% 39.2% 
CD29 52.3 – 73.3% 60.8% 37.4 – 40.1% 38.2% 
CD28 70.2 – 85.8% 77.9% 33.7 – 41.5% 37.2% 
S6F1 46.7 – 68.5% 50.3% 34.5 – 62.1% 48.0% 
CD56 No change No change 
CD19 No change No change 
CD4 : CD8 ratio No change No change 
 
PBMC (1x105 cells/well) were incubated with PHA (0.00575 mitogenic units) or PHA + Ba100 (200 nM) at 37 C.  
Ba100 was pre-incubated for 30 min with PBMC at 37 C prior to the addition of PHA. 
At 72 h, the cells were harvested,then labeled with antibodies directed to the indicated lymphocyte receptors and 
single colour analysis of antibody binding was done by flow cytometry on gated lymphocytes. 
The range of suppression and the median suppression for both the % of cells in the lymphocyte gate expressing the 
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2.2.  PBMC proliferation assays in response to various antigens 
The effect of Ba100 on proliferation of PBMC in response to various antigens was 
investigated and the data from representative experiments are shown in Figure 3a - c. 
 


















































PBMC (1x105 cells/well) were incubated with the antigen PPD without or with Ba100 (200, 100, 50 nM) at 37°C.  
Ba100 was preincubated with PBMC for 30 min at 37°C prior to the addition of PPD. 
On day 7, [3H] thymidine was added, incorporation measured 18 hr later and results are expressed as mean DPM of 6 
replicates  SD. 
Background [3H] thymidine incorporation into PBMC in the absence of PPD was 380  32 DPM and in the presence 
of Ba100 was 376 ± 18 DPM. 
[3H] thymidine incorporation into PBMC in the presence of PPD was 445 432  24 400 DPM. 
Results of a representative dose response to Ba100 are shown and are expressed as % suppression of PBMC 




Ba100 dose dependently (50 – 200 nM) suppressed PBMC proliferation in response to 
the antigen PPD (Figure 3a). 2 further dose response experiments confirmed that the 
relationship between the concentration of Ba100 and % suppression of PBMC 
proliferation in response to PPD was linear with logarithmic transformation  
(p < 0.0001) and the IC50 was  83nM.  
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PBMC (1x105 cells/well) were incubated with the antigen Tetanus toxoid without or with Ba100 (200, 100, 50, 25 
nM) at 37°C.  
Ba100 was preincubated with PBMC for 30 min at 37°C prior to the addition of Tetanus toxoid. 
On day 7, [3H] thymidine was added, incorporation measured 18 hr later and results are expressed as mean DPM of 6 
replicates   SD. 
Background [3H] thymidine incorporation into PBMC in the absence of Tetanus toxoid was 406  52 DPM and in the 
presence of Ba100 was 398  36 DPM. 
[3H] thymidine incorporation into PBMC in the presence of Tetanus toxoid was 20 397  1713 DPM.  
Results of a representative dose response to Ba100 are shown and are expressed as % suppression of PBMC 
proliferation to Tetanus toxoid  SD based on the Tetanus toxoid-stimulated control. * p < 0.0005, comparing % 
suppression at each successive concentration. 
 
Ba100 dose dependently (25 – 200 nM) suppressed PBMC proliferation in response to 
the antigen Tetanus toxoid (Figure 3b). 2 further dose response experiments confirmed 
that the relationship between the concentration of Ba100 and % suppression of PBMC 
proliferation in response to Tetanus toxoid was linear with logarithmic transformation 
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PBMC (1x105 cells/well) were incubated with the antigen Varidase without or with Ba100 (200, 100, 50 nM) at 37°C.   
Ba100 was preincubated with PBMC for 30 min at 37°C prior to the addition of Varidase. 
On day 7, [3H] thymidine was added, incorporation measured 18 hr later and results are expressed as mean DPM of 6 
replicates  SD. 
Background [3H] thymidine incorporation into PBMC in the absence of Varidase was 390  44 DPM and in the 
presence of Ba100 was 364  32 DPM. 
[3H] thymidine incorporation into PBMC in the presence of Varidase was 349 584  23 688 DPM. 
Results of a representative dose response to Ba100 are shown and are expressed as % suppression of PBMC 
proliferation to Varidase  SD based on the Varidase-stimulated control. * p < 0.0005, comparing % suppression at 
each successive concentration. 
 
Ba100 dose dependently (50 – 200 nM) suppressed PBMC proliferation in response to 
the antigen Varidase (Figure 3c). 2 further dose response experiments confirmed that 
the relationship between the concentration of Ba100 and % suppression of PBMC 
proliferation in response to Varidase was linear with logarithmic transformation  
(p < 0.0001) and the IC50 was  95nM.  
A further set of 3 experiments with each antigen was done which confirmed the 
inhibitory effect of a 30 min preincubation period of Ba100 (200nM) on antigen-
stimulated proliferation. The range of suppression of: 
i) PPD-induced proliferation was 75 – 80% (mean 77.6%, median 78% 
suppression). 
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iii) Varidase-induced proliferation was 70 – 76% (mean 73.3%, median 74% 
suppression). 
2.3.  PBMC proliferation to alloantigens in a primary mixed  
        lymphocyte reaction (MLR) 
The immunosuppressive properties of Ba100 on T lymphocyte responses to mitogen 
and antigens was encouraging and suggested to us that Ba100 may be able to inhibit 
proliferation to alloantigens in a mixed lymphocyte reaction, which is an in vitro 
transplant model. 
 
2.3.1.  Primary mixed lymphocyte reaction (MLR) 
The MLR provides a system for analyzing the interactions between subpopulations of 
antigen-presenting macrophages, allo-antigen specific CD4 lymphocytes, cytotoxic T 
lymphocytes and suppressor/regulatory T cells. CD4 lymphocytes constitute a major 
population of the responding cells in the MLR and their activity is essential for inducing 
other lymphocyte subsets to differentiate into effectors of cytotoxicity. 
We thus looked at the potential role of Ba100 in modulating the functional activity of 
effector cells generated in a primary MLR. The first experiment investigated the effect 
of various concentrations of Ba100 on lymphocyte proliferation in a 6 day primary 
mixed lymphocyte reaction. 
Ba100 dose dependently (50 – 200 nM) inhibited the primary mixed lymphocyte 
reaction (Figure 4). 2 further dose response experiments confirmed that there was a 
simple linear relationship between the concentration of Ba100 and % suppression of the 
MLR (p < 0.0001) and the IC50 was  149nM. A further set of 10 experiments with 
different donors was done, which confirmed the consistent inhibitory effect of a 30 min 
pre-incubation period of Ba100 (200nM) on the MLR. For the 10 experiments, the 
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1x105 responder cells (A) were incubated with 1 x 105 irradiated (3000R) stimulator cells (Bx) per well at 37 C in the 
absence or presence of Ba100 at varying concentrations (200, 100 and 50nM). 
Responder cells were pre-incubated with Ba100 for 30 min at 37 C prior to the addition of stimulator cells. 
On day 6, [3H] thymidine was added, incorporation measured 18 h later and results are expressed as mean DPM of 6 
replicates  SD.  
[3H] thymidine incorporation for A+Bx was 74 010  1401 DPM. 
Results of a representative dose response to Ba100 are shown and are expressed as % suppression of proliferation ± 
SD based on the MLR (A+Bx) control. * p < 0.0001, comparing  % suppression at each successive concentration. 
 
 
2.3.2.  Lymphocyte populations and phenotype of the lymphocytes generated in a  
           primary MLR in the absence or presence of Ba100 
Flow cytometry was used to determine the phenotype of the effector cells generated in 
the primary MLR in the absence or presence of Ba100 (200 nM). Both the % of cells in 
the lymphocyte gate (set on lymphocyte forward and side scatter properties) expressing 
a particular receptor and the MFI of the antibody binding was determined. Lymphocytes 
in the lymphocyte gate were analysed for expression of activation markers HLA-DR 
and the interleukin 2 receptor (CD25) and NK cell markers in the form of CD16. Anti-
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Table 5.  Lymphocyte populations and phenotype of effector cells generated in a 6 
day primary MLR in the absence or presence of Ba100 (200 nM). 
Receptor % Positive cells MFI % Change (+ Ba100) 








Experiment 1 (A + Bx) 
CD4 42.1 61.7 5.3 6.9 46.6%  30.2%  
CD8 18.9 17.2 17.8 7.3 No change 58.9%  
CD16 7.3 2.8 4.5 1.8 61.6%  60.0%  
HLA-DR 37.2 4.7 26.6 14.6 87.4%  45.1%  
CD25 29.4 4.3 12.2 7.2 85.4%  40.9%  
CD4 : CD8 2.2 3.6   63.6%   




/ml     
% Suppression of proliferation 42.5%     
Experiment 2 (A + Cx) 
CD4 41.7 46.3 12.5 13.7 11.0%  No change 
CD8 16.5 10.4 25.8 22.9 36.9%  No change 
CD16 16.3 2.4 6.0 4.7 85.3%  21.7%  
HLA-DR 44.6 10.8 31.2 18 75.8%  42.3%  
CD25 36.8 13.2 15.1 8.1 64.1%  46.4%  
CD4 : CD8 2.5 4.5   80.0%   




/ml     
% Suppression of proliferation 58.3%     
Experiment 3 (C + Bx) 
CD4 41.2 48.5 14.3 14.6 17.7%  No change 
CD8 27.5 12 45.3 15.2 56.4%  66.4%  
CD16 21.6 2.6 11.4 8.9 87.9%  21.9%  
HLA-DR 72.4 18.2 92.3 33.9 74.9%  63.3%  
CD25 37.5 6.4 59.1 6.4 82.9%  89.2%  
CD4 : CD8 1.5 4.0   167%   




/ml     
% Suppression of proliferation 45%     
Experiment 4 (C + Ax) 
CD4 45.9 46 15.8 15.6 No change No change 
CD8 25.5 8.2 43.6 12.4 67.8%  71.6%  
CD16 23.1 2.7 10.7 8.1 88.3%  24.3%  
HLA-DR 74.2 11.3 82.6 41.7 84.8%  49.5%  
CD25 34.2 5.2 39.4 6.0 84.8%  84.8%  
CD4 : CD8 1.8 5.6   211%   




/ml     
% Suppression of proliferation 66.7%     
 
Effector cells were generated in 6 day bulk primary MLRs in the absence or presence of Ba100 (200 nM). PBMC 
were used from 3 different donors (A, B, C) in 4 experiments and were used as responder cells (A or C) or irradiated 
(3000 R) stimulator cells (Ax, Bx, Cx) as indicated. On day 6, the cells were harvested and the total cell yield 
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Ba100 (200 nM). Aliquots of cells were then labeled with antibodies directed to the indicated lymphocyte receptors 
and single colour analysis of antibody binding was done by flow cytometry on gated lymphocytes.  
Data from the 4 experiments are shown and are the % of cells in the lymphocyte gate expressing the receptor and the 
MFI (mean fluorescent intensity) of the antibody binding. The change in these parameters in the presence of Ba100 is 
expressed as a % of that in the absence of Ba100.  indicates a decrease from that in the absence of Ba100 and  
indicates an increase from that in the absence of Ba100. 
A change in the % of cells expressing a specific receptor and a change in MFI in the presence of Ba100 was 
considered a real change if this was more than a 10% and 20% change respectively. Only real changes decided by 
these two criteria are shown in the last 2 columns. 
 
 
In summary, all 4 primary MLR (Table 5) confirmed that Ba100: 
i) Suppressed the mixed lymphocyte reaction as the total cell yield on day 6 was 
decreased (Range of inhibition of total cell yield 42.5 - 66.7%, median 51.7%). 
ii) Impaired the generation of lymphocytes expressing the activation markers: 
HLA-DR (range of suppression 74.9 – 87.4%, median 80.4%); CD25 (range of 
suppression 64.1 – 85.4%, median 83.9%);  
Decreased the MFI of HLA-DR expression (range of suppression 42.3 – 
63.3%, median 47.3%); and decreased the MFI of CD25 expression (range of 
suppression 40.9 – 89.2%, median 65.6%) per cell. 
iii) Impaired the generation of NK cells as determined by the number of cells 
expressing CD16 (range of suppression 61.6 – 88.3%, median 86.6%) and 
decreased the MFI of CD16 expression (range of suppression 21.7 – 60%, 
median 23.1%) per cell. 
iv) Increased the CD4:CD8 ratio (range of increase 63.6 - 211%, median 123.5%). 
 
A further 4 primary MLR in the presence of Ba100 (200 nM) confirmed the impaired 
generation of lymphocytes that expressed the activation markers and the increase in the 
CD4:CD8 ratio and looked at the effect of Ba100 on the adhesion molecule CD2 and 
NK cells expressing CD56. The range of suppression and median suppression for the 
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Table 6.  Change in lymphocyte populations and phenotype of effector cells 
generated in a 6 day primary MLR in the absence or presence of Ba100 (200 nM). 
Receptors Primary MLR + Ba100 (200 nM) 
 % Positive cells 
 Range of suppression Median 
HLA-DR 56.2 – 86.7% 67.2% 
CD25 45.4 – 84.2% 72.4% 
CD56 45.2 – 80.7% 74.3% 
CD2 No change  
CD4 : CD8 50.6 – 100% increase 52.4%  
% Suppression of proliferation 46.9 – 65.2% 55.3% 
 
Effector cells were generated in 6 day bulk primary MLRs in the absence or presence of Ba100 (200 nM). 
PBMC were used from 3 different donors (A, B, C) in 4 experiments and were used as responding or irradiated 
stimulator cells. On day 6, the cells were harvested and the total cell yield determined by counting the number of 
cells x 106/ml proliferating in the MLR in the absence or presence of Ba100 (200 nM). Aliquots of cells were then 
labeled with antibodies directed to the indicated lymphocyte receptors and single colour analysis of antibody binding 
was done by flow cytometry on gated lymphocytes. 
The  range of suppression and median suppression of the % of cells in the lymphocyte gate expressing the indicated 





2.4.  Functional analysis of lymphocytes in the primary MLR 
Lymphocytes from a primary MLR cultured in the presence of Ba100 were tested for 
suppressor cell and CTL activity on day 6 of the culture. Cells harvested from the 
primary MLR were incubated for 30 min, followed by 2 washes in fresh complete 
media to remove Ba100 before assessment of CTL and suppressor cell activity. 
 
2.4.1.  Suppressor cell activity of the primary MLR generated effectors on a fresh  
           MLR 
The primed effector cells from the primary MLR were tested for their ability to suppress 
the proliferative response of the fresh responding cells in a new MLR. We looked at 
both specific and non-specific suppression by primed effector cells generated in the 
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Table 7.  Effect of Ba100 on the suppressor cell assays. 
Response being 
tested in the fresh 
MLR 
Primed cells from 
a bulk primary 













of fresh MLR 
1. Autologous (A + Bx) A + Bx 76373  1359 - 
   Autologous (A + Bx+ 200nM 
Ba100) 
A + Bx 46282  943 39.4%  1.41 
2. Heterologous  (A + Bx) C + Ex 105986  1445 - 
   Heterologous (A + Bx+ 200nM 
Ba100) 
C + Ex 78854  1142 25.6%  2.1 
3. Same stimulator, 
   different responder 
(A + Bx) C + Bx 96278  1243 - 
   Same stimulator,  
   different responder 
(A + Bx+ 200nM 
Ba100) 
C + Bx 63832  1049 33.7%  1.41 
4. Same responder,  
   different stimulator 
(A + Bx) A + Cx 95755  1523 - 
   Same responder,  
   different stimulator 
(A + Bx+ 200nM 
Ba100) 
A + Cx 67603  1012 29.4%  2.8 
 
A bulk primary MLR was set up by incubating responder cells, A (1x106 cells/ml) with irradiated (3000 R) stimulator 
cells, Bx (1x106 cells/ml) in complete media in the absence or presence of Ba100 (200 nM) at 37 C. After 6 days 
incubation, the cells were harvested, incubated for 30 min, washed x 2 to remove Ba100 and used as the primed cells 
in the suppressor cell assay. 
Fresh MLR reactions contained the component cells A+Bx, C+Ex, C+Bx, A+Cx: 1x105 responder cells (A or C) 
were incubated with 1x105 irradiated (3000 R) stimulator cells (Bx, Cx or Ex) per well in complete media at 37 C. 
These fresh MLR (A+Bx, C+Ex, C+Bx and A+Cx) were cultured with the primed cells in the following 
combinations. 
1. Primed cells autologous to responders and stimulators. 2. Primed cells, responders and stimulators completely 
heterologous. 3. Same stimulator, different responder. 4. Same responder, different stimulator. 
On day 6, [3H] thymidine was added and incorporation measured 18 h later. 
Results of a representative experiment are shown and expressed as mean DPM of 6 replicates  SD or % suppression 
of proliferation ± SD. 
 
 
Effector cells generated in a primary MLR in the presence of Ba100 (200 nM) exerted a 
suppressive effect on the proliferation of a fresh MLR. This suppressor activity was not 
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2.4.2.  Cell mediated lympholytic (cytotoxic) activity of the MLR generated  
           effectors in a 
51
Cr release assay 
Effectors from primary MLR cultures ( A + Bx or C + Bx) generated in the presence of 
Ba100 (200nM) were tested for their ability to kill PHA blasts (prepared from donor B) 
that were used as targets in a standard 
51
Cr release assay and were compared to effectors 
from a MLR generated in the absence of Ba100. The generation of effectors in the MLR 
with cytolytic activity was reduced when Ba100 was included in the reaction. Two 
experiments were performed (Table 8) and in both the cytolytic activity of effector cells 
generated in a primary MLR in the presence of Ba100 was markedly reduced.  
 
Table 8.  Cell mediated lympholytic (cytotoxic) activity of the MLR generated 
effectors. 
 Experiment 1 Experiment 2 
 % Specific 
51












A + Bx 
+Ba100 (200 nM) 
Effectors from 
MLR 
C + Bx 
- Ba100  
Effectors from 
MLR 
C + Bx 
+Ba100 200 nM) 
40 : 1 47 ± 3 22 ± 3 38 ± 2 17 ± 3 
20 : 1 34 ± 5 12 ± 2 33 ± 4 10 ± 3 
10 : 1 19 ± 5 5 ± 1 16 ± 4 4 ± 1 
 
Cells from a primary bulk MLR cultured in the absence or presence of Ba100 (200 nM) were harvested on day 6 and 
then used at the indicated effector : target ratio in a standard 4h 51Cr release assay.  3-day-old PHA blast cells 
(prepared from donor B) and labelled with 51Cr served as targets.  
The data is expressed as % specific 51Cr release ± SD of triplicate reactions. Activity in control reactions using targets 




2.5.  CD4 lymphocyte proliferation assays 
Considering the critical role of CD4 lymphocytes in the alloimmune response, we have 
looked at the effect of Ba100 on the proliferation of isolated CD4 lymphocytes. We also 
investigated whether Ba100 needed to be processed by antigen-presenting phagocytes in 
order to exert its inhibitory effect on lymphocyte proliferation. CD4 and CD8 
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2.5.1.  Effect of Ba100 on isolated CD4 and CD8 lymphocyte proliferation in  
           response to PHA 
We looked at the ability of Ba100 to inhibit CD4 and CD8 lymphocyte proliferation in 
response to PHA in the absence of antigen-presenting phagocytes. 
 
Figure 5.  Effect of Ba100 on isolated CD4 and CD8 lymphocyte proliferation (60:40% 

















CD4 and CD8 lymphocytes were isolated using Dynal beads, then reconstituted in a 60 : 40% ratio (CD4 : CD8). A 
total of 1x105 CD4 + CD8 cells were cultured per well with PHA (0.00575 mitogenic units) or PHA + Ba100 (200, 
100 and 50 nM concentrations) at 37 C. 
Ba100 was pre-incubated with CD4 and CD8 lymphocytes for 30 min at 37 C prior to the addition of PHA. 
At 72 h, [3H] thymidine was added, incorporation measured 18 h later and results are expressed as mean DPM of 6 
replicates  SD. 
Background counts in the absence of PHA or Ba100 were 326  24 DPM. 
[3H] thymidine incorporation into PHA-stimulated CD4:CD8 lymphocytes was 22 442  2306 DPM. 
Results of a representative dose response to Ba100 are shown and are expressed as % suppression of PHA-induced 
CD4 : CD8 lymphocyte proliferation  SD based on the PHA-stimulated control. 
 
 
Ba100 inhibited proliferation of isolated CD4 and CD8 lymphocytes (mixed at a ratio 
found in whole blood) in response to PHA (Figure 5). 3 dose response experiments 
showed that the concentration curve was linear and flat with a regression coefficient of 
0.004 and SE 0.007. Ba100 at a concentration of 200 nM consistently inhibited 
proliferation of isolated CD4 and CD8 lymphocytes (mixed at a ratio found in whole 
blood) in response to PHA. The range of suppression for 3 experiments was 49.5 – 56% 
(mean 53.3%, median 54.5% suppression). These results suggested that processing of 
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2.5.2.  Effect of Ba100 on OKT3 and fibronectin-induced proliferation of CD4  
           lymphocytes 
Cellular adhesion involving both cell-cell and cell-extracellular matrix interactions are 
involved in lymphocyte trafficking and lymphocyte activation, growth and survival. 
Fibronectin is a key extracellular matrix protein involved in these processes (Hynes 
1986; Yamada et al 1992). Cellular adhesion to fibronectin is mediated via the 1 
integrins, 4 1 (VLA-4) and 5 1 (VLA-5) (Guan & Hynes 1990; Hemler & Lobb 
1995). 
Phenotypic analysis of lymphocytes proliferating in response to PHA in the presence of 
Ba100 demonstrated that Ba100 downregulated the expression of the adhesion 
molecules CD11a, CD49d and CD29 that are important in cell-cell and cell-extracellular 
matrix interactions. 
We next investigated the ability of Ba100 to modulate CD4 lymphocyte proliferation in 
response to OKT3 and fibronectin and thus potentially interfere with cell-extracellular 
matrix interactions. 
Fibronectin has been shown to synergise with anti-CD3 antibody inducing IL-2 gene 
expression which promotes CD4 lymphocyte proliferation in a serum free culture 
system (Matsuyama et al 1989; Yamada et al 1991). Isolated CD4 lymphocytes were 
allowed to proliferate in the presence of OKT3 (a muromonoclonal anti-CD3 antibody) 
and fibronectin either alone or in combination. Proliferation of isolated CD4 
lymphocytes occurred in the presence of fibronectin and immobilised OKT3. A kinetic 
study over 1, 2 and 4 days had shown that day 2 was the optimal time point to assess the 
effect of Ba100, as CD4 lymphocyte proliferation in response to OKT3 and fibronectin 
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Figure 6a-e. Effect of Ba100 on OKT3 and fibronectin-induced proliferation of CD4 
lymphocytes. 
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Figure 6a-e. Effect of Ba100 on OKT3 and fibronectin-induced proliferation of CD4 
lymphocytes. 
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Figure 6a-e. Effect of Ba100 on OKT3 and fibronectin-induced proliferation of CD4 
lymphocytes. 
 






























CD4 lymphocytes were isolated from PBMCs using Dynal beads. 
1x105 CD4 lymphocytes/well were incubated in OKT3-coated flat-bottomed wells in serum free culture medium 
(Serotec medium) with and without fibronectin (30 g/ml) in the absence or presence of Ba100 (200 nM) at 37 C.  
Ba100 was pre-incubated with CD4 lymphocytes for 30 min at 37 C before the addition of fibronectin to the wells. 
[3H] thymidine was added on days 1, 2 and 4 and incorporation measured 18 h later. 
Background [3H] thymidine incorporation for cells only, and cells + Ba100 or + fibronectin alone never averaged 
above 250 DPM. 
Results are expressed as mean DPM of 6 replicates  SD. 
 
These 5 experiments indicated that Ba100 (200 nM) modulated the proliferation of 
isolated CD4 lymphocytes in response to OKT3 and OKT3 with fibronectin as 
measured by tritiated thymidine incorporation after 1, 2 and 4 days proliferation  
(Figure 6a-e).  
Inhibition of OKT3-induced CD4 lymphocyte proliferation by Ba100 (200nM): 
Day 1: Range of suppression: 47.2 – 55% (mean 52.2%, median 54.5% suppression). 
Day 2: Range of suppression: 38.3 – 83.5% (mean 51%, median 43.1% suppression, 
optimal CD4 lymphocyte proliferation time point). 
Day 4: Range of suppression: 16.1 – 57.4% (mean 39.9%, median 45.7% suppression). 
Inhibition of OKT3 and fibronectin-induced CD4 lymphocyte proliferation by 
Ba100 (200nM):  
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Day 2: Range of suppression: 41.2 – 51.1% (mean 46.7%, median 45.4% suppression, 
optimal CD4 lymphocyte proliferation time point). 
Day 4: Range of suppression: 38.7 – 76.8% (mean 57.1%, median 60.4% suppression). 
Ba100 was able to inhibit CD4 lymphocyte proliferation stimulated via the TCR/CD3 
receptor pathway. These results also suggest that Ba100 is able to inhibit the synergistic 
interaction of the fibronectin receptor with TCR/CD3 mediated CD4 lymphocyte 
activation and possibly inhibit IL-2 production needed for proliferation. 
 
2.6.  Effect of Ba100 on PBMC proliferation in response to anti-CD28  
        antibody and a phorbol ester, PMA 
Our data, so far, indicated that Ba100 inhibits calcium-dependent T lymphocyte 
proliferation pathways involving TCR/CD3 interactions with mitogen, antigen and allo-
antigen, as well as T cell receptor/integrin receptor stimulated proliferation. 
We then investigated whether Ba100 could inhibit calcium-independent proliferation 
pathways such as proliferation in response to anti-CD28 antibody and a phorbol ester, 
phorbol 12-myristrate 13-acetate (PMA) that directly stimulates protein kinase C. CD28 
stimulation alone does not stimulate resting T cells, but when combined with PMA, T 
lymphocyte proliferation is induced (June et al 1994). 
Table 9.  Effect of Ba100 on PBMC proliferation in response to anti-CD28 





Suppression of PBMC 
proliferation 
PMA 44 431  1145 - 
PMA + anti-CD28 88 414  2204 - 
PMA + anti-CD28 + Ba100 81 341  2196 7.9%  1.41 
 
PBMC (0.5x106cells/well) were incubated in 1% BSA/PBS with PMA (1 ng/ml); PMA + anti-CD28 antibody  
(1 ng/ml) or PMA + anti-CD28 antibody + Ba100 (200 nM) at 37 C. 
Ba100 was preincubated with PBMC for 30 minutes at 37 C prior to the addition of PMA or PMA + anti-CD28. 
At 72 h, [3H] thymidine was added and incorporation measured 18 h later. 
Results of a representative experiment are shown and are expressed as mean DPM of 6 replicates  SD or % 
suppression of PBMC proliferation to anti-CD28 antibody/PMA  SD. 
 
Ba100 at a concentration of 200 nM did not inhibit PBMC proliferation in response to 
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2.7.  Effect of Ba100 on processes involved in T lymphocyte  
        proliferation 
Our data indicated that Ba100 inhibited calcium-dependent, but not calcium-
independent T lymphocyte proliferation pathways. In addition, Ba100 must be added 
within 2 hours of initiation of lymphocyte proliferation in order to exert its inhibitory 
effect, suggesting that Ba100 acts early in the T cell activation pathway leading to 
proliferation. 
To obtain further insight into the action of Ba100, we investigated the effect of Ba100 
on: 
1. Cytokine production during PBMC stimulation with PMA and ionomycin. 
2. The ability of exogenous IL-2 to reverse the inhibition of PHA-induced PBMC 
proliferation in the presence of Ba100. 
3. Cell cycle progression during PHA-induced PBMC proliferation. 
4. Proliferating cell nuclear antigen expression. 
 
2.7.1.  Effect of Ba100 on cytokine production 
Within 2 – 4 hours of activation, T cells begin to transcribe genes encoding for the 
cytokines IL-2, IL-3, IL-4, IFN- , GM-CSF and TNF- . 
PBMC proliferation in response to mitogens, antigens and alloantigens is dependent on 
IL-1, IL-2, IL-4 and IL-10 as well as IFN-  production by antigen-presenting cells and 
lymphocytes. These cytokines are produced transiently following cell activation and act 
locally as autocrine, paracrine or juxtacrine regulators by binding to specific high 
affinity receptors on the cells that they regulate. 
We have shown that Ba100 inhibits T lymphocyte proliferation and inhibits the 
expression of activation markers including IL-2R expression. This suggests that Ba100 
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We investigated the effect of Ba100 on lymphocyte intracellular production of the 
cytokines IL-2, IFN- , and TNF-  (Th1 cytokines) and the Th2 cytokine, IL-4. We used 
flow cytometry to identify lymphocytes producing cytokines in response to stimulation 
with PMA and ionomycin (a calcium ionophore that elevates intracellular calcium). 
These two agents act together, bypassing the TCR to stimulate the transcription factor 
NF-kB, which is an essential step for the activation of cytokine producing genes 
(Truneh et al 1985). 
i)  Kinetics of lymphocyte intracellular cytokine production in response to PMA  
    and ionomycin stimulation 
The initial study investigated the optimal time point to measure intracellular cytokines.  
The number of cells expressing the cytokines IFN- , TNF-  and IL-2 were measured as 
well as the level of expression of cytokines per cell at 4, 6 and 24 h.  
 
Table 10.  Kinetic study of intracellular cytokine production by PBMC in response 




4 h 6 h 24 h 
% Positive 
cells 
MFI % Positive 
cells 
MFI % Positive 
cells 
MFI 
IFN-  38 2.4 44 1.4 20 0.34 
TNF-  48 1.8 33 0.93 24 0.72 
IL-2 24 2.8 3 0.65 2 0.21 
 
PBMC (20x106/20 ml RPMI 1640/10% AB serum) were incubated in 30ml tissue culture flasks with PMA  
(50 ng/ml), ionomycin (1 µm) and 2.5 g/ml Brefeldin (inhibitor of intracellular protein transport processes) in the 
absence or presence of Ba100 (200 nM) for 4, 6 and 24 h at 37 C.  
The cells were harvested at 4, 6 and 24 h, concentration adjusted to 10x106/ml RPMI 1640/10% AB serum and 100 l 
aliquots of cells were fixed with 4% paraformaldehyde, permeabilised with 0.1% saponin and then labeled with 
antibodies directed to the indicated cytokines (IFN- , TNF-  amd IL-2) and single colour analysis of cytokine 
antibody binding was done by flow cytometry on 10 000 CD3+ gated lymphocytes. 
Results of a representative experiment are shown and are expressed as % of cells in the CD3+ lymphocyte gate 
expressing the cytokine and the MFI of the cytokine antibody binding. 
 
 
This kinetic study indicates that the production of the intracellular cytokines IFN- , 
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2.7.2.  Effect of Ba100 on intracellular IL-2 production by lymphocytes in response  
           to PMA and ionomycin (4 h stimulation) 
Four experiments were performed to investigate the effect of Ba100 on intracellular IL-
2 expression by lymphocytes when stimulated with PMA and ionomycin. 
 
Table 11.  Effect of Ba100 on lymphocytes expressing and production of 
intracellular IL-2 in response to PMA and ionomycin (4h stimulation). 
 










MFI % Positive 
cells 
MFI 
1.  IL-2 25 8.7 2.8 1.9 88.8%  78.2%  
2.  IL-2 26 6.4 2.0 2.5 92.3%  60.9%  
3.  IL-2 28 9.2 6.9 3.3 75.4%  64.1%  
4.  IL-2 26 7.2 5.6 2.5 78.5%  65.3%  
 
PBMC (20x106/20 ml RPMI 1640/10% AB serum) were incubated in 30ml tissue culture flasks with PMA  
(50 ng/ml), ionomycin (1 µm) and 2.5 g/ml Brefeldin (inhibitor of intracellular protein transport processes) in the 
absence or presence of Ba100 (200 nM) for 4 h at 37 C.  
The cells were harvested at 4 h, concentration adjusted to 10x106/ml RPMI 1640/10% AB serum and 100 l aliquots 
of cells were fixed with 4% paraformaldehyde, permeabilised with 0.1% saponin and then labeled with antibodies to 
IL-2 and single colour analysis of anti-IL-2 antibody binding was done by flow cytometry on 10 000 CD3+ gated 
lymphocytes. 
Results of 4 experiments are shown and are expressed as % of cells in the CD3+ lymphocyte gate expressing IL-2 
and the MFI of the cytokine antibody binding. 
The change in intracellular IL-2 expression in the presence of Ba100 is expressed as a % of that in the absence of 
Ba100.  indicates a decrease from that in the absence of Ba100. 
 
 
These experiments (Table 11) indicated that within 4h, Ba100 at a concentration of  
200 nM inhibited: 
i) the generation of activated lymphocytes expressing intracellular IL-2 (range 
of inhibition 75.4 – 92.3%, median 83.7%). 
ii) the level (MFI) of lymphocyte intracellular IL-2 expression (range of MFI 
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2.7.3.  Effect of Ba100 on intracellular IFN- , TNF-  and IL-4 production by   
           lymphocytes in response to PMA and ionomycin (4 h stimulation) 
A further set of 3 experiments was performed to investigate the effect of Ba100 on 
lymphocyte intracellular IFN- , TNF-  and IL-4 production in response to PMA and 
ionomycin. 
Table 12.  Effect of Ba100 on lymphocytes expressing and production of 
intracellular IFN- , TNF-  and IL-4 in response to PMA and ionomycin (4h 
stimulation). 






MFI % positive 
cells 
MFI % positive 
cells 
MFI 
1.   IFN-  36 2.25 8.5 1.23 76.4%  45.3%  
      TNF-  48 1.86 12 0.97 75.0%  47.8%  
      IL-4 28 2.21 6.0 0.77 78.6%  65.2%  
2.   IFN-  38 2.18 10 1.1 73.7%  49.5%  
      TNF-  40 1.49 13 0.83 67.5%  44.3%  
      IL-4 29 2.25 5 0.81 82.7%  64.0%  
3.   IFN-  39 2.24 9.8 1.1 74.9%  50.9%  
      TNF-  42 1.55 7.3 0.85 82.6%  45.2%  
      IL-4 27 1.6 6.5 0.59 75.9%  63.1%  
 
PBMC (20x106/20 ml RPMI 1640/10% AB serum) were incubated in 30 ml tissue culture flasks with PMA  
(50 ng/ml), ionomycin (1 µm) and 2.5 g/ml Brefeldin (inhibitor of intracellular protein transport processes) in the 
absence or presence of Ba100 (200 nM) for 4 h at 37 C.  
The cells were harvested at 4 h, concentration adjusted to 10x106/ml RPMI/10% AB serum and 100 l aliquots of 
cells were fixed with 4% paraformaldehyde, permeabilised with 0.1% saponin and then labeled with antibodies 
directed to the indicated cytokines (IFN- , TNF-  and IL-4) and single colour analysis of cytokine antibody binding 
was done by flow cytometry on 10 000 CD3+ gated lymphocytes. 
Results of 3 experiments are shown and are expressed as % of cells in the CD3+ lymphocyte gate expressing the 
cytokine and the MFI of the cytokine antibody binding. 
The change in intracellular cytokine expression in the presence of Ba100 is expressed as a % of that in the absence of 
Ba100.  indicates a decrease from that in the absence of Ba100. 
 
Ba100 at a concentration of 200 nM inhibited the generation of activated lymphocytes 
expressing the intracellular cytokines (Table 12): 
i) IFN- : range of inhibition 73.7 – 76.4%, median 74.9% inhibition. 
ii) TNF- : range of inhibition 67.5 – 82.6%, median 75% inhibition. 
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There was also a decrease in the level of intracellular expression (MFI) of: 
i) IFN-  per cell: range of inhibition 45.3 – 50.9%, median 49.5% inhibition. 
ii) TNF-  per cell: range of inhibition 44.3 – 47.8%, median 45.2% inhibition. 
iii) IL-4 per cell: range of inhibition 63.1 – 65.2%, median 64% inhibition. 
 
2.7.4.  Effect of addition of exogenous IL-2 on PHA-induced PBMC proliferation in  
           the presence of  Ba100 
Ba100 was shown to inhibit both Th1 and Th2 cytokines. We then looked at whether 
the addition of exogenous IL-2 could reverse the inhibitory action of Ba100 on PHA-
stimulated lymphocytes or whether other pathways besides cytokines were involved in 
the immunomodulation. 
 
Figure 7.  Effect of addition of exogenous IL-2 on PHA-induced PBMC proliferation in the 



















PHA + Ba100 - 55% Suppression
PHA + IL-2
PHA + Ba100 + IL-2 - 49% Suppression
 
 
PBMC (1x105cells/well) were incubated with PHA (0.00575 mitogenic units); PHA + Ba100 (200 nM); PHA + IL-2  
 (10 U/ml) and PHA + Ba100 + IL-2 at 37 C. 
Ba100 was pre-incubated with PBMC for 30 min at 37 C prior to the addition of PHA or PHA + IL-2. 
At 72 hours, [3H] thymidine was added and incorporation measured 18 h later. 
Background [3H] thymidine incorporation into PBMC in the absence of PHA, Ba100 and IL-2 was 310  35 DPM. 
Results of a representative experiment are shown and are expressed as mean DPM of 6 replicates  SD or  
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In the continual presence of Ba100, the addition of exogenous IL-2 was unable to 
reverse the inhibitory effect of Ba100 (200 nM) on PHA-stimulated lymphocyte 
proliferation (Figure 7). This was confirmed in 2 further experiments (p = 0.4 using the 
Mann-Whitney Non-parametric test). This suggests that Ba100 not only inhibits 
cytokine production, but also interferes with other pathways involved in mitogen-
induced T lymphocyte proliferation such as engagement or expression of the IL-2 
receptor. This goes together with our finding that Ba100 inhibits not only the generation 
of activated lymphocytes expressing the IL-2 receptor, but also downregulated IL-2 
receptor expression per cell. 
 
2.7.5.  Effect of Ba100 on the distribution of PHA-stimulated PBMCs in the  
           various phases of the cell cycle 
Ba100 inhibited the induction of cytokines that play an important role in enabling T 
lymphocytes to move from a resting G0 phase to the activated G1 phase. We therefore 
investigated the effect of Ba100 on cell cycle progression. 
 
i)  The distribution of PHA-stimulated PBMCs in the various phases of the cell  
     cycle 
Two initial experiments were set up without Ba100 to determine the percentage of cells 
in the G0G1, S and G2M phases at 24 and 48 h in response to PHA stimulation. At 24 h, 
most of the cells were in the G0G1 phase with minimal progression into the S and G2M 
phases. By 48 h, cell cycling had progressed with cells now being detectable in the S 
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Table 13.  Distribution of PHA-stimulated PBMCs in the various phases of the cell 
cycle (24 and 48 h stimulation). 
Experiment Phase % Cells per cell cycle phase 
  24 hr 48 hr 
Experiment 1 G0G1 92 57 
 S 2 23 
 G2M 2 14 
Experiment 2 G0G1 93 56 
 S 3 15 
 G2M 2 24 
 
PBMC (1x106 cells/ml RPMI 1640/10% AB serum) stimulated with PHA in 30ml tissue culture flasks in the absence 
or presence of Ba100 (200 nM) were harvested at 24 and 48 hours and resuspended at 5x106cells/ml RPMI 1640/10% 
AB serum. 
Cells were stained with propidium iodide (PI) for DNA quantitation by FACS. 
Cells were permeabilised with non-ionic detergent and treated with PI and RNAse. 







ii) The effect of Ba100 on the distribution of PHA-stimulated lymphocytes in the  
     various phases of the cell cycle after 24, 40 and 48 h stimulation 
At 24 h, in the absence of Ba100, the majority of cells are in the G0G1 phase. The 
addition of Ba100 (200 nM) did not accelerate cell cycle progression into the S and 
G2M phases (Table 14). 
 
Table 14.  Effect of Ba100 on the distribution of PHA-stimulated PBMC in the 
various phases of the cell cycle (24 h stimulation). 
Stimulation Phase % cells per cell cycle phase 
  -Ba100 + Ba100  (200 nM) 
Experiment 1 GoG1 92 94 
  24 hours S 2 1 
 G2M 2 1 
Experiment 2 GoG1 93 96 
  24 hours S 3 2 
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Table 15.  Effect of Ba100 on the distribution of PHA-stimulated PBMC in the 
various phases of the cell cycle (40 and 48 h stimulation). 
Stimulation Phase % Cells per cell cycle phase % Change 
  -Ba100 + Ba100 (200 nM)  
Experiment 1 G0G1 57 71 24.6%  
  40 hours S 23 13 43.5%  
 G2M 14 8 42.9%  
Experiment 2 G0G1 54 64 18.5%  
  40 hours S 17 13 23.5%  
 G2M 25 20 20.0%  
Experiment 3 G0G1 43 54 25.6%  
  40 hours S 28 20 28.6%  
 G2M 22 18 18.2%  
Experiment 4 G0G1 52 66 26.9%  
  40 hours S 21 12 42.9%  
 G2M 22 19 13.6%  
Experiment 5 G0G1 29 44 51.7%  
  48 hours S 45 27 40.0%  
 G2M 21 17 19.0%  
Experiment 6 G0G1 33 51 54.5%  
  48 hours S 41 31 24.4%  
 G2M 20 14 30.0%  
Experiment 7 G0G1 49 69 40.8%  
  48 hours S 33 19 42.4%  
 G2M 17 10 41.2%  
 
PBMC (1x106 cells/ml RPMI 1640/10% AB serum) stimulated with PHA in 30ml tissue culture flasks in the absence 
or presence of Ba100 (200 nM) were harvested at 40 and 48 hours and resuspended at 5x106cells/ml RPMI 1640/10% 
AB serum. 
Cells were stained with propidium iodide (PI) for DNA quantitation by FACS. 
Cells were permeabilised with non-ionic detergent and treated with PI and RNAse. 
Single parameter histograms using FL detector 3 (emission spectrum peaks at 650 nm) were used to assess results. 
The change in the distribution of cells in the various cell cycle phases are expressed as a % of that in the absence of 





At 48 h, Ba100 (200 nM) altered the distribution of cells in the various phases of the 
cell cycle. A consistent increase in the cells in the G0G1 phase and a decrease in the 
number of cycling cells, i.e. those cells in the S and G2M
 
cell cycle phases, was 
observed when Ba100 was present (Table 15 and Figure 8a and b). Ba100 inhibits PHA-
stimulated lymphocyte proliferation and this was associated with inhibition of cell cycle 
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Figure 8a and b.  Effect of Ba100 on the distribution of PHA-stimulated PBMC in the various 
phases of the cell cycle at 48 h. 
 
            a.      b. 
 
 
     Phases of the cell cycle at 48 h: G0G1 phase (1 and 2), S phase (3) and G2/M phase (4) in the absence  






2.7.6.  Effect of Ba100 on proliferating cell nuclear antigen (PCNA) expression by  
           PHA-stimulated PBMCs 
Proliferating cell nuclear antigen is involved in DNA replication and is a critical 
requirement for cell cycle progression into the S phase. PCNA is first expressed through 
de novo protein synthesis in the mid G1 phase, peaks in the S phase and is weakly 
expressed in the G2 and M phases of the cell cycle.  
We investigated whether Ba100 altered PCNA expression. 
Ba100 (200 nM) inhibited the generation of cells expressing PCNA (range of 
suppression 21.6 – 28.3%, median 25.1% suppression) as well as the extent of PCNA 
expression per cell (range of suppression 27.6 – 65.5%, median 49.8% suppression) in 
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Table 16.  Effect of Ba100 on PCNA expression by PHA-stimulated PBMC (48 h 
stimulation). 
Experiment -Ba100 + Ba100 (200 nM) % Change 
 % Positive 
cells 
MFI % Positive 
cells 
MFI % Positive 
cells 
MFI 
1 68 2.9 52 2.1 23.5%  27.6%  
2 53 2.1 38 1.0 28.3%  52.4%  
3 60 1.7 44 0.9 26.7%  47.1%  
4 51 2.9 40 1.0 21.6%  65.5%  
 
PBMC (1x106 cells/ml RPMI 1640/10% AB serum) stimulated with PHA in 30ml tissue culture flasks in the absence 
or presence of Ba100 (200 nM) were harvested at 48 h and resuspended at 2x106 cells/ml RPMI 1640/10% AB serum. 
Cells were permeabilised with 20μg/ml lysolecithin, fixed with 1% paraformaldehyde for 2 min and then treated on 
ice for 10 min with methanol, followed by incubation on ice with 0.1% NP-40 for 5 min. 
The intracellular nuclei were then stained with anti-PCNA and analysed by FACS. 
Results are expressed as % cells expressing PCNA or as MFI which represents the extent of PCNA expression per 
cell. The change in PCNA expression in the presence of Ba100 is expressed as a % of that in the absence of Ba100.  
 indicates a decrease from that in the absence of Ba100. 
 
 
3.  DISCUSSION 
Ba100, a novel C-type lectin has been isolated from the venom of the Western Cape, 
South African puff adder, Bitis arietans. Ba100, a protease with fibrinogenase activity 
inhibits platelet aggregation in platelet-rich plasma and clot formation in whole blood. 
This is due to its fibrinogenolytic activity that cleaves the A  and B  chain preventing 
fibrinogen crosslinking and fibrin clot formation (Jennings et al 1999). 
C-type lectins are known to play an important role in direct defense, cell trafficking and 
immune regulation (Zelensky & Gready 2005) and plant lectins such as 
Phytohaemagglutinin (PHA) and Concanavalin A (Con A) are well known stimulators 
of lymphocyte proliferation. (Vermot Desroches et al 1991; Komada et al 1996; Barten 
et al 2001). 
In view of its C-type lectin structure and its protease/fibrinogenase activity on 
fibrinogen, a multifunctional protein interacting with a variety of cells, we postulated 
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This study clearly shows that Ba100 consistently suppresses in a dose-dependent 
manner, lymphocyte proliferation in response to mitogen (IC50  169 nM), antigen 
(IC50  53 - 95 nM depending on the antigen) and alloantigen (IC50  149 nM) 
stimulation. Curve estimation (SPSS) was used to analyse the relationship between the 
concentration of Ba100 and the % suppression of lymphocyte proliferation in response 
to mitogen, antigens and alloantigens: the concentration curves for the mitogen PHA 
and the MLR were simple linear and for the antigens PPD, Tetanus toxoid and 
Varidase, the concentration curves were linear with logarithmic transformation. 
Ba100 was not lymphotoxic as the PBMCs remained viable despite prolonged culture in 
the presence of Ba100. Viability was confirmed microscopically at the end of each 
study by trypan blue exclusion or by the exclusion of propidium iodide where the effect 
of Ba100 on the cell cycle in response to PHA was investigated. Pre-incubation with 
Ba100 was not required for its anti-proliferative effects as the suppression of 
proliferation was the same with no pre-incubation, 30 minutes or 60 minutes pre-
incubation. If Ba100 was washed away after a 30 minute pre-incubation period prior to 
the addition of PHA, the inhibitory effect of Ba100 was lost. These results suggested 
that Ba100 did not interfere with any early plasma membrane associated events in T cell 
activation. For standardization purposes, a 30 minute pre-incubation period was used in 
all the experiments. The inhibitory effect of Ba100 on PHA-induced PBMC 
proliferation was not achieved, if Ba100 was added 2 hours after the initiation of PBMC 
proliferation. This suggested that Ba100 interferes with early events of T cell activation 
prior to DNA synthesis and cell division. 
The addition of exogenous IL-2 to activated T cells did not reverse the inhibitory effects 
of Ba100 on PHA-induced PBMC proliferation, suggesting that Ba100 interferes with 
mitogen-induced T cell proliferation at more than one site. 
Having established that Ba100 did possess immunosuppressive properties with respect 
to mitogen and antigens, we next looked at an in vitro transplant model, the primary 
mixed lymphocyte reaction. The primary mixed lymphocyte reaction involves the 
generation of antigen-specific cytotoxic T lymphocytes (CTLs) and the production of 
cytokines which participate in delayed-type hypersensitivity responses. The generation 
of an immune response to an allograft or cell surface antigen is a complex process 
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stage of this complex cascade would lead to inhibition of lymphocyte proliferation. The 
primary mixed lymphocyte reaction involves a number of significant steps in addition to 
antigen recognition which include: 
i) presentation of antigen by macrophages with subsequent production and 
release of IL-1 by macrophages. 
ii) activation of CD4 lymphocytes with production and release of IL-2 and 
other cytokines (IL-1 augments the production of IL-2). 
iii) IL-18 secretion and the induction of expression of ICAM-1, B7.1 (CD80), 
B7.2 (CD86) on monocytes (Morichika et al 2003). 
iv) activation of precursor CTLs with acquisition of a receptor for IL-2 (Hayry 
& Defendi 1970). 
v) clonal amplification and activation of CTLs by IL-2 (Hayry & Defendi 1970; 
Hodes & Svedmyr 1970). 
vi) activation of suppressive regulatory T lymphocytes which downregulate the 
alloimmune response (Hirschberg & Thorsby 1977). 
 
The IL-2/IL-2 receptor pathway is a critical rate-limiting step within the allo-immune 
response. Its primary effect being to amplify effector function, especially the clonal 
expansion of antigen-specific CTLs. 
Ba100 inhibited the primary mixed lymphocyte reaction in a dose-dependent manner. 
Effector cells generated in a primary MLR in the presence of Ba100 exerted a 
suppressive effect on the proliferation of a fresh MLR. This suppressive activity was not 
antigen specific. Ba100 also inhibited the cytolytic activity of effector cells generated in 
a primary MLR. 
After establishing the inhibitory effects of Ba100 on lymphocyte proliferation, we used 
flow cytometry to look at the effect of Ba100 on lymphocyte activation markers, co-
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Phenotypic analysis of lymphocytes after PHA-induced PBMC proliferation in the 
presence of Ba100 consistently showed: 
i) impaired generation of activated lymphocytes as measured by the number of 
cells expressing HLA-DR and CD25, the marker for the IL-2 receptor, as 
well as a decreased number of HLA-DR and IL-2 receptors expressed per 
cell. 
ii) impaired generation of lymphocytes expressing the costimulatory molecule 
CD28 as well as a decreased number of CD28 molecules expressed per cell. 
iii) impaired generation of lymphocytes expressing the adhesion molecules 
CD11a, CD49d and CD29 as well as a decreased number of CD11a, CD49d 
and CD29 receptors expressed per cell. 
iv) impaired generation of cytotoxic T cells expressing the S6F1 marker that is 
found on the killer effector cells and is induced on CD8 cells during the 
mixed lymphocyte reaction and a decreased number of S6F1 receptors 
expressed per cell. 
The inhibited generation of lymphocytes expressing CD49d and CD29 molecules as 
well as the decreased cellular expression of these molecules suggests that memory cell 
adhesion to the vascular endothelium would be impaired. 
Phenotypic analysis of Ba100-treated effector cells generated in a six day primary MLR 
also confirmed that Ba100 inhibited the generation of activated lymphocytes expressing 
HLA-DR and the IL-2 receptor. There was also impaired generation of natural killer 
cells as measured by the number of cells expressing either CD16 or CD56. Ba100 in the 
MLR increased the CD4:CD8 ratio possibly due to CD8 lymphocytes being unable to 
proliferate as a result of a decreased expression of the IL-2 receptor. Ba100 had no 
effect on B cells. Thus, phenotypic analysis demonstrated that Ba100 affected critical 
components of the alloimmune response. 
T lymphocyte proliferation is dependent not only on recognition of antigen presenting 
Class Ι and Class Π receptors by lymphocyte CD8 and CD4 receptors respectively, 
together with the TCR/CD3 complex, but also on the interaction of antigen-presenting 
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require a number of accessory signals for optimal activation, including molecular 
interactions of cell surface adhesion molecules on antigen-presenting cells (LFA-1 
(CD11a/CD18), ICAM-1, VCAM-1, LFA-3) with T lymphocyte receptors (ICAM-1, 
LFA-1 (CD11a/CD18), VLA-4 (CD49d/CD29), CD2) together with the CD4/CD8 and 
CD28 co-receptors (Davis & van der Merwe 1996; Zuckerman et al 1998; Yashiro et al 
1998). The CD28:B7 co-stimulatory pathway is particularly important and is a powerful 
activator of phosphatydilinositol 3-kinase leading to production of IL-1, IFN , IL-2 and 
IL-10 (Lenschow et al 1996; Salomon & Bluestone 2001; Sharpe & Freeman 2002; Nel 
2002).  
LFA-1 (CD11a/CD18) plays a critical role in leukocyte function and trafficking 
(Kellersh & Kolanus 2006; Graf et al 2007; Smith et al 2007; Stanley et al 2008). LFA-
1 signals bidirectionally with processing of information from extracellular ligands 
(outside-in signaling) and inside-out signaling of cellular activation processes, thereby 
influencing cellular adhesion, migration, cytokine production and proliferation 
(Xingyuan et al 2006; Mor et al 2007).  
VLA-4 (CD49d/CD29) binds to VCAM-1 and fibronectin, mediating adhesion to 
activated endothelial cells and the ECM respectively (Wayner et al 1989; Elices et al 
1990; Collins et al 1995; Blankenberg et al 2003). VLA-4 also interacts with the 
endothelial junctional adhesion molecule-2 (JAM-2) (Cunningham et al 2002b). 
Both LFA-1 and VLA-4 promote the differentiation of Th1 effector lymphocytes 
(González-Amaro et al 2005) and play an important role in lymphocyte-endothelium 
reactions involved in allograft rejection. LFA-1 and VLA-4 expressed on lymphocytes 
bind to the endothelial adhesion molecules ICAM-1 and VCAM-1 respectively (Adams 
& Shaw 1994; Steeber & Tedder 2000; Pribila et al 2004; Steeber et al 2005). This 
results in strong adhesion of lymphocytes to the endothelial wall (Tanaka et al 1993; 
Taub et al 1993a,b; Adams et al 1994; Gonzalez-Amaro & Sanchez 1999; Xingyuan et 
al 2006). Memory cells which are a critical component of the alloimmune response have 
an upregulated expression of LFA-1, CD2 and VLA-4 and adhere to the endothelium 
and ECM via VLA-4. These lymphocyte receptors VLA-4 (CD49d/CD29) and LFA-1 
(CD11a/CD18) are also involved in transendothelial migration (Elices et al 1990; 
Hourihan et al 1993; Gonzalez-Amaro et al 2005; Rao et al 2007). Thus, Ba100, which 
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could potentially interfere with the adhesion cascade involved in the recruitment of T 
lymphocytes and memory cells into allografts (Briscoe et al 1998; Fujisaki et al 1998).  
The formation of the immunological synapse is the initiating step in all T lymphocyte 
dependent immune responses establishing functional contact between T lymphocytes 
and antigen-presenting cells. LFA-1/ICAM-1 interactions are important in maintaining 
the functional unit of the immunological synapse, the peripheral supraclavicular 
activation cluster (pSMAC) (Lin et al 2005). VLA-4 also plays a role in the formation 
of the immunological synapse, relocating to the pSMAC (Mittelbrunn et al 2004). 
Ba100 could thus interfere at this critical point in T cell activation. Ba100 also inhibited 
the generation of activated lymphocytes expressing the costimulatory molecule CD28 
and downregulated CD28 expression per cell. The CD28-B7 pathway provides the 
important second signal required for optimal T cell activation, proliferation and 
differentiation into effector T cells and memory cells (Salomon & Bluestone 2001; 
Sharpe & Freeman 2002; Nel 2002). 
Ba100 inhibited the generation of T cell subsets that play a critical role in the allo-
immune response: CTL, NK cells and memory cells as well as increasing the CD4:CD8 
ratio. Alloreactive memory T cells are relatively resistant to tolerance (Chalasani et al 
2002; Sprent & Surh 2002). Effector memory cells require minimal costimulation 
signaling from B7 and CD40 on antigen-presenting cells (London et al 2000). Thus, the 
impaired generation of memory T cells would be potentially beneficial in inducing 
tolerance. 
In PHA-stimulated PBMC proliferation assays, Ba100 inhibited the generation of CTLs 
which are responsible for lymphocyte mediated cytotoxicity, an important effector 
mechanism in allograft rejection (Kagi et al 1996; Liu et al 1996; Barry & Bleakley 
2002; Russel & Ley 2002; Rocha et al 2003). 
In the mixed lymphocyte reaction assays, Ba100 inhibited the generation of NK cells as 
determined by the number of cells expressing either CD16 or CD56. NK cells have been 
shown to infiltrate allografts shortly after transplantation before T cell infiltration 
(Hsieh et al 2002; McNerney et al 2006). NK cells do not require prior sensitization and 
are not antigen-specific. NK cells have immunomodulatory lectin-like receptors that 
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these receptors determines NK cell activation (Ryan et al 2001). Activated NK cells 
express chemokine receptors CXCR1 and CXCR3 and release numerous cytokines and 
chemokines leading to mononuclear cell recruitment and activation, and recruitment of 
alloreactive T cells (Kondo et al 2000; Obara et al 2005). NK cells lyse target cells via 
the granzyme exocytosis pathway (Shresta et al 1995), but can also induce antibody-
dependent cell cytotoxicity. NK cells have been shown to play a role in solid organ 
allograft rejection (Totterman et al 1989; Blancho et al 1992; Bishara et al 2001; Vampa 
et al 2003) and may play an important role in xenografts (Kirk et al 1993; Seebach & 
Waneck 1997; Manilay & Sykes 1998; Khalfoun et al 2000; Rieben & Seebach 2005; 
Kitchens et al 2006).  
In the MLR, Ba100 constantly increased the CD4:CD8 ratio and this possibly reflects 
the inability of CD8 lymphocytes to proliferate due to inhibition of the IL-2/IL-2 
receptor pathway. 
CD4 lymphocytes play a critical role in the initiation of allograft rejection. Activated 
CD4 lymphocytes in both the direct and indirect pathways proliferate and secrete a 
variety of cytokines that drive the alloimmune response leading to allograft injury 
(Krensky et al 1990; Keane-Myers et al 1998; Lakkis et al 1998; O’Garra 1998). These 
cytokines act in an autocrine and paracrine manner as growth and activating factors for 
CD8 cytotoxic cells, B cells and macrophages leading to destruction of the transplanted 
organ by direct lysis of target cells, antibody production and delayed-type 
hypersensitivity mechanisms respectively (Sayegh & Turka 1998; Rocha et al 2003). 
Ba100 inhibited isolated CD4 and CD8 lymphocyte proliferation in response to PHA in 
the absence of antigen-presenting phagocytes. This suggested that no processing of 
Ba100 by antigen-presenting phagocytes was required for its immunomodulatory 
activity. Furthermore, inhibition of CD4 lymphocyte proliferation in response to OKT3, 
a muromonoclonal anti-CD3 antibody and OKT3 and fibronectin was observed. 
Lymphocyte-extracellular matrix (ECM) interactions play an important role in 
lymphocyte activation, adhesion, migration and positioning within tissue 
microenvironments (Hynes 1986; Shimizu et al 1990; de Sousa et al 1991; Yamada et al 
1992; Hauzenberger et al 1994; Ybarrondo et al 1994; Ostergaard & Ma 1995; Hunter 
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lymphocyte/fibronectin interaction plays an important role in the alloimmune response 
(Coito et al 2000a). Cellular adhesion to fibronectin is mediated via the 1 integrins, 
4 1 (VLA-4) and 5 1 (VLA-5) (Guan & Hynes 1990; Hemler & Lobb 1995). 4 1 
is upregulated during lymphocyte proliferation.  The 5 1 integrin is present on resting 
CD45 RA dim memory cells (Klingemann & Dedhar 1989). The adhesion of T 
lymphocytes to fibronectin is regulated by engagement of the antigen-specific 
TCR/CD3 complex and the engagement of CD2, CD7 and CD28 molecules (Shimizu et 
al 1992, 1995; Chan et al 1997). Chemokines such as RANTES, MCP-1 and MIP-1 also 
play a role in regulating integrin-mediated lymphocyte binding to fibronectin (Weber et 
al 1996, Carr et al 1994, 1996). 
Fibronectin plays an important role in the effector phase of the alloimmune response 
which is dependent on the adhesion and migration of alloreactive cells into the graft 
(Kupiec-Weglinski et al 1993; Coito et al 1994a,b, 2000a). It has been shown that in 
vivo interactions between the lymphocyte 4 1 integrin receptor and the cell associated 
CS-1 motif of fibronectin are critical in the acute allograft rejection cascade (Coito et al 
1998). Blockade of these interactions with CS-1 peptides prevented rejection of rat 
cardiac allografts by reducing intragraft infiltration of CD4 and CD8 lymphocytes, 
decreasing vascular expression of VCAM-1 and ICAM-I and decreasing cytokine (IL-2, 
IFN- , IL-4, IL-5 and IL-6) production (Coito et al 1998; Coito 2000a,b). 
Administration of CS-1 peptide  to mice recipients of islet allografts prevented graft 
infiltration suggesting a role for 4 1/fibronectin interactions in lymphocyte homing to 
the graft site (Stegall et al 1999). Rat cardiac allograft models have shown that 
upregulation of vascular fibronectin is a common early step in both allo- and iso-
transplants and is an important signal that triggers lymphocyte recruitment at the graft 
site (Coito et al 1994a,b, 1997). Later, following cardiac allo-transplantation, cellular 
fibronectin is predominantly expressed in the myocardium, but this is absent in 
isografts.  
Thus, the ability of Ba100 to inhibit CD4 lymphocyte proliferation in response to OKT3 
and fibronectin may in part relate to its ability to downregulate the CD49d and CD29 
adhesion molecules and thus impair cell-extracellular matrix interactions that participate 
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Ba100 inhibits lymphocyte proliferative responses which are initiated by stimuli that 
result in an increase in intracellular calcium concentration, but is unable to inhibit 
PBMC proliferation in response to anti-CD28 antibody and PMA. Growth factor 
stimulation with IL-2 or IL-4 or treatment with anti-CD28 monoclonal antibodies plus 
PMA is not associated with a rise in intracellular calcium. 
These results collectively suggest that the immunosuppressive effects of Ba100 are a 
result of inhibition of an early step in T cell activation involving calcium-dependent 
activation pathways that result in the inhibition of IL-2 production and IL-2 receptor 
expression. 
Having demonstrated that Ba100 inhibited CD4 lymphocyte proliferation, we 
investigated its effect on the generation of cytokines. Within 2-4 hours following 
activation, T cells begin to transcribe genes encoding several cytokines including IL-2, 
IL-3, IL-4, IFN- , GM-CSF and TNF . These cytokines act locally as autocrine, 
paracrine and juxtacrine regulators by binding to specific high affinity receptors on the 
cells that they affect. Ba100 was shown to inhibit the number of activated lymphocytes 
expressing the IL-2 receptor and to downregulate lymphocyte IL-2 receptor expression. 
Ba100 inhibited the generation of Th1 cytokines (IFN- , TNF-  and IL-2) and the Th2 
cytokine, IL-4 by activated lymphocytes. It has been shown in human T cells activated 
via the TCR/CD3 complex that the amount of IL-2 produced correlates closely with the 
level of cellular calcineurin activity (Fruman et al 1992). Ba100 at a concentration of 
200 nM resulted in a mean of 67.1% inhibition of intracellular IL-2 production by 
activated lymphocytes. As Ba100 inhibited activated lymphocyte production of 
cytokines (IL-2, IL-4, IFN-  and TNF- ) in response to stimulation by a combination of 
PMA and ionomycin, this suggests that Ba100 inhibits calcium-dependent activation of 
the transcription factor NF  (Truneh et al 1985), which is an essential step for the 
activation of cytokine producing genes. 
The Th1 cytokines promote immunopathologic functions by mediating delayed-type 
hypersensitivity, promoting generation of cytotoxic T cells (CTLs), activating natural 
killer cells, activating macrophages with consequent production of nitric oxide, reactive 
oxygen intermediates, degradative enzymes and TNF-  production (Rocha et al 2003). 
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enhancing T cell activation (Pechhold et al 1997). IL-4 acts as a growth-promoting 
cytokine in CD4 Th2 cells promoting further cytokine secretion (Swain et al 1990). 
Thus, Ba100 by downregulating intracellular Th1 cytokine production as well as the 
production of the growth-promoting cytokine, IL-4, could potentially impair the 
alloimmune response leading to allograft injury and phenotypic analysis has shown that 
Ba100 impairs the generation of CTLs and NK cells. 
We next investigated the effect of Ba100 on cell cycle progression and proliferating cell 
nuclear antigen expression. 
Engagement of the T cell receptor and activation of co-stimulatory signals such as the 
CD28 co-stimulatory pathway (June et al 1994) allows gene transcription and 
production of cytokines which enable T cells to move from a resting G0 phase to the 
activated G1 phase. The progression from G1 through to the S phase is regulated 
through a variety of receptors on the T cell surface including the IL-2 receptor. The 
binding of T cell growth factors such as IL-2 to high affinity receptors, initiates 
signaling events required for the progression of the T cell in the G1 phase into the S 
phase and ultimately into mitosis. The enzymes critical for the induction of cell division 
include cyclin/cyclin-dependant kinases and de novo purine and pyrimidine synthesis 
which is essential before lymphocytes can complete cell division. Ba100 consistently 
results in a decrease in the number of cycling cells, blocking cell cycle progression from 
the G0G1 into the S phase.  
PCNA (proliferating cell nuclear antigen), a member of the DNA sliding camp family, 
plays an essential role in nucleic acid metabolism, DNA replication and repair in all 
eukaryotes (Kelman 1997; Jonsson & Hubscher 1997; Maga & Hubscher 2003). PCNA 
plays a critical role in cell cycle regulation interacting with several eukaryotic cell cycle 
proteins. It binds to cyclin-CDK complexes (Xiong et al 1992) as well as the CDK 
inhibitor p21 (Gulbis et al 1996; Knibiehler et al 1996). Each phase of the cell cycle is 
under control of a specific CDK-cyclin complex: CDK4,6-cyclin-D complex regulates 
progression through G1, CDK2-cyclin-E regulates transition from the G1 to the S phase 
(a Restriction point), CDK2-cyclin-A and CDK1-cyclin-A act throughout the S phase, 
and CDK1-cyclin-B regulates mitosis (Maga & Hubscher 2003). PCNA is a critical 
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G1 phase (Celis & Celis 1985). PCNA expression peaks in the S phase, but continues to 
be weakly expressed in the G2 and M phases of the cell cycle (Celis & Celis 1985). 
Specific checkpoint mechanisms can be activated, thereby halting progression through 
the cell cycle if necessary. PCNA is able to form complexes with all these CDK-cyclin 
complexes as well as with the critical check point proteins, thereby transducing both 
positive and negative feedback signals on the cell cycle progression (Maga & Hubscher 
2003). 
Ba100 was shown to prevent progression of the cell cycle from the G0G1 phase into the 
S phase and PCNA which is required for progression into the S phase was consistently 
shown to be downregulated. In addition, Ba100 inhibits production of IL-2 and 
downregulates IL-2 receptor expression, both of which are critical in initiating signaling 
events required for progression of the T cell in the G1 phase into the S phase. 
In summary, we find that Ba100, a novel C-type lectin has immunomodulatory potential 
through its ability to inhibit the calcium-dependent activation pathways required for T 
lymphocyte proliferation. This is associated with a decrease in the number of 
lymphocytes expressing the activation markers HLA-DR and CD25 (IL-2 receptor); 
impaired generation of CTLs, NK cells and memory cells; decreased IL-2 receptor 
expression; downregulation of important adhesion/co-stimulatory molecule expression 
and impaired cytokine production (IL-2, IL-4, IFN-  and TNF- ). In addition, Ba100 
interrupts the cell cycle of the lymphocyte, inhibiting cell cycle progression from the 
G0G1 phase into the S phase and this is associated with consistent downregulation of 
PCNA expression. 
Thus, the immunosuppressive properties of Ba100 together with its ability to inhibit 
platelet aggregation and thrombus formation make it a potentially useful 
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CHAPTER SIX: 
EXPERIMENTAL SECTION :  MODULATION OF 
LYMPHOCYTE PROLIFERATION BY Ba25 
 
1.  Introduction 
    1.1.  Experimental approach 
2.  Results 
    2.1.  PBMC proliferation assays in response to the mitogen, PHA 
       i)  Effect of Ba25 on PHA-induced PBMC proliferation 
       ii)  Effect of pre-incubation with Ba25 on PHA-induced PBMC proliferation 
       iii)  Effect of Ba25 on PHA-induced PBMC proliferation when added 2h after PHA 
       iv)  Effect of washing away Ba25 on PHA-induced PBMC proliferation 
       2.1.1.  Lymphocyte populations and phenotype of the lymphocytes after PBMC  
                  proliferation in response to PHA in the absence or presence of Ba25 
    2.2.  PBMC proliferation assays in response to various antigens 
    2.3.  PBMC proliferation to alloantigens in a primary mixed lymphocyte reaction  
           (MLR) 
       2.3.1.  Primary mixed lymphocyte reaction (MLR) 
       2.3.2.  Lymphocyte populations and phenotype of the lymphocytes generated in a  
                  primary MLR in the absence or presence of Ba25 
    2.4.  Functional analysis of lymphocytes in the primary MLR 
       2.4.1.  Suppressor cell activity of the primary MLR generated effectors on a fresh  
                  MLR 
    2.5.  CD4 lymphocyte proliferation assays 
       2.5.1.  Effect of Ba25 on isolated CD4 and CD8 lymphocyte proliferation in  
                  response to PHA 
       2.5.2.  Effect of Ba25 on OKT3 and fibronectin-induced proliferation of CD4  
                  lymphocytes 
    2.6.  Effect of Ba25 on PBMC proliferation in response to anti-CD28 antibody and a  
            phorbol ester, PMA 
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    2.7.  Effect of Ba25 on processes involved in T lymphocyte proliferation 
       2.7.1.  Effect of Ba25 on IFN- , IL-4 and IL-10 production during the mixed  
                  lymphocyte reaction 
       2.7.2.  Effect of addition of exogenous IL-2 on PHA-induced PBMC proliferation  
                  in the presence of Ba25 
       2.7.3.  Effect of Ba25 on the distribution of PHA-stimulated PBMCs in the various  
                  phases of the cell cycle 
       2.7.4.  Effect of Ba25 on proliferating cell nuclear antigen (PCNA) expression by 
                  PHA-stimulated PBMCs 
       2.7.5.  Effect of Ba25 on lymphocyte membrane stability 
                  i)  Effect of -tocopherol on PHA-induced PBMC proliferation in the  
                       presence of Ba25 
                  ii)  Effect of Indomethacin on PHA-induced PBMC proliferation in the  
                        presence of Ba25 
 
3.  Discussion 
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CHAPTER SIX: 
EXPERIMENTAL SECTION :  MODULATION OF 
LYMPHOCYTE PROLIFERATION BY Ba25 
 
1.  INTRODUCTION 
Ba25, a C-type lectin was isolated from the venom of the Western Cape, South African 
puff adder, Bitis arietans, using a GPIIbIIIa affinity column. Functional studies 
demonstrated that Ba25 stimulated platelet agglutination in platelet-rich plasma and 
inhibited clot formation in whole blood. Ba25 interacts with the GPIb  receptor of the 
von Willebrand receptor complex GPIb-IX-V close to the binding site of the von 
Willebrand factor as well as the collagen receptor α2β1 leading to activation of the 
platelet fibrinogen receptor GPIIbIIIa and increased fibrinogen binding without any 
associated platelet activation. Ba25 also inhibited collagen-induced platelet P-selectin 
expression (Jennings et al 2005, Jennings unpublished data).  
Platelets play an important role in inflammation, releasing pro-inflammatory factors and 
expressing both integrins and immunoreceptors that modulate intra/intercellular 
interactions, cellular adhesion and transendothelial migration (Weyrich et al 2003; 
Kasirer-Friede et al 2007). Activated platelets have been shown to enhance activated 
lymphocyte adhesion to the extracellular matrix via integrin, CD40-CD40 ligand and P-
selectin-PSGL-1 mediated interactions (Shenkman et al 2006). Platelet activation is an 
important contributory component to the alloimmune response and allograft injury 
(Zhang et al 2003; 2005; Xu et al 2006). 
Platelets and lymphocytes have a number of integrin receptors in common including the 
collagen receptor 2 1 (Pribila et al 2004, Kasirer-Friede et al 2007). The lymphocyte 
2 1 integrin receptor mediates lymphocyte adhesion to collagen and contributes to 
signaling processes involving the p38 MAPK pathway as well as the PI3-K/Akt 
activation pathway (Heino 2000; Gendron et al 2003; Boisvert et al 2007). 
We thus postulated that Ba25 which modulates platelet function, through its interaction 
with the platelet GPIb  and 2 1 receptors, might modulate lymphocyte function by 










Chapter 6 152 
1.1.  Experimental approach 
We investigated the ability of Ba25 to inhibit T lymphocyte proliferation and the 
experimental approach was similar to that followed for Ba100. These studies indicated 
that although Ba25 inhibited T lymphocyte proliferation, it differed from Ba100 in that 
it did not modulate T lymphocyte activation markers nor cell cycle progression and it 
generated an immunosuppressive cytokine profile. We therefore looked at the potential 
effect of Ba25 on the generation of immunosuppressive prostanoids. 
2.  RESULTS 
2.1.  PBMC proliferation assays in response to the mitogen, PHA 
i)  Effect of Ba25 on PHA-induced PBMC proliferation 
The effect of various concentrations of Ba25 on proliferation of PBMC in response to 
PHA was investigated and the data from a representative experiment is shown in Fig. 1.  

























































PBMC (1x105 cells/well) were incubated with PHA (0.00575 mitogenic units) or PHA + Ba25 (200, 100, 50, 25 nM 
concentrations) at 37 C. 
Ba25 was pre-incubated with PBMC for 30 min at 37 C prior to the addition of PHA. 
At 72 h, [3H] thymidine was added, incorporation measured 18 h later and results are expressed as mean DPM of 6 
replicates  SD. 
Background [3H] thymidine incorporation into PBMC in the absence of PHA or presence of Ba25 were 242  12 
DPM and 225  16 DPM respectively. 
[3H] thymidine incorporation into PHA-stimulated PBMC was 249 316  4031 DPM. 
Results of a representative dose response to Ba25 are shown and are expressed as % suppression of PBMC 
proliferation to PHA  SD based on the PHA-stimulated control. * p < 0.001, ** p < 0.002, *** p <0.0005, 
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In the absence of PHA, Ba25 did not alter background [
3
H] thymidine incorporation. 
When Ba25 was pre-incubated with PBMC for 30 min prior to the addition of PHA, a 
dose-dependent inhibition of the proliferation of the PBMC was observed (Figure 1). 
Two further dose response experiments confirmed that the relationship between the 
concentration of Ba25 and % suppression of PBMC proliferation in response to PHA 
was linear with logarithmic transformation (p < 0.0001) and the IC50 was  138nM. A 
further set of 10 experiments was done to confirm the effect of a 30 min pre-incubation 
period of Ba25 (200 nM) on PHA-induced proliferation. For each experiment, inhibition 
of proliferation was observed and the range of suppression of proliferation for these 10 
experiments was 42 – 76% (mean 59.8%, median 61% suppression). Exclusion of 
trypan blue by cells harvested at 72 h indicated that the cells were not being killed by 
Ba25 and thus the inhibition of proliferation was not due to cytotoxicity. 
 
ii) Effect of pre-incubation with Ba25 on PHA-induced PBMC proliferation 
We investigated whether pre-incubation with Ba25 was required for the inhibitory effect 
on PHA-induced PBMC proliferation. 















































PHA PHA + Ba25 (200nM)
 
 
PBMC (1x105 cells/well) were incubated with PHA (0.00575 mitogenic units) or PHA + Ba25 (200 nM) at 37 C. 
Ba25 was either pre-incubated for 30 min or 60 min with PBMC at 37 C prior to the addition of PHA or added to the 
PBMC when the PHA was added. 
At 72 h, [3H] thymidine was added and incorporation measured 18 h later. 
Background [3H] thymidine incorporation for cells only or cells + Ba25 (200 nM) never averaged above 375 DPM. 
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We found that pre-incubation of PBMC with Ba25 was not required for its anti-
proliferative effect. The percentage suppression of PHA-induced PBMC proliferation 
with a 30 min and 60 min pre-incubation period (61.2%  1.27 (SD) and 59.8%  1.3 
(SD) suppression respectively) was the same as that when Ba25 was added at the time 
of addition of PHA (60.2%  1.2 (SD) suppression) (Figure 2). This was confirmed in 
two further experiments (regression coefficient 0.0001, SE 0.010). For standardization 
purposes, a 30 minute pre-incubation period was used in all the experiments, unless 
otherwise stated. 
 
iii) Effect of Ba25 on PHA-induced PBMC proliferation when added 2 h after PHA 
The ability of Ba25 to modulate PHA-induced PBMC proliferation after the stimulus 
for proliferation had been added, was investigated. 
To assess whether Ba25 acted early or late in T cell signal transduction, Ba25 was 
added 2 h after the addition of the mitogenic stimulus, PHA. 
 






Suppression of PBMC 
proliferation to PHA 
Mitogen Ba25 (200 nM) 
PHA - 244 433  10 060 - 
PHA 30 min pre-incubation 133 438  2019 45.4%  1.2 
PHA Added 2h after PHA 247 127  2684 0% 
 
PBMC (1x105 cells/well) were incubated with PHA (0.00575 mitogenic units) or PHA + Ba25 (200nM) at 37 C. 
Ba25 was pre-incubated with PBMC for 30 min at 37 C prior to the addition of PHA or Ba25 was added 2h after 
PHA. 
At 72 h, [3H] thymidine was added and incorporation measured 18 h later. 
Background [3H] thymidine incorporation into PBMC in the absence of PHA or presence of Ba25 were 201  14 
DPM and 221  17 DPM respectively. 
Results of a representative experiment are shown and are expressed as mean DPM of 6 replicates  SD or % 
suppression of PBMC proliferation to PHA  SD. 
 
Ba25 was unable to inhibit PHA-induced PBMC proliferation if added 2 h after PHA 
(Table 1), suggesting that Ba25 exerted its inhibitory effect early on in T cell activation. 
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iv) Effect of washing away Ba25 on PHA-induced PBMC proliferation 
The effect of pre-incubating Ba25 with PBMC, then washing it away before the 
addition of PHA to initiate proliferation, was investigated. 
 





Suppression of PBMC 
proliferation to PHA 
Mitogen Ba25 (200 nM) 
PHA - 152 621  3775 - 
PHA 30 min pre-incubation 76 347  1459 49.9%  0.42 
PHA 30 min pre-incubation,  
then wash 
159 511  3908 0% 
 
PBMC (1x105 cells/well) were incubated with PHA (0.00575 mitogenic units) or PHA + Ba25 (200nM) at 37 C. 
Ba25 was pre-incubated with PBMC for 30 min at 37 C prior to the addition of PHA. For one reaction Ba25 was 
washed away after the 30 min pre-incubation period. 
At 72 h, [3H] thymidine was added and incorporation measured 18 h later. 
Background [3H] thymidine incorporation into PBMC in the absence of PHA or presence of Ba25 were 390  25 
DPM and 412  37 DPM respectively. 
Results of a representative experiment are shown and are expressed as mean DPM of 6 replicates  SD or % 
suppression of PBMC proliferation to PHA  SD. 
 
Removing Ba25 from the reaction prior to the addition of PHA resulted in a complete 
loss of the inhibitory effect of Ba25 on PHA-induced PBMC proliferation (Table 2). 
Ba25 needs to be present during the proliferation period for its inhibitory effect to be 
observed. This was reproducible in two further experiments. 
 
2.1.1.  Lymphocyte populations and phenotype of the lymphocytes after PBMC  
           proliferation in response to PHA in the absence or presence of Ba25 
Flow cytometry was used to analyse the phenotype of the lymphocyte population after 
proliferation of PBMC in response to PHA in the absence or presence of Ba25 (200 
nM). Both the % of cells in the lymphocyte gate (set on lymphocyte forward and side 
scatter properties) expressing a particular receptor and the MFI (mean fluorescent 
intensity) of the antibody binding was determined. Lymphocytes in the lymphocyte gate 
were analysed for expression of activation markers HLA-DR and the interleukin 2 
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Anti-CD3 was used to detect T cells. Anti-CD4 and anti-CD8 was used to determine T 
cell subsets. 
Table 3.  Lymphocyte populations and phenotype after proliferation of PBMC in 
response to PHA in the absence or presence of Ba25 (200 nM). 
Receptors PHA-stimulated PBMC PHA-stimulated PBMC % Change 
 -Ba25 + Ba25 (200 nM) + Ba25 (200 nM) 
 % Positive 
cells 
MFI % Positive 
cells 
MFI % Positive 
cells 
MFI 
CD3 85.3 5.08 69.2 3.2 18.9%  37.0%  
CD4 39.0 10.2 30.1 5.3 22.8%  48.0%  
CD8 33.1 48.7 36.6 54.7 10.6%  No change 
CD56 10.0 5.7 7.1 5.5 29%  No change 
CD29 91.2 6.6 78.1 5.8 14.4%  No change 
HLA-DR 72.0 39.9 63.0 32.2 12.5%  No change 
CD25 92.2 19.1 83.3 17.8 No change No change 
CD4:CD8 1.2  0.82  31.6%   
 
PBMC (1x105 cells/well) were incubated with PHA (0.00575 mitogenic units) or PHA + Ba25 (200 nM) at 37 C.  
Ba25 was pre-incubated with PBMC for 30 min at 37 C prior to addition of PHA. 
At 72 h, the cells were harvested, then labeled with antibodies directed to the indicated lymphocyte receptors and 
single colour analysis of antibody binding was done by flow cytometry on gated lymphocytes. 
Results of a representative experiment are shown and are expressed as % of cells in the lymphocyte gate expressing 
the receptor and the MFI (mean fluorescent intensity or number of receptors per cell) of the antibody binding. The 
change in these parameters in the presence of Ba25 is expressed as a % of that in the absence of Ba25.  indicates a 
decrease from that in the absence of Ba25 and  indicates an increase from that in the absence of Ba25. 
A change in the % of cells expressing a specific receptor and a change in MFI in the presence of Ba25 was 
considered a real change if this was more than a 10% and 20% change respectively. Only real changes decided by 
these criteria are shown in the last 2 columns. 
 
From the results of a representative experiment given in Table 3, it appears that Ba25 
had little effect on the generation of lymphocytes expressing the activation markers 
HLA-DR and CD25 nor did it affect cellular expression of these receptors. Ba25 
inhibited the generation of natural killer cells expressing CD56 and had minimal effect 
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These results were confirmed in 4 further experiments with PHA-induced PBMC 
proliferation in the presence of Ba25 (200 nM). The range of suppression and median 
suppression for both the percentage of cells expressing a receptor and the number of 
receptors expressed per cell are tabulated in Table 4. 
 
Table 4.  Change in lymphocyte populations and phenotype after proliferation of 
PBMC in response to PHA in the presence of Ba25 (200 nM). 
Receptors PHA-stimulated PBMC + Ba25 (200 nM) 
 % Positive cells MFI 
 Range of suppression Median Range of suppression Median 
HLA-DR 12.0 – 18.4% 17.1% 16.7 – 21.4%  19.9% 
CD25 4.6 – 9.8% 7.1% 6.9 – 9.6% 8.3% 
CD56 16.6 – 30.1% 22.8% 4.2 – 10.9% 7.2% 
CD29 6.2 – 13.6% 10.3% 7.4 – 14.3% 8.9% 
CD4:CD8 28.6 – 31% 29.8%   
 
PBMC (1x105 cells/well) were incubated with PHA (0.00575 mitogenic units) or PHA + Ba25 (200 nM) at 37 C.  
Ba25 was pre-incubated with PBMC for 30 min at 37 C prior to the addition of PHA. 
At 72 h, the cells were harvested, then labeled with antibodies directed at the indicated lymphocyte receptors and 
single colour analysis of antibody binding was done by flow cytometry on gated lymphocytes. 
The range of suppression and the median suppression for both the % of cells in the lymphocyte gate expressing the 
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2.2.  PBMC proliferation assays in response to various antigens 
The effect of Ba25 on proliferation of PBMC in response to various antigens was 
investigated and the data from representative experiments are shown in Figure 3a - c. 
 



















































PBMC (1x105cells/well) were incubated with the antigen PPD without or with Ba25 (200, 100, 50, 25 nM) at 37ºC.   
Ba25 was pre-incubated with PBMC for 30 min at 37ºC prior to the addition of PPD. 
On day 7, [3H] thymidine was added, incorporation measured 18h later and results are expressed as mean DPM of 6 
replicates  SD. 
Background [3H] thymidine incorporation into PBMC in the absence of PPD was 410 ± 24 DPM and in the presence 
of Ba25 was 394   42 DPM. 
[3H] thymidine incorporation into PBMC in the presence of PPD was 133 615  3000 DPM. 
Results of a representative dose response to Ba25 are shown and expressed as % suppression of PBMC proliferation 
to PPD ± SD based on the PPD-stimulated control. * p < 0.0001,** p < 0.005,  *** p < 0.003, comparing % 




Ba25 dose dependently (25 – 200 nM) suppressed PBMC proliferation in response to 
the antigen PPD (Figure 3a). Two further dose response experiments confirmed that the 
relationship between the concentration of Ba25 and % suppression of PBMC 
proliferation in response to PPD was linear with logarithmic transformation  
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      Figure 3b.  Effect of various concentrations of Ba25 on Tetanus toxoid-induced PBMC 


























































PBMC (1x105cells/well) were incubated with the antigen Tetanus toxoid without or with Ba25 (200, 100, 50, 25 nM) 
at 37ºC.  
Ba25 was pre-incubated with PBMC for 30 min at 37ºC prior to the addition of Tetanus toxoid. 
On day 7, [3H] thymidine was added, incorporation measured 18h later and results are expressed as mean DPM of 6 
replicates  SD. 
Background [3H] thymidine incorporation into PBMC in the absence of Tetanus toxoid was 385 ±16 DPM and in the 
presence of Ba25 was 376 ± 20 DPM. 
[3H] thymidine incorporation into PBMC in the presence of Tetanus toxoid was 121 660  5245 DPM.  
Results of a representative dose response to Ba25 are shown and expressed as % suppression of PBMC proliferation 
to Tetanus toxoid ± SD based on the Tetanus toxoid-stimulated control. * p < 0.001, ** p < 0.004, *** p < 0.003, 




Ba25 dose dependently (25 – 200 nM) suppressed PBMC proliferation in response to 
the antigen Tetanus toxoid (Figure 3b). Two further dose response experiments 
confirmed that the relationship between the concentration of Ba25 and % suppression of 
PBMC proliferation in response to Tetanus toxoid was linear with logarithmic 


















Chapter 6 160 

























































PBMC (1x105cells/well) were incubated with the antigen Varidase without or with Ba25 (200, 100, 50, 25 nM) at 
37ºC. 
Ba25 was pre-incubated with PBMC for 30 min at 37ºC prior to the addition of Varidase. 
On day 7, [3H] thymidine was added, incorporation measured 18h later and results are expressed as mean DPM of 6 
replicates  SD. 
Background [3H] thymidine incorporation into PBMC in the absence of Varidase was 354 ± 28 DPM and in the 
presence of Ba25 was 362 ± 33 DPM. 
[3H] thymidine incorporation into PBMC in the presence of Varidase was 41 229  1058 DPM. 
Results of a representative dose response to Ba25 are shown and expressed as % suppression of PBMC proliferation 
to Varidase ± SD based on the Varidase-stimulated control. * p < 0.14, ** p < 0.018, *** p < 0.005, comparing % 
suppression at each successive concentration. 
 
 
Ba25 dose dependently (25 – 200 nM) suppressed PBMC proliferation in response to 
the antigen Varidase (Figure 3c). Two further dose response experiments confirmed that 
the relationship between the concentration of Ba25 and % suppression of PBMC 
proliferation in response to Varidase was linear with logarithmic transformation  
(p < 0.0005) and the IC50 was  20nM.  
A further set of 2 experiments with each antigen was done which confirmed the 
inhibitory effect of a 30 min pre-incubation period of Ba25 (200 nM) on antigen-
stimulated proliferation. The range of suppression of : 
i) PPD-induced proliferation was 85-90% (mean 87.8%, median 87.5% 
suppression). 
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iii) Varidase-induced proliferation was 90-92% (mean 91%, median 91% 
suppression). 
 
2.3.  PBMC proliferation to alloantigens in a primary mixed  
        lymphocyte reaction (MLR) 
The immunosuppressive properties of Ba25 on T lymphocyte responses to mitogen and 
antigens was encouraging and suggested to us that Ba25 may be able to inhibit 
proliferation to alloantigens in a mixed lymphocyte reaction. 
We looked at the potential role of Ba25 in modulating the functional activity of effector 
cells generated in a primary MLR. The first experiment investigated the effect of 
various concentrations of Ba25 on a 6 day primary mixed lymphocyte reaction. 
 
2.3.1.  Primary mixed lymphocyte reaction (MLR) 
Ba25 dose dependently (12.5 – 200 nM) inhibited the primary mixed lymphocyte 
reaction (Figure 4). Two further dose response experiments confirmed that the 
relationship between the concentration of Ba25 and % suppression of the MLR was 
linear with logarithmic transformation (p < 0.0001) and the IC50 was 135nM. A 
further set of 10 experiments with different donors was done, which confirmed the 
consistent inhibitory effect of a 30 min pre-incubation period of Ba25 (200 nM) on the 
MLR. For 10 experiments, the suppression ranged between 56.4% - 78% (mean 67.8%, 
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1x105responder cells (A) were incubated with 1x105 irradiated (3000 R) stimulator cells (Bx) per well at 37 C in the 
absence or presence of Ba25 at varying concentrations (200, 100, 50, 25 and 12.5 nM). 
Responder cells were pre-incubated with Ba25 for 30 min at 37ºC prior to the addition of stimulator cells. 
On day 6, [3H] thymidine was added, incorporation measured 18h later and results are expressed as mean DPM of 6 
replicates  SD. 
[3H] thymidine incorporation for A+Bx was 325 760  15 774 DPM. 
Results of a representative dose response are shown and are expressed as % suppression of proliferation ± SD based 
on the MLR (A+Bx) control. * p < 0.0005, ** p < 0.014, *** p < 0.028, **** p < 0.004, comparing % suppression at 





2.3.2.  Lymphocyte populations and phenotype of the lymphocytes generated in a  
           primary MLR in the absence or presence of Ba25 
Flow cytometry was used to determine the phenotype of the effector cells generated in 
the primary MLR in the absence or presence of Ba25 (200 nM). Both the % of cells in 
the lymphocyte gate (set on forward and site scatter properties) expressing a particular 
receptor and the MFI (mean fluorescent intensity) of the antibody binding was 
determined. Lymphocytes in the lymphocyte gate were analysed for expression of 
activation markers HLA-DR and the IL-2 receptor (CD25) and NK cell markers in the 
form of CD16. Anti-CD3 was used to detect T cells. Anti-CD4 and anti-CD8 was used 
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Table 5.  Lymphocyte populations and phenotype of effector cells generated in a 6 
day primary MLR in the absence or presence of Ba25 (200 nM). 
Receptor % Positive cells MFI % Change 
 -Ba25 +Ba25  
(200 nM) 






Experiment 1 (A + Cx) 
CD3 91.3 86.4 8.4 6.1 No change 27.4%  
CD4 75.6 69.3 17.7 11.9 No change 32.8%  
CD8 31.4 34.0 4.1 4.5 No change No change 
CD16 11.0 10.3 4.6 4.1 No change No change 
HLA-DR 69.3 64.2 10.3 8.7 No change No change 
CD25 47.0 38.2 10.4 9.4 18.7%  No change 
CD4:CD8 2.4 2.0   16.7%   




/ml     
% suppression of proliferation 57.5%      
Experiment 2 (B + Ax) 
CD3 89.4 90.1 7.8 8.8 No change No change 
CD4 67.7 67.5 14.5 10.3 No change 28.9%  
CD8 32.3 38.2 3.7 3.9 18.3%  No change 
CD16 6.5 6.1 3.1 2.8 No change No change 
HLA-DR 70.0 59.5 11.6 9.5 15.0%  No change 
CD25 53.1 48.7 12.6 11.6 No change No change 
CD4:CD8 2.1 1.8   14.3%   




/ml     
% suppression of proliferation 49.1%      
 
Effector cells generated in 6 day bulk primary MLRs in the absence or presence of Ba25 (200 nM). PBMC were used 
from 3 different donors (A, B, C) in 4 experiments and were used as responder cells (A, B or C) or irradiated (3000 
R) stimulator cells (Ax, Bx or Cx) as indicated. On day 6, the cells were harvested and the total cell yield determined 
by counting the number of PBMC x 106/ml proliferating in the MLR in the absence or presence of Ba25 (200 nM). 
Aliquots of cells were then labeled with antibodies directed to the indicated lymphocyte receptors and single colour 
analysis of antibody binding was done by flow cytometry on gated lymphocytes.  
Data from the 4 experiments are shown and are the % of cells in the lymphocyte gate expressing the receptor and the 
MFI of the antibody binding. The change in these parameters in the presence of Ba25 is expressed as a % of that in 
the absence of Ba25.  indicates a decrease from that in the absence of Ba25 and  indicates an increase from that in 
the absence of Ba25. 
A change in the % of cells expressing a specific receptor and a change in MFI in the presence of Ba25 was 
considered a real change if this was more than a 10% and 20% change respectively. Only real changes decided by 
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Table 5 cont.  Lymphocyte populations and phenotype of effector cells generated in 
a 6 day primary MLR in the absence or presence of Ba25 (200 nM). 
Receptor % Positive cells MFI % Change 
 -Ba25 +Ba25  
(200 
nMm) 






Experiment 3 (B + Cx) 
CD3 90.0 89.9 9.7 6.0 No change 38.1%  
CD4 64.6 55.0 13.3 8.4 14.9%  36.8%  
CD8 37.3 46.3 3.9 4.1 24.1%  No change 
CD16 10.4 6.3 3.3 3.1 39.4%  No change 
HLA-DR 60.5 47.8 8.9 7.3 21.0%  No change 
CD25 48.7 40.7 11.2 10.1 16.4%  No change 
CD4:CD8 1.7 1.2   29.4%   




/ml     
% suppression of proliferation 32.1%      
Experiment 4 (C + Bx) 
CD3 84.9 82.5 9.3 8.0 No change No change 
CD4 68.3 62.5 13.8 8.9 No change 35.5%  
CD8 33.9 36.4 3.7 4.0 No change No change 
CD16 14.3 11.0 3.1 2.9 23.1%  No change 
HLA-DR 62.4 44.8 13.2 11.1 28.2%  No change 
CD25 50.1 41.8 13.3 12.6 16.6%  No change 
CD4:CD8 2.0 1.7   15.0%   




/ml     
% suppression of proliferation 74.7%      
 
Effector cells generated in 6 day bulk primary MLRs in the absence or presence of Ba25 (200 nM). PBMC were used 
from 3 different donors (A, B, C) in 4 experiments and were used as responder cells (A, B or C) or irradiated (3000 
R) stimulator cells (Ax, Bx or Cx) as indicated. On day 6, the cells were harvested and the total cell yield determined 
by counting the number of PBMC x 106/ml proliferating in the MLR in the absence or presence of Ba25 (200 nM). 
Aliquots of cells were then labeled with antibodies directed to the indicated lymphocyte receptors and single colour 
analysis of antibody binding was done by flow cytometry on gated lymphocytes.  
Data from the 4 experiments are shown and are the % of cells in the lymphocyte gate expressing the receptor and the 
MFI of the antibody binding. The change in these parameters in the presence of Ba25 is expressed as a % of that in 
the absence of Ba25.  indicates a decrease from that in the absence of Ba25 and  indicates an increase from that in 
the absence of Ba25. 
A change in the % of cells expressing a specific receptor and a change in MFI in the presence of Ba25 was 
considered a real change if this was more than a 10% and 20% change respectively. Only real changes decided by 
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In summary, all 4 primary MLR (Table 5) confirmed that Ba25: 
i) suppressed the mixed lymphocyte reaction as the total cell yield on day 6 
was decreased (range of inhibition of total cell yield 32.1 – 74.7%, median 
53.3%). 
ii) had minimal effect on the generation of lymphocytes expressing the 
activation markers: HLA-DR (range of suppression 7.4 – 28.2%, median 
18%); CD25 (range of suppression 8.3 – 18.7%, median 16.5%). 
iii) had minimal effect on the MFI of HLA-DR expression (range of suppression 
15.5 – 18.1%, median 16.9%) and had no effect on the MFI of CD25 
expression (range of suppression 5.3 – 9.8%, median 8.8%). 
iv) minimally impaired the generation of NK cells as determined by the number 
of cells expressing CD16 (range of suppression 6.2 – 39.4%, median 14.7%) 
and had no effect on the MFI of CD16 expression (range of suppression  
6.1 – 10.9%, median 8.1%). 
v) decreased the CD4:CD8 ratio (range of suppression 14.3 – 29.4%, median 
15.9%). 
 
2.4.  Functional analysis of lymphocytes in the primary MLR 
Lymphocytes from a primary MLR cultured in the presence of Ba25 were tested for 
suppressor cell activity on day 6 of the culture. Cells harvested from the primary MLR 
were incubated for 30 min, followed by 2 washes in fresh complete media to remove 
Ba25 before assessment of suppressor cell activity. 
2.4.1.  Suppressor cell activity of the primary MLR generated effectors on a fresh  
           MLR 
We investigated the ability of primed effector cells harvested from a bulk primary MLR 
in the presence of Ba25 to inhibit the proliferative response of a fresh MLR. We looked 
at both specific and non-specific suppression by primed effector cells generated in the 
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Table 6.  Effect of Ba25 on the suppressor cell assays. 
Response being 
tested in the fresh 
MLR 
Primed cells from 
a bulk primary 













of fresh MLR 
1. Autologous (A + Bx) A + Bx 60464  1058 - 
   Autologous (A + Bx+ 200nM 
Ba100) 
A + Bx 27269  969 54.9%  2.1 
2. Heterologous  (A + Bx) C + Ex 112428   3542 - 
   Heterologous (A + Bx+ 200nM 
Ba100) 
C + Ex 60374  1781 46.3%  1.2 
3. Same stimulator, 
   different responder 
(A + Bx) C + Bx 88532  2128 - 
   Same stimulator,  
   different responder 
(A + Bx+ 200nM 
Ba100) 
C + Bx 46745  1062 47.2 %  1.8 
4. Same responder,  
   different stimulator 
(A + Bx) A + Cx 90058  2117 - 
   Same responder, 
   different stimulator 
(A + Bx+ 200nM 
Ba100) 
A + Cx 45506  1120 49.4%  2.4 
 
A bulk primary MLR was set up by incubating responder cells, A (1x106 cells/ml) with irradiated (3000 R) stimulator 
cells, Bx (1x106 cells/ml) in complete media in the absence or presence of Ba25 (200 nM) at 37 C. After 6 days 
incubation, the cells were harvested, incubated for 30 min, washed x 2 to remove Ba25 and used as the primed cells 
in the suppressor cell assay. 
Fresh MLR reactions contained the component cells A+Bx, C+Ex, C+Bx, A+Cx: 1x105 responder cells (A or C) 
were incubated with 1x105 irradiated (3000 R) stimulator cells (Bx, Cx or Ex) per well in complete media at 37 C. 
These fresh MLR (A+Bx, C+Ex, C+Bx and A+Cx) were cultured with the primed cells in the following 
combinations. 
1. Primed cells autologous to responders and stimulators. 2. Primed cells, responders and stimulators completely 
heterologous. 3. Same stimulator, different responder. 4. Same responder, different stimulator. 
On day 6, [3H] thymidine was added and incorporation measured 18 h later. 
Results of a representative experiment are shown and expressed as mean DPM of 6 replicates  SD or % suppression 
of proliferation ± SD. 
 
 
Effector cells generated in a primary MLR in the presence of Ba25 (200 nM) exerted a 
suppressive effect on the proliferation of a fresh MLR. This suppressor activity was not 
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2.5.  CD4 lymphocyte proliferation assays 
We investigated the ability of Ba25 to inhibit isolated CD4 lymphocyte proliferation 
and whether Ba25 needed to be processed by the antigen-presenting phagocytes in order 
to exert its inhibitory effect on lymphocyte proliferation. 
 
2.5.1.  Effect of Ba25 on isolated CD4 and CD8 lymphocyte proliferation in  
           response to PHA 
We looked at the ability of Ba25 to inhibit CD4 and CD8 lymphocyte proliferation in 
response to PHA in the absence of antigen-presenting phagocytes. CD4 and CD8 
lymphocytes were isolated using Dynal beads. 
 
Figure 5.  Effect of Ba25 on isolated CD4 and CD8 lymphocyte proliferation (60:40% CD4:CD8 

































































CD4 and CD8 lymphocytes were isolated using Dynal beads, then reconstituted in a 60:40% ratio (CD4:CD8). A 
total of 1x105 CD4 + CD8 cells were cultured per well with PHA (0.00575 mitogenic units) or PHA + Ba25 (200, 20, 
2 and 0.2 nM concentrations) at 37ºC. 
Ba25 was pre-incubated with the CD4 and CD8 lymphocytes for 30 min at 37ºC prior to the addition of PHA. 
At 72 h, [3H] thymidine was added, incorporation measured 18 h later and results are expressed as mean DPM of 6 
replicates  SD. 
Background counts in the absence of PHA or Ba25 were 220 ± 14 DPM. 
[3H] thymidine incorporation into PHA-stimulated CD4:CD8 lymphocytes was 15 666  828 DPM. 
Results of a representative dose response to Ba25 are shown and expressed as % suppression of PHA-induced 
CD4:CD8 lymphocyte proliferation ± SD based on the PHA-stimulated control. * p < 0.002, ** p < 0.008, comparing 
% suppression at each successive concentration. 
 
 
   * 
    
  *    
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Ba25 inhibited proliferation of isolated CD4 and CD8 lymphocytes (mixed at a ratio 
found in whole blood) in response to PHA (Figure 5). 3 dose response experiments 
confirmed that the relationship between the concentration of Ba100 and % suppression 
of CD4 and CD8 lymphocyte proliferation in response to PHA was linear with 
logarithmic transformation (p < 0.0001) and the IC50 was  343nM. 
Ba25 at a concentration of 200 nM consistently inhibited proliferation of isolated CD4 
and CD8 lymphocytes (mixed at a ratio found in whole blood) in response to PHA. The 
range of suppression for a further 5 experiments was 40-46.2% (mean 43.5%, median 
44% suppression). 
 
2.5.2.  Effect of Ba25 on OKT3 and fibronectin-induced proliferation of CD4  
           lymphocytes 
We next investigated the ability of Ba25 to modulate CD4 lymphocyte proliferation in 
response to OKT3 and fibronectin and thus its potential to interfere with cell-
extracellular matrix interactions. The previous kinetic studies for Ba100 had shown that 
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OKT3+Ba25 - 69.5% Suppression
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OKT3+Ba25 - 51.1% Suppression
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OKT3+Ba25 - 69.9% Suppression
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OKT3+Ba25 - 65.2% Suppression
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OKT3+Ba25 - 58% Suppression
OKT3+Fn




CD4 lymphocytes were isolated from PBMCs using Dynal beads. 
1x105 CD4 lymphocytes/well were incubated in OKT3-coated flat-bottomed wells in serum free culture medium 
(Serotec medium) with and without fibronectin (30 g/ml) in the absence or presence of Ba25 (200 nM) at 37 C.  
Ba25 was pre-incubated with CD4 lymphocytes for 30 min at 37 C before the addition of fibronectin to the wells. 
[3H] thymidine was added on day 2 and incorporation measured 18 h later. 
Background [3H] thymidine incorporation for cells only and cells + Ba25 or + fibronectin alone never averaged above 
247 DPM. 
Results are expressed as mean DPM of 6 replicates  SD. 
 
 
Ba25 at a concentration of 200 nM consistently inhibited CD4 lymphocyte proliferation 
(2 day proliferation assay) in response to OKT3 and OKT3 with fibronectin  
(Figure 6a-e). The range of suppression of: 
i) OKT3-induced CD4 lymphocyte proliferation was 51.1–69.9% (mean 
62.7%, median 65.2% suppression). 
ii) OKT3 and fibronectin-induced CD4 lymphocyte proliferation was 48.5–
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2.6.  Effect of Ba25 on PBMC proliferation in response to anti-CD28  
        antibody and a phorbol ester, PMA 
We found that Ba25 inhibited calcium-dependent T lymphocyte proliferation pathways 
involving TCR/CD3 interactions with mitogen, antigen and allo-antigen, as well as T 
cell receptor/integrin receptor stimulated proliferation. 
We then investigated whether Ba25 could inhibit calcium-independent proliferation 
pathways such as proliferation in response to anti-CD28 antibody and a phorbol ester, 
PMA. 
 






Effect on PBMC 
proliferation 
PMA 22 220 ± 165 - 
PMA + anti-CD28 antibody 64 855 ± 2543 - 
PMA + anti-CD28 antibody + Ba25 (200 nM) 58 629 ± 2041 9.6% ± 1.06 
 
PBMC (0.5x106 cells/well) were incubated in 1% BSA/PBS with PMA (1 ng/ml); PMA + anti-CD28 antibody 
(1 ng/ml) or PMA + anti-CD28 antibody + Ba25 (200 nM) at 37 C. 
Ba25 was pre-incubated with PBMC for 30 minutes at 37 C prior to the addition of PMA or PMA + anti-CD28. 
At 72 h, [3H] thymidine was added and incorporation measured 18 h later. 
Results of a representative experiment are shown and expressed as mean DPM of 6 replicates ± SD or % suppression 
of PBMC proliferation to anti-CD28 antibody/PMA ± SD. 
 
Ba25 at a concentration of 200 nM was unable to inhibit PBMC proliferation in 




2.7.  Effect of Ba25 on processes involved in T lymphocyte proliferation 
Our data indicated that Ba25 inhibited calcium-dependent, but not calcium-independent 
T lymphocyte proliferation pathways. In addition, Ba25 must be added within 2 hours 
of initiation of lymphocyte proliferation in order to exert its inhibitory effect, suggesting 
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To obtain further insight into the action of Ba25, we investigated the effect of Ba25 on: 
i) Cytokine production during a mixed lymphocyte reaction. 
ii) The ability of exogenous IL-2 to reverse the inhibition of PHA-induced 
PBMC proliferation in the presence of Ba25. 
iii) Cell cycle progression during PHA-induced PBMC proliferation. 
iv) Proliferating cell nuclear antigen expression. 
v) Lymphocyte membrane stability. 
 
2.7.1.  Effect of Ba25 on IFN- , IL-4 and IL-10 production during the mixed  
           lymphocyte reaction 
We have shown that Ba25 inhibits T lymphocyte proliferation, but had little effect on 
the generation of lymphocytes expressing the activation markers HLA-DR and CD25 
and did not alter lymphocyte IL-2 receptor expression. We next investigated whether 
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Figure 7a-b. Effect of Ba25 on cytokine production during a mixed lymphocyte reaction 
 

























































1x105  responder cells (A) were incubated with 1x105 irradiated (3000R) stimulator cells (Bx) per well at 37 C in the 
absence or presence of Ba25 (200 nM). 
Responder cells were pre-incubated with Ba25 for 30 min at 37 C prior to the addition of stimulator cells. 
On day 6, [3H] thymidine was added and incorporation measured 18 h later to confirm the inhibitory effect of Ba25 
on the MLR or cells were harvested and the supernatant collected for cytokine analysis by ELISA. 
Cytokine production in the presence of A+Bx with and without Ba25 was within the sensitivity range of the ELISA. 
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Ba25 inhibited the MLR (52% inhibition), induced a Th2 cytokine response (increased 
production of IL-4 and IL-10) and inhibited the production of the Th1 cytokine IFN-  
(Figure 7a-b). This was confirmed in two further experiments. 
Ba25 at a concentration of 200 nM induced a Th2 cytokine profile. 
i) Inhibited IFN-  production: 2.2 – 4.8 fold decrease, median 3.6 fold decrease. 
ii) Stimulated IL-4 production: 8.3 – 27.5 fold increase, median 9.7 fold increase. 
iii) Stimulated IL-10 production: 6.7 – 20.7 fold increase, median 9.4 fold increase. 
 
2.7.2.  Effect of addition of exogenous IL-2 on PHA-induced PBMC proliferation  
           in the presence of Ba25 
We then looked at whether the addition of exogenous IL-2 could reverse the inhibit ry 
action of Ba25 on PHA-stimulated lymphocytes or whether other pathways besides 
cytokines were involved in the immunomodulation. 
    Figure 8.  Effect of addition of exogenous IL-2 on PHA-induced PBMC proliferation in the  
















PHA + Ba25 - 65% Suppression
PHA + IL-2
PHA + Ba25 + IL-2 - 53.8% Suppression
 
 
PBMC (1x105 cells/well) were incubated with PHA (0.00575 mitogenic units); PHA + Ba25 (200 nM); PHA + IL-2  
(10 U/ml)  and PHA + Ba25 + IL-2 at 37ºC. 
Ba25 was pre-incubated with PBMC for 30 min at 37ºC prior to the addition of PHA or PHA + IL-2. 
At 72 h, [3H] thymidine was added and incorporation was measured 18 h later. 
Background [3H] thymidine incorporation into PBMC in the absence of PHA, Ba25 or IL-2 was 388 ± 24 DPM. 
Results of a representative experiment are shown and expressed as the mean DPM of 6 replicates ± SD or as % 
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In the continual presence of Ba25, the addition of exogenous IL-2 was unable to reverse 
the inhibitory effect of Ba25 (200 nM) on PHA-induced lymphocyte proliferation 
(Figure 8). This was confirmed in 2 further experiments (p = 0.1 using Mann-Whitney 
Non-parametric test). This suggested that Ba25 interferes with other pathways, besides 
IL-2, involved in mitogen-induced T lymphocyte proliferation. Ba25 had been shown to 
induce a Th2 cytokine profile. 
2.7.3.  Effect of Ba25 on the distribution of PHA-stimulated PBMCs in the various  
           phases of the cell cycle 
We next investigated the effect of Ba25 on cell cycle progression. 
The percentage of cells in the G0G1, S and G2M phases during stimulation with PHA 
were measured at 24 and 48 h. At 24 h, most of the cells were in the G0G1 phase with 
minimal progression into the S and G2M phases. At 48 h, cell cycling had progressed 
with cells now being detectable in the S and G2M phases. 
Ba25 (200 nM) had minimal effect on cell cycle progression in response to PHA 
stimulation (Table 8 and Figure 9a and b). 
Table 8.  Effect of Ba25 on the distribution of PHA-stimulated PBMC in the 
various phases of the cell cycle (24 and 48 h stimulation). 
Stimulation Phase % Cells per cell cycle phase 
  - Ba25 + Ba25 (200 nM) 
Experiment 1. 












































PBMC (1x106 cells/ml RPMI 1640/10% AB serum) stimulated with PHA in 30 ml tissue culture flasks in the absence 
or presence of Ba25 (200 nM) were harvested at 24 and 48 h and resuspended at 5x106 cells/ml RPMI 1640/10% AB 
serum. 
Cells were stained with propidium iodide (PI) for DNA quantitation by FACS. 
Cells were permeabilised with non-ionic detergent and treated with PI and RNAse. 
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Figure 9a and b.  Effect of Ba25 on the distribution of PHA-stimulated PBMC in the various phases 
of the cell cycle at 48 h. 
 
        a.            b. 
 
    Phases of the cell cycle at 48 h: G0G1 phase (1and 2), S phase (3) and G2M phase (4) in the absence of  
    Ba25 (Fig. 9a) and in the presence of Ba25 (Fig. 9b). 
 
 
2.7.4.  Effect of Ba25 on proliferating cell nuclear antigen (PCNA) expression by  
           PHA-stimulated PBMCs 
We then investigated the effect of Ba25 on PCNA expression. 
Table 9.  Effect of Ba25 on proliferating cell nuclear antigen (PCNA) expression by 
PHA-stimulated PBMC (48 h stimulation). 
Experiment - Ba25  + Ba25 (200 nM) % Change 
 % Positive 
cells 
MFI % Positive 
cells 
MFI % Positive 
cells 
MFI 
1 72 2.5 68 2.4 5.6%  4.0%  
2 64 1.7 65 1.8 1.6%  5.9%  
3 39 1.9 39 1.9 0% 0% 
 
PBMC (1x106 cells/ml RPMI 1640/10% AB serum) stimulated with PHA in 30 ml tissue culture flasks in the absence 
or presence of Ba25 (200 nM) were harvested at 48 h and resuspended at 2x106 cells/ml RPMI 1640/10% AB serum. 
Cells were permeabilised with 20 μg/ml lysolecithin, fixed with 1% paraformaldehyde for 2 min and then treated on 
ice for 10 min with methanol, followed by incubation on ice with 0.1% NP-40 for 5 min. 
The intracellular nuclei were then stained with anti-PCNA and analysed by FACS. 
Results are expressed as % cells expressing PCNA or as MFI which represents the extent of PCNA expression per 
cell. The change in PCNA expression in the presence of Ba25 is expressed as a % of that in the absence of Ba25.  
indicates a decrease from that in the absence of Ba25 and  indicates an increase from that in the absence of Ba25. 
 
 
Ba25 at a concentration of 200 nM did not inhibit the generation of cells expressing 
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2.7.5.  Effect of Ba25 on lymphocyte membrane stability 
Ba25 inhibited T lymphocyte proliferation and induced a Th2 cytokine profile. Ba25 
had minimal effect on the generation of lymphocytes expressing the activation markers 
HLA-DR and CD25 and did not affect cell cycle progression nor PCNA expression. We 
then investigated whether the immunomodulatory effects of Ba25 might be due to 
effects on lymphocyte membrane stability and the catabolism of the major plasma 
membrane phospholipid, phosphatidylcholine with production of immunosuppressive 
metabolites. 
We investigated whether Ba25 exerted its immunomodulatory effects via the 
phospholipase breakdown products of phosphatidylcholine. The major degradation 
products of phospholipase A2 are lysophosphatidylcholine and arachidonic acid. 
Lysophosphatidylcholine and prostaglandin E2 (arachidonic acid metabolite) are 
inhibitory to lymphocyte proliferation. 
i)  Effect of -tocopherol on PHA-induced PBMC proliferation in the presence of  
    Ba25 
-Tocopherol stabilizes membrane phospholipids, preventing degradation by 
phospholipase A2 by forming complexes with the lysophospholipids (Kagan 1989; 
Anderson et al 1993).  
We investigated whether -tocopherol was able to reverse the inhibitory effects of Ba25 
on PHA-induced PBMC proliferation. 
-Tocopherol at a concentration of 50 µg/ml and 100 µg/ml was unable to reverse the 
inhibitory effects of Ba25 on PHA-induced PBMC proliferation. This was reproducible 
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Table 10.  Effect of -tocopherol on PHA-induced PBMC proliferation in the 





Suppression of PBMC 
proliferation 
Cells only 445  47 - 
PHA 817 310 ± 1320 - 
PHA + Ba25 (200 nM) 470 381 ± 1090 42.4% ±1.97 
PHA + -tocopherol (50 g/ml) + 
Ba25 (200 nM) 
482 213 ± 1954 41.0% ± 1.8 
PHA -tocopherol (100 g/ml) + 
Ba25 (200 nM) 
506 577 ± 1281 38% ± 2.26 
 
PBMC (1x105 cells/well) were incubated with PHA (0.00575 mitogenic units); PHA + Ba25 (200 nM); -tocopherol 
(50 g/ml or 100 g/ml) + Ba25 (200 nM) + PHA at 37 C. 
PBMC were pre-incubated with Ba25 (200 nM) or Ba25 + -tocopherol for 30 min at 37 C prior to the addition of 
PHA. 
At 72 h, [3H] thymidine was added and incorporation measured 18 h later. 
Results of a representative experiment are shown and are expressed as the mean DPM of 6 replicates  SD or as % 
suppression of PBMC proliferation to PHA ± SD. 
 
ii)  Effect of Indomethacin on PHA-induced PBMC proliferation in the presence of  
     Ba25 
Indomethacin, a non-selective cyclooxygenase inhibitor, was able to reverse the 
inhibitory effect of Ba25 on PHA-induced PBMC proliferation. This was reproducible 
in 3 further experiments (Table 11). 
Table 11.  Effect of Indomethacin on PHA-induced PBMC proliferation in the 





Suppression of PBMC 
proliferation 
Cells only 396 ± 18 - 
PHA 663 246 ± 1682 - 
PHA + Ba25 (200 nM) 336 666 ± 2142 49.2% ± 2.47 
PHA + Indomethacin (10 g/ml) + 
Ba25 (200 nM) 
617 413 ± 2846 6.9% ± 0.42 
PHA + Indomethacin (5 g/ml) + 
Ba25 (200 nM) 
627 477 ± 2348 5.4% ± 0.56 
 
PBMC (1x105cells/well) were incubated with PHA (0.00575 mitogenic units); PHA + Ba25 (200nM); indomethacin 
(10 g/ml or 5 g/ml) + Ba25 (200 nM) + PHA at 37 c. 
PBMC were pre-incubated with Ba25 (200 nM) or Ba25+ Indomethacin for 30 min at 37 C prior to the addition of 
PHA. 
At 72 h, [3H] thymidine was added and incorporation measured 18 h later. 
Results of a representative experiment are shown and are expressed as the mean DPM of 6 replicates  SD or as % 
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3.  DISCUSSION 
Ba25, a novel C-type lectin has been isolated from the venom of the Western Cape, 
South African puff adder, Bitis arietans. Functional studies demonstrated the ability of 
Ba25 to cause agglutination of platelets in platelet-rich plasma without the 
degranulation of platelets. Ba25 interacts with the GPIb  receptor of the von 
Willebrand receptor complex, GPIb-IX-V complex as well as the collagen receptor 2 1 
leading to activation of the platelet fibrinogen receptor GPIIbIIIa, increased fibrinogen 
binding to the GPIIbIIIa receptor and consequent platelet agglutination. Ba25 induces 
platelet agglutination without associated platelet activation (Jennings et al 2005, 
Jennings unpublished data). The thromboelastogram studies looking at the effect of 
Ba25 on whole blood clotting, especially the reduction in the reaction time, suggested 
that Ba25 was an inhibitor of early stage blood clotting events such as cell-cell or cell-
surface interactions and had no direct effect on fibrinogen (Jennings et al 2005).  Thus, 
Ba25 modulates platelet-platelet interactions and coagulation processes involved in 
thrombus formation. 
Platelets play an important role in inflammation including the alloresponse leading to 
allograft injury (Zhang et al 2003, 2005; Xu et al 2006). Activated platelets promote 
activated T cell adhesion to fibronectin via integrin ( 5 1 and L 2), CD40-CD40 
ligand and P-selectin-PSGL-1 mediated interactions (Shenkman et al 2006). The degree 
of platelet activation pre-transplantation (increased surface expression of CD61, CD63 
and PAC-1) has been shown to clinically correlate with acute rejection (Zhang et al 
2003). 
Platelets and lymphocytes have a number of receptors in common including the 
collagen receptor 2 1 (Pribila et al 2004, Kasirer-Friede et al 2007). We therefore 
postulated that Ba25 with its ability to modulate platelet interactions by targeting 
receptors without associated activation and to prevent blood clotting by interfering with 
cellular interactions, might be able to modulate lymphocyte function and inhibit 
important processes involved in the alloimmune response. We therefore investigated the 
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Ba25 consistently inhibited in a dose dependent manner lymphocyte proliferation in 
response to mitogen (IC50  138 nM), antigen (IC50  20-118 nM depending on the 
antigen) and alloantigen (IC50  135 nM) stimulation. Curve estimation (SPSS) was 
used to analyse the relationship between the concentration of Ba25 and the % 
suppression of lymphocyte proliferation in response to mitogen, antigens and 
alloantigens. The concentration curves for the mitogen PHA, the antigens (PPD, 
Tetanus toxoid and Varidase) and the MLR were linear with logarithmic transformation. 
Ba25 was not lymphotoxic as the PBMCs remained viable despite prolonged culture in 
the presence of Ba25. Viability was confirmed microscopically at the end of each study 
by trypan blue exclusion or by exclusion of propidium iodide where the effect of Ba25 
on the cell cycle in response to PHA was investigated. Preincubation with Ba25 was not 
required for its anti-proliferative effects as the suppression of proliferation was the same 
with no pre-incubation, 30 minutes or 60 minutes pre-incubation. If Ba25 was washed 
away after a 30 minute pre-incubation period prior to the addition of PHA, the 
inhibitory effect of Ba25 was lost. These results suggested that Ba25 did not interfere 
with any early plasma membrane associated events in T cell activation.For 
standardization purposes, a 30 minute pre-incubation period was used in all the 
experiments. The inhibitory effect of Ba25 on PHA-induced PBMC proliferation was 
not achieved, if Ba25 was added 2 hours after the initiation of PBMC proliferation. This 
suggested that Ba25 interferes with early events of T cell activation prior to DNA 
synthesis and cell division. 
The addition of exogenous IL-2 did not reverse the inhibitory effects of Ba25 on PHA-
induced PBMC proliferation, suggesting that Ba25 interferes with mitogen-induced T 
cell proliferation at more than one site. 
Having established that Ba25 did possess immunosuppressive properties with respect to 
mitogen and antigens, we next looked at the in vitro model of transplantation, the 
primary mixed lymphocyte reaction. Ba25 inhibited the primary mixed lymphocyte 
reaction in a dose dependent manner. Effector cells generated in a primary MLR in the 
presence of Ba25 also exerted a suppressive effect on the proliferation of a fresh MLR. 
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After establishing the inhibitory effects of Ba25 on lymphocyte proliferation, we used 
flow cytometry to look at the effect of Ba25 on lymphocyte activation markers and T 
cell subsets. Phenotypic analysis of lymphocytes after PHA-induced PBMC 
proliferation in the presence of Ba25 consistently showed that Ba25: 
i) had minimal effect on both the generation of activated lymphocytes 
expressing HLA-DR and the number of HLA-DR receptors expressed per 
cell. 
ii) had no effect on the generation of activated lymphocytes expressing CD25 
(the IL-2 receptor) and did not affect cellular expression of the IL-2 receptor. 
iii) minimally impaired the generation of NK cells expressing CD56 (median 
22.8% suppression). 
iv) decreased the CD4:CD8 ratio possibly due to decreased proliferation of CD4 
lymphocytes. 
Phenotypic analysis of Ba25-treated effector cells generated in a 6 day primary MLR 
confirmed that Ba25 had minimal effect on the generation of activated lymphocytes 
expressing the activation markers HLA-DR and CD25. Ba25 had minimal effect on the 
number of HLA-DR receptors expressed per cell and did not affect the cellular 
expression of CD25. Ba25 decreased the CD4:CD8 ratio.  
Thus, the immunomodulatory effects of Ba25 did not appear to be due to inhibition of 
the generation of activated T lymphocytes, but rather a marked reduction in overall 
proliferation.  Minimal suppression of NK cells was observed. The decreased CD4:CD8 
ratio in response to PHA and alloantigen stimulation suggested that the proliferation of 
CD4 lymphocytes was being suppressed by Ba25. We next looked at the effect of Ba25 
on CD4 lymphocytes which are pivotal to the alloimmune response. 
Ba25 consistently inhibited isolated CD4 and CD8 lymphocyte proliferation in response 
to PHA in the absence of antigen-presenting phagocytes. This suggested that no 
processing of Ba25 by antigen-presenting phagocytes was required for its 
immunomodulatory activity. Furthermore, Ba25 inhibited CD4 lymphocyte 
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important role in the effector phase of the alloimmune response promoting adhesion and 
migration of alloreactive cells into the allograft (Coito et al 1998; Korom et al 1998; 
Coito et al 2000a,b), this inhibitory effect of Ba25 is potentially beneficial. 
Ba25 inhibited calcium-dependent T lymphocyte proliferation pathways, but was unable 
to inhibit calcium-independent T lymphocyte proliferation pathways (PBMC 
proliferation in response to anti-CD28 antibody and PMA). 
Having demonstrated that Ba25 inhibited CD4 lymphocyte proliferation with minimal 
modulation of the activation markers (HLA-DR and CD25), we investigated whether 
Ba25 could be inducing an immunosuppressive cytokine profile. Ba25 was consistently 
shown to induce a Th2 cytokine response increasing IL-4 and IL-10 and decreasing 
IFN-  production. IL-10 is a potent anti-inflammatory and immunosuppressive cytokine 
(Zhou et al 2005; Taylor et al 2006). IL-10 inhibits CD28 tyrosine phosphorylation, 
preventing the binding of phosphatidylinositol 3-kinase p85, thereby inhibiting the 
CD28 signaling pathway (Taylor et al 2006). IL-10 has been shown to impair the DTH 
response (VanBuskirk et al 2000), suppressing the alloimmune response and to be a 
marker of immune tolerance in animal models of transplantation (Blancho et al 1995; 
Arai et al 1999; Shinozaki et al 1999; Tashiro et al 2000). Thus, IL-10 is an important 
regulator of the alloimmune response. 
IL-4 is a pleiotropic cytokine which promotes the differentiation of Th2 effectors, and 
inhibits the development of Th1 responses (Le Gros et al 1990; Swain et al 1990; 





 regulatory T cells (Yates et al 2007). 
A Th2 alloimmune response (IL-4 and IL-10) is able to regulate indirect Th1 
alloimmune responses, preventing chronic rejection and promoting tolerance (Kist-van 
Holthe 2002). IL-4 and IL-10 also play a regulatory feedback role by inhibiting COX-2 
gene expression and PGE2 production in mature dendritic cells (Teloni et al 2006), 
neutrophils (Niiro et al 1997) and monocytes (Niiro et al 1998). 
Ba25 caused minimal change in the number of lymphocytes cycling in response to PHA 
stimulation and did not alter PCNA expression. We next investigated whether Ba25 
affected lymphocyte membrane stability and the production of immuno-inhibitory 
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complexes with lysophospholipids and preventing degradation by phospholipase A2, 
was unable to reverse the inhibitory effects of Ba25. Indomethacin, a non-selective 
cyclooxygenase inhibitor was able to reverse the inhibitory effects of Ba25 on PHA-
induced PBMC proliferation. This suggested that Ba25 might be inducing the 
production of the immuno-inhibitory prostaglandin E2 through the activation of 
cyclooxygenase. 
Phosphatidylcholine is the major phospholipid in plasma membranes and is catabolised 
through the hydrolytic action of phospholipase A1 or A2. The major degradation 
products of phosphatidylcholine are lysophosphatidylcholine and arachidonic acid. 
Arachidonic acid can be metabolised to a number of immunologically active products 
including prostanoids (prostaglandins and thromboxane), leukotrienes, isoprostones and 
p450 metabolites (HETE). The prostanoids and leukotrienes have been shown to play a 
role in the alloimmune response with thromboxane and leukotrienes promoting allograft 
injury and prostaglandin E2 promoting allograft survival (Tilley et al 2001; Rocha & 
Carvalho 2005). 
Arachidonic acid is converted to prostaglandin H2 by the cyclooxygenase enzymes 
COX-1 and COX-2 (Vane et al 1998). PGH2 is then acted on by prostaglandin 
synthases to produce the various inhibitory prostaglandins including PGI2 and PGE2 
(Kingston et al 1985). Arachidonic acid may also be converted by thromboxane 
synthase to thromboxane and hydroxylicosate traenoic acid (HETE) which stimulate 
lymphocyte responses to mitogen (Kelly et al 1979; Tilley et al 2001). Animal models 
of allograft rejection have shown that thromboxane impairs graft function (Tannenbaum 
et al 1984; Coffmann et al 1985; Mangino et al 1987; Thomas et al 2003). In contrast, 
prostaglandin E2 has been shown to prolong survival of renal (Strom & Carpenter 
1983), cardiac (Fabrega et al 1992) and small intestine (Koh et al 1992) allografts in 
rats. 
PGE2 modulates macrophage function, downregulating the expression of MHC class II 
antigens (Snyder et al 1982), inhibiting IL-1 (Kunkel et al 1986), IL-12 (van der Pouw 
Kraan 1995, 1996), TNF-  (Scales et al 1989) and superoxide (Metzger et al 1981) 
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PGE2 has diverse effects on the regulation and activity of T cells, predominantly CD4 
lymphocytes. PGE2-induced inhibition of T lymphocyte proliferation involves inhibition 
of polyamine synthesis (Ruggeri et al 2000), inhibition of intracellular calcium release 
(Choudhry et al 1999a) and suppression of p59 (Fyn) protein tyrosine kinase activity 
(Choudhry et al 1999b). PGE2 binds to G-protein complex receptors E2 and E4 and 
suppresses T cell immune responses by eliciting a cAMP (protein kinase A) Csk 
inhibitory pathway localized to the lipid rafts (Vang et al 2001, 2003; Okano et al 
2006). 
PGE2 decreases chemokine production in various cell types. It inhibits CCL3 and CCL4 
production in dendritic cells (Jing et al 2003) and inhibits CCL27 production in 
keratinocytes (Kanda et al 2004). PGE2 is in important modulator of DC function 
including its cytokine production, increasing IL-10 production and downregulating  
IL-12 production (Harizi et al 2002). PGE2 has been shown to promote polarization of 
dendritic cells into mature cells that promote naïve T cell differentiation into Th2 cells. 
PGE2 upregulates DC production of Th2-attracting chemokines CCL17 and CCL22 and 
downregulates IFN-  induced CXCL10 production by immature DC (McIlroy et al 







 Tregs (Yamakazi et al 2006). 
PGE2 differentially affects apoptosis in resting mature T cells and activated T cells. 
PGE2 induces apoptosis of resting mature T cells via a c-Myc dependent and Bcl-2 
independent pathway (Pica et al 1996). PGE2 protects T cells from TCR-mediated 
activation induced cell death by decreasing T cell Fas-ligand expression (Porter et al 
1999). 
PGE2 has been shown to induce a Th2 cytokine response, enhancing IL-4 and IL-10 
production and inhibiting production of Th1 cytokines, IFN-  and IL-2 by Th1 cells 
(Snijdewint et al 1993; Katamura et al 1995; Hilkens et al 1996; Huang et al 1998; 
Stolina et al 2000; Pockaj et al 2004). PGE2 inhibits CD8 lymphocyte proliferation and 
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PGE2 inhibits the human MLR, inhibiting the upregulation of ICAM-1, B7-1 (CD80) 
and B7-2 (CD86) on monocytes and inhibits IL-12 and IFN-  production. This occurs 
through the stimulation of the EP2 and EP4 receptors leading to cAMP production 
(Morichika et al 2003). 
PGE2 induces the expression of functional inhibitory CD94/NKG2A receptors (a C-type 
lectin receptor) on CD8
+ 
T lymphocytes via a cAMP-dependent protein kinase A type I 
pathway (Zeddou et al 2005). 





 Treg cells, which play a role in maintaining peripheral immune tolerance 
and inhibiting autoreactive T cells (Powrie et al 1994; Sakaguchi 2000; Shevach 2002). 
Treg cells have been shown to effectively inhibit effector T cell responses such as 
cytokine production and proliferation (Thornton & Shevach 1998). Treg cells have 
increasingly been shown to play a role in longterm allograft acceptance and 
transplantation tolerance (Jiang et al 2006a; Yong et al 2007; Kang et al 2007; Bestard 
et al 2007; Kitazawa et al 2007; Coenen et al 2007b). 










 T cells (Baratelli et al 2005). PGE2 induces the Treg cell-specific 









 Treg cells. PGE2 
upregulates FOXP3 at both mRNA and protein levels and enhances FOXP3 promotor 
activity (Baratelli et al 2005). 




 Treg cell-induced suppression 













adaptive Treg cells 
express COX-2 and suppress effector T cells via a PGE2-dependent mechanism (Mahic 
et al 2006). 
Overexpression of cyclooxygenase-2 and prostaglandin E2 secretion in breast cancer 
patients has been shown to be associated with reduced T cell effector function, 
decreased dendritic phagocytic cell function and a Th2 cytokine profile (increased IL-4 
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Thus, the immunosuppressive effects of Ba25 may be due to a combination of the direct 
inhibitory effects of prostaglandin E2 on T lymphocyte proliferation, the ability of PGE2 
to promote a Th2 cytokine profile and to modulate Treg function. The status of Treg 
cells during proliferation in the presence of Ba25 was not investigated in this study. 
However, it is acknowledged that PGE2 is able to enhance the suppressive effect of Treg 




T lymphocytes and this 
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CHAPTER SEVEN: 
EXPERIMENTAL SECTION :  EFFECT OF Ba100 AND 
Ba25 ON RODENT MODELS OF TRANSPLANTATION  
ALLOGRAFT SURVIVAL AND HISTOLOGICAL 
STUDIES 
 
1.  Effect of Ba100 and Ba25 on allograft survival following heterotopic heart  
     transplantation 
    1.1.  Surgical procedure in brief 
    1.2.  Results 
2.  Histological assessment following rat orthotopic renal transplantation in the 
     absence or presence of Ba100 and Ba25     
 
    2.1.  Surgical procedure in brief 
    2.2.  Histological findings 
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CHAPTER SEVEN: 
EXPERIMENTAL SECTION :  EFFECT OF BA100 AND 
BA25 ON RODENT MODELS OF TRANSPLANTATION  
ALLOGRAFT SURVIVAL AND HISTOLOGICAL 
STUDIES 
 
The data from Chapters 5 and 6 shows that Ba100 and Ba25 inhibit T lymphocyte 
proliferation in response to mitogen, recall antigens and alloantigens. In summary, 
Ba100 inhibits the generation of lymphocytes expressing the activation markers HLA-
DR and CD25, and downregulates the expression of the adhesion molecules CD11a, 
CD49d and CD29 and the costimulatory molecule CD28. Ba100 impairs cytokine 
production (IL-2, IL-4, IFN-γ and TNF-) and prevents cell cycle progression and 
proliferating cell nuclear antigen expression. Ba25 has little effect on the generation of 
lymphocytes expressing activation markers, does not alter cell cycle progression nor 
PCNA expression, but generates an immunosuppressive Th2 cytokine profile. The 
immunosuppressive effects of Ba25 appear to be related to its ability to induce the 
generation of immunosuppressive prostaglandins. Thus, both proteins may well have in 
vivo immunomodulatory properties with the potential to prevent allograft rejection.  
We therefore investigated whether Ba100 and Ba25 could prolong allograft survival in a 
rodent transplant rejection model and looked at their potential toxicity. All procedures 
were approved by the University of Cape Town Animal Ethics Committee and the rats 
were obtained from The University of Cape Town Animal Unit. 
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1.  EFFECT OF BA100 AND BA25 ON ALLOGRAFT SURVIVAL  
     FOLLOWING HETEROTOPIC HEART TRANSPLANTATION 
We used a simplified model for heterotopic rat heart transplantation (Lee et al 1982). 
BD IX and Long Evans rats weighing between 180 – 220 g were used. The rats were 
housed in an animal room at 22C under a 12 h light – dark cycle and fed a commercial 
pelleted diet. The animals had free access to food and water. 
1.1.  Surgical procedure in brief 
The donor heart was placed transversely in the right side of the abdominal cavity of the 
recipient. An end-to-side anastomosis of the donor aorta to the recipient’s abdominal 
aorta was performed. The pulmonary artery was anastomosed end-to-side to the inferior 
vena cava. The heterotopic transplanted heart started beating immediately, with no 
period of fibrillation and a warm ischaemic period of less than 30 minutes. The 
circulation in the heterotopic transplanted heart was established through an in vivo 
coronary perfusion of the graft. The rats were assessed daily: i) General wellbeing ii) 
Abdominal palpitation to monitor the heart rate and the strength of contraction of the 
heterotopic heart transplant. 
Ba100 (400 l of a 200nM solution in PBS) and Ba25 (400 l of a 200nM solution in 
PBS) were given intravenously via the tail vein of the rat, the day before the surgical 
procedure, during the operation just before unclamping the vessels and then on alternate 
days for 10 days.  
All surgical procedures were performed under sterile conditions under ether anesthesia.  
Heterotopic heart transplants were performed in the following groups and allograft 
survival time in days was measured.  
Group 1: BD IX to BD IX recipients (non-rejecting model), n = 5. 
Group 2: Long Evans to Long Evans recipients (non-rejecting model), n = 5. 
Group 3: BD IX to Long Evans recipients (rejection model), n = 10. 
Group 4: BD IX to Long Evans recipients + Ba100 (treatment model), n = 5. 
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* Control groups 1 and 2 were setup to establish a baseline allograft survival time in a 
non-rejecting heterotopic heart transplant model against which the allograft survival of 
the rejection model (group 3) and the treatment models (group 4 and 5) could be 
compared. The rats in these 2 control groups were killed between 90-120 days and were 
all healthy with functional heterotopic cardiac grafts. The rats in groups 3, 4 and 5 were 
killed when the heterotopic transplanted heart stopped beating. 
 
1.2.  Results 
Table 1.  Effect of Ba100 and Ba25 on allograft survival following heterotopic 
heart transplantation. 
Rat model Allograft survival in days 
 Range Median 
1.  BD IX to BD IX (non-rejecting model) *Killed between 90 
– 120 days 
90 
2.  Long Evans to Long Evans (non-rejecting 
model) 
*Killed between 90 
– 120 days 
90 
3.  BD IX to Long Evans (rejection model) 6 – 9 days 7 
4.  BD IX to Long Evans + Ba100  
(treatment model) 
22– 68 days 26 
5.  BD IX to Long Evans + Ba25 (treatment model) 18 – 24 days 24 
 
The dosing regimen of Ba100 and Ba25 prolonged allograft survival following 
heterotopic cardiac allograft transplantation (p = 0.001, Mann-Whitney Non-parametric 
test). There was no evidence of any bleeding in the rats receiving either Ba100 or Ba25. 
 
2.  HISTOLOGICAL ASSESSMENT FOLLOWING RAT ORTHO- 
     TOPIC RENAL TRANSPLANTATION IN THE ABSENCE OR  
      PRESENCE OF BA100 AND BA25 
A rapid technique for renal transplantation in the rat was used (Engelbrecht et al 1992). 
Sprague-Dawley (SD) and Dark Agouti (DA) rats weighing between 180 – 220 g were 
used. The rats were housed in an animal room at 22C under a 12 h light – dark cycle 
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2.1.  Surgical procedure in brief 
The left renal artery and vein of the recipient kidney were mobilised and the vessels 
divided as close as possible to the hilum of the kidney, the ureter was ligated and cut 
and the recipient kidney removed. The donor kidney was placed in the orthotopic 
position. The renal arterial anastomosis was performed using a modified sleeve 
technique. The renal vein was anastomosed end-to-end. The ureter was anastomosed to 
the bladder with the ureter tip being placed flush against the inside wall of the bladder. 
The warm ischaemic time was less than 15 minutes. The right kidney was removed 
from the recipient. 
All surgical procedures were performed under sterile conditions under ether anaesthesia. 
Ba100 (400 l of a 200nM solution in PBS) and Ba25 (400 l of a 200nM solution in 
PBS) were given intravenously via the tail vein of the rat, the day before the surgical 
procedure, during the operation just before unclamping the vessels and then on alternate 
days for 10 days.  
Orthotopic renal transplants were performed in the following groups. 
Group 1: SD to SD recipients (non-rejecting model), n = 5. 
Group 2: DA to SD recipients (rejection model), n = 10. 
Group 3: DA to SD recipients + Ba100 (treatment model), n = 5. 
Group 4: DA to SD recipients + Ba25 (treatment model), n = 5. 
Table 2. Rat survival following orthotopic renal transplantation. 
Rat model Survival in days 
 Range Median 
1.  SD to SD (non-rejecting model) All 5 survived > 100 days 
2.  DA to SD (rejection model) 3 – 8 7 
3.  DA to SD + Ba100 (treatment model) Killed on day 10 to assess histology 
4.  DA to SD + Ba25 (treatment model) Killed on day 10 to assess histology 
 
Rats in Group 3 (Ba100) and Group 4 (Ba25) were killed on day 10 to histologically 
assess for rejection and signs of toxicity. The median survival in the rejection model 
was 7 days. The kidney, spleen, liver and lungs were removed from rats in groups 2, 3 
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2.2.  Histological findings 
Group 2: DA to SD (rejection model) 
Kidney: Grade 3 T cell mediated rejection in 8 animals, grade 2 T cell mediated 
rejection in 2 animals. 
Spleen: Reactive in all 10 animals. 
Lungs:  Congested in all 10 animals. 
Liver:  Normal in all 10 animals. 
 
Group 3: DA to SD + Ba100  
Kidney: Histology showed no rejection in 4 animals, grade 1 T cell mediated 
rejection in 1 animal 
Spleen: Reactive in 1 animal. 
Lungs:  Normal in all 5 animals. 
Liver:  Normal in all 5 animals. 
 
Group 4: DA to SD + Ba25  
Kidney: Histology showed no rejection in 3 animals, grade 1 T cell mediated 
rejection in 1 animal, and a focal infarct, but no rejection in 1 animal. 
Spleen: Reactive in 2 animals. 
Lungs: Normal in all 5 animals. 
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This proof of concept rodent model of heterotopic cardiac allograft transplantation 
demonstrated that both Ba100 and Ba25 could prolong cardiac allograft survival.  
Histological studies in the rat orthotopic kidney allograft model showed minimal or no 
rejection in the rats treated with Ba100 or Ba25. 
Histological examination of the liver, lungs and spleen in the animals treated with 
Ba100 or Ba25 showed no evidence of haemorrhage, thrombosis or toxicity. 
These proof of concept experiments demonstrated the in vivo immunosuppressive 
potential of Ba100 and Ba25. Ideal dosing regimens for optimal immunosuppression 
need to be established as well as their potential synergistic/additive immunosuppressive 
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CHAPTER EIGHT: 
SUMMARY AND CONCLUSIONS 
 
We have isolated two novel C-type lectins, Ba100 and Ba25, from the venom of the 
Western Cape, South African puff adder, Bitis arietans. Both Ba100 and Ba25 modulate 
platelet function:  
 Ba100 through its fibrinogenase activity prevents fibrinogen crosslinking and 
interferes with the formation of a completely cross-linked fibrin matrix, thereby 
inhibiting platelet aggregation and clot formation (Jennings et al 1999). 
 Ba25 through its interaction with the GPIb  receptor of the von Willebrand receptor 
complex GPIb-IX-V and the collagen receptor 2 1, leads to activation of the 
platelet fibrinogen receptor GPIIaIIIb and increased fibrinogen binding to the 
GPΠbIIIa receptor. Platelet agglutination in the absence of overall platelet activation 
occurs as a consequence of these interactions. Ba25 also inhibited collagen-induced 
expression of the platelet P-selectin (Jennings et al 2005; Jennings unpublished 
data).  
Platelets play an integral role in inflammation by releasing pro-inflammatory factors 
and expressing cell surface receptors that bind to other blood cells, the extracellular 
matrix and the endothelium (Weyrich et al 2003; Kasirer-Friede et al 2007). Platelets 
are thus able to modulate intercellular interactions, adhesion and transendothelial 
migration of cells. Platelets and lymphocytes have a number of common integrin 
receptors including 2 1, 5 1, v 3 and 6 1, which mediate adhesive interactions 
between platelets, lymphocytes and the extracellular matrix. (Pribilia et al 2004; 
Kasirer-Friede et al 2007). Platelets have been shown to enhance T lymphocyte 
adhesion to the extracellular matrix (Solpov et al 2006; Shenkman et al 2006) and to 
play a role in the alloimmune response (Zhang et al 2003, 2005; Xu et al 2006). 
The integrin receptor, 2 1 is expressed on a variety of cells including platelets, mast 
cells, NK cells, activated T cells and endothelial cells (Shimizu et al 1999; Arase et al 
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2001; Sasaki et al 2003; Pribila et al 2004; Zutter & Edelson 2007; Kasirer-Friede et al 
2007). The 2 1 integrin acts as a receptor for a number of extracellular matrix ligands 
including collagen, laminin, E-cadherin and matrix-metalloproteinase-I and these 
interactions play an important role in inflammation (Zutter & Edelson et al 2007). 2 1 
also acts as a receptor for C1q complement protein and the collectins including the 
mannose-binding ligand and the surfactant protein A (Edelson at al 2006; Zutter & 
Edelson 2007). Therefore, the 2 1 integrin plays a potentially important role in the 
innate immune response. (Edelson et al 2006; Zutter & Edelson 2007; McCall-
Culbreath et al 2008). 
The platelet collagen receptor 2 1 plays an important role in the activation of the 
platelet fibrinogen receptor GPIIbIIIa and consequent platelet agglutination or 
aggregation depending on the level of signaling. GPIb-IX-V, GPVI and 2 1 play 
synergistic roles in inducing platelet adhesion (Kuijpers et al 2003; Lecut et al 2004; 
Ozaki et al 2005). 
The collagen binding 1 1 and 2 1 integrins mediate lymphocyte adhesion to collagen 
(Hemler 1990) and are involved in inside-out and outside-in signaling to the 
lymphocyte. The 2 1 integrin regulates the p38 MAPK pathway (Heino 2000). 
Lymphocyte 2 1 integrin interaction with collagen type 1 has been shown to augment 
TCR-dependent expression and production of IFN-  by T effector cells through 
activation of the ERK and JNK MAPK as well as the PI3-K/Akt activation pathways 
(Boisvert et al 2007). Lymphocyte 2 1 also inhibits Fas-mediated apoptosis and 
caspase-8 activation through a protein phosphatase 2A-dependent activation of the 
MAPK/ERK pathway (Gendron et al 2003). 
We thus postulated that our two novel C-type lectins, Ba100 and Ba25 that modulate 
platelet function either through their protease/fibrinogenase activity or through their 
targeting of platelet receptors, might be able to modulate T lymphocyte function. 
The aim of our study was to assess the ability of Ba100 and Ba25 to inhibit T 
lymphocyte proliferative responses. We used standard lymphocyte proliferation assays 
used in assessing the function of known immunosuppressant agents (Hess & Tutschka 
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1990b; Bierer et al 1991a) to investigate the potential immunosuppressive effects of the 
two novel C-type lectins, Ba100 and Ba25. 
Both Ba100 and Ba25 inhibited in a dose-dependent manner calcium-dependent T 
lymphocyte proliferation in response to the mitogenic lectin PHA, several recall 
antigens and alloantigens participating in a mixed lymphocyte reaction. This was not 
due to cytotoxicity as the lymphocytes remained viable despite prolonged culture in the 
presence of Ba100 and Ba25. 
Neither Ba100 nor Ba25 were able to inhibit calcium-independent T lymphocyte 
proliferation pathways such as proliferation in response to anti-CD28 antibody and a 
phorbol ester, PMA. 
This inhibition of calcium-dependent, but not calcium-independent T lymphocyte 
proliferation pathways is similar to the inhibitory effects of the calcineurin inhibitors, 
Cyclosporin (Hess & Tutschka 1980; Fidelus & Laughter 1986; Gelfand et al 1987; 
Bloemena et al 1989; Ryffel 1990; Schreiber & Crabtree 1992) and FK506/Tacrolimus 
(Kino et al 1987b; Kay et al 1989a; Dumont et al 1990b; Bierer et al 1990a, 1991a; 
Johansson & Möller 1990), which are used in clinical practice to prevent allograft 
rejection. 
Both Ba100 and Ba25, like Cyclosporin and FK506 (Hess & Tutschka 1980; Kay & 
Benzie 1984; Kay et al 1989b, 1990; Tocci et al 1989; Dumont et al 1990b; Metcalfe & 
Richards 1990; Henderson et al 1991) need to be added within the first 2 hours of the 
initiation of mitogen-induced PBMC proliferation in order to be effective and this 
suggests that Ba100 and Ba25 interfere with early events of T cell activation prior to 
DNA synthesis and cell division that involve calcium-dependent activation pathways 
leading to IL-2 production and IL-2 receptor expression. This is in contrast to 
Rapamycin, which acts late in T cell activation and inhibits both calcium-dependent and 
-independent T cell activation pathways (Sehgal & Bansbach 1993; Sehgal et al 1994; 
Wood & Bierer 1994; Sehgal 1995). 
Proliferation in the presence of Ba100 at a concentration of 200 nM resulted in the 
inhibition of the generation of lymphocytes expressing the activation markers HLA-DR 
and CD25 and downregulated the expression of the adhesion/costimulatory molecules 










Chapter 8 200 
These adhesion/costimulatory molecules together with the CD28 costimulatory 
molecule play a critical role in optimizing T lymphocyte activation through the 
bidirectional activation of antigen-presenting cells and T lymphocytes and the 
involvement of the CD28:B7 costimulatory pathway generating the second 
costimulatory signal (Salomon & Bluestone 2001; Sharpe & Freeman 2002; Nel 2002). 
Ba100 also inhibited the generation of T cell subsets that play a role as effector cells in 
the alloimmune response: the CTLs, NK cells and memory cells as well as increasing 
the CD4:CD8 ratio possibly reflecting the inability of CD8 lymphocytes to proliferate 
due to inhibition of the IL-2/IL-2 receptor pathway as Ba100 downregulated IL-2 
receptor expression. The inhibitory effects of Ba100 and Ba25 on PHA-induced PBMC 
proliferation could not be reversed by the addition of exogenous IL-2, suggesting that 
both C-type lectins interfere with mitogen-induced T lymphocyte proliferation at more 
than one site. This is similar to the calcineurin inhibitors whose inhibitory activity is 
only partially reversed by exogenous IL-2 (Hess 1985; Gelfand et al 1987; Dumont et al 
1990b; Lin et al 1991). Like Cyclosporin, Ba100 was able to inhibit the cytolytic 
activity of effector cells generated in a primary MLR (Hess & Tutschka 1980). 
Both Ba100 and Ba25 were able to inhibit the proliferation of isolated CD4 and CD8 
lymphocytes in the absence of antigen-presenting phagocytes suggesting that processing 
of these two C-type lectins by antigen-presenting phagocytes was not necessary for their 
immunosuppressive action. 
Inhibition of proliferation of isolated CD4 lymphocytes in response to anti-CD3 
antibody and the extracellular matrix protein, fibronectin was a characteristic of both 
Ba100 and Ba25. This may reflect the ability of these C-type lectins to either act as 
competitive antagonistic ligands for the fibrinogen receptors 5 1 (VLA-5) and 4 1 
(VLA-4) or to downregulate receptor expression as was seen with Ba100 which was 
able to downregulate the expression of CD49d and CD29 adhesion molecules and thus 
impair cell-extracellular matrix interactions. Fibronectin plays an important role in the 
effector phase of the alloimmune response which is dependent on adhesion and 
migration of alloreactive cells into the graft (Kupiec-Weglinski et al 1993; Coito 1994a, 
1998, 2000a) and therefore these inhibitory effects are potentially advantageous in 










Chapter 8 201 
Ba100 inhibited the production of Th1 cytokines (IL-2, IFN- , TNF ) and the Th2 
cytokine IL-4 which play an important role in mediating allograft injury through 
delayed-type hypersensitivity reactions, promoting the generation of CTLs and the 
activation of NK cells and macrophages. This is similar to the effect of the calcineurin 
inhibitors (Hess et al 1982; Kronke et al 1984; Granelli-Piperno et al 1988a, 1990; 
Tocci et al 1989; Thomson et al 1995), but in contrast to rapamycin which has limited 
effects on cytokine production and instead blocks cytokine-mediated proliferative 
responses (Sehgal et al 1994; Wood & Bierer 1994; Bertagnolli et al 1994). 
Like Cyclosporin and FK506/Tacrolimus (Metcalfe & Richards 1990; Chang et al 1991; 
Morris et al 1991), Ba100 inhibited lymphocyte cell cycle progression from the G0 – 
G1 phase into the S phase and this was associated with downregulation of the 
proliferating cell nuclear antigen, an obligate cofactor of DNA-polymerase-δ and a 
critical requirement for cell cycle progression into the S phase (Celis & Celis 1985; 
Maga & Hubscher 2003). Rapamycin prevents progression from the G1 phase into the S 
phase of the cell cycle and blocks IL-2 induced PCNA gene expression (Terada et al 
1993; Feuerstein et al 1995).  
Although Ba25 inhibited T lymphocyte proliferative responses, a minimal change in the 
expression of T cell activation markers was observed. An immunosuppressive cytokine 
profile characterized by increased IL-4 and IL-10 production and decreased IFN-  
production was detected during a mixed lymphocyte reaction in the presence of Ba25 
(200 nM). Ba25 did not affect cell cycle progression nor PCNA expression. The 
inhibitory effects of Ba25 on T lymphocyte proliferation appeared to be related to its 
ability to induce the generation of immunosuppressive prostaglandins. Indomethacin, a 
non-selective cyclooxygenase inhibitor added to PHA-induced PBMC proliferation 
reactions in the presence of Ba25, was able to reverse the Ba25-dependent inhibition of 
proliferation. 
The immunosuppressive effects of Ba25 may be due to a combination of the immuno-
inhibitory effects of prostaglandins: the direct inhibitory effects of prostaglandins on T 
lymphocyte proliferation (Choudhry et al 1999a,b; Ruggeri et al 2000; Vang et al 2001, 
2003; Okano et al 2006), its ability to promote a Th2 cytokine profile (Snijdewint et al 
1993; Katamura et al 1995; Hilkens et al 1996; Huang et al 1996, 1998; Stolina et al 
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lymphocytes (Baratelli et al 2005) and this may have occurred. 
Cyclosporin, FK506 and Rapamycin can all modulate Tregs. Cyclosporin and FK506 
inhibit induced Treg FOXP3 gene transcription (Baan et al 2005) and Cyclosporin 




 Tregs (Lim et al 2007) following alloantigen 













 Tregs in renal transplant recipients 
(Korczak-Kowalska et al 2007). 











 T effector cells (Battaglia et al 
2005, 2006; Strauss et al 2007). 
We did not investigate the biochemical targets and molecular mechanisms of action 
involved in the inhibition of T lymphocyte proliferative responses by Ba100 and Ba25. 
Possible molecular mechanisms of action in view of their C-type lectin structure 
include: 
i) acting as competitive ligands for the lymphocyte integrin receptors LFA-1 and the 1 
integrins 4 1 and 2 1, thereby preventing inside-out and outside-in signaling and the 
formation of the mature immunological synapse which is needed for effective TCR-
mediated T cell activation (Hogg et al 2003) as well as preventing cell-extracellular 
matrix interactions involved in cellular activation, adhesion and migration. This may be 
mediated by the binding of Ba100 and Ba25 to the Lewis x trisaccharide known to be 
the binding site for other C-type lectins including the selectins (Sanders et al 1996),  
dendritic cell lectin receptors such as DC-SIGN (Engering et al 2002; Van Liempt et al 
2004) and the scavenger receptor C-type lectin (Nakamura et al 2001; Coombs et al 
2005). 
ii) preventing optimal antigen-presenting cell including dendritic cell function by 
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The demonstrated immunosuppressive effects of Ba100: Inhibition of calcium-
dependent T lymphocyte proliferation associated with the downregulation of activation 
markers (HLA-DR and CD25) and adhesive/costimulatory molecules (CD11a, CD49d, 
CD29 and CD28), together with the inhibited generation of critical T cell subsets 
(CTLs, NK cells and memory cells) involved in the alloimmune response and the 
impaired production of Th1 cytokines and IL-4 that drives the alloimmune response 
leading to allograft injury suggest a potential therapeutic role for Ba100 as an 
immunosuppressive agent. 
Ba25 similarly affected calcium-dependent T lymphocyte proliferation, but did not 
modulate the activation markers nor cell cycle progression. Instead, Ba25 generated an 
immunosuppressive Th2 cytokine profile possibly through the generation of 
immunosuppressive prostaglandins. Thus, the immunosuppressive effects of Ba25 may 
be due to a combination of direct inhibitory effects of PGE2 on T lymphocyte 
proliferation, the ability of PGE2 to promote a Th2 cytokine profile and to enhance the 





lymphocytes. The potential ability of Ba25 to enhance Treg function without interfering 
with T lymphocyte activation suggests a potential role for Ba25 as an agent capable of 
promoting immune tolerance. 
Thus, the ability of Ba100 and Ba25 to modulate platelet function and inhibit calcium-
dependent T lymphocyte proliferation, both critical components of the alloimmune 
response leading to allograft injury, suggests a potential therapeutic role for these two 
novel C-type lectins. Proof of concept rodent models of allograft rejection demonstrated 
that both Ba100 and Ba25 could prolong allograft survival without any evidence of 
haemorrhage, thrombosis or toxicity. Thus, Ba100 and Ba25 may well prove after 
indepth analysis of their structure-function relationships to be capable of being 
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1.  Materials 
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     1.2.  Antibodies 
         1.2.1.  Antibodies for phenotypic analysis of lymphocytes 
         1.2.2.  Antibodies for measurement of lymphocyte intracellular cytokine  
                    production in response to PMA and ionomycin in the absence or presence 
                    of Ba100 
         1.2.3.  Antibodies for measurement of cytokine production by activated  
                    lymphocytes in the MLR in the absence or presence of Ba25 
         1.2.4.  Antibodies used to assess PCNA expression by flow cytometry 
         1.2.5.  Antibodies used in OKT3/fibronectin stimulated CD4 proliferation assays  
                    and in calcium-independent PBMC proliferation assays 
2.  Collection of blood and lymphocyte isolation 
     2.1.  Isolation of human peripheral blood mononuclear cells (PBMC) 




 lymphocytes from whole blood 
3.  Isolation of Ba100 and Ba25 
     3.1.  Gel filtration 
     3.2.  Affinity chromatography 
         3.2.1.  Isolation of Ba100 
         3.2.2. Isolation of Ba25 
4.  Preparation of fibronectin 
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[H] incorporation to assess lymphocyte  
     proliferation 
7.  Lymphocyte proliferation assays  
     7.1.  PBMC proliferation assays 
         7.1.1.  PBMC proliferation assays in response to mitogen and antigens 
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         7.1.3.  Primary mixed lymphocyte reaction (micro-MLR)  
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14.  Effect of -tocopherol on PHA-induced PBMC proliferation in the absence or  
       presence of Ba25 
15.  Analysis of data 
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APPENDIX ONE: 
MATERIALS AND METHODS 
 
1.  Materials 
1.1.  Reagents 
All chemicals and reagents were obtained from Sigma Chemical Co (St Louis, MO), 
except for those listed below: 
RPMI 1640 medium (Gibco, The Scientific Group/Adcock-Ingram, RSA), AB serum 
and fresh frozen plasma (Western Province Blood Transfusion Service, RSA), Serum-
free culture medium (CG medium from Serotec), Bovine serum albumin (Seravac 
Biotech Pty (Ltd), Epping, RSA), Penicillin (Gibco, The Scientific Group/Adcock-
Ingram, RSA), Streptomycin (Gibco, The Scientific Group/Adcock-Ingram, RSA), 
Phytohaemagglutinin/PHA (Murex Diagnostics Ltd., Dartford, England), PPD - a 
purified protein derivative of Mycobacterium tuberculosis (Central Veterinary 
Laboratory, Weybridge, UK), Tetanus toxoid (Lederle Laboratory, Wayne, NJ), 
Varidase (Lederle Laboratory, Wayne, NJ), Recombinant human Interleukin-2 (10
7
 
U/mg, Pharmingen, San Diego, CA), Dynabeads M-450 CD4 and CD8 and 




 lymphocytes (Dynal, Southern Cross 
Biotechnology, Claremont, RSA), Tritiated thymidine and 
51
Chromium (Amersham 
Corporation,UK), DNA-Prep (Coulter Corporation, Maine, Florida) - a Coulter reagent 
kit with cell lysing solution, permeabilising solution and DNA staining reagent was 
used to assess progression through the cell cycle using flow cytometry. 
1.2.  Antibodies 
1.2.1.  Antibodies for phenotypic analysis of lymphocytes 
The following FITC-labelled monoclonal antibodies used for phenotypic analysis of 
lymphocytes following PHA and alloantigen (MLR) stimulation were purchased from 
Immunotech, a Coulter Company (Marseille, France). 
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i) Monoclonal antibodies (IgG1 and IgG2a mouse) used as isotypic controls. 
ii) Monclonal antibodies (IgG1κ mouse) to CD3, CD4, CD56, HLA-DR, 
CD11a, S6F1, CD19. 
iii) Monoclonal antibodies (IgG2a mouse) to CD29. 
iv) Monoclonal antibodies (IgG1 mouse) to CD8, CD28 and CD49d. 
v) Monoclonal antibody (IgG2a rat) to CD2. 
vi) Monoclonal antibody (IgG2aκ mouse) to CD25. 
 
1.2.2. Antibodies for measurement of lymphocyte intracellular cytokine production 
          in response to PMA and ionomycin in the absence or presence of Ba100 
The following FITC- or R-Phycoerythrin-labelled monoclonal antibodies for measuring 
intracellular cytokine production by flow cytometry were purchased from Pharmingen 
(San Diego, CA): FITC-rat anti-human IL-4, FITC-
 
mouse anti-human TNF-, FITC- 
mouse anti-human IFN- , FITC-mouse anti-human IgG1 isotype control 
immunoglobulin, R-PE-rat anti-human IL-2, R-PE-rat IgG2a isotype control 
immunoglobulin. 
 
1.2.3.  Antibodies for measurement of cytokine production by activated lymphocytes  
          in the MLR in the absence or presence of Ba25 
ELISA assay kits were purchased from Pharmingen (San Diego, CA) for measurement 
of IL-4, TNF- and IFN-  production. 
 
1.2.4.  Antibodies used to assess PCNA expression by flow cytometry 
The following Coulter clone monoclonal antibodies were purchased from Coulter 
Electronics: PCNA (IgG1 and IgM), Coulter clone isotypic controls (MsIgG1, MsIgM)  
 
Formatted: Space After:  0 pt
Formatted: Left, Line spacing:  1.5 lines
Formatted: Line spacing:  1.5 lines
Formatted: Left, Line spacing:  1.5 lines










Appendix 1 209 
1.2.5.  Antibodies used in OKT3/fibronectin stimulated CD4 proliferation assays and  
          in calcium-independent PBMC proliferation assays 
i) OKT3 (orthoclone OKT3, a muromonoclonal anti-CD3 antibody from Ortho 
Pharmaceuticals Corporation, Raritan, NJ), ii) anti-CD28 antibody (monoclonal IgG2b 
rat from Serotec).  
 
2.  Collection of blood and lymphocyte isolation 




 T lymphocytes were 
isolated from venous blood donated by healthy adult volunteers. Blood was collected 
into 10ml lithium heparinised vacutainer tubes. 
 
2.1.  Isolation of human peripheral blood mononuclear cells (PBMC) 
PBMC were isolated from heparinised venous blood by Ficoll-Hypaque density-layer 
centrifugation. The isolated cells contained > 95% mononuclear cells and viability of 
the cells was > 95% as judged by trypan blue exclusion. 
PBMC were washed x3 and resuspended in complete culture medium containing RPMI- 
1640 supplemented with 10% heat inactivated human AB serum, penicillin (100 
units/ml) and streptomycin (100 g/ml) at a concentration of 1x10
6
 cells/ml for use in 
PBMC proliferation assays unless otherwise stated. 
 




 lymphocytes from whole blood 
Immunomagnetic cell isolation using Dynabeads M-450 coated with a monoclonal 





 T cells (Leivestad et al 1987) according to manufacturer’s instructions. Briefly 
the CD4
+
 and CD8 
+
 cells were isolated from the mononuclear cell layer obtained from 
heparinised whole blood after Ficoll-hypaque density-layer centrifugation. Following a 




 T cells bind to the Dynabeads. The 
positively selected cells are then detached from the Dynabeads using appropriate 
detachabeads. The isolated cells are > 99% pure, > 98% viable and are not activated by 
the process. 
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3.  Isolation of Ba100 and Ba25 
The 2 novel C-type lectins were isolated from the venom of the Western Cape, South 
African puff adder, Bitis arietans using fibrinogen and platelet receptor affinity 
chromatography respectively and provided for the project by Mr. Brent Jennings 
(Jennings et al 1999, 2005).  
 
3.1.  Gel filtration 
Lyophilised crude venom (100 mg), from puff adders found in the Western Cape region 
of South Africa, was dissolved in 3 ml 0.1 M acetic acid (glacial, Riedel-deHaën), 
clarified by centrifugation at 3000 rpm, 10 min, then applied to a Toyopearl (Tosohaas) 
HW-50 column (1.8 cm x 70 cm) equilibrated in 0.1 M acetic acid. Fractions (2 ml) 
were eluted from the column in the same buffer and protein was detected by absorbance 
at 280 nm (Hitachi U-2000 spectrophotometer) (Fig. 1A). The nature of proteins in each 
fraction was determined by mixing an aliquot with one-third volume of three-fold 
strength SDS-sample buffer containing 0.01 M Tris (pH 6.8), 6% SDS and 36% 
glycerol and analysed on 10% SDS-PAGE. Fractions were combined as indicated in 
Fig. 1A to give pools A, B and C, then lyophilised and redissolved in 10 ml buffer A: 
10mM Tris, pH 7.4 with 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, followed by 
dialysis in buffer A. The nature of the proteins in pools A, B and C was determined by 
analysis on 10% SDS-PAGE (Fig. 1B). 
 
3.2.  Affinity chromatography 
3.2.1.  Isolation of Ba100 
A fibrinogen-affinity column was made by coupling purified human fibrinogen (isolated 
by (NH4)2 SO4 precipitation of plasma (Kalvaria et al 1986)) to cyanogen bromide-
activated Sepharose CL4B (Sigma) according to manufacturer’s instructions and 
equilibrated with buffer A. The presence of fibrinogen binding proteins in Pools A, B 
and C (Fig. 1A) were investigated by passing the individual pools over the fibrinogen 
affinity column. Protein bound to the column was eluted in 1 ml fractions with 0.1 M 
sodium acetate buffer, pH 4.0, containing 1 M NaCl. Fractions containing protein as 
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assessed by measuring the absorbance at 280 nm were pooled, then dialysed 
immediately afterwards into one-tenth strength phosphate buffered saline (PBS) and 
then lyophilised and redissolved in Milli-Q filtered water (Millipore) to one-tenth 
original volume. Protein concentration was determined by the method of Lowry and the 
nature of the isolated protein assessed by analysis on 10% SDS-PAGE in the presence 
and absence of a reducing agent. A fibrinogen binding protein with an apparent 
molecular mass of 100 kDa in the absence of reducing agent was isolated from both 
Pool A and Pool B and was called Ba100 (Fig. 2).  No fibrinogen binding protein was 
found in pool C. 
Subsequently, Ba100 was isolated by fibrinogen affinity chromatography from a pool of 
A and B (Fig. 1A). The eluted protein was dialysed into one-tenth strength phosphate 
buffered saline (PBS), then lyophilised and redissolved in Milli-Q filtered water 
(Millipore) to one-tenth original volume. The purity and apparent molecular mass of the 
protein in each batch of Ba100 that was prepared, was confirmed using 10% SDS-
PAGE in the absence of reducing agent. Protein concentration of the batches of Ba100 
was determined by the method of Lowry and then adjusted with sterile PBS to a final 
concentration of 1mg/ml before use in cell culture experiments.  
 
3.2.2. Isolation of Ba25 
The presence of GPIIbIIIa binding proteins in Pools A, B and C (Fig. 1A) were 
investigated using a GPIIbIIIa affinity column. This column was prepared by coupling a 
preparation of fibrinogen depleted (using a fibrinogen affinity column prepared as 
described above) GPIIbIIIa receptor, isolated from outdated platelets (Fitzgerald et al 
1985) to Sepharose CL-4B. The protein in pools A, B and C, (Fig. 1A) were dialysed 
into Tris saline buffer (TS150 C/M, 10mM Tris pH 7.4, 150 mM NaCl, 1 mM CaCl2, 1 
mM MgCl2) before being loaded onto a GPIIbIIIa-affinity column, after which the 
column was washed with 10 column volumes of TS150 C/M. Bound protein was eluted 
with 0.1 M sodium acetate buffer, pH 4, containing 1 M NaCl. Protein in each fraction 
(1 ml) was estimated by measuring the absorbance at 280 nm. Peak fractions were 
pooled and immediately dialysed into one-tenth strength PBS, lyophilised and 
redissolved in Milli-Q filtered water (Millipore) to one-tenth original volume. Protein 
concentration was determined by the method of Lowry and the nature of the isolated 
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protein assessed by analysis on a 5-13% SDS-PAGE in the presence and absence of a 
reducing agent.  Only Pool C (Fig 1A) was found to contain a protein with an apparent 
molecular mass of 25 kDA that bound to the GPIIbIIIa affinity column and was called 
Ba25 (Fig. 3).  
Subsequently, Ba25 was isolated by GPIIbIIIa affinity chromatography from Pool C 
(Fig. 1A).  The eluted protein was dialysed into one-tenth strength phosphate buffered 
saline (PBS), then lyophilised and redissolved in Milli-Q filtered water (Millipore) to 
one-tenth original volume. The purity and apparent molecular mass of the protein in 
each batch of Ba25 that was prepared was confirmed using 5-13% SDS-PAGE in the 
absence of reducing agent. Protein concentration of the batches of Ba25 was determined 
by the method of Lowry and then adjusted with sterile PBS to a final concentration of 

































Fig. 1 (A):  Gel filtration of crude venom on HW-50 
column.  
 
100 mg crude venom was dissolved in 3 ml 0.1 M acetic 
acid, then applied to a Toyopearl HW-50 column (1.8 cm 
 70 cm) at 0.5 ml/min and eluted with the same buffer. 
2 ml fractions were collected at 4°C. Protein was 







Fig. 1(B):  Nature of the proteins in pools A, B and C.  
 
Fractions eluting off the HW-50 column were pooled as 
described for isolating Ba100 and Ba25 and analysed on 
10% SDS-polyacrylamide gels under non-reducing 
conditions. Proteins were stained by Coomassie blue. 




























4. Preparation of fibronectin 
Fibronectin (Fn) isolated from 500ml aliquots of fresh frozen plasma obtained from the 
Western Province Blood Transfusion Service was a protein regularly prepared in the 
laboratory and provided for the project. 5mM benzamidine was added to the plasma 
immediately after centrifugation and plasma was filtered (Whatman’s No.1 filter paper) 
to remove insoluble lipid.  
4.1. Gelatin-sepharose affinity chromatography 
The non-denaturing affinity chromatography method of Vuento and Vaheri (1979) was 
routinely used to prepare fibronectin. 
Gelatin-sepharose affinity matrix was prepared by coupling gelatin to cyanogen 
bromide (CNBr)-activated Sepharose 4B according to the manufacturer’s instructions. 
 
 
Fig. 2. Fibrinogen-affinity chromatography isolation 
of Ba100. Pools A and B (Fig. 1 A), obtained from 
gel filtration of crude venom, were combined, 
lyophilised and re-dissolved in buffer A and then 
passed over a fibrinogen-affinity column as described 
in the methods. 10% SDS-PAGE of: (a) proteins in 
pools A and B prior to affinity column treatment, (b) 
nature of proteins not bound to the fibrinogen 
column, (c) nature of Ba100 eluted from the affinity 
column, (d) nature of Ba100 under reducing 
conditions. Relative molecular masses (in kDa) are 
shown.  
Fig. 3. GPIIbIIIa affinity chromatography isolation of 
Ba25. Pool C (Fig. 1A) obtained from gel filtration of 
crude venom was lyophilized, re-dissolved in buffer A 
and then passed over the GPIIbIIIa affinity column as 
described in the methods. SDS-PAGE analysis (5–13% 
polyacrylamide gradient gel) of: Lane 1, molecular 
weight markers (weights in kDa on the left); Lane 2, 
protein from pool C prior to loading on the GPIIbIIIa 
column; Lane 3, Protein eluted from the affinity 
column called Ba25; Lane 4, Ba25 in the presence of a 
reducing agent. 
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5mM benzamidine was added to all buffers to prevent proteolysis and 0.02% sodium 
azide was added to the buffers to prevent bacterial contamination. 
A 1.5 x 13 cm column (Amicon) loaded with gelatin-sepharose affinity matrix was 
equilibrated with equilibrating buffer (0.05M Tris-HCI, pH 7.5). 50 ml plasma was 
loaded and washed through the column with equilibrating buffer until the UV monitor 
recording (280 nm) returned to zero. 1M NaCl was added to the equilibration buffer and 
the column washed again. Fibronectin was then eluted with 2M arginine in equilibrating 
buffer without 1M NaCl in 1ml aliquots. The column was regenerated with 8M urea. 
The eluate fractions containing the protein peak were analysed by SDS-PAGE 
(Laemmli, 1970). The protein peak was dialysed into phosphate buffered saline (PBS), 
pH 7.3 using a Spectrapor 4 dialysis membrane (MWT cut-off 12-14 000) and the 
protein concentration was determined by means of the Biorad method (Bradford, 1976) 
 
5.  Preparation of OKT3-coated wells/microtitre plates 
200 l of OKT3, a muromonoclonal anti-CD3 antibody at a concentration of 100 ng/ml 
in 0.01M PBS, pH 7.4 was pipetted into each well of a 96-well flat-bottomed microtitre 
plate, incubated at room temperature for 3 h and then kept overnight at 4C. The 
following day, the microtitre plate was washed x2 with PBS and used in the CD4 
lymphocyte proliferation assays (Matsuyama et al 1989). 
 
6.  Measurement of tritiated thymidine 
3
[H] incorporation to assess  
     lymphocyte proliferation 
After the prescribed length of culture, 1 Ci of [
3
H]-thymidine was added to each 
microtitre plate well and cultures incubated for a further 18 h before harvesting onto 
glass fibre filter paper with a multiple automated sample harvester. The filter papers 
were dried and processed for liquid scintillation counting. 
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7.  Lymphocyte proliferation assays  
7.1.  PBMC proliferation assays 
7.1.1.  PBMC proliferation assays in response to mitogen and antigens 
PBMC (1x10
5
 cells/well) were cultured in triplicate with the mitogen, 
Phytohaemagglutinin (PHA 0.00575 mitogenic units) in a 96-well round-bottomed 
microtitre plate in the absence or presence of Ba100 or Ba25 in a humidified 5% CO2 in 
air incubator at 37C. Ba100 or Ba25 was pre-incubated with PBMC for 30 min at 37C 
prior to the addition of PHA. Ba100 or Ba25 was used at the following final 
concentrations: 200, 100, 50, 25 or 12.5 nM as stated in the results section. At 72 h, 1 
Ci [
3
H] thymidine was added to each well and incorporation measured 18 h later. 
The effect of preincubation with Ba100 or Ba25 for varying periods (0,  30 and 60min 
preincubation) on PHA-induced PBMC proliferation was assessed. Pre-incubation with 
Ba100 or Ba25 did not influence the inhibitory effect on lymphocyte proliferation and 
for standardization purposes, a 30 minute pre-incubation period was used for all 
subsequent experiments unless otherwise stated. The effect of preincubating Ba100 or 
Ba25 with PBMC for 30 min at 37C, then washing it away before the addition of PHA 
to initiate proliferation, was also investigated. 
The experiments assessing the effect of various concentrations of Ba100 or Ba25 on 
PBMC proliferation were repeated using the following recall antigens: 
i) PPD, a purified protein derivative of Mycobacterium tuberculosis at a final 
concentration of 3 g/ml. 
ii) Tetanus toxoid antigen (formol toxoid, stock concentration 10 Lf/0.5 ml) at a 
final concentration of 1:20. 
iii) Varidase (streptokinase – streptodornase: 250 U/ml streptokinase, 62.5 U/ml 
streptodornase) at a final concentration of 1:40. 
Formatted: Left, Line spacing:  1.5 lines










Appendix 1 216 
7.1.2.  PBMC proliferation assays in flasks 
These assays were setup to assess the effect of Ba100 or Ba25 on  
i) Lymphocyte intracellular cytokine production in response to PMA and 
ionomycin stimulation.  
ii) Cell cycle progression and PCNA expression in PHA-stimulated PBMC. 
Isolated PBMC were suspended at 1x10
6
 cells/ml RPMI-1640/10% AB serum in 30 ml 
tissue culture flasks. PBMC (20x10
6
/20 ml RPMI-1640/10% AB serum) were cultured 
with the stimulant in the absence or presence of Ba100 (200 nM) or Ba25 (200 nM) in a 
humidified 5% CO2 in air incubator at 37C. Ba100 (200 nM) or Ba25 (200 nM) was 
preincubated with PBMC for 30 min at 37C prior to the addition of the stimulant. At 
72 h, proliferation was measured by counting the number of cells/ml or by standard [
3
H] 
thymidine incorporation to confirm the inhibitory effect of Ba100 or Ba25. 
 
7.1.3.  Primary mixed lymphocyte reaction (micro-MLR)  
PBMC were isolated by Ficoll-Hypaque density centrifugation. A primary mixed 
lymphocyte reaction was initiated by adding 1x10
5
 irradiated (3000R) stimulator cells to 
1x10
5
 responder cells (each in a volume of 0.05 ml) per well in a 96-well round-
bottomed microtitre plate and incubated in a humidified 5% CO2 in air incubator at 
37C. Responder cells were preincubated with Ba100 or Ba25 in varying concentrations 
(12.5 – 200 nM) for 30 min at 37C prior to the addition of the stimulator cells. In the 
control primary MLR, the responder cells were not exposed to Ba100 or Ba25. On day 
6, 1 Ci [
3
H] thymidine was added to each well and incorporation was measured 18 h 
later. 
 
7.1.4.  Bulk MLR 
Bulk MLRs were setup in 30ml tissue culture flasks for  
i) The determination of T cell subsets and phenotypic analysis of effector cells 
generated in a primary MLR in the absence or presence of Ba100 or Ba25.  
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ii) Assessment of suppressor cell activity of primary MLR generated effectors 




 cells/ml) were cultured with 1x10
6
 cells/ml irradiated (3000R) 
stimulator cells in the absence or presence of Ba100 (200 nM)  or Ba25 (200 nM) in a 
humidified 5% CO2 in air incubator at 37C . Ba100 (200 nM) or Ba25 (200 nM) was 
pre-incubated with the responder cells for 30 min at 37C prior to the addition of the 
stimulator cells. On day 6, proliferation was assessed either by counting the number of 
cells/ml or by pipetting 100 l cell suspension into triplicate wells of a microtitre plate, 
adding 1 Ci [
3
H] thymidine to each well and measuring incorporation 18 h later. 
 
7.1.5.  PBMC proliferation in response to anti-CD28 antibody and a phorbol ester,  
           phorbol 12-myristate 13-acetate (PMA) 
PBMC (0.5x10
6
 cells/well) in 1% BSA/PBS were cultured in triplicate with PMA (1 
ng/ml); PMA (1 ng/ml) + anti-CD28 antibody (1 ng/ml) and PMA + anti-CD28 
antibody + Ba100 (200 nM) or Ba25 (200 nM) in a humidified 5% CO2 in air incubator 
at 37C. Ba100 or Ba25 was pre-incubated with PBMC for 30 minutes at 37C prior to 
the addition of PMA or PMA + anti-CD28 antibody. At 72 h, 1 Ci [
3
H] thymidine was 
added and incorporation measured 18 h later. 
 
7.1.6.  Addition of exogenous IL-2 to PHA-induced PBMC proliferation assays 
PBMC (1x10
5
 cell/well) were cultur d in triplicate with PHA (0.00575 mitogenic 
units); PHA + Ba100 (200 nM) or Ba25 (200 nM); PHA + IL-2 (10 U/ml) and PHA + 
Ba100 or Ba25 + IL-2 in a humidified 5% CO2 in air incubator at 37C. Ba100 or Ba25 
was preincubated with PBMC for 30 minutes at 37C prior to the addition of PHA or 
PHA + IL-2. At 72 h, [
3
H] thymidine was added and incorporation measured 18 h later. 
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7.2.  CD4 and CD8 lymphocyte proliferation assays 





 lymphocytes were isolated from PBMC using Dynabeads as described 








 lymphocytes/well were cultured in triplicate with PHA (0.00575 
mitogenic units) or PHA + Ba100 or Ba25 in varying concentrations (as stated in the  





lymphocyte suspension was pre-incubated with Ba100 or Ba25 for 30 min at 37C prior 
to the addition of PHA. At 72 h, 1 Ci [
3
H] thymidine was added and incorporation 
measured 18 h later. 
7.2.2.  CD4 lymphocyte proliferation in response to OKT3 and fibronectin 
CD4
+ 





lymphocytes/well were cultured in triplicate in an OKT3-coated 96-well flat-bottomed 
microtitre plate in serum-free culture medium (Serotec medium) with or without 
fibronectin (30 g/ml) in the absence or presence of Ba100 (200 nM) or Ba25 (200 nM) 
in a 5% CO2 in air incubator at 37C. The CD4 lymphocytes were pre-incubated with 
Ba100 or Ba25 for 30 min at 37C prior to the addition of fibronectin to the wells. 1 Ci 
[
3
H] thymidine was added on days 1, 2 and 4 and incorporation measured 18 h later. 
7.3.  Suppressor cell assay 
Assessment of suppressor cell activity of effector cells generated in a primary bulk 
MLR was performed by using a slight modification of the technique described by 
Hirschberg and Thorsby (1977). 
A bulk primary MLR was set up by incubating responder cells, A (1x10
6
 cells/ml) with 
irradiated (3000 R) stimulator cells, Bx (1x10
6
 cells/ml) in complete media in the 
absence or presence of Ba100 (200 nM) or Ba25 (200 nM) in a humidified 5% CO2 in 
air incubator at 37C. On day 6, the cells were harvested, incubated for 30 min, washed 
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x 2 in fresh complete media to remove Ba100 or Ba25, and used as the primed cells in 
the suppressor cell assay. 
Fresh MLR reactions contained the component cells A+Bx, C+Ex, C+Bx, A+Cx: 1x10
5
 
responder cells (A or C) were cultured in triplicate with 1x10
5
 irradiated (3000 R) 
stimulator cells (Bx, Cx or Ex) per well in complete media in a 96-well round-bottomed 
plate at 37C. 
These fresh MLR (A+Bx, C+Ex, C+Bx and A+Cx) were cultured with the primed cells 
in the following combinations. 
1. Primed cells autologous to responders and stimulators. 2. Primed cells, responders 
and stimulators completely heterologous. 3. Same stimulator, different responder. 4. 
Same responder, different stimulator. 
On day 6, [
3
H] thymidine was added and incorporation measured 18 h later. 
 
7.4.  Measurement of cell mediated lympholytic (cytotoxic) activity of the MLR  
       generated effectors in a 
51
Cr release assay 
A bulk primary MLR (A+Bx) was set up in the absence and presence of Ba100 (200 
nM). After 6 days culture, primed cells were harvested from bulk MLR cultures and 
used as effectors in the cell-mediated lympholysis assay. Primed cells harvested from 
the bulk MLR were incubated for 30 min, washed x2 in fresh complete media to remove 
Ba100 before assessment of cell mediated lympholytic activity. 
1x10
4
 3-day-old PHA blast cells (prepared from donor B) labeled with 
51




 target cells) served as targets. 
The effectors and targets were incubated in 96-well round-bottomed microtitre plates in 
the following effector: target ratios: 40 : 1, 20 : 1 and 10 : 1 in a final volume of 200 l. 
Before incubation for 4 h at 37C, the plates were subjected to light centrifugation (100 
G, 1 min). At the end of the incubation period, the plates were centrifuged (500 G, 5 
min) and 100 l supernatant was removed and counted for released 
51
Cr. Maximum and 
spontaneous 
51
Cr release was obtained by adding 0.1 ml 1N HCl or 0.1 ml medium 
respectively to wells containing 1x10
4
 target cells. 
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% specific 
51




Cr release =                                                                            x 100  
 
 
8.  Lymphocyte populations and phenotype after proliferation of  
     PBMC in response to PHA in the absence or presence of Ba100 or  
     Ba25 
Flow cytometry was used to analyse the phenotype of the lymphocyte population after 
proliferation of PBMC in response to PHA in the absence or presence of Ba100 (200 
nM) or Ba25 (200 nM). Both the % of cells in the lymphocyte gate (set on lymphocyte 
forward and side scatter properties) expressing a particular receptor and the MFI (mean 
fluorescent intensity) of the antibody binding was determined. 
 
8.1.  Methods of antibody labeling 
Cells were harvested at the end of PHA-induced PBMC proliferation assays. 10 l of 
each antibody to be tested was added per well of a V-bottomed plate. Harvested cells 
were resuspended and pipetted with mixing into the V-bottomed wells containing the 
antibody. The V-bottomed plate containing the cell suspension and labeling antibodies 
was incubated for 15 min in a dark cupboard and then spun at 2000 rpm for 4 min at 2 - 
8C. The supernatant was removed and 200 l PBS/10% AB serum was added to each 
well and mixed well. The plate was then spun at 2000 rpm for 4 min at 2 – 8C, the 
supernatant removed and 100 l PBS/10% AB serum added.100 l 2% 
paraformaldehyde was added to Kimble tubes, the cell suspension was added and 
mixed. A further 100 l 1% paraformaldehyde was then added to the Kimble tubes. 
Single colour analysis of antibody binding was done by flow cytometry (EPICS XL 
flow cytometer, Beckman Coulter) on gated lymphocytes. Both the percentage of cells 
in the lymphocyte gate expressing the receptor and the MFI was measured. 
DPM experimental – DPM spontaneous 
 
DPM maximum – DPM spontaneous 
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The receptors analysed included: 
i) Activation markers: HLA-DR and CD25 ( chain of IL-2 receptor) 
ii) Adhesion receptors: CD2, CD11a, CD49d and CD29 
iii) Costimulatory molecules: CD28 
iv) CTL markers: S6F1 
v) NK cell markers: CD56 and CD16 
vi) B cell markers: CD19 
vii) Anti-CD3 to detect T cells 
viii) Anti-CD4 and anti-CD8 to determine T cell subsets 
 
9.  Lymphocyte populations and phenotype of effector cells generated  
     in a 6 day primary MLR in the absence or presence of Ba100 or  
     Ba25 
A bulk primary MLR in the absence or presence of Ba100 (200 nM) or Ba25 (200 nM) 
was set up in 30 ml tissue culture flasks. 1x10
6
/ml responder cells were cultured with 
1x10
6
/ml irradiated (3000R) stimulator cells in the absence or presence of Ba100 (200 
nM) or Ba25 (200 nM) in a humidified 5% CO2 in air incubator at 37C.  Ba100 (200 
nM) or Ba25 (200 nM) was pre-incubated with the responder cells for 30 min at 37C 
prior to the addition of the stimulator cells. On day 6, cells were harvested, cell 
proliferation assessed by counting the number of cells/ml. Cells were labelled as 
described for the PHA-stimulated PBMC proliferation assays with antibodies directed to 
the indicated lymphocyte receptors and single colour analysis of antibody binding was 
done by flow cytometry on gated lymphocytes. Both the percentage of cells in the 
lymphocyte gate expressing the receptor and the MFI was measured. 
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10.  Measurement of cytokine production 
Cytokine production by activated lymphocytes was determined by using: 
i) Flow cytometry to detect intracellular cytokine production by PBMC in response to 
PMA and ionomycin in the absence or presence of Ba100. 
ii) Immunoassays to assess cytokine production during a primary mixed lymphocyte 
reaction in the absence or presence of Ba25. 
 
10.1.  Intracellular cytokine production by PBMCs after PMA and Ionomycin  
          stimulation (method according to Sander et al 1991). 
PBMC (20x10
6
/20 ml RPMI 1640/10% AB serum were cultured in 30 ml tissue culture 
flasks with PMA (50 ng/ml), ionomycin (1 M) and 2.5 g/ml Brefeldin (an inhibitor of 
intracellular protein transport process) in the absence or presence of Ba100 (200 nM) in 
a humidified 5% CO2 in air incubator at 37C . 
At varying time points (4, 6 and 24 h of stimulation), stimulated PBMC were harvested 
and the concentration adjusted to 10x10
6
 cells/ml RPMI 1640/10% AB serum. 100 l 
cell suspension aliquots were fixed with 4% Paraformaldehyde and permeabilised with 
0.1% Saponin. The cells were then labelled with antib dies to IL-2, IL-4, TNF- and 
IFN-. Single colour analysis of cytokine antibody binding was done by flow cytometry 
on 10 000 gated CD3
+
 lymphocytes. The percentage of cells in the lymphocyte gate 
expressing the cytokine as well as the mean fluorescent intensity of the cytokine 
antibody binding was measured. 
The kinetic study was performed, harvesting cells at 4, 6 and 24 h to establish the 
optimal time point for measuring the intracellular IL-2, IL-4, IFN- and TNF. The 
optimal time point was 4 h. 
Standard ELISA kits (Pharmingen, San Diego, CA) were utilised according to 
instructions to measure IL-4, IL-10 and IFN-γ production during a mixed lymphocyte 
reaction in the absence or presence of Ba25 (200 nM) 
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11.  Assessment of the distribution of PHA-stimulated PBMC in the  
       various phases of the cell cycle 
PHA-stimulated PBMC proliferation assays in the absence or presence of Ba100 (200 
nM)   or Ba25 (200 nM) were set up in 30 ml tissue culture flasks and incubated in a 
humidified 5% CO2 in air incubator at 37C.  
PHA-stimulated PBMC were harvested at 24, 40 and 48 h and resuspended at 5x10
6 
cells/ml RPMI 1640/10% AB serum. 100 l cell suspension aliquots were pipetted into 
Kimble tubes and cells stained with propidium iodide for DNA quantitation by FACS. 
Cells were first permeabilised with a non-ionic detergent and then treated with 
propidium iodide and RNAse (DNA-Prep, a Coulter Reagent kit). 
Single parameter histograms using a FL detector 3 (emission spectrum peaks at 650 nm) 
was used to quantify DNA content. 
 
12.  Measurement of proliferating cell nuclear antigen (PCNA)  
       expression by PHA-stimulated PBMCs 
PHA-stimulated PBMC proliferation assays in the absence or presence of Ba100 (200 
nM) or Ba25 (200 nM) were set up in 30 ml tissue culture flasks and incubated in a 
humidified 5% CO2 in air incubator at 37C. PHA-stimulated PBMCs were harvested at 
48 h and resuspended at 2x10
6 
cells/ml RPMI 1640/10% AB serum. Cells were 
permeabilised with    20 g/ml lysolecithin and fixed with 1% paraformaldehyde for 2 
min at room temperature. The cells were then harvested, resuspended in 200 l ice cold 
HPLC grade methanol and incubated on ice for 10 min. The cells were then harvested, 
200 l 0.1% Nonidet P-40 (NP-40) added and cells incubated on ice for 5 min. 
The intracellular nuclei were then stained with anti-PCNA and analysed by FACS. The 
results are expressed as percentage cells expressing PCNA and as the mean fluorescent 
intensity (extent of PCNA expression/cell). 
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13.  Effect of Indomethacin on PHA-induced PBMC proliferation in  
       the absence or presence of Ba25 
PBMC (1x10
5
 cells/well) were cultured in triplicate with PHA (0.00575 mitogenic 
units); PHA + Ba25 (200 nM) or PHA + Ba25 (200 nM) + indomethacin (5 or 10 
g/ml) in a humidified 5% CO2 in air incubator at 37C. PBMC were pre-incubated 
with Ba25 (200 nM) or Ba 25 + indomethacin for 30 min at 37C prior to the addition 
of PHA. At 72 h, 1 Ci [
3
H] thymidine was added and incorporation measured 18 h 
later. 
 
14.  Effect of -tocopherol on PHA-induced PBMC proliferation in the  
       absence or presence of Ba25 
PBMC (1x10
5
 cells/well) were cultured in triplicate with PHA (0.00575 mitogenic 
units), PHA + Ba25 (200 nM) or PHA + Ba25 (200 nM) + -tocopherol (50 or 100 
g/ml) in a humidified 5% CO2 in air incubator at 37C.  PBMC were pre-incubated 
with Ba25 (200 nM) or Ba25 + -tocopherol for 30 min at 37C prior to the addition of 
PHA. At 72 h, 1 Ci [
3
H] thymidine was added and incorporation measured 18 h later. 
 
15.  Analysis of data 
The results of lymphocyte proliferation as ays were expressed as mean DPM of 6 
replicates  SD or as % suppression of lymphocyte proliferation  SD. 
The % suppression of lymphocyte proliferation was calculated using the following 
formula:  
 
% Suppression =                                                 x100     
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Appendix 1 225 
Where baseline is the mean DPM of 6 replicates of the control lymphocyte proliferation 
assay and test is the mean DPM of 6 replicates of lymphocyte proliferation in the 
presence of Ba100 or Ba25. 
We used curve estimation to find the best equation (simple linear, linear with 
logarithmic transformation, exponential etc.) to analyse the relationship between the 
concentration of the 2 novel C-type lectins, Ba100 and Ba25 and % suppression of 
lymphocyte proliferation and to calculate the IC50. Repeated measures analysis was 
used to compare the % suppression of lymphocyte proliferation at successive 
concentrations of Ba100 and Ba25 in dose response experiments. The size of the 
regression coefficient was used to assess the degree of change in % suppression of 
lymphocyte proliferation with different pre-incubation periods of Ba100 or Ba25 
(regression coefficient of 0 is equivalent to no change). The Mann-Whitney test was 
used to compare small samples where indicated. The Statistical Package for Social 
Sciences was used for these analyses. Where individual differences were complex, 
interpretative analysis was done.  
 
 
Formatted: Justified, Space After:  12 pt, Line
spacing:  1.5 lines































H] thymidine : Tritiated thymidine 
3
[H] incorporation 
ADCC : Antibody-determined cell mediated cytotoxicity 
ADP : Adenosine diphosphate 
AICD : Activation-induced cell death 
Akt : alternative name for PKB 
AP-1 : Activator protein 1 
APCs : Antigen presenting cells 
APTT : Activated partial thromboplastin time 
ATG : Antithymocyte globulin 
BSA : Bovine serum albumin 
CD : Cluster of differentiation 
CDK-cyclin : Cyclin dependent kinase-cyclin 
CLEC-2 : C-type lectin receptor 
CNBr : Cyanogen bromide 
Con A : Concanavalin A 
COX-1 : Cyclooxygenase enzyme-1 
COX-2 : Cyclooxygenase enzyme-2 
CRD : Carbohydrate recognition domain 
CRE : cAMP-responsive element 
CREB/ATF : cAMP-responsive element binding factor 
CS-1 : Connecting segment-1 
CTLD : C-type lectin-like domain 
CTLs : Cytotoxic T cells 
d RVVT : dilute Russel’s viper venom time  
DAG : Diacylglycerol 
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DCIR: Dendritic cell inhibitory immunoreceptor 
DC-SIGN : Dendritic cell-specific intercellular adhesion molecule-3-grabbing 
                   nonintegrin (CD209) 
dl : Decilitre 
DLEC : Dendritic cell lectin 
DTH : Delayed-type hypersensitivity 
ECD : Glu-Cys-Asp 
ECM : Extracellular matrix 
eIF-4E complex : eukaryotic initiation factor-4E complex 
ELISA : Enzyme linked immunosorbent assay 
ERK : Extracellular signal-regulated kinase 
FACS : Fluorescence-activated cell sorter 
FasL : Fas ligand 
FGF : Fibroblast growth factor 
FITC-1 : Fluorescein isothiocyanate-1 
FKBP : FK506 binding protein 
Fn : Fibronectin 
FOXP3 : Forkhead/winged helix transcription factor 3 
GATA-3 : Member of GATA family of zinc finger proteins 
GITR : glucocorticoid-induced TNF-receptor family related receptor 
GM-CSF : Granulocyte macrophage-colony stimulating factor 
GP : Glycoprotein 
h : Hour 
HATT  : Heparin-associated thrombocytopaenia and thrombosis 
HETE : Hydroxylicosate traenoic acid 
HLA : Human leukocyte antigen 
HPLC : High performance liquid chromatography 
HVEM : Herpes virus entry mediator 
ICAM : Intracellular adhesion molecule  
IC50 : 50% Inhibitory concentration 











ICOS : Inducible costimulator 
ICOS-L : Inducible costimulator ligand 
IDO : Indole amine 2,3-dioxygenase 
IFN-  : Interferon gamma 
Ig : Immunoglobulin 
IL : Interleukin  
IP-10 :  IFN-  inducible protein 
IP3 : Inositol triphosphate 
I-TAC : Chemokine CXCL11 
ITAM : Immunoreceptor tyrosine-based activation motif 
IU : International units 
JAK 3 : Janus kinase 3 
JNK : N-terminal c-Jun kinase 
JT : Jarastatin 
KCT : Kaolin clotting time 
kDa : Kilodaltons 
KGD : Lys-Gly-Asp 
KIRs : Killer Ig-like receptors 
KTS : Lys-Thr-Ser 
L : Ligand 
LDV : Leu-Asp-Val 
LFA-1 (CD11a/CD18) : Lymphocyte function-associated antigen 1 
LFA-3 (CD53) : Lymphocyte function-associated antigen 3 
LIBS : Ligand-induced binding site 
LIGHT : TNF superfamily member 14 (TNFSF14) 
LPS : Lipopolysaccharide 
MAPK : Mitogen-activated protein kinase  
MCP-1 : Monocyte chemoattractant protein 1 











MFI : Mean fluorescent intensity 
mg : Milligram 
MHC : Major histocompatibility complex 
MIG : Monokine-induced by IFN-  
min : Minutes 
MIP-1 : Macrophage inflammatory protein-1 
ml : Millilitre 
MLD : Met-Leu-Asp 
MLR : Mixed lymphocyte reaction 
mLT : Membrane lymphotoxin 
mRNA : messenger RNA 
mTOR : Mammalian target of rapamycin 
MVD : Met-Val-Asp 
n : Number in study, group 
nAChR : Nicotinic acetylcholine receptors 
NF- B : Nuclear factor- B 
NFAT : Nuclear factor of activated T cells 
NK cell : Natural killer cell 
nM : Nanomolar 
NO : Nitric oxide 
NP-40 : Nonidet P-40 
Oct-1 : Octamer-binding transcription factor 
OKT3 : Anti-CD3 antibody 
PBMC : Peripheral blood mononuclear cell 
PBS : Phosphate buffered saline 
PCD : Passive cell death 
PCNA : Proliferating cell nuclear antigen 
PD-1 : Programmed death-1 











PD-L1 : Programmed death ligand 1 
PD-L2 : Programmed death ligand 2 
PECAM-1 : Platelet-endothelial cell adhesion molecule 
pg : Picogram 
PG : Prostaglandin 
PGE2 : Prostaglandin E2 
PHA : Phytohaemagglutinin A 
PHAS-I : Phosphorylatable heat stable protein 1 (eIF4E-binding protein) 
PI-3 kinase : Phosphotidyl-inositol 3-kinase 
PICT : Prothrombinase induced clotting time 
PKB : Protein kinase B 
PKC : Protein kinase C 
PLC : Phospholipase C 
PMA :  Phorbol 12-myristrate 13-acetate 
PPD : Purified protein derivative 
PPIases : Peptidyl-prolyl isomerases 
PSGL : P-selectin glycoprotein ligand 
pSMAC : Peripheral supraclavicular activation cluster 
PT : Prothrombin time 
PTT : Partial prothrombin time 
R-PE : R-Phycoerythrin-conjugated 
RANTES : Regulated upon activation normal T cell expressed and secreted 
RGD : Arg-Gly-Asp  
RGDX : Arg-Gly-Asp (x = Trp, Tyr, Phe, Leu, Val, Cys, Gln or Ser) 
RVV-V : Russell’s viper venom containing an activator of factor V 
RVV-X : Russell’s viper venom containing an activator of factor X  
SAC : Staphylococcus aureas Cowan strain 1  
SD : Standard deviation 
SDS-PAGE : Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
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SE : Standard error 
SPSS : Statistical Package for Social Sciences 
SRCL : Scavenger receptor C-type lectin 
SVMPs : Snake venom metalloproteinases 
SVTLEs : Snake venom thrombin-like enzymes 
TAP : Transporters associated with antigen processing 
T-bet : T-box expressed in T cells 
TCR : T cell receptor 
TEG : Thromboelastogram 
TGF-  : Transforming growth factor-  
Th : T helper cell 
TNF : Tumour necrosis factor 
TNFR : Tumour necrosis factor receptor 
Treg : Regulatory T cell 
TTK : Threonine tyrosine kinase 
VCAM-1 : Vascular cell adhesion molecule 1 
VEGF : Vascular endothelial growth factor 
VGD : Val-Gly-Asp 
VLA-4 ( 4 1) : Very late antigen-4 
VLA-5 ( 5 1) : Very late antigen-5 
vWF : von Willebrand Factor 
l : Microlitre 
g : Microgram 
 
 
